Clustering	Clustering	C423	NN	B-NP	O
of	of	O100	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	B-Disease
T	T	T000	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
leukaemia	leukaemia	L250	NN	I-NP	I-Disease
.	.	0000	.	O	O

Ataxia	Ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
recessive	recessive	R210	JJ	I-NP	B-Disease
multi	multi	M430	AFX	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
system	system	S235	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
at	at	A300	IN	B-PP	O
11q22	11q22	Q000	NN	B-NP	O
-	-	0000	HYPH	O	O
q23	q23	Q000	NN	B-NP	O
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
especially	especially	E212	RB	B-NP	O
lymphoid	lymphoid	L513	JJ	I-NP	B-Disease
neoplasias	neoplasia	N142	NNS	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
substantially	substantially	S123	RB	I-VP	O
elevated	elevate	E413	VBN	I-VP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
long	long	L520	RB	I-VP	O
been	be	B500	VBN	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
analysing	analyse	A542	VBG	B-VP	O
tumour	tumour	T560	NN	B-NP	B-Disease
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
T	T	T000	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
prolymphocytic	prolymphocytic	P645	JJ	I-NP	I-Disease
leukaemia	leukaemia	L250	NN	I-NP	I-Disease
(	(	0000	(	O	O
T	T	T000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
PLL	PLL	P400	NN	I-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
clonal	clonal	C454	JJ	I-NP	B-Disease
malignancy	malignancy	M425	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
similarities	similarity	S546	NNS	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
mature	mature	M360	JJ	I-NP	B-Disease
T	T	T000	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
leukaemia	leukaemia	L250	NN	I-NP	I-Disease
seen	see	S500	VBN	B-VP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	B-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
T	T	T000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
PLL	PLL	P400	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
marked	marked	M623	JJ	B-NP	O
contrast	contrast	C536	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
in	in	I500	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
T	T	T000	NN	B-NP	I-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequent	frequent	F625	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
leukaemia	leukaemia	L250	NN	I-NP	B-Disease
were	be	W600	VBD	B-VP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
clustered	cluster	C423	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
corresponding	correspond	C621	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
kinase	kinase	K520	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
highly	highly	H240	RB	I-VP	O
conserved	conserve	C526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
in	in	I500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
,	,	0000	,	O	O
yeast	yeast	Y230	NN	B-NP	O
and	and	A530	CC	O	O
Drosophila	Drosophila	D621	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
resulting	result	R243	VBG	I-NP	O
amino	amino	A500	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
interfere	interfere	I536	VB	I-VP	O
with	with	W300	IN	B-PP	O
ATP	ATP	A310	NN	B-NP	O
binding	binding	B535	NN	I-NP	O
or	or	O600	CC	O	O
substrate	substrate	S123	NN	B-NP	O
recognition	recognition	R253	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
seventeen	seventeen	S153	CD	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
T	T	T000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
PLL	PLL	P400	NN	I-NP	I-Disease
samples	sample	S514	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
p53	p53	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
frequently	frequently	F625	RB	I-VP	O
altered	alter	A436	VBN	I-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
leukaemia	leukaemia	L250	NN	I-NP	B-Disease
.	.	0000	.	O	O

Occasional	Occasional	O254	JJ	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
tumour	tumour	T560	NN	B-NP	B-Disease
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
B	B	B000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
non	non	N500	AFX	B-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Hodgkins	Hodgkins	H325	NNP	I-NP	I-Disease
lymphomas	lymphoma	L515	NNS	I-NP	I-Disease
(	(	0000	(	O	O
B	B	B000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
NHL	NHL	N400	NN	B-NP	I-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
B	B	B000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
NHL	NHL	N400	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
function	function	F523	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
copy	copy	C100	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutated	mutate	M300	VBN	B-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
establishes	establish	E231	VBZ	B-VP	O
somatic	somatic	S532	JJ	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
T	T	T000	NN	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
PLL	PLL	P400	NN	I-NP	I-Disease
and	and	A530	CC	O	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
ATM	ATM	A350	NN	B-NP	O
acts	act	A232	VBZ	B-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
constitutional	constitutional	C523	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
available	available	A141	JJ	B-ADJP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
hereditary	hereditary	H636	JJ	I-NP	O
predisposition	predisposition	P632	NN	I-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
PLL	PLL	P400	NN	I-NP	I-Disease
will	will	W400	MD	B-VP	O
require	require	R260	VB	I-VP	O
further	far	F636	JJR	B-NP	O
investigation	investigation	I512	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
modulation	modulation	M343	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ca2	Ca2	C000	NN	I-NP	O
+	+	0000	SYM	B-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
in	in	I500	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
prevalent	prevalent	P614	JJ	I-NP	O
muscular	muscular	M246	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
adults	adult	A343	NNS	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
;	;	0000	:	O	O
DMPK	DMPK	D512	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
involves	involve	I514	VBZ	B-VP	O
changes	change	C520	NNS	B-NP	O
in	in	I500	IN	B-PP	O
cytoarchitecture	cytoarchitecture	C362	NN	B-NP	O
and	and	A530	CC	I-NP	O
ion	ion	I500	NN	I-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
obtain	obtain	O135	VB	I-VP	O
clues	clue	C420	NNS	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
biological	biological	B424	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
in	in	I500	IN	B-PP	O
cellular	cellular	C460	JJ	B-NP	O
ion	ion	I500	NN	I-NP	O
homeostasis	homeostasis	H523	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
compared	compare	C516	VBN	I-VP	O
the	the	T000	DT	B-NP	O
resting	resting	R235	NN	I-NP	O
[	[	0000	(	O	O
Ca2	Ca2	C000	NN	B-NP	O
+	+	0000	SYM	O	O
]	]	0000	)	O	O
i	i	I000	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
amplitude	amplitude	A514	NN	I-NP	O
and	and	A530	CC	I-NP	O
shape	shape	S100	NN	I-NP	O
of	of	O100	IN	B-PP	O
depolarization	depolarization	D146	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
Ca2	Ca2	C000	NN	I-NP	O
+	+	0000	SYM	B-NP	O
transients	transient	T652	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
content	content	C535	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATP	ATP	A310	NN	B-NP	O
-	-	0000	HYPH	O	O
driven	drive	D615	VBN	B-NP	O
ion	ion	I500	NN	I-NP	O
pumps	pump	P512	NNS	I-NP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
skeletal	skeletal	S243	JJ	I-NP	O
muscle	muscle	M240	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
and	and	A530	CC	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
[	[	0000	(	O	O
-	-	0000	HYPH	B-NP	O
/	/	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
]	]	0000	)	I-NP	O
knockout	knockout	K523	NN	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
-	-	0000	HYPH	B-VP	O
differentiated	differentiate	D165	VBN	B-NP	O
DMPK	DMPK	D512	NN	I-NP	O
[	[	0000	(	O	O
-	-	0000	HYPH	O	O
/	/	0000	SYM	O	O
-	-	0000	HYPH	O	O
]	]	0000	)	O	O
myotubes	myotube	M312	NNS	B-NP	O
exhibit	exhibit	E213	VBP	B-VP	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
resting	rest	R235	VBG	I-NP	O
[	[	0000	(	O	O
Ca2	Ca2	C000	NN	O	O
+	+	0000	SYM	O	O
]	]	0000	)	O	O
i	i	I000	NN	B-NP	O
than	than	T500	IN	B-SBAR	O
do	do	D000	VBP	B-VP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
myotubes	myotube	M312	NNS	I-NP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
an	an	A500	DT	B-NP	O
altered	altered	A436	JJ	I-NP	O
open	open	O150	JJ	I-NP	O
probability	probability	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
voltage	voltage	V432	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
l	l	L000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
Ca2	Ca2	C000	NN	I-NP	O
+	+	0000	SYM	B-NP	O
and	and	A530	CC	O	O
Na	Na	N000	NN	B-NP	O
+	+	0000	SYM	I-NP	O
channels	channel	C542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
myotubes	myotube	M312	NNS	I-NP	O
exhibit	exhibit	E213	VBP	B-VP	O
smaller	small	S546	JJR	B-NP	O
and	and	A530	CC	I-NP	O
slower	slow	S460	JJR	I-NP	O
Ca2	Ca2	C000	NN	I-NP	O
+	+	0000	SYM	I-NP	O
responses	response	R215	NNS	I-NP	O
upon	upon	U150	IN	B-PP	O
triggering	triggering	T626	NN	B-NP	O
by	by	B000	IN	B-PP	O
acetylcholine	acetylcholine	A234	NN	B-NP	O
or	or	O600	CC	O	O
high	high	H200	JJ	B-NP	O
external	external	E236	JJ	I-NP	O
K	K	K000	NN	I-NP	O
+	+	0000	SYM	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
Ca2	Ca2	C000	NN	I-NP	O
+	+	0000	SYM	O	O
transients	transient	T652	NNS	B-NP	O
partially	partially	P634	RB	B-ADVP	O
result	result	R243	VBP	B-VP	O
from	from	F650	IN	B-PP	O
an	an	A500	DT	B-NP	O
influx	influx	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
extracellular	extracellular	E236	JJ	B-NP	O
Ca2	Ca2	C000	NN	I-NP	O
+	+	0000	SYM	B-ADVP	O
through	through	T620	IN	B-PP	O
the	the	T000	DT	B-NP	O
l	l	L000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
Ca2	Ca2	C000	NN	I-NP	O
+	+	0000	SYM	B-NP	O
channel	channel	C540	NN	I-NP	O
.	.	0000	.	O	O

Neither	Neither	N360	CC	O	O
the	the	T000	DT	B-NP	O
content	content	C535	NN	I-NP	O
nor	nor	N600	CC	O	O
the	the	T000	DT	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
Na	Na	N000	NN	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
K	K	K000	NN	B-NP	O
+	+	0000	SYM	I-NP	O
ATPase	ATPase	A312	NN	I-NP	O
and	and	A530	CC	O	O
sarcoplasmic	sarcoplasmic	S621	JJ	B-NP	O
reticulum	reticulum	R324	NN	I-NP	O
Ca2	Ca2	C000	NN	I-NP	O
+	+	0000	SYM	O	O
-	-	0000	HYPH	O	O
ATPase	ATPase	A312	NN	B-NP	O
are	be	A600	VBP	B-VP	O
affected	affect	A123	VBN	I-VP	O
by	by	B000	IN	B-PP	O
DMPK	DMPK	D512	NN	B-NP	O
absence	absence	A125	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
conclusion	conclusion	C524	NN	B-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
DMPK	DMPK	D512	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
modulating	modulate	M343	VBG	B-VP	O
the	the	T000	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
of	of	O100	IN	B-PP	O
excitation	excitation	E235	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
contraction	contraction	C536	NN	I-NP	O
coupling	coupling	C145	NN	I-NP	O
in	in	I500	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Constitutional	Constitutional	C523	JJ	B-NP	O
RB1	RB1	R100	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	O
unilateral	unilateral	U543	JJ	I-NP	B-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	O
unilateral	unilateral	U543	JJ	I-NP	B-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
,	,	0000	,	O	O
tumor	tumor	T560	NN	B-NP	B-Disease
development	development	D141	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
initiated	initiate	I530	VBN	I-VP	O
by	by	B000	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
some	some	S500	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
can	can	C500	MD	B-VP	O
transmit	transmit	T652	VB	I-VP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
predisposition	predisposition	P632	NN	I-NP	O
to	to	T000	TO	B-PP	O
their	their	T600	PRP$	B-NP	O
offspring	offspring	O121	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
and	and	A530	CC	I-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
constitutional	constitutional	C523	JJ	B-NP	O
RB1	RB1	R100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	O
unilateral	unilateral	U543	JJ	I-NP	B-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
and	and	A530	CC	B-PP	O
from	from	F650	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
tissue	tissue	T200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
from	from	F650	IN	B-PP	O
54	54	0000	CD	B-NP	O
(	(	0000	(	O	O
71	71	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
76	76	0000	CD	B-NP	O
informative	informative	I516	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
constitutional	constitutional	C523	JJ	B-NP	O
heterozygosity	heterozygosity	H362	NN	I-NP	O
(	(	0000	(	O	O
LOH	LOH	L000	NN	B-NP	O
)	)	0000	)	O	O
at	at	A300	IN	B-PP	O
intragenic	intragenic	I536	JJ	B-NP	O
loci	locus	L200	NNS	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
13	13	0000	CD	B-NP	O
uninformative	uninformative	U516	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
constitutional	constitutional	C523	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
39	39	0000	CD	B-NP	O
randomly	randomly	R535	RB	I-NP	O
selected	select	S423	VBN	I-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
,	,	0000	,	O	O
SSCP	SSCP	S210	NN	B-NP	O
,	,	0000	,	O	O
hetero	hetero	H360	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
duplex	duplex	D142	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
sequencing	sequencing	S252	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Southern	Southern	S365	JJ	B-NP	O
blot	blot	B430	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
mutations	mutation	M352	NNS	B-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
21	21	0000	CD	B-NP	O
(	(	0000	(	O	O
91	91	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
23	23	0000	CD	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
with	with	W300	IN	B-PP	O
LOH	LOH	L000	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
6	6	0000	CD	B-NP	O
(	(	0000	(	O	O
38	38	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
16	16	0000	CD	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
without	without	W300	IN	B-PP	O
LOH	LOH	L000	NN	B-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
9	9	0000	CD	B-NP	O
(	(	0000	(	O	O
56	56	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
without	without	W300	IN	B-PP	O
LOH	LOH	L000	NN	B-NP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
45	45	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
of	of	O100	IN	B-PP	O
36	36	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Thirty	Thirty	T630	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
nine	nine	N500	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
-	-	0000	HYPH	B-PP	O
including	include	I524	VBG	B-PP	O
34	34	0000	CD	B-NP	O
small	small	S540	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
2	2	0000	CD	B-NP	O
large	large	L620	JJ	I-NP	O
structural	structural	S362	JJ	I-NP	O
alterations	alteration	A436	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
hypermethylation	hypermethylation	H165	NN	B-NP	O
in	in	I500	IN	B-PP	O
3	3	0000	CD	B-NP	O
tumors	tumor	T562	NNS	I-NP	O
-	-	0000	HYPH	B-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
corresponding	correspond	C621	VBG	I-NP	O
peripheral	peripheral	P616	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
6	6	0000	CD	B-NP	O
(	(	0000	(	O	O
17	17	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
36	36	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
constitutional	constitutional	C523	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
known	know	K500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
expressivity	expressivity	E216	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
constitutional	constitutional	C523	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
early	early	E640	JJ	I-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
treatment	treatment	T635	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
1	1	0000	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
somatic	somatic	S532	JJ	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
was	be	W200	VBD	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
and	and	A530	CC	I-NP	O
RNA	RNA	R500	NN	I-NP	O
from	from	F650	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
2	2	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
without	without	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
,	,	0000	,	O	O
mosaicism	mosaicism	M250	NN	B-NP	O
was	be	W200	VBD	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
because	because	B200	IN	B-SBAR	O
1	1	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
multifocal	multifocal	M431	JJ	B-NP	O
tumors	tumor	T562	NNS	I-NP	B-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
later	later	L360	RB	B-ADVP	O
developed	develop	D141	VBD	B-VP	O
bilateral	bilateral	B436	JJ	B-NP	B-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
conclusion	conclusion	C524	NN	B-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
emphasize	emphasize	E512	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
manifestation	manifestation	M512	NN	I-NP	O
and	and	A530	CC	I-NP	O
transmissibility	transmissibility	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
depend	depend	D153	VBP	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
its	its	I320	PRP$	B-NP	O
time	time	T500	NN	I-NP	O
in	in	I500	IN	B-PP	O
development	development	D141	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
and	and	A530	CC	O	O
types	type	T120	NNS	B-NP	O
of	of	O100	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
affected	affect	A123	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
fifth	fifth	F130	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
.	.	0000	.	O	O

I	I	I000	PRP	B-NP	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
,	,	0000	,	I-NP	O
immunochemical	immunochemical	I525	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
family	family	F540	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
recognized	recognize	R252	VBN	I-NP	O
human	human	H500	JJ	I-NP	O
kindred	kindred	K536	NN	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
fifth	fifth	F130	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
(	(	0000	(	O	O
C5	C5	C000	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
20	20	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
old	old	O430	JJ	I-NP	O
black	black	B420	JJ	I-NP	O
female	female	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
systemic	systemic	S235	JJ	B-NP	B-Disease
lupus	lupus	L120	NN	I-NP	I-Disease
erythematosus	erythematosus	E635	NN	I-NP	I-Disease
since	since	S520	IN	B-PP	O
age	age	A200	NN	B-NP	O
11	11	0000	CD	I-NP	O
,	,	0000	,	O	O
lacked	lack	L230	VBD	B-VP	O
serum	serum	S650	NN	B-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	O
complement	complement	C514	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
even	even	E150	RB	B-ADVP	O
during	during	D652	IN	B-PP	O
remission	remission	R525	NN	B-NP	O
.	.	0000	.	O	O

C5	C5	C000	NN	B-NP	O
was	be	W200	VBD	B-VP	O
undetectable	undetectable	U532	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
serum	serum	S650	NN	I-NP	O
by	by	B000	IN	B-PP	O
both	both	B300	CC	O	O
immunodiffusion	immunodiffusion	I531	NN	B-NP	O
and	and	A530	CC	O	O
hemolytic	hemolytic	H543	JJ	B-NP	O
assays	assay	A200	NNS	I-NP	O
.	.	0000	.	O	O

Other	Other	O360	JJ	B-NP	O
complement	complement	C514	NN	I-NP	O
components	component	C515	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
during	during	D652	IN	B-PP	O
remission	remission	R525	NN	B-NP	O
of	of	O100	IN	B-PP	O
lupus	lupus	L120	NN	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
C1	C1	C000	NN	B-NP	O
,	,	0000	,	O	O
C4	C4	C000	NN	B-NP	O
,	,	0000	,	O	O
C2	C2	C000	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
C3	C3	C000	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
fell	fall	F400	VBD	B-VP	O
during	during	D652	IN	B-PP	O
exacerbations	exacerbation	E261	NNS	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
younger	young	Y526	JJR	I-NP	O
half	half	H410	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
sister	sister	S236	NN	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
lack	lack	L200	VB	I-VP	O
immunochemically	immunochemically	I525	RB	B-NP	O
detectable	detectable	D323	JJ	I-NP	O
C5	C5	C000	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
hemolytic	hemolytic	H543	JJ	B-NP	O
assay	assay	A200	NN	I-NP	O
,	,	0000	,	O	O
she	she	S000	PRP	B-NP	O
exhibited	exhibit	E213	VBD	B-VP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
2	2	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
serum	serum	S650	NN	I-NP	O
C5	C5	C000	NN	I-NP	O
level	level	L140	NN	I-NP	O
and	and	A530	CC	O	O
normal	normal	N654	JJ	B-NP	O
concentrations	concentration	C525	NNS	I-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
complement	complement	C514	NN	I-NP	O
components	component	C515	NNS	I-NP	O
.	.	0000	.	O	O

C5	C5	C000	NN	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
other	other	O360	JJ	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
either	either	E360	CC	O	O
normal	normal	N654	JJ	B-ADJP	O
or	or	O600	CC	O	O
approximately	approximately	A162	RB	B-ADVP	O
half	half	H410	RB	B-ADJP	O
-	-	0000	HYPH	I-ADJP	O
normal	normal	N654	JJ	B-ADJP	O
,	,	0000	,	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
codominant	codominant	C353	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
determining	determine	D365	VBG	B-VP	O
C5	C5	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Normal	Normal	N654	JJ	B-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	O
titers	titer	T362	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
restored	restore	R236	VBN	I-VP	O
to	to	T000	TO	B-PP	O
both	both	B300	CC	O	O
homozygous	homozygous	H520	JJ	B-NP	O
C5	C5	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
(	(	0000	(	O	O
C5D	C5D	C300	NN	B-NP	B-Disease
)	)	0000	)	O	O
sera	serum	S600	NNS	B-NP	O
by	by	B000	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
of	of	O100	IN	B-PP	O
highly	highly	H240	RB	B-NP	O
purified	purify	P613	VBN	I-NP	O
human	human	H500	JJ	I-NP	O
C5	C5	C000	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
specific	specific	S121	JJ	B-NP	O
C5	C5	C000	NN	I-NP	O
titrations	titration	T363	NNS	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
noted	note	N300	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
when	when	W500	WRB	B-ADVP	O
limited	limited	L530	JJ	B-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
C5	C5	C000	NN	B-NP	O
were	be	W600	VBD	B-VP	O
assayed	assay	A230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
low	low	L000	JJ	B-NP	O
dilutions	dilution	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
either	either	E360	CC	O	O
C5D	C5D	C300	NN	B-NP	B-Disease
serum	serum	S650	NN	I-NP	O
,	,	0000	,	O	O
curving	curve	C615	VBG	B-VP	O
rather	rather	R360	RB	B-PP	O
than	than	T500	IN	I-PP	O
linear	linear	L560	JJ	B-NP	O
dose	dose	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
response	response	R215	NN	I-NP	O
plots	plot	P432	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
consistently	consistently	C523	RB	I-VP	O
obtained	obtain	O135	VBN	I-VP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
some	some	S500	DT	B-NP	O
inhibitory	inhibitory	I513	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
low	low	L000	JJ	B-NP	O
dilutions	dilution	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
C5D	C5D	C300	NN	B-NP	B-Disease
serum	serum	S650	NN	I-NP	O
contain	contain	C535	VBP	B-VP	O
a	a	A000	DT	B-NP	O
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
or	or	O600	CC	O	O
factors	factor	F236	NNS	B-NP	O
)	)	0000	)	O	O
interfering	interfere	I536	VBG	B-VP	O
at	at	A300	IN	B-PP	O
some	some	S500	DT	B-NP	O
step	step	S310	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	O
assay	assay	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
C5	C5	C000	NN	B-NP	O
,	,	0000	,	O	O
rather	rather	R360	RB	B-CONJP	O
than	than	T500	IN	I-CONJP	O
a	a	A000	DT	B-NP	O
true	true	T600	JJ	I-NP	O
C5	C5	C000	NN	I-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
or	or	O600	CC	I-NP	O
inactivator	inactivator	I523	NN	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
interest	interest	I536	NN	I-NP	O
are	be	A600	VBP	B-VP	O
(	(	0000	(	B-LST	O
a	a	A000	LS	I-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
documentation	documentation	D253	NN	I-NP	O
of	of	O100	IN	B-PP	O
membranous	membranous	M516	JJ	B-NP	O
glomerulonephritis	glomerulonephritis	G456	NN	I-NP	B-Disease
,	,	0000	,	O	O
vasculitis	vasculitis	V243	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
arthritis	arthritis	A636	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
individual	individual	I531	JJ	I-NP	O
lacking	lack	L252	VBG	I-NP	O
C5	C5	C000	NN	I-NP	O
(	(	0000	(	O	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
biologic	biologic	B420	JJ	I-NP	O
functions	function	F523	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
b	b	B000	LS	I-LST	O
)	)	0000	)	O	O
a	a	A000	DT	B-NP	O
remarkable	remarkable	R562	JJ	I-NP	O
propensity	propensity	P615	NN	I-NP	O
to	to	T000	TO	B-PP	O
bacterial	bacterial	B236	JJ	B-NP	B-Disease
infections	infection	I512	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
,	,	0000	,	O	O
even	even	E150	RB	B-ADVP	O
during	during	D652	IN	B-PP	O
periods	period	P632	NNS	B-NP	O
of	of	O100	IN	B-PP	O
low	low	L000	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
dose	dose	D200	NN	I-NP	O
or	or	O600	CC	I-NP	O
alternate	alternate	A436	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
day	day	D000	NN	I-NP	O
corticosteroid	corticosteroid	C632	NN	I-NP	O
therapy	therapy	T610	NN	I-NP	O
.	.	0000	.	O	O

Other	Other	O360	JJ	B-NP	O
observations	observation	O126	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
C5D	C5D	C300	NN	I-NP	B-Disease
state	state	S300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
coagulation	coagulation	C243	NN	I-NP	O
function	function	F523	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
capacity	capacity	C123	NN	I-NP	O
to	to	T000	TO	B-VP	O
mount	mount	M530	VB	I-VP	O
a	a	A000	DT	B-NP	O
neutrophilic	neutrophilic	N361	JJ	I-NP	O
leukocytosis	leukocytosis	L232	NN	I-NP	O
during	during	D652	IN	B-PP	O
pyogenic	pyogenic	P252	JJ	B-NP	B-Disease
infection	infection	I512	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Susceptibility	Susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
in	in	I500	IN	B-PP	O
twins	twin	T520	NNS	B-NP	O
:	:	0000	:	O	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
,	,	0000	,	O	O
HLA	HLA	H400	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
environment	environment	E516	NN	I-NP	O
.	.	0000	.	O	O

OBJECTIVE	OBJECTIVE	O123	NN	B-NP	O
To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
and	and	A530	CC	I-NP	O
environmental	environmental	E516	JJ	I-NP	O
factors	factor	F236	NNS	I-NP	O
in	in	I500	IN	B-PP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
ankylosing	ankylose	A524	VBG	B-VP	B-Disease
spondylitis	spondylitis	S153	NN	B-NP	I-Disease
(	(	0000	(	O	O
AS	AS	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
Twins	Twin	T520	NNS	I-NP	O
with	with	W300	IN	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Royal	Royal	R400	NNP	I-NP	O
National	National	N354	NNP	I-NP	O
Hospital	Hospital	H213	NNP	I-NP	O
for	for	F600	IN	B-PP	O
Rheumatic	Rheumatic	R532	NNP	B-NP	B-Disease
Diseases	Diseases	D200	NNP	I-NP	I-Disease
database	database	D312	NN	I-NP	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
and	and	A530	CC	I-NP	O
radiographic	radiographic	R326	JJ	I-NP	O
examinations	examination	E253	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
to	to	T000	TO	I-VP	O
establish	establish	E231	VB	I-VP	O
diagnoses	diagnosis	D252	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
disease	disease	D200	NN	B-NP	O
severity	severity	S163	NN	I-NP	O
was	be	W200	VBD	B-VP	O
assessed	assess	A230	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
validated	validate	V430	VBN	B-NP	O
scoring	scoring	S265	NN	I-NP	O
systems	system	S235	NNS	I-NP	O
.	.	0000	.	O	O

HLA	HLA	H400	NN	B-NP	O
typing	typing	T152	NN	I-NP	O
for	for	F600	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
B27	B27	B000	NN	I-NP	O
,	,	0000	,	O	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
B60	B60	B000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
DR1	DR1	D600	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
with	with	W300	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
primers	primer	P656	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
zygosity	zygosity	Z230	NN	B-NP	O
was	be	W200	VBD	B-VP	O
assessed	assess	A230	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
microsatellite	microsatellite	M262	NN	B-NP	O
markers	marker	M626	NNS	I-NP	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
and	and	A530	CC	I-NP	O
environmental	environmental	E516	JJ	I-NP	O
variance	variance	V652	NN	I-NP	O
components	component	C515	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
assessed	assess	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
program	program	P626	NN	I-NP	O
Mx	Mx	M200	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
data	datum	D300	NNS	B-NP	O
from	from	F650	IN	B-PP	O
this	this	T200	DT	B-NP	O
and	and	A530	CC	I-NP	O
previous	previous	P612	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
twins	twin	T520	NNS	B-NP	O
with	with	W300	IN	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
Six	Six	S200	CD	B-NP	O
of	of	O100	IN	B-PP	O
8	8	0000	CD	B-NP	O
monozygotic	monozygotic	M523	JJ	I-NP	O
(	(	0000	(	O	O
MZ	MZ	M200	JJ	B-ADJP	O
)	)	0000	)	O	O
twin	twin	T500	NN	B-NP	O
pairs	pair	P620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
disease	disease	D200	NN	B-ADJP	O
concordant	concordant	C526	JJ	I-ADJP	O
,	,	0000	,	O	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
4	4	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
15	15	0000	CD	B-NP	O
B27	B27	B000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
positive	positive	P231	JJ	I-NP	O
dizygotic	dizygotic	D232	JJ	I-NP	O
(	(	0000	(	O	O
DZ	DZ	D200	NN	B-NP	O
)	)	0000	)	O	O
twin	twin	T500	NN	B-NP	O
pairs	pair	P620	NNS	I-NP	O
(	(	0000	(	O	O
27	27	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
4	4	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
32	32	0000	CD	B-NP	O
DZ	DZ	D200	NN	I-NP	O
twin	twin	T500	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
overall	overall	O164	JJ	B-ADVP	O
(	(	0000	(	O	O
12	12	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Nonsignificant	Nonsignificant	N525	JJ	B-NP	O
increases	increase	I526	NNS	I-NP	O
in	in	I500	IN	B-PP	O
similarity	similarity	S546	NN	B-NP	O
with	with	W300	IN	B-PP	O
regard	regard	R263	NN	B-NP	O
to	to	T000	TO	B-PP	O
age	age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
onset	onset	O523	NN	I-NP	O
and	and	A530	CC	O	O
all	all	A400	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
severity	severity	S163	NN	I-NP	O
scores	score	S262	NNS	I-NP	O
assessed	assess	A230	VBN	B-VP	O
were	be	W600	VBD	B-VP	O
noted	note	N300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
concordant	concordant	C526	JJ	I-NP	O
MZ	MZ	M200	NN	I-NP	O
twins	twin	T520	NNS	I-NP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
concordant	concordant	C526	JJ	B-NP	O
DZ	DZ	D200	NN	I-NP	O
twins	twin	T520	NNS	I-NP	O
.	.	0000	.	O	O

HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
B27	B27	B000	NN	I-NP	O
and	and	A530	CC	I-NP	O
B60	B60	B000	NN	I-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
in	in	I500	IN	B-PP	O
probands	proband	P615	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
rate	rate	R300	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
concordance	concordance	C526	NN	I-NP	O
was	be	W200	VBD	B-VP	O
significantly	significantly	S251	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
among	among	A520	IN	B-PP	O
DZ	DZ	D200	NN	B-NP	O
twin	twin	T500	NN	I-NP	O
pairs	pair	P620	NNS	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
the	the	T000	DT	B-NP	O
co	co	C000	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
twin	twin	T500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
positive	positive	P231	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
both	both	B300	CC	O	O
B27	B27	B000	NN	B-NP	O
and	and	A530	CC	I-NP	O
DR1	DR1	D600	NN	I-NP	O
.	.	0000	.	O	O

Additive	Additive	A310	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
to	to	T000	TO	I-VP	O
contribute	contribute	C536	VB	I-VP	O
97	97	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
population	population	P143	NN	I-NP	O
variance	variance	V652	NN	I-NP	O
.	.	0000	.	O	O

CONCLUSION	CONCLUSION	C524	NN	B-NP	O
Susceptibility	Susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
largely	largely	L624	RB	I-VP	O
genetically	genetically	G532	RB	I-VP	O
determined	determine	D365	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
environmental	environmental	E516	JJ	I-NP	O
trigger	trigger	T626	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
probably	probably	P614	RB	B-ADVP	O
ubiquitous	ubiquitous	U123	JJ	B-ADJP	O
.	.	0000	.	O	O

HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
B27	B27	B000	NN	I-NP	O
accounts	account	A253	VBZ	B-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
minority	minority	M563	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
overall	overall	O164	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-PP	O
AS	AS	A200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Cell	Cell	C400	NN	B-NP	O
cycle	cycle	C240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
colocalization	colocalization	C424	NN	I-NP	O
of	of	O100	IN	B-PP	O
BARD1	BARD1	B630	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
in	in	I500	IN	B-PP	O
discrete	discrete	D263	JJ	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
domains	domain	D520	NNS	I-NP	O
.	.	0000	.	O	O

Germ	Germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
predispose	predispose	P632	NN	I-NP	O
women	woman	W500	NNS	I-NP	O
to	to	T000	TO	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
by	by	B000	IN	B-PP	O
compromising	compromise	C516	VBG	B-VP	O
the	the	T000	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
presumptive	presumptive	P625	JJ	B-NP	O
function	function	F523	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
properties	property	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
polypeptides	polypeptide	P413	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	I-VP	O
understood	understand	U536	VBN	I-VP	O
,	,	0000	,	O	O
their	their	T600	PRP$	B-NP	O
expression	expression	E216	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
and	and	A530	CC	O	O
subcellular	subcellular	S124	JJ	B-NP	O
localization	localization	L242	NN	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
cycle	cycle	C240	NN	I-NP	O
regulation	regulation	R243	NN	I-NP	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
resting	rest	R235	VBG	B-NP	O
cells	cell	C420	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
induced	induce	I532	VBN	I-VP	O
to	to	T000	TO	I-VP	O
proliferate	proliferate	P641	VB	I-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
steady	steady	S300	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
state	state	S300	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
late	late	L300	JJ	B-NP	O
G1	G1	G000	NN	I-NP	O
and	and	A530	CC	O	O
reach	reach	R200	VB	B-VP	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
during	during	D652	IN	B-PP	O
S	S	S000	NN	B-NP	O
phase	phase	P200	NN	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
S	S	S000	NN	B-NP	O
phase	phase	P200	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
polypeptides	polypeptide	P413	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
hyperphosphorylated	hyperphosphorylate	H161	VBN	I-VP	O
and	and	A530	CC	O	O
accumulate	accumulate	A254	VBP	B-VP	O
into	into	I530	IN	B-PP	O
discrete	discrete	D263	JJ	B-NP	O
subnuclear	subnuclear	S152	JJ	I-NP	O
foci	focus	F200	NNS	I-NP	O
termed	term	T653	VBN	B-VP	O
"	"	0000	``	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
dots	dot	D320	NNS	I-NP	O
.	.	0000	.	O	O

"	"	0000	``	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
associates	associate	A232	VBZ	B-VP	O
in	in	I500	FW	B-ADVP	O
vivo	vivo	V100	FW	I-ADVP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
structurally	structurally	S362	RB	I-NP	O
related	relate	R430	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
termed	term	T653	VBN	I-NP	O
BARD1	BARD1	B630	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
steady	steady	S300	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
state	state	S300	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
BARD1	BARD1	B630	NN	B-NP	O
,	,	0000	,	O	O
unlike	unlike	U542	IN	B-PP	O
those	those	T200	DT	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
remain	remain	R500	VBP	B-VP	O
relatively	relatively	R431	RB	B-ADJP	O
constant	constant	C523	JJ	I-ADJP	O
during	during	D652	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
cycle	cycle	C240	NN	I-NP	O
progression	progression	P626	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
immunostaining	immunostaining	I523	NN	B-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
BARD1	BARD1	B630	NN	B-NP	O
resides	reside	R232	VBZ	B-VP	O
within	within	W350	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
dots	dot	D320	NNS	I-NP	O
during	during	D652	IN	B-PP	O
S	S	S000	NN	B-NP	O
phase	phase	P200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
cycle	cycle	C240	NN	I-NP	O
,	,	0000	,	B-PP	O
but	but	B300	CC	I-PP	O
not	not	N300	RB	B-PP	O
during	during	D652	IN	I-PP	O
the	the	T000	DT	B-NP	O
G1	G1	G000	NN	I-NP	O
phase	phase	P200	NN	I-NP	O
.	.	0000	.	O	O

Nevertheless	Nevertheless	N163	RB	B-ADVP	O
,	,	0000	,	O	O
BARD1	BARD1	B630	NN	B-NP	O
polypeptides	polypeptide	P413	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
exclusively	exclusively	E242	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
fractions	fraction	F623	NNS	I-NP	O
of	of	O100	IN	B-PP	O
both	both	B300	CC	O	O
G1	G1	G000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
and	and	A530	CC	I-NP	O
S	S	S000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
phase	phase	P200	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Therefore	Therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
progression	progression	P626	NN	B-NP	O
to	to	T000	TO	B-PP	O
S	S	S000	NN	B-NP	O
phase	phase	P200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
accompanied	accompany	A251	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
aggregation	aggregation	A262	NN	I-NP	O
of	of	O100	IN	B-PP	O
nuclear	nuclear	N246	JJ	B-NP	O
BARD1	BARD1	B630	NN	I-NP	O
polypeptides	polypeptide	P413	NNS	I-NP	O
into	into	I530	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
dots	dot	D320	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
cycle	cycle	C240	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
colocalization	colocalization	C424	NN	I-NP	O
of	of	O100	IN	B-PP	O
BARD1	BARD1	B630	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
BARD1	BARD1	B630	NN	B-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
mediated	mediate	M300	VBN	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppression	suppression	S162	NN	I-NP	O
.	.	0000	.	O	O

Ethnic	Ethnic	E352	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HFE	HFE	H100	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
282	282	0000	CD	I-NP	O
(	(	0000	(	O	O
Cys	Cys	C200	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Tyr	Tyr	T600	NN	I-NP	O
)	)	0000	)	O	O
polymorphism	polymorphism	P456	NN	B-NP	O
.	.	0000	.	O	O

Recent	Recent	R253	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
(	(	0000	(	O	O
HH	HH	H000	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
homozygosity	homozygosity	H523	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
Cys282Tyr	Cys282Tyr	C236	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HFE	HFE	H100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
located	located	L230	JJ	B-NP	O
4	4	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
Mb	Mb	M100	NN	I-NP	O
telomeric	telomeric	T456	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
.	.	0000	.	O	O

Population	Population	P143	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
are	be	A600	VBP	B-VP	O
facilitated	facilitate	F243	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
fact	fact	F230	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
Cys282Tyr	Cys282Tyr	C236	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
creates	create	C632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
Rsal	Rsal	R240	JJ	I-NP	O
restriction	restriction	R236	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
the	the	T000	DT	B-NP	O
codon	codon	C350	NN	I-NP	O
282	282	0000	CD	I-NP	O
(	(	0000	(	O	O
Cys	Cys	C200	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Tyr	Tyr	T600	NN	I-NP	O
)	)	0000	)	O	O
polymorphism	polymorphism	P456	NN	B-NP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
agreement	agreement	A265	NN	I-PP	O
with	with	W300	IN	I-PP	O
previous	previous	P612	JJ	B-NP	O
observations	observation	O126	NNS	I-NP	O
the	the	T000	DT	B-NP	O
Tyr	Tyr	T600	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
rare	rare	R600	JJ	B-ADJP	O
or	or	O600	CC	I-ADJP	O
absent	absent	A125	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
Asiatic	Asiatic	A232	JJ	O	O
(	(	0000	(	O	O
Indian	Indian	I535	JJ	B-ADJP	O
,	,	0000	,	O	O
Chinese	Chinese	C520	JJ	B-ADJP	O
)	)	0000	)	O	O
populations	population	P143	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
highest	high	H230	JJS	I-NP	O
allele	allele	A400	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
(	(	0000	(	O	O
7	7	0000	CD	B-NP	O
.	.	0000	.	O	O
5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Swedes	Swedes	S320	NNP	B-NP	O
.	.	0000	.	O	O

Saamis	Saamis	S520	NNP	B-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Mordvinians	Mordvinian	M631	NNPS	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
significantly	significantly	S251	RB	B-NP	O
lower	low	L600	JJR	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Tyr	Tyr	T600	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Comparisons	Comparison	C516	NNS	B-NP	O
with	with	W300	IN	B-PP	O
allele	allele	A400	NN	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
based	base	B230	VBN	B-VP	O
on	on	O500	IN	B-PP	O
prevalence	prevalence	P614	NN	B-NP	O
estimates	estimate	E235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
HH	HH	H000	NN	B-NP	B-Disease
showed	show	S300	VBD	B-VP	O
some	some	S500	DT	B-NP	O
disagreements	disagreement	D265	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
RFLP	RFLP	R141	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
,	,	0000	,	O	O
particularly	particularly	P632	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
Finns	Finn	F520	NNS	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
newly	newly	N400	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
HFE	HFE	H100	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
approach	approach	A162	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
screening	screening	S265	NN	I-NP	O
of	of	O100	IN	B-PP	O
HH	HH	H000	NN	B-NP	B-Disease
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
studies	study	S320	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
HFE	HFE	H100	NN	I-NP	O
Tyr	Tyr	T600	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	O	O
different	different	D165	JJ	B-NP	O
disorders	disorder	D263	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease

Autosomal	Autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
neurohypophyseal	neurohypophyseal	N612	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
Gly23	Gly23	G400	NN	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	B-VP	O
Val	Val	V400	NN	B-NP	O
in	in	I500	IN	B-PP	O
neurophysin	neurophysin	N612	NN	B-NP	O
II	II	I000	CD	I-NP	O
.	.	0000	.	O	O

Autosomal	Autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
neurohypophyseal	neurohypophyseal	N612	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
(	(	0000	(	O	O
ADNDI	ADNDI	A353	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
progressive	progressive	P626	JJ	B-NP	O
degeneration	degeneration	D256	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
magnocellular	magnocellular	M252	JJ	I-NP	O
neurons	neuron	N652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypothalamus	hypothalamus	H134	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
decreased	decrease	D262	VBN	B-NP	O
ability	ability	A143	NN	I-NP	O
to	to	T000	TO	B-VP	O
produce	produce	P632	VB	I-VP	O
the	the	T000	DT	B-NP	O
hormone	hormone	H650	NN	I-NP	O
arginine	arginine	A625	NN	I-NP	O
vasopressin	vasopressin	V216	NN	I-NP	O
(	(	0000	(	O	O
AVP	AVP	A100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Affected	Affected	A123	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
symptomatic	symptomatic	S513	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
usually	usually	U240	RB	B-VP	O
develop	develop	D141	VBP	I-VP	O
diabetes	diabetes	D132	NN	B-NP	B-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
6	6	0000	CD	I-NP	O
yr	yr	Y600	NN	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
AVP	AVP	A100	NN	I-NP	O
-	-	0000	HYPH	O	O
neurophysin	neurophysin	N612	NN	B-NP	O
II	II	I000	CD	I-NP	O
(	(	0000	(	O	O
NPII	NPII	N100	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
mutations	mutation	M352	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
cause	cause	C200	VBP	B-VP	O
ADNDI	ADNDI	A353	NNP	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
signal	signal	S254	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
prepro	prepro	P616	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
AVP	AVP	A100	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
NPII	NPII	N100	NN	I-NP	O
precursor	precursor	P626	NN	I-NP	O
and	and	A530	CC	B-PP	O
within	within	W350	IN	B-PP	O
NPII	NPII	N100	NN	B-NP	O
itself	itself	I324	PRP	B-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
girl	girl	G640	NN	I-NP	O
who	who	W000	WP	B-NP	O
presented	present	P625	VBD	B-VP	O
at	at	A300	IN	B-PP	O
9	9	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
and	and	A530	CC	O	O
her	her	H600	PRP	B-NP	O
similarly	similarly	S546	RB	B-VP	O
affected	affect	A123	VBD	I-VP	O
younger	young	Y526	JJR	B-NP	O
brother	brother	B636	NN	I-NP	O
and	and	A530	CC	I-NP	O
father	father	F360	NN	I-NP	O
were	be	W600	VBD	B-VP	O
all	all	A400	DT	O	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
G1758	G1758	G000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
T	T	T000	NN	B-NP	O
)	)	0000	)	O	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
Gly23	Gly23	G400	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Val	Val	V400	NN	I-NP	O
within	within	W350	IN	B-PP	O
NPII	NPII	N100	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
restriction	restriction	R236	NN	B-NP	O
endonuclease	endonuclease	E535	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
T1	T1	T000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
weighted	weight	W230	VBN	I-VP	O
magnetic	magnetic	M253	JJ	B-NP	O
resonance	resonance	R252	NN	I-NP	O
imaging	imaging	I525	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
fathers	father	F362	NNS	I-NP	O
pituitary	pituitary	P360	JJ	B-NP	O
gland	gland	G453	NN	I-NP	O
demonstrates	demonstrate	D523	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
attenuated	attenuate	A353	VBN	I-NP	O
posterior	posterior	P236	JJ	I-NP	O
pituitary	pituitary	P360	JJ	I-NP	O
bright	bright	B623	JJ	I-NP	O
spot	spot	S130	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
valuable	valuable	V414	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
developing	develop	D141	VBG	B-VP	O
models	model	M342	NNS	B-NP	O
of	of	O100	IN	B-PP	O
dominantly	dominantly	D534	RB	B-NP	B-Disease
inherited	inherit	I563	VBN	I-NP	I-Disease
neurodegeneration	neurodegeneration	N632	NN	I-NP	I-Disease
,	,	0000	,	O	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
early	early	E640	JJ	I-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
symptoms	symptom	S513	NNS	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
particularly	particularly	P632	RB	B-ADJP	O
deleterious	deleterious	D436	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
magnocellular	magnocellular	M252	JJ	I-NP	O
neuron	neuron	N650	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Frequent	Frequent	F625	JJ	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
PTEN	PTEN	P350	NN	B-NP	O
/	/	0000	SYM	B-VP	O
MMAC1	MMAC1	M520	NN	B-NP	O
in	in	I500	IN	B-PP	O
primary	primary	P656	JJ	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Sporadic	Sporadic	S163	JJ	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
male	male	M400	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Western	Western	W236	JJ	I-NP	O
world	world	W643	NN	I-NP	O
,	,	0000	,	O	O
yet	yet	Y300	RB	O	O
many	many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
progression	progression	P626	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
often	often	O135	RB	I-NP	O
fatal	fatal	F340	JJ	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
remain	remain	R500	VBP	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
elucidated	elucidate	E423	VBN	I-VP	O
.	.	0000	.	O	O

Numerous	Numerous	N562	JJ	B-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
and	and	A530	CC	I-NP	O
allelotype	allelotype	A431	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
reported	report	R163	VBN	I-VP	O
frequent	frequent	F625	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
on	on	O500	IN	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
arm	arm	A650	NN	I-NP	O
10q	10q	Q000	NN	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Deletion	Deletion	D435	NN	B-NP	O
mapping	mapping	M152	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
unambiguously	unambiguously	U512	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
10q23	10q23	Q000	CD	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
the	the	T000	DT	B-NP	O
minimal	minimal	M540	JJ	I-NP	O
area	area	A600	NN	I-NP	O
of	of	O100	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
PTEN	PTEN	P350	NN	B-NP	O
/	/	0000	SYM	B-NP	O
MMAC1	MMAC1	M520	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
isolated	isolate	I243	VBN	I-VP	O
recently	recently	R253	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
10q23	10q23	Q000	CD	I-NP	O
and	and	A530	CC	O	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
inactivated	inactivate	I523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
screened	screen	S265	VBD	B-VP	O
80	80	0000	CD	B-NP	O
prostate	prostate	P623	NN	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
by	by	B000	IN	B-PP	O
microsatellite	microsatellite	M262	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
found	find	F530	VBN	B-VP	O
chromosome	chromosome	C652	NN	B-NP	O
10q23	10q23	Q000	CD	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
deleted	delete	D430	VBN	I-VP	O
in	in	I500	IN	B-PP	O
23	23	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
then	then	T500	RB	B-ADVP	O
proceeded	proceed	P623	VBD	B-VP	O
with	with	W300	IN	B-PP	O
sequence	sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
PTEN	PTEN	P350	NN	I-NP	O
/	/	0000	SYM	B-NP	O
MMAC1	MMAC1	M520	NN	I-NP	O
coding	coding	C352	NN	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	O	O
tested	test	T230	VBN	B-VP	O
for	for	F600	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
deletion	deletion	D435	NN	I-NP	O
with	with	W300	IN	B-PP	O
new	new	N000	JJ	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
23	23	0000	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
with	with	W300	IN	B-PP	O
10q23	10q23	Q000	CD	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
heterozygosity	heterozygosity	H362	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
mutational	mutational	M354	JJ	I-NP	O
event	event	E153	NN	I-NP	O
in	in	I500	IN	B-PP	O
10	10	0000	CD	B-NP	O
(	(	0000	(	O	O
43	43	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
tumors	tumor	T562	NNS	B-NP	B-Disease
establishes	establish	E231	VBZ	B-VP	O
PTEN	PTEN	P350	NN	B-NP	O
/	/	0000	SYM	B-NP	O
MMAC1	MMAC1	M520	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
main	main	M500	JJ	I-NP	O
inactivation	inactivation	I523	NN	I-NP	O
target	target	T623	NN	I-NP	O
of	of	O100	IN	B-PP	O
10q	10q	Q000	NN	B-NP	O
loss	loss	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Risk	Risk	R200	NN	B-NP	O
reversals	reversal	R162	NNS	I-NP	O
in	in	I500	IN	B-PP	O
predictive	predictive	P632	JJ	B-NP	O
testing	testing	T235	NN	I-NP	O
for	for	F600	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
predictive	predictive	P632	JJ	I-NP	O
testing	testing	T235	NN	I-NP	O
for	for	F600	IN	B-PP	O
Huntington	Huntington	H535	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
HD	HD	H300	NN	B-NP	B-Disease
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
based	base	B230	VBN	I-VP	O
on	on	O500	IN	B-PP	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
linked	link	L523	VBN	B-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
to	to	T000	TO	B-VP	O
estimate	estimate	E235	VB	I-VP	O
the	the	T000	DT	B-NP	O
likelihood	likelihood	L243	NN	I-NP	O
of	of	O100	IN	B-PP	O
inheriting	inherit	I563	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
for	for	F600	IN	B-PP	O
HD	HD	H300	NN	B-NP	B-Disease
.	.	0000	.	O	O

Limits	Limit	L532	NNS	B-NP	O
to	to	T000	TO	B-PP	O
accuracy	accuracy	A262	NN	B-NP	O
included	include	I524	VBD	B-VP	O
recombination	recombination	R251	NN	B-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
markers	marker	M626	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
pedigree	pedigree	P326	NN	B-NP	O
structure	structure	S362	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
whether	whether	W360	IN	B-SBAR	O
DNA	DNA	D500	NN	B-NP	O
samples	sample	S514	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
available	available	A141	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
family	family	F540	NN	B-NP	O
members	member	M516	NNS	I-NP	O
.	.	0000	.	O	O

With	With	W300	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
tests	test	T232	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
HD	HD	H300	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
assessed	assess	A230	VBN	I-VP	O
the	the	T000	DT	B-NP	O
accuracy	accuracy	A262	NN	I-NP	O
of	of	O100	IN	B-PP	O
results	result	R243	NNS	B-NP	O
obtained	obtain	O135	VBN	B-VP	O
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
approaches	approach	A162	NNS	I-NP	O
when	when	W500	WRB	B-ADVP	O
requested	request	R230	VBN	B-VP	O
to	to	T000	TO	B-VP	O
do	do	D000	VB	I-VP	O
so	so	S000	RB	B-ADVP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
test	test	T230	NN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

For	For	F600	IN	B-PP	O
six	six	S200	CD	B-NP	O
such	such	S200	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
significant	significant	S251	JJ	B-NP	O
disparity	disparity	D216	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
tests	test	T232	NNS	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
went	go	W530	VBD	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
decreased	decrease	D262	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
another	another	A536	DT	B-NP	O
three	three	T600	CD	I-NP	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
.	.	0000	.	O	O

Knowledge	Knowledge	K543	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
reasons	reason	R252	NNS	I-NP	O
for	for	F600	IN	B-PP	O
these	these	T200	DT	B-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
results	result	R243	NNS	B-NP	O
and	and	A530	CC	I-NP	O
impact	impact	I512	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
reversals	reversal	R162	NNS	I-NP	O
on	on	O500	IN	B-PP	O
both	both	B300	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
counseling	counseling	C524	NN	I-NP	O
team	team	T500	NN	I-NP	O
can	can	C500	MD	B-VP	O
assist	assist	A230	VB	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
strategies	strategy	S363	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
prevention	prevention	P615	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
necessary	necessary	N260	JJ	B-ADJP	O
,	,	0000	,	O	O
management	management	M525	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
reversal	reversal	R162	NN	I-NP	O
in	in	I500	IN	B-PP	O
any	any	A500	DT	B-NP	O
predictive	predictive	P632	JJ	I-NP	O
testing	testing	T235	NN	I-NP	O
program	program	P626	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
common	common	C500	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
G301C	G301C	G200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
N	N	N000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
acetylgalactosamine	acetylgalactosamine	A234	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
sulfatase	sulfatase	S413	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
mucopolysaccharidosis	mucopolysaccharidosis	M214	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
.	.	0000	.	O	O

Mucopolysaccharidosis	Mucopolysaccharidosis	M214	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
(	(	0000	(	O	O
MPS	MPS	M120	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
lysosomal	lysosomal	L254	JJ	I-NP	I-Disease
storage	storage	S362	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
N	N	N000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
acetylgalactosamine	acetylgalactosamine	A234	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
sulfatase	sulfatase	S413	NN	I-NP	O
(	(	0000	(	O	O
GALNS	GALNS	G452	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
previous	previous	P612	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
two	two	T000	CD	B-NP	O
common	common	C500	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Caucasians	Caucasian	C252	NNPS	B-NP	O
and	and	A530	CC	I-NP	O
Japanese	Japanese	J152	NNPS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
characterize	characterize	C623	VB	I-VP	O
the	the	T000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
various	various	V620	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
groups	group	G612	NNS	I-NP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALNS	GALNS	G452	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
Colombian	Colombian	C451	JJ	B-NP	O
MPS	MPS	M120	NN	I-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
genetic	genetic	G532	JJ	B-NP	O
backgrounds	background	B265	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
extensively	extensively	E235	RB	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
to	to	T000	TO	I-VP	O
identify	identify	I353	VB	I-VP	O
racial	racial	R240	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
mitochondrial	mitochondrial	M325	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
(	(	0000	(	O	O
mtDNA	mtDNA	M350	NN	B-NP	O
)	)	0000	)	O	O
lineages	lineage	L520	NNS	B-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
never	never	N160	RB	B-VP	O
identified	identify	I353	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
and	and	A530	CC	O	O
found	find	F530	VBN	B-VP	O
in	in	I500	IN	B-PP	O
16	16	0000	CD	B-NP	O
out	out	O300	IN	B-PP	O
of	of	O100	IN	B-PP	O
19	19	0000	CD	B-NP	O
Colombian	Colombian	C451	JJ	I-NP	O
MPS	MPS	M120	NN	I-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
unrelated	unrelated	U564	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
84	84	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
G301C	G301C	G200	NN	I-NP	O
and	and	A530	CC	I-NP	O
S162F	S162F	S100	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
68	68	0000	CD	B-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	O	O
10	10	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
remaining	remain	R520	VBG	I-NP	O
F69V	F69V	F100	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
limited	limit	L530	VBN	I-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
skewed	skewed	S230	JJ	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
G301C	G301C	G200	NN	B-NP	O
in	in	I500	IN	B-PP	O
only	only	O540	JJ	B-NP	O
Colombian	Colombian	C451	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
haplotype	haplotype	H143	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
by	by	B000	IN	B-PP	O
restriction	restriction	R236	NN	B-NP	O
fragment	fragment	F625	NN	I-NP	O
length	length	L523	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALNS	GALNS	G452	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
G301C	G301C	G200	NN	B-NP	O
originated	originate	O625	VBN	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
ancestor	ancestor	A523	NN	I-NP	O
.	.	0000	.	O	O

Investigation	Investigation	I512	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
background	background	B265	NN	I-NP	O
by	by	B000	IN	B-PP	O
means	mean	M520	NNS	B-NP	O
of	of	O100	IN	B-PP	O
mtDNA	mtDNA	M350	NN	B-NP	O
lineages	lineage	L520	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
all	all	A400	PDT	B-NP	O
our	our	O600	PRP$	I-NP	O
patients	patient	P353	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
probably	probably	P614	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
native	native	N310	JJ	B-NP	O
American	American	A562	JJ	I-NP	O
descent	descent	D253	NN	I-NP	O

Low	Low	L000	JJ	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
45	45	0000	CD	B-NP	O
German	German	G650	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
we	we	W000	PRP	B-NP	O
investigated	investigate	I512	VBD	B-VP	O
45	45	0000	CD	B-NP	O
German	German	G650	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
for	for	F600	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
four	four	F600	CD	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O
among	among	A520	IN	B-PP	O
these	these	T200	DT	B-NP	O
were	be	W600	VBD	B-VP	O
one	one	O500	CD	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

8	8	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
disease	disease	D200	NN	B-NP	O
associated	associate	A230	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
average	average	A162	JJ	I-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
onset	onset	O523	NN	I-NP	O
in	in	I500	IN	B-PP	O
those	those	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
harbouring	harbour	H616	VBG	B-VP	O
causative	causative	C231	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
between	between	B350	IN	B-PP	O
32	32	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
37	37	0000	CD	I-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
harbouring	harbour	H616	VBG	B-VP	O
the	the	T000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
had	have	H300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
average	average	A162	JJ	I-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
51	51	0000	CD	B-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
suggesting	suggest	S235	VBG	B-VP	O
the	the	T000	DT	B-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
another	another	A536	DT	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O

Paternal	Paternal	P365	JJ	B-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
myotonic	myotonic	M352	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
paternally	paternally	P365	RB	B-NP	O
transmitted	transmit	T652	VBN	I-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
myotonic	myotonic	M352	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
23	23	0000	CD	I-NP	O
year	year	Y600	NN	I-NP	O
old	old	O430	JJ	B-ADJP	O
,	,	0000	,	O	O
mentally	mentally	M534	RB	B-NP	B-Disease
retarded	retarded	R363	JJ	I-NP	I-Disease
male	male	M400	NN	I-NP	O
who	who	W000	WP	B-NP	O
suffers	suffer	S162	VBZ	B-VP	O
severe	severe	S160	JJ	B-NP	O
muscular	muscular	M246	JJ	I-NP	B-Disease
weakness	weakness	W252	NN	I-NP	I-Disease
.	.	0000	.	O	O

He	He	H000	PRP	B-NP	O
presented	present	P625	VBD	B-VP	O
with	with	W300	IN	B-PP	O
respiratory	respiratory	R216	JJ	B-NP	O
and	and	A530	CC	I-NP	O
feeding	feeding	F352	NN	I-NP	O
difficulties	difficulty	D124	NNS	I-NP	O
at	at	A300	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
.	.	0000	.	O	O

His	His	H200	PRP$	B-NP	O
two	two	T000	CD	I-NP	O
sibs	sib	S120	NNS	I-NP	O
suffer	suffer	S160	VBP	B-VP	O
from	from	F650	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
onset	onset	O523	NN	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
.	.	0000	.	O	O

Their	Their	T600	PRP$	B-NP	O
late	late	L300	JJ	I-NP	O
father	father	F360	NN	I-NP	O
had	have	H300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
adult	adult	A343	JJ	I-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
around	around	A653	IN	B-PP	O
30	30	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

Only	Only	O540	RB	B-NP	O
six	six	S200	CD	I-NP	O
other	other	O360	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
paternal	paternal	P365	JJ	B-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
DM	DM	D500	NN	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
recently	recently	R253	RB	B-ADVP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
review	review	R100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
sex	sex	S200	NN	I-NP	O
related	relate	R430	VBN	B-VP	O
effects	effect	E123	NNS	B-NP	O
on	on	O500	IN	B-PP	O
transmission	transmission	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
DM	DM	D500	NN	I-NP	I-Disease
.	.	0000	.	O	O

Decreased	Decrease	D262	VBN	B-NP	O
fertility	fertility	F634	NN	I-NP	O
of	of	O100	IN	B-PP	O
males	male	M420	NNS	B-NP	O
with	with	W300	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
onset	onset	O523	NN	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
contraction	contraction	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
upon	upon	U150	IN	B-PP	O
male	male	M400	JJ	B-NP	O
transmission	transmission	T652	NN	I-NP	O
contribute	contribute	C536	VBP	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
almost	almost	A452	RB	I-NP	O
absent	absent	A125	JJ	I-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
paternal	paternal	P365	JJ	B-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
DM	DM	D500	NN	I-NP	I-Disease
.	.	0000	.	O	O

Also	Also	A420	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
fathers	father	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
reported	report	R163	VBN	I-NP	O
congenitally	congenitally	C525	RB	I-NP	O
affected	affect	A123	VBN	I-NP	O
children	child	C436	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
average	average	A162	NN	B-NP	O
,	,	0000	,	O	O
shorter	short	S636	JJR	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
lengths	length	L523	NNS	I-NP	O
and	and	A530	CC	O	O
hence	hence	H520	RB	B-NP	O
less	less	L200	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
than	than	T500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mothers	mother	M362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
children	child	C436	NNS	B-NP	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
DM	DM	D500	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
paternal	paternal	P365	JJ	B-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
DM	DM	D500	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
rare	rare	R600	JJ	B-ADJP	O
and	and	A530	CC	O	O
preferentially	preferentially	P616	RB	B-VP	O
occurs	occur	O262	VBZ	I-VP	O
with	with	W300	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
past	past	P230	JJ	B-NP	O
30	30	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
father	father	F360	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
ectopic	ectopic	E231	JJ	B-NP	B-Disease
intracranial	intracranial	I536	JJ	I-NP	I-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
child	child	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
ectopic	ectopic	E231	JJ	B-NP	B-Disease
intracranial	intracranial	I536	JJ	I-NP	I-Disease
retinoblastoma	retinoblastoma	R351	NN	I-NP	I-Disease
using	use	U252	VBG	B-VP	O
DNA	DNA	D500	NN	B-NP	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
pineal	pineal	P540	JJ	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
retinal	retinal	R354	JJ	I-NP	I-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
17	17	0000	CD	I-NP	O
(	(	0000	(	O	O
codon	codon	C350	NN	B-NP	O
556	556	0000	CD	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
present	present	P625	JJ	B-ADJP	O
homozygously	homozygously	H524	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
retinal	retinal	R354	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
the	the	T000	DT	B-NP	I-Disease
pineal	pineal	P540	JJ	I-NP	I-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
heterozygously	heterozygously	H362	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
constitutional	constitutional	C523	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
,	,	0000	,	O	O
proving	prove	P615	VBG	B-VP	O
it	it	I300	PRP	B-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
of	of	O100	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
initial	initial	I534	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
occurred	occur	O263	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
paternally	paternally	P365	RB	I-NP	O
derived	derive	D613	VBN	I-NP	O
RB1	RB1	R100	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
area	area	A600	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
-	-	0000	HYPH	B-PP	O
binding	bind	B535	VBG	B-NP	O
region	region	R250	NN	I-NP	O
known	know	K500	VBN	B-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
pocket	pocket	P230	NN	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
retinoblastoma	retinoblastoma	R351	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Low	Low	L000	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
beta	beta	B300	NN	B-NP	O
hexosaminidase	hexosaminidase	H253	NN	I-NP	O
A	A	A000	NN	I-NP	O
in	in	I500	IN	B-PP	O
healthy	healthy	H430	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
apparent	apparent	A165	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
.	.	0000	.	O	O

Appreciable	Appreciable	A162	JJ	B-NP	O
beta	beta	B300	NN	I-NP	O
hexosaminidase	hexosaminidase	H253	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
hex	hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
activity	activity	A231	NN	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
skin	skin	S250	NN	I-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
and	and	A530	CC	O	O
melanoma	melanoma	M450	NN	B-NP	B-Disease
tissue	tissue	T200	NN	I-NP	O
from	from	F650	IN	B-PP	O
healthy	healthy	H430	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
previously	previously	P612	RB	B-VP	O
reported	report	R163	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
hex	hex	H200	NN	B-NP	I-Disease
A	A	A000	NN	I-NP	I-Disease
activity	activity	A231	NN	I-NP	O
indistinguishable	indistinguishable	I532	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
and	and	A530	CC	I-NP	O
quantitation	quantitation	Q535	NN	I-NP	O
of	of	O100	IN	B-PP	O
hex	hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
amounting	amounte	A535	VBG	B-VP	O
to	to	T000	TO	B-PP	O
3	3	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

9	9	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
total	total	T340	JJ	B-NP	O
beta	beta	B300	SYM	I-NP	O
hexosaminidase	hexosaminidase	H253	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
obtained	obtain	O135	VBN	I-VP	O
by	by	B000	IN	B-PP	O
cellulose	cellulose	C420	NN	B-NP	O
acetate	acetate	A230	NN	I-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
,	,	0000	,	O	O
DEAE	DEAE	D000	NN	B-NP	O
-	-	0000	HYPH	O	O
cellulose	cellulose	C420	NN	B-NP	O
ion	ion	I500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
exchange	exchange	E252	NN	I-NP	O
chromatography	chromatography	C653	NN	I-NP	O
,	,	0000	,	O	O
radial	radial	R340	JJ	B-NP	O
immunodiffusion	immunodiffusion	I531	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
radioimmunoassay	radioimmunoassay	R352	NN	B-NP	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
family	family	F540	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
suggested	suggest	S230	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
compound	compound	C515	JJ	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
(	(	0000	(	O	O
allelic	allelic	A420	JJ	B-ADJP	O
)	)	0000	)	O	O
mutant	mutant	M353	JJ	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
postulated	postulate	P234	VBN	I-NP	O
rate	rate	R300	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
code	code	C300	VB	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
low	low	L000	JJ	B-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
hex	hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
.	.	0000	.	O	O

Heterozygotes	Heterozygote	H362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
mutant	mutant	M353	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
indistinguishable	indistinguishable	I532	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
heterozygotes	heterozygote	H362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
mutant	mutant	M353	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
direct	direct	D623	JJ	B-NP	O
visualization	visualization	V242	NN	I-NP	O
and	and	A530	CC	I-NP	O
quantitation	quantitation	Q535	NN	I-NP	O
of	of	O100	IN	B-PP	O
hex	hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
methods	method	M320	NNS	I-NP	O
described	describe	D261	VBN	B-VP	O
may	may	M000	MD	B-VP	O
prevent	prevent	P615	VB	I-VP	O
false	false	F420	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
positive	positive	P231	JJ	I-NP	O
prenatal	prenatal	P653	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
TSD	TSD	T230	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
fetuses	fetus	F320	NNS	B-NP	O
having	have	H152	VBG	B-VP	O
the	the	T000	DT	B-NP	O
incomplete	incomplete	I525	JJ	I-NP	O
hex	hex	H200	NN	I-NP	B-Disease
A	A	A000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
described	describe	D261	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
healthy	healthy	H430	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O

The	The	T000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
Smad4	Smad4	S530	NN	I-NP	O
/	/	0000	SYM	B-NP	O
Dpc4	Dpc4	D120	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
required	require	R263	VBN	I-VP	O
for	for	F600	IN	B-PP	O
gastrulation	gastrulation	G236	NN	B-NP	O
and	and	A530	CC	B-PP	O
later	later	L360	RB	B-ADVP	O
for	for	F600	IN	B-PP	O
anterior	anterior	A536	JJ	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
embryo	embryo	E516	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
SMAD4	SMAD4	S530	NN	I-NP	O
/	/	0000	SYM	B-NP	O
DPC4	DPC4	D120	NN	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
key	key	K000	JJ	I-NP	O
signal	signal	S254	NN	I-NP	O
transducer	transducer	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
TGFbeta	TGFbeta	T213	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
pathways	pathway	P320	NNS	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
pancreatic	pancreatic	P526	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Homozygous	Homozygous	H520	JJ	B-NP	O
Smad4	Smad4	S530	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
die	die	D000	VBP	B-VP	O
before	before	B160	IN	B-SBAR	O
day	day	D000	NN	B-NP	O
7	7	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
embryogenesis	embryogenesis	E516	NN	B-NP	O
.	.	0000	.	O	O

Mutant	Mutant	M353	JJ	B-NP	O
embryos	embryo	E516	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
reduced	reduce	R323	VBN	I-VP	O
size	size	S200	NN	B-NP	O
,	,	0000	,	O	O
fail	fail	F400	VBP	B-VP	O
to	to	T000	TO	I-VP	O
gastrulate	gastrulate	G236	VB	I-VP	O
or	or	O600	CC	I-VP	O
express	express	E216	VB	I-VP	O
a	a	A000	DT	B-NP	O
mesodermal	mesodermal	M236	JJ	I-NP	O
marker	marker	M626	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
show	show	S000	VBP	B-VP	O
abnormal	abnormal	A156	JJ	B-NP	O
visceral	visceral	V264	JJ	I-NP	O
endoderm	endoderm	E536	NN	I-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O

Growth	Growth	G630	NN	B-NP	B-Disease
retardation	retardation	R363	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Smad4	Smad4	S530	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
deficient	deficient	D125	JJ	I-NP	O
embryos	embryo	E516	NNS	I-NP	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
cell	cell	C400	NN	I-NP	O
proliferation	proliferation	P641	NN	I-NP	O
rather	rather	R360	RB	B-CONJP	O
than	than	T500	IN	I-CONJP	O
increased	increase	I526	VBN	B-NP	O
apoptosis	apoptosis	A132	NN	I-NP	O
.	.	0000	.	O	O

Aggregation	Aggregation	A262	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
Smad4	Smad4	S530	NN	I-NP	O
ES	ES	E200	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
with	with	W300	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
tetraploid	tetraploid	T361	JJ	I-NP	O
morulae	morula	M640	NNS	I-NP	O
rescues	rescue	R200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
gastrulation	gastrulation	G236	NN	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
Smad4	Smad4	S530	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
initially	initially	I534	RB	I-VP	O
required	require	R263	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
differentiation	differentiation	D165	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
visceral	visceral	V264	JJ	I-NP	O
endoderm	endoderm	E536	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
gastrulation	gastrulation	G236	NN	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
epiblast	epiblast	E142	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
secondary	secondary	S253	JJ	B-ADJP	O
and	and	A530	CC	O	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	O	O
cell	cell	C400	NN	B-NP	O
autonomous	autonomous	A352	JJ	B-ADJP	O
.	.	0000	.	O	O

Rescued	Rescue	R230	VBN	B-NP	O
embryos	embryo	E516	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
severe	severe	S160	JJ	B-NP	O
anterior	anterior	A536	JJ	I-NP	O
truncations	truncation	T652	NNS	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
important	important	I516	JJ	I-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
Smad4	Smad4	S530	NN	B-NP	O
in	in	I500	IN	B-PP	O
anterior	anterior	A536	JJ	B-NP	O
patterning	patterning	P365	NN	I-NP	O
during	during	D652	IN	B-PP	O
embryogenesis	embryogenesis	E516	NN	B-NP	O
.	.	0000	.	O	O

Prevalence	Prevalence	P614	NN	B-NP	O
of	of	O100	IN	B-PP	O
p16	p16	P000	NN	B-NP	O
and	and	A530	CC	I-NP	O
CDK4	CDK4	C320	NN	I-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
48	48	0000	CD	B-NP	O
melanoma	melanoma	M450	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
prone	prone	P650	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
France	France	F652	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
French	French	F652	NNP	I-NP	O
Familial	Familial	F540	NNP	I-NP	B-Disease
Melanoma	Melanoma	M450	NNP	I-NP	I-Disease
Study	Study	S300	NNP	I-NP	O
Group	Group	G610	NNP	I-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
p16	p16	P000	NN	I-NP	O
and	and	A530	CC	I-NP	O
CDK4	CDK4	C320	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
melanoma	melanoma	M450	NN	B-NP	B-Disease
pedigrees	pedigree	P326	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
their	their	T600	PRP$	B-NP	O
prevalence	prevalence	P614	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
well	well	W400	RB	I-VP	O
known	know	K500	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
searched	search	S623	VBD	B-VP	O
for	for	F600	IN	B-PP	O
such	such	S200	JJ	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
48	48	0000	CD	B-NP	O
French	French	F652	JJ	I-NP	O
melanoma	melanoma	M450	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	O
prone	prone	P650	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
selected	select	S423	VBN	B-VP	O
according	accord	A263	VBG	B-PP	O
to	to	T000	TO	B-PP	O
two	two	T000	CD	B-NP	O
major	major	M260	JJ	I-NP	O
criteria	criterion	C636	NNS	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
three	three	T600	CD	I-NP	O
affected	affect	A123	VBN	I-NP	O
members	member	M516	NNS	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
affected	affect	A123	VBN	I-NP	O
members	member	M516	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
affected	affect	A123	VBD	B-VP	O
before	before	B160	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
50	50	0000	CD	B-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
28	28	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
minor	minor	M560	JJ	I-NP	O
criterion	criterion	C636	NN	I-NP	O
.	.	0000	.	O	O

Sixteen	Sixteen	S235	CD	B-NP	O
different	different	D165	JJ	I-NP	O
p16	p16	P000	NN	I-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
21	21	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
one	one	O500	CD	B-NP	O
germline	germline	G654	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
Arg24His	Arg24His	A620	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CDK4	CDK4	C320	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
p16	p16	P000	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
sample	sample	S514	NN	I-NP	O
(	(	0000	(	O	O
44	44	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
highest	high	H230	JJS	I-NP	O
rates	rate	R320	NNS	I-NP	O
yet	yet	Y300	RB	B-VP	O
reported	report	R163	VBN	I-VP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
CDK4	CDK4	C320	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
detected	detect	D323	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
worldwide	worldwide	W643	RB	B-ADVP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
summary	summary	S560	NN	B-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
frequent	frequent	F625	JJ	B-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
p16	p16	P000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
melanoma	melanoma	M450	NN	I-NP	I-Disease
and	and	A530	CC	O	O
confirm	confirm	C516	VBP	B-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CDK4	CDK4	C320	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
melanoma	melanoma	M450	NN	I-NP	B-Disease
-	-	0000	HYPH	O	O
predisposing	predispose	P632	VBG	B-VP	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Progression	Progression	P626	NN	B-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
length	length	L523	NN	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
blood	blood	B430	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
34	34	0000	CD	I-NP	O
UTR	UTR	U360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
19	19	0000	CD	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
principal	principal	P652	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
extraordinarily	extraordinarily	E236	RB	I-NP	O
high	high	H200	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
,	,	0000	,	O	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
extremely	extremely	E236	RB	I-NP	O
high	high	H200	JJ	I-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
both	both	B300	CC	B-PP	O
within	within	W350	IN	B-PP	O
and	and	A530	CC	I-PP	O
between	between	B350	IN	I-PP	O
different	different	D165	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
instability	instability	I523	NN	I-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
biased	bias	B230	VBN	I-VP	O
towards	towards	T632	IN	B-PP	O
further	further	F636	JJ	B-NP	O
expansion	expansion	E215	NN	I-NP	O
and	and	A530	CC	O	O
continuous	continuous	C535	JJ	B-ADJP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
life	life	L100	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
,	,	0000	,	O	O
features	feature	F362	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
progressive	progressive	P626	JJ	I-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
increasing	increase	I526	VBG	B-VP	O
measured	measure	M263	VBN	B-NP	O
allele	allele	A400	NN	I-NP	O
size	size	S200	NN	I-NP	O
between	between	B350	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
clearly	clearly	C464	RB	B-ADVP	O
correlates	correlate	C643	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
severity	severity	S163	NN	I-NP	O
of	of	O100	IN	B-PP	O
symptoms	symptom	S513	NNS	B-NP	O
and	and	A530	CC	O	O
an	an	A500	DT	B-NP	O
earlier	early	E646	JJR	I-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
precise	precise	P620	JJ	B-NP	O
and	and	A530	CC	I-NP	O
measured	measure	M263	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
length	length	L523	NN	I-NP	O
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
used	use	U230	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
accurate	accurate	A263	JJ	I-NP	O
predictor	predictor	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
further	further	F636	RB	I-VP	O
characterize	characterize	C623	VB	I-VP	O
the	the	T000	DT	B-NP	O
dynamics	dynamic	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
repeat	repeat	R130	NN	B-NP	O
length	length	L523	NN	I-NP	O
changes	change	C520	VBZ	B-VP	O
over	over	O160	IN	B-PP	O
time	time	T500	NN	B-NP	O
in	in	I500	IN	B-PP	O
111	111	0000	CD	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
varying	vary	V652	VBG	B-VP	O
clinical	clinical	C452	JJ	B-NP	O
severity	severity	S163	NN	I-NP	O
and	and	A530	CC	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
size	size	S200	NN	I-NP	O
over	over	O160	IN	B-PP	O
time	time	T500	NN	B-NP	O
intervals	interval	I536	NNS	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
7	7	0000	CD	I-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
progression	progression	P626	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
size	size	S200	NN	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
over	over	O160	IN	B-PP	O
time	time	T500	NN	B-NP	O
related	relate	R430	VBN	B-VP	O
to	to	T000	TO	B-PP	O
initial	initial	I534	JJ	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
size	size	S200	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
time	time	T500	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
and	and	A530	CC	O	O
always	always	A420	RB	B-VP	O
biased	bias	B230	VBN	I-VP	O
towards	towards	T632	IN	B-PP	O
further	further	F636	JJ	B-NP	O
expansion	expansion	E215	NN	I-NP	O
.	.	0000	.	O	O

Attempts	Attempt	A351	NNS	B-NP	O
to	to	T000	TO	B-VP	O
mathematically	mathematically	M353	RB	I-VP	O
model	model	M340	VB	I-VP	O
the	the	T000	DT	B-NP	O
dynamics	dynamic	D520	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
proved	prove	P613	VBN	I-VP	O
only	only	O540	RB	B-ADJP	O
partially	partially	P634	RB	I-ADJP	O
successful	successful	S214	JJ	I-ADJP	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
individual	individual	I531	JJ	B-NP	O
specific	specific	S121	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
and	and	A530	CC	I-NP	O
/	/	0000	SYM	I-NP	O
or	or	O600	CC	O	O
environmental	environmental	E516	JJ	B-NP	O
factors	factor	F236	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
play	play	P400	VBP	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Aspartylglucosaminuria	Aspartylglucosaminuria	A216	NN	B-NP	B-Disease
among	among	A520	IN	B-PP	O
Palestinian	Palestinian	P423	JJ	B-NP	O
Arabs	Arab	A612	NNS	I-NP	O
.	.	0000	.	O	O

Aspartylglucosaminuria	Aspartylglucosaminuria	A216	NN	B-NP	B-Disease
(	(	0000	(	O	O
AGU	AGU	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
disorder	disorder	D263	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
glycoprotein	glycoprotein	G421	NN	B-NP	I-Disease
metabolism	metabolism	M314	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
lysosomal	lysosomal	L254	JJ	I-NP	I-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
aspartylglucosaminidase	aspartylglucosaminidase	A216	NN	I-NP	I-Disease
(	(	0000	(	O	O
AGA	AGA	A200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

AGU	AGU	A200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
inherited	inherit	I563	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
trait	trait	T630	NN	I-NP	O
and	and	A530	CC	O	O
occurs	occur	O262	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
Finland	Finland	F545	NNP	B-NP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
very	very	V600	RB	B-NP	O
few	few	F000	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
AGU	AGU	A200	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
from	from	F650	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Finnish	Finnish	F520	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
diagnosed	diagnose	D252	VBD	B-VP	O
the	the	T000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
in	in	I500	IN	B-PP	O
8	8	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
originating	originate	O625	VBG	B-VP	O
from	from	F650	IN	B-PP	O
3	3	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
Palestinian	Palestinian	P423	JJ	I-NP	O
Arabs	Arab	A612	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
Jerusalem	Jerusalem	J624	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
AGU	AGU	A200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
often	often	O135	RB	B-ADVP	O
difficult	difficult	D124	JJ	B-ADJP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
particular	particular	P632	JJ	B-NP	O
early	early	E640	JJ	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
course	course	C620	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
after	after	A136	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
5	5	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
since	since	S520	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
excrete	excrete	E263	VBP	B-VP	O
early	early	E640	JJ	B-NP	O
large	large	L620	JJ	I-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
aspartylglucosamine	aspartylglucosamine	A216	NN	B-NP	O
in	in	I500	IN	B-PP	O
urine	urine	U650	NN	B-NP	O
,	,	0000	,	O	O
biochemical	biochemical	B252	JJ	B-NP	O
screening	screening	S265	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
easy	easy	E200	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
urine	urine	U650	NN	B-NP	O
chromatography	chromatography	C653	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Detection	Detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
ATM	ATM	A350	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
by	by	B000	IN	B-PP	O
G2	G2	G000	NN	B-NP	O
phase	phase	P200	NN	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
radiosensitivity	radiosensitivity	R325	NN	I-NP	O
of	of	O100	IN	B-PP	O
peripheral	peripheral	P616	JJ	B-NP	O
blood	blood	B430	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
patients	patient	P353	NNS	B-NP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
ATM	ATM	A350	NN	B-NP	O
,	,	0000	,	O	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
embraces	embrace	E516	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
and	and	A530	CC	O	O
manifests	manifest	M512	VBZ	B-VP	O
extreme	extreme	E236	JJ	B-NP	O
radiosensitivity	radiosensitivity	R325	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
strong	strong	S365	JJ	I-NP	O
pre	pre	P600	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
disposition	disposition	D212	NN	I-NP	O
to	to	T000	TO	B-PP	O
malignancy	malignancy	M425	NN	B-NP	B-Disease
.	.	0000	.	O	O

Heterozygotes	Heterozygote	H362	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
no	no	N000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
but	but	B300	CC	O	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
cancer	cancer	C526	NN	B-NP	B-Disease
prone	prone	P650	NN	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
moderate	moderate	M363	JJ	I-NP	O
increase	increase	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
in	in	I500	FW	B-NP	O
vitro	vitro	V360	FW	I-NP	O
radiosensitivity	radiosensitivity	R325	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
a	a	A000	DT	B-NP	O
blind	blind	B453	JJ	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
on	on	O500	IN	B-PP	O
G2	G2	G000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phase	phase	P200	NN	I-NP	O
lymphocytes	lymphocyte	L512	NNS	I-NP	O
from	from	F650	IN	B-PP	O
7	7	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
13	13	0000	CD	B-NP	O
obligate	obligate	O142	NN	I-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
(	(	0000	(	O	O
parents	parent	P653	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
14	14	0000	CD	B-NP	O
normal	normal	N654	JJ	I-NP	O
controls	control	C536	NNS	I-NP	O
following	follow	F452	VBG	B-VP	O
X	X	X000	NN	B-NP	O
-	-	0000	HYPH	O	O
irradiation	irradiation	I635	NN	B-NP	O
with	with	W300	IN	B-PP	O
1	1	0000	CD	B-NP	O
Gy	Gy	G000	NN	I-NP	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
evaluate	evaluate	E143	VB	I-VP	O
this	this	T200	DT	B-NP	O
cytogenetic	cytogenetic	C325	JJ	I-NP	O
method	method	M300	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
tool	tool	T400	NN	I-NP	O
for	for	F600	IN	B-PP	O
detection	detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
homozygotes	homozygote	H523	NNS	I-NP	O
and	and	A530	CC	I-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
significantly	significantly	S251	RB	B-NP	O
increased	increase	I526	VBN	I-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
radiation	radiation	R350	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
induced	induce	I532	VBN	I-NP	O
chromatid	chromatid	C653	NN	I-NP	O
damage	damage	D520	NN	I-NP	O
relative	relative	R431	JJ	B-ADVP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
G2	G2	G000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phase	phase	P200	NN	I-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
radiosensitivity	radiosensitivity	R325	NN	I-NP	O
assay	assay	A200	NN	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
used	use	U230	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
combination	combination	C515	NN	B-NP	O
with	with	W300	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
test	test	T230	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
of	of	O100	IN	B-PP	O
value	value	V400	NN	B-NP	O
in	in	I500	IN	B-PP	O
studies	study	S320	NNS	B-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
sporadic	sporadic	S163	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
aimed	aim	A530	VBN	B-VP	O
at	at	A300	IN	B-PP	O
determination	determination	D365	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
potential	potential	P353	JJ	I-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
tumor	tumor	T560	NN	B-NP	B-Disease
risk	risk	R200	NN	I-NP	O
or	or	O600	CC	I-NP	O
development	development	D141	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Ataxia	Ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
:	:	0000	:	O	O
identification	identification	I353	NN	B-NP	O
and	and	A530	CC	I-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
founder	founder	F536	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
effect	effect	E123	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
ethnic	ethnic	E352	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
evaluation	evaluation	E143	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
diseases	disease	D200	NNS	I-NP	O
,	,	0000	,	O	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
attempted	attempt	A351	VBN	I-VP	O
to	to	T000	TO	I-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
in	in	I500	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
homozygotes	homozygote	H523	NNS	B-NP	O
from	from	F650	IN	B-PP	O
10	10	0000	CD	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
effects	effect	E123	NNS	I-NP	O
on	on	O500	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
were	be	W600	VBD	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
.	.	0000	.	O	O

Protein	Protein	P635	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
truncation	truncation	T652	NN	I-NP	O
testing	testing	T235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
ATM	ATM	A350	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
detected	detect	D323	VBN	B-VP	O
92	92	0000	CD	B-NP	O
(	(	0000	(	O	O
66	66	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
truncating	truncating	T652	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
140	140	0000	CD	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
screened	screen	S265	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
haplotyping	haplotyping	H143	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
identical	identical	I353	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
almost	almost	A452	RB	B-NP	O
all	all	A400	DT	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
represent	represent	R162	JJ	I-NP	O
common	common	C500	JJ	I-NP	O
ancestry	ancestry	A523	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
very	very	V600	RB	B-NP	O
few	few	F000	JJ	I-NP	O
spontaneously	spontaneously	S153	RB	B-VP	O
recurring	recur	R265	VBG	I-VP	O
ATM	ATM	A350	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
exist	exist	E230	VBP	B-VP	O
.	.	0000	.	O	O

Assays	Assay	A200	NNS	B-NP	O
requiring	require	R265	VBG	B-VP	O
minimal	minimal	M540	JJ	B-NP	O
amounts	amount	A532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
designed	design	D253	VBN	I-VP	O
to	to	T000	TO	B-VP	O
allow	allow	A400	VB	I-VP	O
rapid	rapid	R130	JJ	B-NP	O
screening	screening	S265	NN	I-NP	O
for	for	F600	IN	B-PP	O
common	common	C500	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
rapid	rapid	R130	JJ	I-NP	O
assays	assay	A200	NNS	I-NP	O
detected	detect	D323	VBD	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
76	76	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
Costa	Costa	C230	JJ	B-NP	O
Rican	Rican	R250	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
50	50	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
Norwegian	Norwegian	N625	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
25	25	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
Polish	Polish	P420	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
14	14	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
Italian	Italian	I345	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Amish	Amish	A520	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Mennonite	Mennonite	M530	NN	I-NP	O
and	and	A530	CC	O	O
Irish	Irish	I620	JJ	B-NP	O
English	English	E524	JJ	I-NP	O
backgrounds	background	B265	NNS	I-NP	O
.	.	0000	.	O	O

Additional	Additional	A354	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	NNP	B-NP	O
,	,	0000	,	O	O
Utah	Utah	U300	NNP	B-NP	O
Mormon	Mormon	M650	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
African	African	A162	JJ	B-NP	O
American	American	A562	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
assays	assay	A200	NNS	I-NP	O
should	should	S430	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
screening	screening	S265	NN	B-NP	O
for	for	F600	IN	B-PP	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
heterozygotes	heterozygote	H362	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
populations	population	P143	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
von	von	V500	NNP	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
required	require	R263	VBN	I-VP	O
for	for	F600	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
cycle	cycle	C240	NN	I-NP	O
exit	exit	E230	NN	I-NP	O
upon	upon	U150	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
withdrawal	withdrawal	W364	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
inactivation	inactivation	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
von	von	V500	NNP	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
(	(	0000	(	O	I-Disease
VHL	VHL	V400	NNP	O	I-Disease
)	)	0000	)	O	I-Disease
tumor	tumor	T560	NN	B-NP	I-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
predisposes	predispose	P632	VBZ	B-VP	O
affected	affect	A123	VBN	I-VP	O
individuals	individual	I531	NNS	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
(	(	0000	(	O	O
RCC	RCC	R200	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
brain	brain	B650	NN	B-NP	B-Disease
hemangioblastomas	hemangioblastoma	H521	NNS	I-NP	I-Disease
.	.	0000	.	O	O

VHL	VHL	V400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
negative	negative	N231	JJ	I-NP	O
786	786	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
0	0	0000	CD	I-NP	O
RCC	RCC	R200	NN	I-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
tumorigenic	tumorigenic	T562	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
nude	nude	N300	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
suppressed	suppress	S162	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
reintroduction	reintroduction	R536	NN	I-NP	O
of	of	O100	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
.	.	0000	.	O	O

Remarkably	Remarkably	R562	RB	B-ADVP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
occurs	occur	O262	VBZ	B-VP	O
without	without	W300	IN	B-PP	O
affecting	affect	A123	VBG	B-VP	O
the	the	T000	DT	B-NP	O
growth	growth	G630	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
and	and	A530	CC	O	O
cell	cell	C400	NN	B-NP	O
cycle	cycle	C240	NN	I-NP	O
profile	profile	P614	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
culture	culture	C436	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
786	786	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
0	0	0000	CD	I-NP	O
cell	cell	C400	NN	I-NP	O
line	line	L500	NN	I-NP	O
,	,	0000	,	O	O
like	like	L200	IN	B-PP	O
many	many	M500	JJ	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
fails	fail	F420	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
exit	exit	E230	VB	I-VP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
cycle	cycle	C240	NN	I-NP	O
upon	upon	U150	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
withdrawal	withdrawal	W364	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
reintroduction	reintroduction	R536	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
restores	restore	R236	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
negative	negative	N231	JJ	I-NP	O
RCC	RCC	R200	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cells	cell	C420	NNS	I-NP	O
to	to	T000	TO	B-VP	O
exit	exit	E230	VB	I-VP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
cycle	cycle	C240	NN	I-NP	O
and	and	A530	CC	O	O
enter	enter	E536	NN	B-NP	O
G0	G0	G000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
quiescence	quiescence	Q252	NN	I-NP	O
in	in	I500	IN	B-PP	O
low	low	L000	JJ	B-NP	O
serum	serum	S650	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
VHL	VHL	V400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
positive	positive	P231	JJ	I-NP	O
and	and	A530	CC	I-NP	O
VHL	VHL	V400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
negative	negative	N231	JJ	I-NP	O
RCC	RCC	R200	NN	I-NP	B-Disease
cells	cell	C420	NNS	I-NP	O
exit	exit	E230	VBP	B-VP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
cycle	cycle	C240	NN	I-NP	O
by	by	B000	IN	B-PP	O
contact	contact	C532	NN	B-NP	O
inhibition	inhibition	I513	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cyclin	cyclin	C245	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
kinase	kinase	K520	NN	I-NP	O
inhibitor	inhibitor	I513	NN	I-NP	O
,	,	0000	,	O	O
p27	p27	P000	NN	B-NP	O
,	,	0000	,	O	O
accumulates	accumulate	A254	VBZ	B-VP	O
upon	upon	U150	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
withdrawal	withdrawal	W364	NN	I-NP	O
,	,	0000	,	O	O
only	only	O540	RB	B-PP	O
in	in	I500	IN	I-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
VHL	VHL	V400	NN	B-NP	B-Disease
,	,	0000	,	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
stabilization	stabilization	S314	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
cellular	cellular	C460	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
growth	growth	G630	NN	I-NP	O
control	control	C536	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
may	may	M000	MD	B-VP	O
initiate	initiate	I530	VB	I-VP	O
tumor	tumor	T560	NN	B-NP	B-Disease
formation	formation	F653	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
corrected	correct	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
reintroduction	reintroduction	R536	NN	I-NP	O
of	of	O100	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
,	,	0000	,	O	O
implicating	implicate	I514	VBG	B-VP	O
VHL	VHL	V400	NN	B-NP	B-Disease
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
cycle	cycle	C240	NN	I-NP	O
exit	exit	E230	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
gatekeeper	gatekeeper	G321	NN	I-NP	O
function	function	F523	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
kidney	kidney	K350	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Piebaldism	Piebaldism	P143	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
deafness	deafness	D152	NN	B-NP	B-Disease
:	:	0000	:	O	O
molecular	molecular	M424	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
syndrome	syndrome	S536	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
South	South	S300	JJ	I-NP	O
African	African	A162	JJ	I-NP	O
girl	girl	G640	NN	I-NP	O
of	of	O100	IN	B-PP	O
Xhosa	Xhosa	X200	NNP	B-NP	O
stock	stock	S320	NN	I-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
piebaldism	piebaldism	P143	NN	I-NP	B-Disease
and	and	A530	CC	O	O
profound	profound	P615	JJ	B-NP	O
congenital	congenital	C525	JJ	I-NP	O
sensorineural	sensorineural	S526	JJ	I-NP	B-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
conserved	conserve	C526	VBN	I-NP	O
residue	residue	R230	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
intracellular	intracellular	I536	JJ	I-NP	O
kinase	kinase	K520	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
KIT	KIT	K300	NN	I-NP	O
proto	proto	P630	AFX	O	O
-	-	0000	HYPH	O	O
oncogene	oncogene	O525	NN	B-NP	O
,	,	0000	,	O	O
R796G	R796G	R200	NN	B-NP	O
.	.	0000	.	O	O

Though	Though	T200	IN	B-SBAR	O
auditory	auditory	A360	JJ	B-NP	B-Disease
anomalies	anomaly	A542	NNS	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
dominant	dominant	D530	JJ	B-NP	O
white	white	W300	JJ	I-NP	O
spotting	spotting	S135	NN	I-NP	O
(	(	0000	(	O	O
W	W	W000	NN	B-NP	O
)	)	0000	)	O	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
KIT	KIT	K300	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
deafness	deafness	D152	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
typical	typical	T124	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
piebaldism	piebaldism	P143	NN	I-NP	B-Disease
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
sensorineural	sensorineural	S526	JJ	B-NP	B-Disease
deafness	deafness	D152	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
extends	extend	E235	VBZ	B-VP	O
considerably	considerably	C523	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
piebaldism	piebaldism	P143	NN	B-NP	B-Disease
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
KIT	KIT	K300	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
and	and	A530	CC	O	O
tightens	tighten	T235	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
similarity	similarity	S546	NN	I-NP	O
between	between	B350	IN	B-PP	O
piebaldism	piebaldism	P143	NN	B-NP	B-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
various	various	V620	JJ	I-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Waardenburg	Waardenburg	W635	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Cycloheximide	Cycloheximide	C242	NN	B-NP	O
facilitates	facilitate	F243	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
aberrant	aberrant	A165	JJ	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
COL17A1	COL17A1	C400	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
generalized	generalize	G564	VBN	B-NP	O
atrophic	atrophic	A361	JJ	I-NP	B-Disease
benign	benign	B525	JJ	I-NP	I-Disease
epidermolysis	epidermolysis	E136	NN	I-NP	I-Disease
bullosa	bullosa	B420	NN	I-NP	I-Disease
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
generalized	generalize	G564	VBN	B-NP	O
atrophic	atrophic	A361	JJ	I-NP	B-Disease
benign	benign	B525	JJ	I-NP	I-Disease
epidermolysis	epidermolysis	E136	NN	I-NP	I-Disease
bullosa	bullosa	B420	NN	I-NP	I-Disease
often	often	O135	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
decreased	decrease	D262	VBN	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
type	type	T100	NN	B-NP	O
XVII	XVII	X100	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
transmembrane	transmembrane	T652	NN	I-NP	O
hemidesmosomal	hemidesmosomal	H532	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
COL17A1	COL17A1	C400	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
documents	document	D253	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
COL17A1	COL17A1	C400	NN	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
generalized	generalize	G564	VBN	B-NP	O
atrophic	atrophic	A361	JJ	I-NP	B-Disease
benign	benign	B525	JJ	I-NP	I-Disease
epidermolysis	epidermolysis	E136	NN	I-NP	I-Disease
bullosa	bullosa	B420	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
applies	apply	A142	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
methodology	methodology	M342	NN	I-NP	O
to	to	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
and	and	A530	CC	I-VP	O
characterize	characterize	C623	VB	I-VP	O
the	the	T000	DT	B-NP	O
resulting	result	R243	VBG	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

Mutational	Mutational	M354	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
COL17A1	COL17A1	C400	NN	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
maternally	maternally	M365	RB	I-NP	O
inherited	inherit	I563	VBN	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	HYPH	B-ADVP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
transversion	transversion	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
-	-	0000	HYPH	I-NP	O
1	1	0000	CD	I-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
32	32	0000	CD	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
acceptor	acceptor	A213	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
formation	formation	F653	NN	I-NP	O
of	of	O100	IN	B-PP	O
aberrant	aberrant	A165	JJ	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
present	present	P625	VBP	B-VP	O
at	at	A300	IN	B-PP	O
extremely	extremely	E236	RB	B-NP	O
low	low	L000	JJ	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

Based	Base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
recent	recent	R253	JJ	I-NP	O
finding	finding	F535	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
cycloheximide	cycloheximide	C242	NN	B-NP	O
stabilized	stabilize	S314	VBD	B-VP	O
mutant	mutant	M353	JJ	B-NP	O
COL17A1	COL17A1	C400	NN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
in	in	I500	IN	B-PP	O
keratinocytes	keratinocyte	K635	NNS	B-NP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
effects	effect	E123	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
on	on	O500	IN	B-PP	O
splicing	splicing	S142	NN	B-NP	O
of	of	O100	IN	B-PP	O
COL17A1	COL17A1	C400	NN	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
reverse	reverse	R162	JJ	B-NP	O
transcriptase	transcriptase	T652	NN	I-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
of	of	O100	IN	B-PP	O
total	total	T340	JJ	B-NP	O
RNA	RNA	R500	NN	I-NP	O
from	from	F650	IN	B-PP	O
keratinocytes	keratinocyte	K635	NNS	B-NP	O
incubated	incubate	I521	VBN	B-VP	O
for	for	F600	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
h	h	H000	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
or	or	O600	CC	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
microg	microg	M262	NN	I-NP	O
cycloheximide	cycloheximide	C242	NN	I-NP	O
per	per	P600	IN	B-PP	O
ml	ml	M400	NN	B-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
this	this	T200	DT	B-NP	O
approach	approach	A162	NN	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
abnormally	abnormally	A156	RB	I-NP	O
spliced	splice	S142	VBN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
that	that	T300	WDT	B-NP	O
contains	contain	C535	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
extra	extra	E236	JJ	I-NP	O
264	264	0000	CD	I-NP	O
bases	base	B200	NNS	I-NP	O
upstream	upstream	U123	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
32	32	0000	CD	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
27	27	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
downstream	downstream	D523	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
cryptic	cryptic	C613	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
other	other	O360	JJ	I-NP	O
splice	splice	S142	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
one	one	O500	CD	B-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
skipping	skipping	S215	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
32	32	0000	CD	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
the	the	T000	DT	B-NP	O
usefulness	usefulness	U214	NN	I-NP	O
of	of	O100	IN	B-PP	O
cycloheximide	cycloheximide	C242	NN	B-NP	O
treatment	treatment	T635	NN	I-NP	O
in	in	I500	IN	B-PP	O
evaluating	evaluate	E143	VBG	B-VP	O
the	the	T000	DT	B-NP	O
abnormal	abnormal	A156	JJ	I-NP	O
processing	processing	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
mRNA	mRNA	M650	NN	B-NP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
splice	splice	S142	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
site	site	S300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
because	because	B200	IN	B-SBAR	O
(	(	0000	(	B-LST	O
i	i	I000	LS	I-LST	O
)	)	0000	)	O	O
aberrant	aberrant	A165	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
often	often	O135	RB	B-ADVP	O
generates	generate	G563	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
,	,	0000	,	O	O
(	(	0000	(	B-LST	O
ii	ii	I000	LS	I-LST	O
)	)	0000	)	O	O
transcripts	transcript	T652	NNS	B-NP	O
with	with	W300	IN	B-PP	O
premature	premature	P653	JJ	B-NP	O
termination	termination	T653	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
can	can	C500	MD	B-VP	O
occur	occur	O260	VB	I-VP	O
at	at	A300	IN	B-PP	O
low	low	L000	JJ	B-NP	O
or	or	O600	CC	I-NP	O
undetectable	undetectable	U532	JJ	I-NP	O
levels	level	L142	NNS	I-NP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
nonsense	nonsense	N525	NN	B-NP	O
-	-	0000	HYPH	O	O
mediated	mediate	M300	VBN	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
decay	decay	D200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
iii	iii	I000	LS	I-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
can	can	C500	MD	B-VP	O
be	be	B000	VB	I-VP	O
increased	increase	I526	VBN	I-VP	O
by	by	B000	IN	B-PP	O
cycloheximide	cycloheximide	C242	NN	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
COL17A1	COL17A1	C400	NN	B-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
Austrian	Austrian	A236	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
generalized	generalize	G564	VBN	B-NP	O
atrophic	atrophic	A361	JJ	I-NP	B-Disease
benign	benign	B525	JJ	I-NP	I-Disease
epidermolysis	epidermolysis	E136	NN	I-NP	I-Disease
bullosa	bullosa	B420	NN	I-NP	I-Disease
represents	represent	R162	VBZ	B-VP	O
propagation	propagation	P612	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
generalized	generalize	G564	VBN	B-NP	O
atrophic	atrophic	A361	JJ	I-NP	B-Disease
benign	benign	B525	JJ	I-NP	I-Disease
epidermolysis	epidermolysis	E136	NN	I-NP	I-Disease
bullosa	bullosa	B420	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
usually	usually	U240	RB	I-NP	O
nonlethal	nonlethal	N543	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
junctional	junctional	J523	JJ	B-NP	B-Disease
epidermolysis	epidermolysis	E136	NN	I-NP	I-Disease
bullosa	bullosa	B420	NN	I-NP	I-Disease
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
generalized	generalize	G564	VBN	I-VP	O
blistering	blistering	B423	NN	B-NP	B-Disease
,	,	0000	,	O	O
nail	nail	N400	NN	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
patchy	patchy	P320	NN	B-NP	B-Disease
alopecia	alopecia	A412	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
dental	dental	D534	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Skin	Skin	S250	NN	B-NP	B-Disease
fragility	fragility	F624	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
cases	case	C200	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
type	type	T100	NN	B-NP	O
XVII	XVII	X100	NN	I-NP	O
collagen	collagen	C425	NN	I-NP	O
(	(	0000	(	O	O
COL17A1	COL17A1	C400	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
reported	report	R163	VBD	B-VP	O
five	five	F100	CD	B-NP	O
Austrian	Austrian	A236	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
generalized	generalize	G564	VBN	B-NP	O
atrophic	atrophic	A361	JJ	I-NP	B-Disease
benign	benign	B525	JJ	I-NP	I-Disease
epidermolysis	epidermolysis	E136	NN	I-NP	I-Disease
bullosa	bullosa	B420	NN	I-NP	I-Disease
who	who	W000	WP	B-NP	O
share	share	S600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
COL17A1	COL17A1	C400	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Affected	Affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
4003delTC	4003delTC	D432	NN	B-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
those	those	T200	DT	B-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
others	other	O362	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
compound	compound	C515	NN	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
if	if	I100	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
4003delTC	4003delTC	D432	NN	B-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
signifies	signify	S251	VBZ	B-VP	O
propagation	propagation	P612	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
or	or	O600	CC	O	O
a	a	A000	DT	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
hot	hot	H300	JJ	I-NP	O
spot	spot	S130	NN	I-NP	O
,	,	0000	,	O	O
haplotypes	haplotype	H143	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
for	for	F600	IN	B-PP	O
polymorphisms	polymorphism	P456	NNS	B-NP	O
both	both	B300	CC	B-PP	O
within	within	W350	IN	B-PP	O
and	and	A530	CC	O	O
flanking	flank	F452	VBG	B-VP	O
COL17A1	COL17A1	C400	NN	B-NP	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
chosen	choose	C250	VBN	I-VP	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
informativeness	informativeness	I516	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
,	,	0000	,	O	O
not	not	N300	RB	O	O
previously	previously	P612	RB	B-VP	O
reported	report	R163	VBN	I-VP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
2988	2988	0000	CD	B-NP	O
A	A	A000	NN	I-NP	O
or	or	O600	CC	I-NP	O
C	C	C000	NN	I-NP	O
that	that	T300	WDT	B-NP	O
introduces	introduce	I536	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
restriction	restriction	R236	NN	I-NP	O
site	site	S300	NN	I-NP	O
for	for	F600	IN	B-PP	O
Eco0109	Eco0109	E200	NN	B-NP	O
I	I	I000	CD	I-NP	O
.	.	0000	.	O	O

All	All	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
4003delTC	4003delTC	D432	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
for	for	F600	IN	B-PP	O
these	these	T200	DT	B-NP	O
five	five	F100	CD	I-NP	O
polymorphic	polymorphic	P456	JJ	I-NP	O
markers	marker	M626	NNS	I-NP	O
.	.	0000	.	O	O

Fourteen	Fourteen	F635	CD	B-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
selected	select	S423	VBN	I-VP	O
based	base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
high	high	H200	JJ	I-NP	O
heterozygosity	heterozygosity	H362	NN	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
location	location	L235	NN	I-NP	O
within	within	W350	IN	B-PP	O
10q23	10q23	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q25	q25	Q000	NN	I-NP	O
near	near	N600	IN	B-PP	O
COL17A1	COL17A1	C400	NN	B-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
shared	share	S630	VBD	B-VP	O
microsatellite	microsatellite	M262	NN	B-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
covering	cover	C165	VBG	B-VP	O
at	at	A300	IN	B-PP	O
most	most	M230	JJS	B-NP	O
19	19	0000	CD	I-NP	O
cM	cM	C500	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
others	other	O362	NNS	I-NP	O
shared	share	S630	VBD	B-VP	O
smaller	small	S546	JJR	B-NP	O
regions	region	R252	NNS	I-NP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
cross	cross	C620	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
over	over	O160	IN	B-PP	O
events	event	E153	NNS	B-NP	O
during	during	D652	IN	B-PP	O
passage	passage	P200	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
through	through	T620	IN	B-PP	O
several	several	S164	JJ	B-NP	O
generations	generation	G563	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
4003delTC	4003delTC	D432	NN	B-NP	O
occurs	occur	O262	VBZ	B-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
haptoglobin	haptoglobin	H132	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
gene	gene	G500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
anhaptoglobinemia	anhaptoglobinemia	A513	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
an	an	A500	DT	B-NP	O
allelic	allelic	A420	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
haptoglobin	haptoglobin	H132	NN	I-NP	O
(	(	0000	(	O	O
Hp	Hp	H100	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
from	from	F650	IN	B-PP	O
an	an	A500	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
with	with	W300	IN	B-PP	O
anhaptoglobinemia	anhaptoglobinemia	A513	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Hp	Hp	H100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
cluster	cluster	C423	NN	I-NP	O
consists	consist	C523	VBZ	B-VP	O
of	of	O100	IN	B-PP	O
coding	cod	C352	VBG	B-VP	O
regions	region	R252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
and	and	A530	CC	O	O
beta	beta	B300	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
haptoglobin	haptoglobin	H132	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
Hp	Hp	H100	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
and	and	A530	CC	O	O
beta	beta	B300	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
haptoglobin	haptoglobin	H132	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
gene	gene	G500	NN	B-NP	O
(	(	0000	(	O	O
Hpr	Hpr	H160	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
tandem	tandem	T535	NN	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
side	side	S300	NN	I-NP	O
.	.	0000	.	O	O

Southern	Southern	S365	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
and	and	A530	CC	I-NP	O
PCR	PCR	P260	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
indicated	indicate	I532	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
with	with	W300	IN	B-PP	O
anhaptoglobinemia	anhaptoglobinemia	A513	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
was	be	W200	VBD	B-VP	O
included	include	I524	VBN	I-VP	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
promoter	promoter	P653	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
Hp	Hp	H100	NN	B-NP	O
to	to	T000	TO	B-PP	O
Hpr	Hpr	H160	NN	B-NP	O
alpha	alpha	A410	NN	I-NP	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-PP	O
to	to	T000	TO	I-PP	O
Hpr	Hpr	H160	NN	B-NP	O
beta	beta	B300	NN	I-NP	O
(	(	0000	(	O	O
Hpdel	Hpdel	H134	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
seven	seven	S150	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hypohaptoglobinemia	hypohaptoglobinemia	H132	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
of	of	O100	IN	B-PP	O
six	six	S200	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
seven	seven	S150	CD	I-NP	O
individuals	individual	I531	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
Hp2	Hp2	H100	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Hpdel	Hpdel	H134	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
and	and	A530	CC	I-NP	O
genotypes	genotype	G531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
three	three	T600	CD	I-NP	O
families	family	F542	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
father	father	F360	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
hypohaptoglobinemic	hypohaptoglobinemic	H132	JJ	B-ADJP	B-Disease
(	(	0000	(	O	O
Hp2	Hp2	H100	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Hp2	Hp2	H100	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Hpdel	Hpdel	H134	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
Hp2	Hp2	H100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
Hp1	Hp1	H100	NN	I-NP	O
/	/	0000	SYM	I-NP	O
Hp2	Hp2	H100	NN	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
children	child	C436	NNS	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
hypohaptoglobinemic	hypohaptoglobinemic	H132	JJ	B-ADJP	B-Disease
(	(	0000	(	O	O
Hp2	Hp2	H100	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Hp2	Hp2	H100	NN	B-NP	O
/	/	0000	SYM	O	O
Hpdel	Hpdel	H134	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
child	child	C430	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
Hp1	Hp1	H100	NN	B-NP	O
and	and	A530	CC	I-NP	O
Hp1	Hp1	H100	NN	I-NP	O
/	/	0000	SYM	B-NP	O
Hpdel	Hpdel	H134	NN	I-NP	O
,	,	0000	,	O	O
showing	show	S520	VBG	B-VP	O
an	an	A500	DT	B-NP	O
anomalous	anomalous	A542	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
Hp	Hp	H100	NN	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
child	child	C430	NN	I-NP	O
with	with	W300	IN	B-PP	O
Hp1	Hp1	H100	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Hp2	Hp2	H100	NN	I-NP	O
/	/	0000	SYM	B-VP	O
Hpdel	Hpdel	H134	NN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
extremely	extremely	E236	RB	I-NP	O
low	low	L000	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
Hp	Hp	H100	NN	B-NP	O
(	(	0000	(	O	O
mean	mean	M500	NN	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	O	O
SD	SD	S300	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
049	049	0000	CD	I-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
043	043	0000	CD	I-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
ml	ml	M400	NN	I-NP	O
;	;	0000	:	O	O
n	n	N000	NN	B-NP	O
=	=	0000	JJ	B-VP	O
6	6	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
level	level	L140	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
64	64	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	B-NP	O
-	-	0000	SYM	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
07	07	0000	CD	I-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
ml	ml	M400	NN	I-NP	O
)	)	0000	)	O	O
obtained	obtain	O135	VBN	B-VP	O
from	from	F650	IN	B-PP	O
52	52	0000	CD	B-NP	O
healthy	healthy	H430	JJ	I-NP	O
volunteers	volunteer	V453	NNS	I-NP	O
having	have	H152	VBG	B-VP	O
phenotype	phenotype	P531	NN	B-NP	O
Hp2	Hp2	H100	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
the	the	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
Hp	Hp	H100	NN	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
individual	individual	I531	NN	I-NP	O
with	with	W300	IN	B-PP	O
Hp1	Hp1	H100	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Hpdel	Hpdel	H134	NN	I-NP	O
was	be	W200	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

50	50	0000	CD	B-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
ml	ml	M400	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
approximately	approximately	A162	RB	B-NP	O
half	half	H410	PDT	I-NP	O
the	the	T000	DT	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
Hp	Hp	H100	NN	B-NP	O
in	in	I500	IN	B-PP	O
control	control	C536	NN	B-NP	O
sera	serum	S600	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Hp1	Hp1	H100	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
26	26	0000	CD	B-NP	O
+	+	0000	SYM	O	O
/	/	0000	SYM	O	O
-	-	0000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
33	33	0000	CD	I-NP	O
mg	mg	M200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
ml	ml	M400	NN	I-NP	O
;	;	0000	:	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
9	9	0000	CD	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
showing	show	S520	VBG	B-VP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dosage	dosage	D200	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
(	(	0000	(	O	O
Hp2	Hp2	H100	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Hp2	Hp2	H100	NN	B-NP	O
/	/	0000	SYM	B-NP	O
Hpdel	Hpdel	H134	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
exons	exon	E252	NNS	I-NP	O
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
anhaptoglobinemia	anhaptoglobinemia	A513	NN	B-NP	B-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
anomalous	anomalous	A542	JJ	B-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
Hp	Hp	H100	NN	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
well	well	W400	RB	I-VP	O
explained	explain	E214	VBN	I-VP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
hypohaptoglobinemia	hypohaptoglobinemia	H132	NN	B-NP	B-Disease
remains	remain	R520	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O

ATM	ATM	A350	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
British	British	B632	JJ	I-NP	O
Isles	Isle	I242	NNPS	I-NP	O
:	:	0000	:	O	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
ATM	ATM	A350	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
leukemia	leukemia	L250	NN	B-NP	B-Disease
,	,	0000	,	O	O
lymphoma	lymphoma	L515	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
59	59	0000	CD	B-NP	O
ATM	ATM	A350	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
ataxia	ataxia	A320	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
)	)	0000	)	O	O
patients	patient	P353	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
British	British	B632	JJ	I-NP	O
Isles	Isle	I242	NNPS	I-NP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
51	51	0000	CD	B-NP	O
ATM	ATM	A350	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
native	native	N310	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
British	British	B632	JJ	I-NP	O
Isles	Isle	I242	NNPS	I-NP	O
,	,	0000	,	O	O
11	11	0000	CD	B-NP	O
were	be	W600	VBD	B-VP	O
founder	founder	F536	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
2	2	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
11	11	0000	CD	I-NP	O
conferred	confer	C516	VBD	B-VP	O
a	a	A000	DT	B-NP	O
milder	mild	M436	JJR	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
with	with	W300	IN	B-PP	O
respect	respect	R212	NN	B-NP	O
to	to	T000	TO	B-PP	O
both	both	B300	CC	O	O
cerebellar	cerebellar	C614	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
and	and	A530	CC	O	O
cellular	cellular	C460	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
7271T	7271T	T000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
homozygotes	homozygote	H523	NNS	I-NP	O
and	and	A530	CC	I-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
(	(	0000	(	O	O
relative	relative	R431	JJ	B-NP	O
risk	risk	R200	NN	I-NP	O
12	12	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
7	7	0000	CD	I-NP	O
;	;	0000	:	O	O
P	P	P000	NN	B-NP	O
=	=	0000	JJ	I-NP	O
.	.	0000	.	I-NP	O
0025	0025	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
less	less	L200	RBR	I-NP	O
severe	severe	S160	JJ	I-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
terms	term	T652	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
cerebellar	cerebellar	C614	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
7271T	7271T	T000	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
also	also	A420	RB	B-ADVP	O
allows	allow	A420	VBZ	B-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
full	full	F400	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
length	length	L523	NN	I-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
level	level	L140	NN	I-NP	O
comparable	comparable	C516	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
that	that	T300	DT	B-NP	O
in	in	I500	IN	B-PP	O
unaffected	unaffected	U512	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
18	18	0000	CD	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
15	15	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
who	who	W000	WP	B-NP	O
developed	develop	D141	VBD	B-VP	O
leukemia	leukemia	L250	NN	B-NP	B-Disease
,	,	0000	,	O	O
lymphoma	lymphoma	L515	NN	B-NP	B-Disease
,	,	0000	,	O	O
preleukemic	preleukemic	P642	JJ	B-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
cell	cell	C400	NN	I-NP	O
proliferation	proliferation	P641	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
Hodgkin	Hodgkin	H325	NN	B-NP	B-Disease
lymphoma	lymphoma	L515	NN	I-NP	I-Disease
,	,	0000	,	O	O
mostly	mostly	M234	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATM	ATM	A350	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
types	type	T120	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
25	25	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
carried	carry	C630	VBD	B-VP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
or	or	O600	CC	O	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
many	many	M500	JJ	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
ATM	ATM	A350	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
DMPK	DMPK	D512	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
severely	severely	S164	RB	B-NP	O
affected	affect	A123	VBN	I-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
hypermethylated	hypermethylate	H165	VBN	I-VP	O
proximal	proximal	P625	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
largely	largely	L624	RB	I-NP	O
expanded	expand	E215	VBN	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
.	.	0000	.	O	O

Using	Use	U252	VBG	B-VP	O
methylation	methylation	M343	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
restriction	restriction	R236	NN	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
characterized	characterize	C623	VBD	B-VP	O
the	the	T000	DT	B-NP	O
methylation	methylation	M343	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
side	side	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMPK	DMPK	D512	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
of	of	O100	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
affected	affect	A123	VBN	B-VP	O
with	with	W300	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
,	,	0000	,	O	O
showing	show	S520	VBG	B-VP	O
expansions	expansion	E215	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
repetitive	repetitive	R131	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
segment	segment	S253	NN	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
corresponds	correspond	C621	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
SacI	SacI	S200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
HindIII	HindIII	H530	NN	I-NP	O
fragment	fragment	F625	NN	I-NP	O
carrying	carry	C652	VBG	B-VP	O
exons	exon	E252	NNS	B-NP	O
11	11	0000	CD	B-NP	O
-	-	0000	:	O	O
15	15	0000	CD	B-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
constitutive	constitutive	C523	JJ	B-NP	O
methylation	methylation	M343	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
12	12	0000	CD	I-NP	O
at	at	A300	IN	B-PP	O
restriction	restriction	R236	NN	B-NP	O
sites	site	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
SacII	SacII	S200	NN	B-NP	O
and	and	A530	CC	I-NP	O
HhaI	HhaI	H000	NN	I-NP	O
,	,	0000	,	O	O
localized	localize	L242	VBD	B-VP	O
1	1	0000	CD	B-NP	O
,	,	0000	,	I-NP	O
159	159	0000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
232	232	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
upstream	upstream	U123	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
most	most	M230	JJS	O	O
,	,	0000	,	O	O
if	if	I100	IN	B-SBAR	O
not	not	N300	RB	B-NP	O
all	all	A400	DT	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
sites	site	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
SacII	SacII	S200	NN	B-NP	O
,	,	0000	,	O	O
HhaI	HhaI	H000	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
HpaII	HpaII	H100	NN	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
are	be	A600	VBP	B-VP	O
unmethylated	unmethylate	U534	VBN	I-VP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
and	and	A530	CC	O	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
young	young	Y520	JJ	O	O
and	and	A530	CC	O	O
severely	severely	S164	RB	B-VP	O
affected	affect	A123	VBN	I-VP	O
patients	patient	P353	NNS	B-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
complete	complete	C514	JJ	B-NP	O
methylation	methylation	M343	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
restriction	restriction	R236	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
was	be	W200	VBD	B-VP	O
congenital	congenital	C525	JJ	B-ADJP	O
.	.	0000	.	O	O

Preliminary	Preliminary	P645	JJ	B-NP	O
in	in	I500	FW	I-NP	O
vivo	vivo	V100	FW	I-NP	O
footprinting	footprinting	F316	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
gave	give	G100	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
DNA	DNA	D500	NN	I-NP	O
contact	contact	C532	NN	I-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
at	at	A300	IN	B-PP	O
an	an	A500	DT	B-NP	O
Sp1	Sp1	S100	NN	I-NP	O
consensus	consensus	C525	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
site	site	S300	NN	I-NP	O
upstream	upstream	U123	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
reduction	reduction	R323	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
interaction	interaction	I536	NN	I-NP	O
in	in	I500	IN	B-PP	O
cells	cell	C420	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
hypermethylated	hypermethylate	H165	VBN	I-NP	O
DMPK	DMPK	D512	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
complexes	complex	C514	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
transferrin	transferrin	T652	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
and	and	A530	CC	O	O
lowers	lower	L620	VBZ	B-VP	O
its	its	I320	PRP$	B-NP	O
affinity	affinity	A153	NN	I-NP	O
for	for	F600	IN	B-PP	O
ligand	ligand	L253	NN	B-NP	O
binding	binding	B535	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
recently	recently	R253	RB	B-ADVP	O
reported	report	R163	VBD	B-VP	O
the	the	T000	DT	B-NP	O
positional	positional	P235	JJ	I-NP	O
cloning	cloning	C452	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
called	call	C430	VBN	B-VP	O
HFE	HFE	H100	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
product	product	P632	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
class	class	C420	NN	I-NP	O
I	I	I000	CD	I-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
Cys	Cys	C200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
282	282	0000	CD	I-NP	O
-	-	0000	HYPH	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
Tyr	Tyr	T600	NN	B-NP	O
(	(	0000	(	O	O
C282Y	C282Y	C000	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
85	85	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
eliminates	eliminate	E453	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
to	to	T000	TO	B-VP	O
associate	associate	A230	VB	I-VP	O
with	with	W300	IN	B-PP	O
beta2	beta2	B300	NN	B-NP	O
-	-	0000	HYPH	O	O
microglobulin	microglobulin	M262	NN	B-NP	O
(	(	0000	(	O	O
beta2m	beta2m	B350	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
prevents	prevent	P615	VBZ	B-VP	O
cell	cell	C400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
surface	surface	S612	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
that	that	T300	WDT	B-NP	O
has	have	H200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
on	on	O500	IN	B-PP	O
beta2m	beta2m	B350	NN	B-NP	O
association	association	A235	NN	I-NP	O
,	,	0000	,	O	O
H63D	H63D	H300	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
out	out	O300	IN	B-PP	O
of	of	O100	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutant	mutant	M353	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
report	report	R163	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
in	in	I500	IN	B-PP	O
cultured	culture	C436	VBN	B-NP	O
293	293	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
overexpressing	overexpresse	O162	VBG	B-VP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
or	or	O600	CC	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
HFE	HFE	H100	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
and	and	A530	CC	I-NP	O
H63D	H63D	H300	NN	I-NP	O
HFE	HFE	H100	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
form	form	F650	VBP	B-VP	O
stable	stable	S314	JJ	B-NP	O
complexes	complex	C514	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
transferrin	transferrin	T652	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
(	(	0000	(	O	O
TfR	TfR	T160	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
C282Y	C282Y	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
nearly	nearly	N640	RB	B-ADVP	O
completely	completely	C514	RB	I-ADVP	O
prevents	prevent	P615	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
association	association	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
HFE	HFE	H100	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
TfR	TfR	T160	NN	I-NP	O
.	.	0000	.	O	O

Studies	Study	S320	NNS	B-NP	O
on	on	O500	IN	B-PP	O
cell	cell	C400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
transferrin	transferrin	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
37	37	0000	CD	B-NP	O
degrees	degree	D262	NNS	I-NP	O
C	C	C000	NN	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
overexpressed	overexpresse	O162	VBN	I-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
HFE	HFE	H100	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
decreases	decrease	D262	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
affinity	affinity	A153	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
TfR	TfR	T160	NN	I-NP	O
for	for	F600	IN	B-PP	O
transferrin	transferrin	T652	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
overexpressed	overexpresse	O162	VBN	I-NP	O
H63D	H63D	H300	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
have	have	H100	VB	I-VP	O
this	this	T200	DT	B-NP	O
effect	effect	E123	NN	I-NP	O
,	,	0000	,	O	O
providing	provide	P613	VBG	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
direct	direct	D623	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
consequence	consequence	C525	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
H63D	H63D	H300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Addition	Addition	A350	NN	B-NP	O
of	of	O100	IN	B-PP	O
soluble	soluble	S414	JJ	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
HFE	HFE	H100	NN	I-NP	O
/	/	0000	SYM	B-NP	O
beta2m	beta2m	B350	NN	I-NP	O
heterodimers	heterodimer	H363	NNS	I-NP	O
to	to	T000	TO	B-PP	O
cultured	culture	C436	VBN	B-NP	O
cells	cell	C420	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
decreased	decrease	D262	VBD	B-VP	O
the	the	T000	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
affinity	affinity	A153	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
TfR	TfR	T160	NN	I-NP	O
for	for	F600	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
ligand	ligand	L253	NN	I-NP	O
under	under	U536	IN	B-PP	O
steady	steady	S300	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
state	state	S300	NN	I-NP	O
conditions	condition	C535	NNS	I-NP	O
,	,	0000	,	O	O
both	both	B300	CC	O	O
in	in	I500	IN	B-PP	O
293	293	0000	CD	B-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
HeLa	HeLa	H400	NN	B-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
at	at	A300	IN	B-PP	O
4	4	0000	CD	B-NP	O
degrees	degree	D262	NNS	I-NP	O
C	C	C000	JJ	B-ADJP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
added	add	A300	VBN	I-NP	O
soluble	soluble	S414	JJ	I-NP	O
complex	complex	C514	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
/	/	0000	SYM	B-NP	O
beta2m	beta2m	B350	NN	I-NP	O
inhibited	inhibit	I513	VBD	B-VP	O
binding	binding	B535	NN	B-NP	O
of	of	O100	IN	B-PP	O
transferrin	transferrin	T652	NN	B-NP	O
to	to	T000	TO	B-PP	O
HeLa	HeLa	H400	NN	B-NP	O
cell	cell	C400	NN	I-NP	O
TfR	TfR	T160	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
concentration	concentration	C525	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
manner	manner	M560	NN	I-NP	O
.	.	0000	.	O	O

Scatchard	Scatchard	S232	NNP	B-NP	O
plots	plot	P432	NNS	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
added	add	A300	VBN	I-NP	O
heterodimer	heterodimer	H363	NN	I-NP	O
substantially	substantially	S123	RB	B-VP	O
reduced	reduce	R323	VBD	I-VP	O
the	the	T000	DT	B-NP	O
affinity	affinity	A153	NN	I-NP	O
of	of	O100	IN	B-PP	O
TfR	TfR	T160	NN	B-NP	O
for	for	F600	IN	B-PP	O
transferrin	transferrin	T652	NN	B-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
establish	establish	E231	VBP	B-VP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
link	link	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
key	key	K000	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
transport	transport	T652	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
TfR	TfR	T160	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
raise	raise	R200	VB	B-VP	O
the	the	T000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
alterations	alteration	A436	NNS	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
regulatory	regulatory	R243	JJ	I-NP	O
mechanism	mechanism	M252	NN	I-NP	O
may	may	M000	MD	B-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Genomic	Genomic	G520	JJ	B-NP	O
organization	organization	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
UBE3A	UBE3A	U100	NN	I-NP	O
/	/	0000	SYM	B-NP	O
E6	E6	E000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
AP	AP	A100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
related	related	R430	JJ	B-NP	O
pseudogenes	pseudogene	P232	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
UBE3A	UBE3A	U100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
E6	E6	E000	NN	I-NP	O
-	-	0000	HYPH	O	O
AP	AP	A100	NN	B-NP	O
ubiquitin	ubiquitin	U123	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
protein	protein	P635	NN	I-NP	O
ligase	ligase	L200	NN	I-NP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Angelman	Angelman	A524	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
lack	lack	L200	VBP	B-VP	O
15q11	15q11	Q000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
or	or	O600	CC	O	O
chromosome	chromosome	C652	NN	B-NP	O
15	15	0000	CD	I-NP	O
paternal	paternal	P365	JJ	I-NP	O
uniparental	uniparental	U516	JJ	I-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
UBE3A	UBE3A	U100	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
shown	show	S500	VBN	I-VP	O
a	a	A000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
UTR	UTR	U360	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
<	<	0000	SYM	B-NP	O
50	50	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
,	,	0000	,	O	O
whereas	whereas	W620	IN	O	O
Northern	Northern	N636	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
indicated	indicate	I532	VBN	I-VP	O
mRNA	mRNA	M650	NN	B-NP	O
sizes	size	S200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
8	8	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
additional	additional	A354	JJ	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
clones	clone	C452	NNS	I-NP	O
and	and	A530	CC	O	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
UTR	UTR	U360	NN	I-NP	O
and	and	A530	CC	O	O
>	>	0000	JJR	B-NP	O
2	2	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
UTR	UTR	U360	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
established	establish	E231	VBN	I-VP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
organization	organization	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
UBE3A	UBE3A	U100	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
exon	exon	E250	NN	I-NP	O
borders	border	B636	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
mapped	map	M130	VBN	I-VP	O
two	two	T000	CD	B-NP	O
highly	highly	H240	RB	I-NP	O
homologous	homologous	H542	JJ	I-NP	O
processed	process	P623	VBN	I-NP	O
pseudogenes	pseudogene	P232	NNS	I-NP	O
,	,	0000	,	I-NP	O
UBE3AP1	UBE3AP1	U100	NN	I-NP	O
and	and	A530	CC	I-NP	O
UBE3AP2	UBE3AP2	U100	NN	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
chromosomes	chromosome	C652	NNS	B-NP	O
2	2	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
21	21	0000	CD	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
determined	determine	D365	VBD	B-VP	O
their	their	T600	PRP$	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
organization	organization	O625	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
will	will	W400	MD	B-VP	O
form	form	F650	VB	I-VP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
for	for	F600	IN	B-PP	O
studies	study	S320	NNS	B-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
and	and	A530	CC	I-NP	O
imprinting	imprinting	I516	NN	I-NP	O
of	of	O100	IN	B-PP	O
UBE3A	UBE3A	U100	NN	B-NP	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
and	and	A530	CC	I-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Cowden	Cowden	C350	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Bannayan	Bannayan	B500	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Zonana	Zonana	Z500	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
hamartoma	hamartoma	H563	NN	I-NP	B-Disease
syndromes	syndrome	S536	NNS	I-NP	I-Disease
with	with	W300	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
PTEN	PTEN	P350	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
PTEN	PTEN	P350	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
maps	map	M120	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
10q23	10q23	Q000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
and	and	A530	CC	O	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
403	403	0000	CD	I-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
dual	dual	D400	JJ	I-NP	O
specificity	specificity	S121	NN	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
(	(	0000	(	O	O
protein	protein	P635	NN	B-NP	O
tyrosine	tyrosine	T625	NN	I-NP	O
phosphatase	phosphatase	P213	NN	I-NP	O
;	;	0000	:	O	O
PTPase	PTPase	P312	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
recently	recently	R253	RB	B-ADVP	O
to	to	T000	TO	B-VP	O
play	play	P400	VB	I-VP	O
a	a	A000	DT	B-NP	O
broad	broad	B630	JJ	I-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
malignancy	malignancy	M425	NN	I-NP	B-Disease
.	.	0000	.	O	O

Somatic	Somatic	S532	JJ	B-NP	O
PTEN	PTEN	P350	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
and	and	A530	CC	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
,	,	0000	,	I-NP	I-Disease
brain	brain	B650	NN	I-NP	I-Disease
,	,	0000	,	I-NP	I-Disease
prostate	prostate	P623	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
kidney	kidney	K350	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
several	several	S164	JJ	B-NP	O
primary	primary	P656	JJ	I-NP	O
tumours	tumour	T562	NNS	I-NP	B-Disease
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
endometrial	endometrial	E535	JJ	B-NP	B-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
,	,	0000	,	O	O
malignant	malignant	M425	JJ	B-NP	B-Disease
melanoma	melanoma	M450	NN	I-NP	I-Disease
and	and	A530	CC	O	O
thyroid	thyroid	T630	JJ	B-NP	B-Disease
tumours	tumour	T562	NNS	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
PTEN	PTEN	P350	NN	B-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
two	two	T000	CD	B-NP	O
hamartoma	hamartoma	H563	NN	I-NP	B-Disease
syndromes	syndrome	S536	NNS	I-NP	I-Disease
Cowden	Cowden	C350	NN	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
CD	CD	C300	NN	B-NP	B-Disease
;	;	0000	:	O	O
MIM	MIM	M500	NN	B-NP	O
158350	158350	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Bannayan	Bannayan	B500	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Zonana	Zonana	Z500	NNP	I-NP	I-Disease
(	(	0000	(	O	I-Disease
BZS	BZS	B200	NNP	B-NP	I-Disease
)	)	0000	)	O	I-Disease
or	or	O600	CC	O	I-Disease
Ruvalcaba	Ruvalcaba	R142	NNP	B-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
Riley	Riley	R400	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Smith	Smith	S530	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
MIM	MIM	M500	NN	B-NP	O
153480	153480	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Constitutive	Constitutive	C523	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
37	37	0000	CD	B-NP	O
CD	CD	C300	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
and	and	A530	CC	O	O
seven	seven	S150	CD	B-NP	O
BZS	BZS	B200	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
germline	germline	G654	NN	B-NP	O
PTEN	PTEN	P350	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

PTEN	PTEN	P350	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
30	30	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
37	37	0000	CD	B-NP	O
(	(	0000	(	O	O
81	81	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
CD	CD	C300	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
missense	missense	M252	JJ	B-NP	O
and	and	A530	CC	I-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
deletions	deletion	D435	NNS	B-NP	O
,	,	0000	,	O	O
insertions	insertion	I526	NNS	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
/	/	0000	SYM	B-NP	O
insertion	insertion	I526	NN	B-NP	O
and	and	A530	CC	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
scattered	scatter	S236	VBN	I-VP	O
over	over	O160	IN	B-PP	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
length	length	L523	NN	I-NP	O
of	of	O100	IN	B-PP	O
PTEN	PTEN	P350	NN	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
exception	exception	E213	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
,	,	0000	,	I-NP	O
fourth	fourth	F630	JJ	I-NP	O
and	and	A530	CC	I-NP	O
last	last	L230	JJ	I-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
hot	hot	H300	JJ	I-NP	O
spot	spot	S130	NN	I-NP	O
for	for	F600	IN	B-PP	O
PTEN	PTEN	P350	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
CD	CD	C300	NN	B-NP	B-Disease
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
5	5	0000	CD	I-NP	O
that	that	T300	WDT	B-NP	O
contains	contain	C535	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
PTPase	PTPase	P312	NN	I-NP	O
core	core	C600	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
13	13	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
30	30	0000	CD	B-NP	O
(	(	0000	(	O	O
43	43	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
CD	CD	C300	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
.	.	0000	.	O	O

Seven	Seven	S150	CD	B-NP	O
of	of	O100	IN	B-PP	O
30	30	0000	CD	B-NP	O
(	(	0000	(	O	O
23	23	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
core	core	C600	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
(	(	0000	(	O	O
five	five	F100	CD	B-NP	O
of	of	O100	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
possibly	possibly	P214	RB	B-VP	O
pointing	point	P535	VBG	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
functional	functional	F523	JJ	I-NP	O
significance	significance	S251	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
PTEN	PTEN	P350	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
(	(	0000	(	O	O
57	57	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
BZS	BZS	B200	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
.	.	0000	.	O	O

Interestingly	Interestingly	I536	RB	B-ADVP	O
,	,	0000	,	O	O
none	none	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
PTPase	PTPase	P312	NN	I-NP	O
core	core	C600	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
worthy	worthy	W630	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
note	note	N300	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
point	point	P530	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
R233X	R233X	R200	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
CD	CD	C300	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
BZS	BZS	B200	NN	I-NP	B-Disease
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Genotype	Genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
performed	perform	P616	VBN	I-VP	O
on	on	O500	IN	B-PP	O
this	this	T200	DT	B-NP	O
small	small	S540	JJ	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
BZS	BZS	B200	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
inthe	inthe	I530	VBP	B-VP	O
group	group	G610	NN	B-NP	O
of	of	O100	IN	B-PP	O
CD	CD	C300	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
two	two	T000	CD	B-NP	O
possible	possible	P214	JJ	I-NP	O
associations	association	A235	NNS	I-NP	O
worthy	worthy	W630	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
follow	follow	F400	VB	B-VP	O
-	-	0000	HYPH	O	O
up	up	U100	RP	B-PRT	O
in	in	I500	IN	B-PP	O
independent	independent	I531	JJ	B-NP	O
analyses	analysis	A542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
was	be	W200	VBD	B-VP	O
an	an	A500	DT	B-NP	O
association	association	A235	NN	I-NP	O
noted	note	N300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
CD	CD	C300	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
/	/	0000	SYM	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
PTEN	PTEN	P350	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	O
involvement	involvement	I514	NN	I-NP	O
(	(	0000	(	O	O
unaffected	unaffected	U512	JJ	B-ADJP	O
versus	versus	V620	IN	B-PP	O
benign	benign	B525	JJ	B-NP	O
versus	versus	V620	CC	I-NP	O
malignant	malignant	M425	JJ	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Specifically	Specifically	S121	RB	B-ADVP	O
and	and	A530	CC	O	O
more	more	M600	RBR	B-ADVP	O
directly	directly	D623	RB	I-ADVP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
association	association	A235	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
PTEN	PTEN	P350	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
malignant	malignant	M425	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Secondly	Secondly	S253	RB	B-ADVP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
appeared	appear	A163	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
an	an	A500	DT	B-NP	O
interdependent	interdependent	I536	JJ	I-NP	O
association	association	A235	NN	I-NP	O
between	between	B350	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
upstream	upstream	U123	RB	B-ADVP	O
and	and	A530	CC	O	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
PTPase	PTPase	P312	NN	I-NP	O
core	core	C600	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
core	core	C600	NN	I-NP	O
motif	motif	M310	NN	I-NP	O
containing	contain	C535	VBG	B-VP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
major	major	M260	JJ	I-NP	O
organ	organ	O625	NN	I-NP	O
systems	system	S235	NNS	I-NP	O
(	(	0000	(	O	O
central	central	C536	JJ	B-NP	O
nervous	nervous	N612	JJ	I-NP	O
system	system	S235	NN	I-NP	O
,	,	0000	,	O	O
thyroid	thyroid	T630	NN	B-NP	O
,	,	0000	,	O	O
breast	breast	B623	NN	B-NP	O
,	,	0000	,	O	O
skin	skin	S250	NN	B-NP	O
and	and	A530	CC	O	O
gastrointestinal	gastrointestinal	G236	JJ	B-NP	O
tract	tract	T623	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
observations	observation	O126	NNS	I-NP	O
would	would	W430	MD	B-VP	O
need	need	N300	VB	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
studying	study	S352	VBG	B-VP	O
a	a	A000	DT	B-NP	O
larger	large	L626	JJR	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
CD	CD	C300	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
defects	defect	D123	NNS	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
complement	complement	C514	NN	I-NP	B-Disease
component	component	C515	NN	I-NP	I-Disease
C6	C6	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
African	African	A162	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
American	American	A562	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Complement	Complement	C514	NN	B-NP	B-Disease
component	component	C515	NN	I-NP	I-Disease
C6	C6	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
C6D	C6D	C300	NN	B-NP	B-Disease
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
diagnosed	diagnose	D252	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
16	16	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
African	African	A162	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
American	American	A562	JJ	I-NP	O
male	male	M400	NN	I-NP	O
with	with	W300	IN	B-PP	O
meningococcal	meningococcal	M524	JJ	B-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
father	father	F360	NN	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
brothers	brother	B636	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
had	have	H300	VBD	B-VP	O
C6D	C6D	C300	NN	B-NP	B-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
gave	give	G100	VBD	B-VP	O
no	no	N000	DT	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
meningitis	meningitis	M523	NN	B-NP	B-Disease
or	or	O600	CC	O	O
other	other	O360	JJ	B-NP	O
neisserial	neisserial	N264	JJ	I-NP	B-Disease
infection	infection	I512	NN	I-NP	I-Disease
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
exon	exon	E250	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
(	(	0000	(	O	O
PCR	PCR	P260	NN	B-NP	O
)	)	0000	)	O	O
/	/	0000	SYM	B-NP	O
single	single	S524	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
screening	screening	S265	NN	I-NP	O
step	step	S310	NN	I-NP	O
and	and	A530	CC	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
target	target	T623	NN	B-NP	O
exons	exon	E252	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
determined	determine	D365	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
compound	compound	C515	NN	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
for	for	F600	IN	B-PP	O
two	two	T000	CD	B-NP	O
C6	C6	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
,	,	0000	,	I-NP	O
1195delC	1195delC	D420	NN	I-NP	O
located	located	L230	JJ	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
7	7	0000	CD	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
while	while	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
,	,	0000	,	I-NP	O
1936delG	1936delG	D420	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
12	12	0000	CD	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
before	before	B160	RB	B-ADVP	O
to	to	T000	TO	B-VP	O
cause	cause	C200	VB	I-VP	O
C6D	C6D	C300	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
African	African	A162	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
American	American	A562	JJ	I-NP	O
individual	individual	I531	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
premature	premature	P653	JJ	B-NP	O
termination	termination	T653	NN	I-NP	O
codons	codon	C352	NNS	I-NP	O
and	and	A530	CC	O	O
C6	C6	C000	NN	B-NP	O
null	null	N400	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

Allele	Allele	A400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
PCR	PCR	P260	NN	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
probands	proband	P615	NNS	I-NP	O
two	two	T000	CD	B-NP	O
brothers	brother	B636	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
inherited	inherit	I563	VBD	B-VP	O
the	the	T000	DT	B-NP	O
1195delC	1195delC	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
from	from	F650	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
mother	mother	M360	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
1936delG	1936delG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
from	from	F650	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
father	father	F360	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

PAX6	PAX6	P200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
reviewed	review	R130	VBN	B-VP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
human	human	H500	JJ	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Peters	Peters	P362	NNP	B-NP	B-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
cataracts	cataract	C362	NNS	I-NP	I-Disease
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
keratitis	keratitis	K632	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
with	with	W300	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	B-Disease
foveal	foveal	F140	JJ	I-NP	I-Disease
hypoplasia	hypoplasia	H142	NN	I-NP	I-Disease
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
other	other	O360	JJ	B-ADJP	O
than	than	T500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11p13	11p13	P000	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
PAX6	PAX6	P200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
clearly	clearly	C464	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
,	,	0000	,	O	O
if	if	I100	IN	B-SBAR	O
not	not	N300	RB	B-CONJP	O
only	only	O540	RB	I-CONJP	O
,	,	0000	,	O	O
gene	gene	G500	NN	B-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
.	.	0000	.	O	O

Twenty	Twenty	T530	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
eight	eight	E230	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
identified	identify	I353	VBN	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
C	C	C000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
T	T	T000	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
at	at	A300	IN	B-PP	O
CpG	CpG	C120	NN	B-NP	O
dinucleotides	dinucleotide	D524	NNS	I-NP	O
,	,	0000	,	O	O
20	20	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
are	be	A600	VBP	B-VP	O
splicing	splice	S142	VBG	I-VP	O
errors	error	E620	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
30	30	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
are	be	A600	VBP	B-VP	O
deletion	deletion	D435	NN	B-NP	O
or	or	O600	CC	I-NP	O
insertion	insertion	I526	NN	I-NP	O
events	event	E153	NNS	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
noticeably	noticeably	N321	RB	I-NP	O
elevated	elevated	E413	JJ	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
paired	paired	P630	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
rest	rest	R230	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Increased	Increase	I526	VBN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
homeodomain	homeodomain	H535	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
accounted	account	A253	VBN	I-VP	O
for	for	F600	IN	B-PP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypermutable	hypermutable	H165	JJ	I-NP	O
CpG	CpG	C120	NN	I-NP	O
dinucleotide	dinucleotide	D524	NN	I-NP	O
in	in	I500	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
240	240	0000	CD	I-NP	O
.	.	0000	.	O	O

Very	Very	V600	RB	B-ADVP	O
nearly	nearly	N640	RB	B-NP	O
all	all	A400	DT	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
cause	cause	C200	VB	I-VP	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
function	function	F523	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
80	80	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
exonic	exonic	E252	JJ	B-NP	O
substitutions	substitution	S123	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
nonsense	nonsense	N525	JJ	B-NP	O
codons	codon	C352	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
with	with	W300	IN	B-PP	O
such	such	S200	JJ	B-NP	O
extraordinarily	extraordinarily	E236	RB	I-NP	O
high	high	H200	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
conservation	conservation	C526	NN	I-NP	O
throughout	throughout	T623	IN	B-PP	O
evolution	evolution	E143	NN	B-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
presumed	presume	P625	VBN	I-VP	O
undiscovered	undiscovered	U532	JJ	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
are	be	A600	VBP	B-VP	O
hypothesized	hypothesize	H132	VBN	I-VP	O
to	to	T000	TO	I-VP	O
exist	exist	E230	VB	I-VP	O
in	in	I500	IN	B-PP	O
as	as	A200	RB	O	O
-	-	0000	HYPH	B-ADJP	O
yet	yet	Y300	RB	B-NP	O
unidentified	unidentified	U535	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
and	and	A530	CC	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
Breast	Breast	B623	NNP	I-NP	B-Disease
Cancer	Cancer	C526	NNP	I-NP	I-Disease
Linkage	Linkage	L520	NNP	I-NP	O
Consortium	Consortium	C526	NNP	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
contribution	contribution	C536	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
to	to	T000	TO	B-PP	O
inherited	inherit	I563	VBN	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
assessed	assess	A230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
and	and	A530	CC	I-NP	O
mutation	mutation	M350	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
237	237	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
each	each	E200	DT	B-NP	O
with	with	W300	IN	B-PP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
four	four	F600	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
collected	collect	C423	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
Breast	Breast	B623	NNP	I-NP	B-Disease
Cancer	Cancer	C526	NNP	I-NP	I-Disease
Linkage	Linkage	L520	NNP	I-NP	O
Consortium	Consortium	C526	NNP	I-NP	O
.	.	0000	.	O	O

Families	Family	F542	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
included	include	I524	VBN	I-VP	O
without	without	W300	IN	B-PP	O
regard	regard	R263	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
or	or	O600	CC	I-NP	I-Disease
other	other	O360	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Overall	Overall	O164	RB	B-ADVP	O
,	,	0000	,	O	O
disease	disease	D200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
52	52	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
32	32	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
,	,	0000	,	B-PP	O
and	and	A530	CC	I-PP	O
to	to	T000	TO	B-PP	O
neither	neither	N360	CC	O	O
gene	gene	G500	NN	B-NP	O
in	in	I500	IN	B-PP	O
16	16	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
[	[	0000	(	O	O
CI	CI	C000	NN	B-NP	O
]	]	0000	)	O	O
6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
28	28	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
other	other	O360	JJ	B-NP	O
predisposition	predisposition	P632	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
(	(	0000	(	O	O
81	81	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
most	most	M230	JJS	B-NP	O
others	other	O362	NNS	I-NP	O
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	I-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
.	.	0000	.	O	O

Conversely	Conversely	C516	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
male	male	M400	JJ	B-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
female	female	F540	JJ	I-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
(	(	0000	(	O	O
76	76	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
largest	large	L623	JJS	I-NP	O
proportion	proportion	P616	NN	I-NP	O
(	(	0000	(	O	O
67	67	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
due	due	D000	JJ	B-PP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
genes	gene	G520	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
four	four	F600	CD	B-NP	O
or	or	O600	CC	I-NP	O
five	five	F100	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
female	female	F540	JJ	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
only	only	O540	RB	B-ADVP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
estimates	estimate	E235	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
substantially	substantially	S123	RB	I-VP	O
affected	affect	A123	VBN	I-VP	O
either	either	E360	CC	O	O
by	by	B000	IN	B-PP	O
changing	change	C525	VBG	B-VP	O
the	the	T000	DT	B-NP	O
assumed	assume	A253	VBN	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
or	or	O600	CC	B-PP	O
by	by	B000	IN	B-PP	O
including	include	I524	VBG	B-VP	O
or	or	O600	CC	I-VP	O
excluding	exclude	E243	VBG	I-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
data	datum	D300	NNS	I-NP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
those	those	T200	DT	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
that	that	T300	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
tested	test	T230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
standard	standard	S353	JJ	I-NP	O
screening	screening	S265	NN	I-NP	O
methods	method	M320	NNS	I-NP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
sequence	sequence	S252	NN	I-NP	O
or	or	O600	CC	I-NP	O
splice	splice	S142	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
63	63	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
CI	CI	C000	NN	I-NP	O
51	51	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
77	77	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
sensitivity	sensitivity	S523	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identical	identical	I353	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
techniques	technique	T252	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
penetrance	penetrance	P536	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
was	be	W200	VBD	B-VP	O
estimated	estimate	E235	VBN	I-VP	O
by	by	B000	IN	B-PP	O
maximizing	maximize	M252	VBG	B-VP	O
the	the	T000	DT	B-NP	O
LOD	LOD	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
mutation	mutation	M350	NN	I-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
over	over	O160	IN	B-PP	O
all	all	A400	DT	B-NP	O
possible	possible	P214	JJ	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
functions	function	F523	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
cumulative	cumulative	C543	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
reached	reach	R230	VBD	B-VP	O
28	28	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
CI	CI	C000	NN	I-NP	O
9	9	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
44	44	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
by	by	B000	IN	B-PP	O
age	age	A200	NN	B-NP	O
50	50	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
and	and	A530	CC	O	O
84	84	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
CI	CI	C000	NN	I-NP	O
43	43	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
by	by	B000	IN	B-PP	O
age	age	A200	NN	B-NP	O
70	70	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
corresponding	correspond	C621	VBG	I-NP	O
ovarian	ovarian	O165	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
risks	risk	R200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
CI	CI	C000	NN	I-NP	O
0	0	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
by	by	B000	IN	B-PP	O
age	age	A200	NN	B-NP	O
50	50	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
and	and	A530	CC	O	O
27	27	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
CI	CI	C000	NN	I-NP	O
0	0	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
47	47	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
by	by	B000	IN	B-PP	O
age	age	A200	NN	B-NP	O
70	70	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
lifetime	lifetime	L135	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
appears	appear	A162	VBZ	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
some	some	S500	DT	B-NP	O
suggestion	suggestion	S235	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
lower	low	L600	JJR	I-NP	O
risk	risk	R200	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA2	BRCA2	B620	NN	B-NP	O
carriers	carrier	C620	NNS	I-NP	O
<	<	0000	SYM	B-VP	O
50	50	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
.	.	0000	.	O	O

Eye	Eye	E000	NN	B-NP	B-Disease
movement	movement	M153	NN	I-NP	I-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
correlate	correlate	C643	VBP	B-VP	O
with	with	W300	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
in	in	I500	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
cerebellar	cerebellar	C614	JJ	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
I	I	I000	CD	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
compared	compare	C516	VBD	B-VP	O
horizontal	horizontal	H625	JJ	B-NP	O
eye	eye	E000	NN	I-NP	O
movements	movement	M153	NNS	I-NP	O
(	(	0000	(	O	O
visually	visually	V240	RB	B-NP	O
guided	guide	G300	VBN	I-NP	O
saccades	saccade	S232	NNS	I-NP	O
,	,	0000	,	O	O
antisaccades	antisaccade	A532	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
smooth	smooth	S530	JJ	B-NP	O
pursuit	pursuit	P623	NN	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
control	control	C536	JJ	B-NP	O
subjects	subject	S123	NNS	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
14	14	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
three	three	T600	CD	B-NP	O
forms	form	F652	NNS	I-NP	O
of	of	O100	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
cerebellar	cerebellar	C614	JJ	I-NP	B-Disease
ataxias	ataxias	A320	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
I	I	I000	CD	I-NP	I-Disease
spinocerebellar	spinocerebellar	S152	NN	I-NP	B-Disease
ataxias	ataxia	A320	NNS	I-NP	I-Disease
1	1	0000	CD	B-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
(	(	0000	(	O	O
SCA1	SCA1	S200	NN	B-NP	B-Disease
,	,	0000	,	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
11	11	0000	CD	B-NP	O
;	;	0000	:	O	O
SCA2	SCA2	S200	NN	B-NP	B-Disease
,	,	0000	,	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
SCA3	SCA3	S200	NN	B-NP	B-Disease
/	/	0000	SYM	O	O
Machado	Machado	M230	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Joseph	Joseph	J210	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
MJD	MJD	M230	NN	B-NP	B-Disease
)	)	0000	)	O	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
16	16	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
SCA1	SCA1	S200	NN	B-NP	B-Disease
,	,	0000	,	O	O
saccade	saccade	S230	NN	B-NP	O
amplitude	amplitude	A514	NN	I-NP	O
was	be	W200	VBD	B-VP	O
significantly	significantly	S251	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
hypermetria	hypermetria	H165	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
smooth	smooth	S530	JJ	I-NP	O
pursuit	pursuit	P623	NN	I-NP	O
gain	gain	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
decreased	decrease	D262	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
SCA2	SCA2	S200	NN	B-NP	B-Disease
,	,	0000	,	O	O
saccade	saccade	S230	NN	B-NP	O
velocity	velocity	V423	NN	I-NP	O
was	be	W200	VBD	B-VP	O
markedly	markedly	M623	RB	I-VP	O
decreased	decrease	D262	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
errors	error	E620	NNS	B-NP	O
in	in	I500	IN	B-PP	O
antisaccades	antisaccade	A532	NNS	B-NP	O
was	be	W200	VBD	B-VP	O
greatly	greatly	G634	RB	I-VP	O
increased	increase	I526	VBN	I-VP	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
significantly	significantly	S251	RB	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
with	with	W300	IN	B-PP	O
age	age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
onset	onset	O523	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
smooth	smooth	S530	JJ	B-NP	O
pursuit	pursuit	P623	NN	I-NP	O
gain	gain	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
trinucleotide	trinucleotide	T652	NN	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
SCA3	SCA3	S200	NN	B-NP	B-Disease
,	,	0000	,	O	O
gaze	gaze	G200	NN	B-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
evoked	evoke	E123	VBN	B-NP	I-Disease
nystagmus	nystagmus	N232	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
often	often	O135	RB	B-ADVP	O
present	present	P625	JJ	B-ADJP	O
as	as	A200	IN	B-SBAR	O
was	be	W200	VBD	B-VP	O
saccade	saccade	S230	NN	B-NP	O
hypometria	hypometria	H153	NN	I-NP	O
and	and	A530	CC	O	O
smooth	smooth	S530	JJ	B-NP	O
pursuit	pursuit	P623	NN	I-NP	O
gain	gain	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
markedly	markedly	M623	RB	I-VP	O
decreased	decrease	D262	VBN	I-VP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
major	major	M260	JJ	I-NP	O
criteria	criterion	C636	NNS	I-NP	O
,	,	0000	,	O	O
saccade	saccade	S230	NN	B-NP	O
amplitude	amplitude	A514	NN	I-NP	O
,	,	0000	,	O	O
saccade	saccade	S230	NN	B-NP	O
velocity	velocity	V423	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
presence	presence	P625	NN	B-NP	O
of	of	O100	IN	B-PP	O
gaze	gaze	G200	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
evoked	evoke	E123	VBN	I-NP	I-Disease
nystagmus	nystagmus	N232	NN	I-NP	I-Disease
,	,	0000	,	O	O
permitted	permit	P653	VBD	B-VP	O
the	the	T000	DT	B-NP	O
correct	correct	C623	JJ	I-NP	O
assignment	assignment	A253	NN	I-NP	O
of	of	O100	IN	B-PP	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
SCA1	SCA1	S200	NN	I-NP	B-Disease
,	,	0000	,	O	O
90	90	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
SCA2	SCA2	S200	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
93	93	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
SCA3	SCA3	S200	NN	B-NP	B-Disease
to	to	T000	TO	B-PP	O
their	their	T600	PRP$	B-NP	O
genetically	genetically	G532	RB	I-NP	O
confirmed	confirm	C516	VBN	I-NP	O
patient	patient	P353	NN	I-NP	O
group	group	G610	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
therefore	therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
may	may	M000	MD	B-VP	O
help	help	H410	VB	I-VP	O
orient	orient	O653	JJ	B-NP	O
diagnoses	diagnosis	D252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
SCA1	SCA1	S200	NN	B-NP	B-Disease
,	,	0000	,	O	O
SCA2	SCA2	S200	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
SCA3	SCA3	S200	NN	B-NP	B-Disease
at	at	A300	IN	B-PP	O
early	early	E640	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
stages	stage	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
diseases	disease	D200	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
and	and	A530	CC	O	O
molecular	molecular	M424	JJ	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
for	for	F600	IN	B-PP	O
idiopathic	idiopathic	I313	JJ	B-NP	B-Disease
ventricular	ventricular	V536	JJ	I-NP	I-Disease
fibrillation	fibrillation	F164	NN	I-NP	I-Disease
.	.	0000	.	O	O

Ventricular	Ventricular	V536	JJ	B-NP	B-Disease
fibrillation	fibrillation	F164	NN	I-NP	I-Disease
causes	cause	C200	VBZ	B-VP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
300	300	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
sudden	sudden	S350	JJ	I-NP	O
deaths	death	D320	NNS	I-NP	O
each	each	E200	DT	B-NP	O
year	year	Y600	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
USA	USA	U200	NNP	I-NP	O
alone	alone	A450	RB	B-ADVP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
are	be	A600	VBP	B-VP	O
no	no	N000	DT	B-NP	O
demonstrable	demonstrable	D523	JJ	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
or	or	O600	CC	I-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
causes	cause	C200	NNS	I-NP	O
to	to	T000	TO	B-VP	O
account	account	A253	VB	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
episode	episode	E123	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
therefore	therefore	T616	RB	I-VP	O
classified	classify	C421	VBN	I-VP	O
as	as	A200	IN	B-PP	O
idiopathic	idiopathic	I313	JJ	B-NP	B-Disease
ventricular	ventricular	V536	JJ	I-NP	I-Disease
fibrillation	fibrillation	F164	NN	I-NP	I-Disease
(	(	0000	(	O	O
IVF	IVF	I100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
IVF	IVF	I100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
present	present	P625	VB	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
characteristic	characteristic	C623	JJ	I-NP	O
electrocardiographic	electrocardiographic	E423	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
the	the	T000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
most	most	M230	JJS	B-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
sudden	sudden	S350	JJ	B-NP	B-Disease
death	death	D300	NN	I-NP	I-Disease
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
molecular	molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
IVF	IVF	I100	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
not	not	N300	RB	I-VP	O
yet	yet	Y300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
done	do	D500	VBN	I-VP	O
.	.	0000	.	O	O

Because	Because	B200	IN	B-SBAR	O
IVF	IVF	I100	NN	B-NP	B-Disease
causes	cause	C200	VBZ	B-VP	O
cardiac	cardiac	C632	JJ	B-NP	O
rhythm	rhythm	R350	NN	I-NP	O
disturbance	disturbance	D236	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
investigated	investigate	I512	VBD	B-VP	O
whether	whether	W360	IN	B-SBAR	O
malfunction	malfunction	M415	NN	B-NP	O
of	of	O100	IN	B-PP	O
ion	ion	I500	NN	B-NP	O
channels	channel	C542	NNS	I-NP	O
could	could	C430	MD	B-VP	O
cause	cause	C200	VB	I-VP	O
the	the	T000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
by	by	B000	IN	B-PP	O
studying	study	S352	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
sodium	sodium	S350	NN	I-NP	O
channel	channel	C540	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
SCN5A	SCN5A	S250	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
now	now	N000	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
donor	donor	D560	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
SCN5A	SCN5A	S250	NN	B-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
IVF	IVF	I100	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
sodium	sodium	S350	NN	B-NP	O
channels	channel	C542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
recover	recover	R216	NN	I-NP	O
from	from	F650	IN	B-PP	O
inactivation	inactivation	I523	NN	B-NP	O
more	more	M600	RBR	B-ADVP	O
rapidly	rapidly	R134	RB	I-ADVP	O
than	than	T500	IN	B-PP	O
normal	normal	N654	JJ	B-ADJP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
frameshift	frameshift	F652	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
sodium	sodium	S350	NN	I-NP	O
channel	channel	C540	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
non	non	N500	AFX	B-ADJP	O
-	-	0000	HYPH	I-ADJP	O
functional	functional	F523	JJ	I-ADJP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
cardiac	cardiac	C632	JJ	B-NP	O
ion	ion	I500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
channel	channel	C540	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
contribute	contribute	C536	VBP	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
developing	develop	D141	VBG	B-VP	O
IVF	IVF	I100	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
mucopolysaccharidosis	mucopolysaccharidosis	M214	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Australia	Australia	A236	NNP	B-NP	O
and	and	A530	CC	I-NP	O
Northern	Northern	N636	NNP	I-NP	O
Ireland	Ireland	I645	NNP	I-NP	O
:	:	0000	:	O	O
nine	nine	N500	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
T312S	T312S	T200	NN	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
that	that	T300	WDT	B-NP	O
confers	confer	C516	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Mucopolysaccharidosis	Mucopolysaccharidosis	M214	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
(	(	0000	(	O	O
MPS	MPS	M120	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
lysosomal	lysosomal	L254	JJ	I-NP	I-Disease
storage	storage	S362	NN	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
N	N	N000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
acetylgalactosamine	acetylgalactosamine	A234	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
sulfatase	sulfatase	S413	NN	I-NP	O
(	(	0000	(	O	O
GALNS	GALNS	G452	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
British	British	B632	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
Irish	Irish	I620	JJ	I-NP	O
population	population	P143	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
I113F	I113F	I100	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
single	single	S524	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
among	among	A520	IN	B-PP	O
MPS	MPS	M120	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
produces	produce	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
GALNS	GALNS	G452	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
from	from	F650	IN	B-PP	O
23	23	0000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
MPS	MPS	M120	NN	I-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
15	15	0000	CD	B-NP	O
from	from	F650	IN	B-PP	O
Australia	Australia	A236	NNP	B-NP	O
,	,	0000	,	O	O
8	8	0000	CD	B-NP	O
from	from	F650	IN	B-PP	O
Northern	Northern	N636	NNP	B-NP	O
Ireland	Ireland	I645	NNP	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
various	various	V620	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
(	(	0000	(	O	O
severe	severe	S160	JJ	B-ADJP	O
,	,	0000	,	O	O
16	16	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
;	;	0000	:	O	O
intermediate	intermediate	I536	NN	B-NP	O
,	,	0000	,	O	O
4	4	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
;	;	0000	:	O	O
mild	mild	M430	JJ	B-ADJP	O
,	,	0000	,	O	O
3	3	0000	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
two	two	T000	CD	B-NP	O
common	common	C500	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
together	together	T236	RB	B-ADVP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
32	32	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
44	44	0000	CD	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
T312S	T312S	T200	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
found	find	F530	VBN	B-VP	O
exclusively	exclusively	E242	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
milder	milder	M436	NN	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
previously	previously	P612	RB	I-NP	O
described	describe	D261	VBN	I-NP	O
I113F	I113F	I100	NN	I-NP	O
that	that	T300	WDT	B-NP	O
produces	produce	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
I113F	I113F	I100	NN	I-NP	O
and	and	A530	CC	I-NP	O
T312S	T312S	T200	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
accounted	account	A253	VBD	B-VP	O
for	for	F600	IN	B-PP	O
8	8	0000	CD	B-NP	O
(	(	0000	(	O	O
18	18	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
6	6	0000	CD	B-NP	O
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
44	44	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
high	high	H200	JJ	I-NP	O
residual	residual	R234	JJ	I-NP	O
GALNS	GALNS	G452	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
seen	see	S500	VBN	B-VP	O
when	when	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
T312S	T312S	T200	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
overexpressed	overexpresse	O162	VBN	I-VP	O
in	in	I500	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
provides	provide	P613	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
explanation	explanation	E214	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mild	mild	M430	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
distribution	distribution	D236	NN	I-NP	O
and	and	A530	CC	I-NP	O
relative	relative	R431	JJ	I-NP	O
frequencies	frequency	F625	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
I113F	I113F	I100	NN	I-NP	O
and	and	A530	CC	I-NP	O
T312S	T312S	T200	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Australia	Australia	A236	NNP	B-NP	O
corresponded	correspond	C621	VBD	B-VP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Northern	Northern	N636	NNP	B-NP	O
Ireland	Ireland	I645	NNP	I-NP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
unique	unique	U520	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
populations	population	P143	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
probably	probably	P614	RB	I-VP	O
introduced	introduce	I536	VBN	I-VP	O
to	to	T000	TO	B-PP	O
Australia	Australia	A236	NNP	B-NP	O
by	by	B000	IN	B-PP	O
Irish	Irish	I620	JJ	B-NP	O
migrants	migrant	M265	NNS	I-NP	O
during	during	D652	IN	B-PP	O
the	the	T000	DT	B-NP	O
19th	19th	T000	JJ	I-NP	O
century	century	C536	NN	I-NP	O
.	.	0000	.	O	O

Haplotype	Haplotype	H143	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
using	use	U252	VBG	B-VP	O
6	6	0000	CD	B-NP	O
RFLPs	RFLP	R141	NNS	I-NP	O
provides	provide	P613	VBZ	B-VP	O
additional	additional	A354	JJ	B-NP	O
data	datum	D300	NNS	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
I113F	I113F	I100	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
originated	originate	O625	VBD	B-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
ancestor	ancestor	A523	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
9	9	0000	CD	I-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
23	23	0000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
each	each	E200	DT	O	O
limited	limit	L530	VBN	B-VP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
further	further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
extensive	extensive	E235	JJ	B-NP	O
allelic	allelic	A420	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
MPS	MPS	M120	NN	B-NP	B-Disease
IVA	IVA	I100	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
British	British	B632	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
Irish	Irish	I620	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
provide	provide	P613	VBP	B-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
transmission	transmission	T652	NN	I-NP	O
to	to	T000	TO	B-PP	O
Australia	Australia	A236	NNP	B-NP	O
by	by	B000	IN	B-PP	O
British	British	B632	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
Irish	Irish	I620	JJ	I-NP	O
migrants	migrant	M265	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
constitutional	constitutional	C523	JJ	B-NP	O
WT1	WT1	W300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	O
diffuse	diffuse	D120	JJ	I-NP	B-Disease
mesangial	mesangial	M252	JJ	I-NP	I-Disease
sclerosis	sclerosis	S246	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
analysis	analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
/	/	0000	SYM	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
by	by	B000	IN	B-PP	O
use	use	U200	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
computerized	computerized	C513	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
database	database	D312	NN	I-NP	O
.	.	0000	.	O	O

Constitutional	Constitutional	C523	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
encoding	encode	E523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
finger	finger	F526	NN	I-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
renal	renal	R540	JJ	B-NP	O
and	and	A530	CC	I-NP	O
gonadal	gonadal	G534	JJ	I-NP	O
development	development	D141	NN	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Denys	Deny	D520	NNPS	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Drash	Drash	D620	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
DDS	DDS	D320	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
diffuse	diffuse	D120	JJ	B-NP	B-Disease
mesangial	mesangial	M252	JJ	I-NP	I-Disease
sclerosis	sclerosis	S246	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMS	DMS	D520	NN	B-NP	B-Disease
)	)	0000	)	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
pseudohermaphroditism	pseudohermaphroditism	P236	NN	B-NP	B-Disease
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
(	(	0000	(	O	O
WT	WT	W300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
DDS	DDS	D320	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
lie	lie	L000	VBP	B-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
or	or	O600	CC	O	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	O	O
encoding	encode	E523	VBG	B-VP	O
zinc	zinc	Z520	NN	B-NP	O
finger	finger	F526	NN	I-NP	O
2	2	0000	CD	I-NP	O
or	or	O600	CC	I-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
hot	hot	H300	JJ	I-NP	O
spot	spot	S130	NN	I-NP	O
(	(	0000	(	O	O
R394W	R394W	R000	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
a	a	A000	DT	B-NP	O
series	series	S620	NN	I-NP	O
of	of	O100	IN	B-PP	O
24	24	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
10	10	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	B-Disease
DMS	DMS	D520	NN	I-NP	I-Disease
(	(	0000	(	O	O
IDMS	IDMS	I352	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
10	10	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
DDS	DDS	D320	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
4	4	0000	CD	B-NP	O
with	with	W300	IN	B-PP	O
urogenital	urogenital	U625	JJ	B-NP	B-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
WT	WT	W300	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
WT1	WT1	W300	NN	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
16	16	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
4	4	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
presented	present	P625	VBD	B-VP	O
with	with	W300	IN	B-PP	O
IDMS	IDMS	I352	NN	B-NP	B-Disease
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
male	male	M400	JJ	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
female	female	F540	JJ	I-NP	O
IDMS	IDMS	I352	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
WT1	WT1	W300	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
underwent	undergo	U536	VBD	B-VP	O
normal	normal	N654	JJ	B-NP	O
puberty	puberty	P163	NN	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
IDMS	IDMS	I352	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
different	different	D165	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
those	those	T200	DT	B-NP	O
described	describe	D261	VBN	B-VP	O
in	in	I500	IN	B-PP	O
DDS	DDS	D320	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
six	six	S200	CD	I-NP	O
other	other	O360	JJ	I-NP	O
IDMS	IDMS	I352	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
genetic	genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
genotype	genotype	G531	NN	B-NP	O
/	/	0000	SYM	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
constitution	constitution	C523	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
WT1	WT1	W300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
database	database	D312	NN	I-NP	O
of	of	O100	IN	B-PP	O
84	84	0000	CD	B-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-VP	O
compare	compare	C516	VB	I-VP	O
the	the	T000	DT	B-NP	O
distribution	distribution	D236	NN	I-NP	O
and	and	A530	CC	I-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
,	,	0000	,	O	O
according	accord	A263	VBG	B-PP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
symptoms	symptom	S513	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
(	(	0000	(	B-LST	O
1	1	0000	LS	I-LST	O
)	)	0000	)	O	O
the	the	T000	DT	B-NP	O
association	association	A235	NN	I-NP	O
between	between	B350	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
8	8	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
9	9	0000	CD	I-NP	O
and	and	A530	CC	O	O
DMS	DMS	D520	NN	B-NP	B-Disease
;	;	0000	:	O	O
(	(	0000	(	B-LST	O
2	2	0000	LS	I-LST	O
)	)	0000	)	O	O
among	among	A520	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
DMS	DMS	D520	NN	B-NP	B-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
among	among	A520	IN	B-PP	O
46	46	0000	CD	B-NP	O
,	,	0000	,	O	O
XY	XY	X000	NN	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
female	female	F540	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
than	than	T500	IN	B-PP	O
among	among	A520	IN	B-PP	O
46	46	0000	CD	B-NP	O
,	,	0000	,	O	O
XY	XY	X000	NN	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
sexual	sexual	S240	JJ	B-NP	O
ambiguity	ambiguity	A512	NN	I-NP	O
or	or	O600	CC	O	O
male	male	M400	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
;	;	0000	:	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
3	3	0000	LS	I-LST	O
)	)	0000	)	O	O
statistically	statistically	S323	RB	B-NP	O
significant	significant	S251	JJ	I-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
exons	exon	E252	NNS	B-NP	O
8	8	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
9	9	0000	CD	I-NP	O
preferentially	preferentially	P616	RB	B-VP	O
affect	affect	A123	VB	I-VP	O
amino	amino	A500	NN	B-NP	O
acids	acid	A232	NNS	I-NP	O
with	with	W300	IN	B-PP	O
different	different	D165	JJ	B-NP	O
functions	function	F523	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
185delAG	185delAG	D420	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
originated	originate	O625	VBD	B-VP	O
before	before	B160	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
dispersion	dispersion	D216	NN	I-NP	O
of	of	O100	IN	B-PP	O
Jews	Jew	J200	NNPS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
diaspora	diaspora	D216	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
limited	limit	L530	VBN	I-VP	O
to	to	T000	TO	B-PP	O
Ashkenazim	Ashkenazim	A252	NNP	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
185delAG	185delAG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jews	Jews	J200	NNP	I-NP	O
both	both	B300	CC	B-PP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
tested	test	T230	VBN	I-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
mutation	mutation	M350	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
share	share	S600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
previous	previous	P612	JJ	I-NP	O
study	study	S300	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
mutation	mutation	M350	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
Iraqi	Iraqi	I620	NNP	B-NP	O
Jews	Jew	J200	NNPS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
similar	similar	S546	JJ	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
extended	extend	E235	VBD	B-VP	O
our	our	O600	PRP$	B-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-PP	O
other	other	O360	JJ	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Ashkenazi	Ashkenazi	A252	NN	I-NP	O
subsets	subset	S123	NNS	I-NP	O
354	354	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
Moroccan	Moroccan	M625	NNP	B-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
200	200	0000	CD	B-NP	O
Yemenites	Yemenite	Y532	NNS	I-NP	O
and	and	A530	CC	O	O
150	150	0000	CD	B-NP	O
Iranian	Iranian	I650	JJ	I-NP	O
Jews	Jew	J200	NNS	I-NP	O
.	.	0000	.	O	O

Heteroduplex	Heteroduplex	H363	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
complemented	complement	C514	VBN	B-VP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
abnormally	abnormally	A156	RB	B-VP	O
migrating	migrate	M263	VBG	I-VP	O
bands	band	B532	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
employed	employ	E514	VBN	I-VP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
Moroccan	Moroccan	M625	NN	B-NP	O
origin	origin	O625	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
none	none	N500	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Yemenites	Yemenite	Y532	NNPS	I-NP	O
or	or	O600	CC	I-NP	O
Iranians	Iranian	I652	NNPS	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
carrier	carrier	C600	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
185delAG	185delAG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
allelic	allelic	A420	JJ	I-NP	O
patterns	pattern	P365	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
for	for	F600	IN	B-PP	O
four	four	F600	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
and	and	A530	CC	O	O
for	for	F600	IN	B-PP	O
12	12	0000	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Ashkenazi	Ashkenazi	A252	NN	I-NP	O
185delAG	185delAG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
who	who	W000	WP	B-NP	O
had	have	H300	VBD	B-VP	O
breast	breast	B623	NN	B-NP	B-Disease
/	/	0000	SYM	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Ashkenazi	Ashkenazi	A252	NN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
shared	share	S630	VBD	B-VP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
,	,	0000	,	O	O
four	four	F600	CD	B-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
closely	closely	C424	RB	I-NP	O
related	related	R430	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
rest	rest	R230	NN	I-NP	O
(	(	0000	(	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
6	6	0000	CD	B-NP	O
)	)	0000	)	O	O
displayed	display	D214	VBD	B-VP	O
a	a	A000	DT	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
185delAG	185delAG	D420	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Ashkenazi	Ashkenazi	A252	NN	I-NP	O
populations	population	P143	NNS	I-NP	O
at	at	A300	IN	B-PP	O
rates	rate	R320	NNS	B-NP	O
comparable	comparable	C516	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
Ashkenazim	Ashkenazim	A252	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
Jewish	Jewish	J200	JJ	B-NP	O
185delAG	185delAG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
,	,	0000	,	O	O
supporting	support	S163	VBG	B-VP	O
the	the	T000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
notion	notion	N350	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
dating	date	D352	VBG	B-VP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
origin	origin	O625	VBP	B-VP	O
to	to	T000	TO	B-PP	O
an	an	A500	DT	B-NP	O
earlier	early	E646	JJR	I-NP	O
date	date	D300	NN	I-NP	O
than	than	T500	IN	B-SBAR	O
currently	currently	C653	RB	B-ADVP	O
estimated	estimate	E235	VBN	B-VP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
allelic	allelic	A420	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
even	even	E150	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
,	,	0000	,	O	O
might	might	M230	MD	B-VP	O
suggest	suggest	S230	VB	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
arose	arise	A620	VBD	B-VP	O
independently	independently	I531	RB	B-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Crystal	Crystal	C623	JJ	B-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
HFE	HFE	H100	NN	I-NP	O
and	and	A530	CC	O	O
characterization	characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
interaction	interaction	I536	NN	I-NP	O
with	with	W300	IN	B-PP	O
transferrin	transferrin	T652	NN	B-NP	O
receptor	receptor	R213	NN	I-NP	O
.	.	0000	.	O	O

HFE	HFE	H100	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
MHC	MHC	M200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
related	relate	R430	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
iron	iron	I650	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
overload	overload	O164	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
hereditary	hereditary	H636	JJ	I-NP	B-Disease
hemochromatosis	hemochromatosis	H526	NN	I-NP	I-Disease
.	.	0000	.	O	O

HFE	HFE	H100	NN	B-NP	O
binds	bind	B532	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
transferrin	transferrin	T652	NN	B-NP	O
receptor	receptor	R213	NN	I-NP	O
(	(	0000	(	O	O
TfR	TfR	T160	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
reduces	reduce	R320	VBZ	B-VP	O
its	its	I320	PRP$	B-NP	O
affinity	affinity	A153	NN	I-NP	O
for	for	F600	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
loaded	load	L300	VBN	I-NP	O
transferrin	transferrin	T652	NN	I-NP	O
,	,	0000	,	O	O
implicating	implicate	I514	VBG	B-VP	O
HFE	HFE	H100	NN	B-NP	O
in	in	I500	IN	B-PP	O
iron	iron	I650	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
2	2	0000	CD	I-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
A	A	A000	NN	I-NP	O
crystal	crystal	C623	NN	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
reveals	reveal	R142	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
locations	location	L235	NNS	I-NP	O
of	of	O100	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
patch	patch	P320	NN	I-NP	O
of	of	O100	IN	B-PP	O
histidines	histidine	H235	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
pH	pH	P000	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
interactions	interaction	I536	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
soluble	soluble	S414	JJ	B-NP	O
TfR	TfR	T160	NN	I-NP	O
and	and	A530	CC	I-NP	O
HFE	HFE	H100	NN	I-NP	O
bind	bind	B530	VBP	B-VP	O
tightly	tightly	T234	RB	B-ADVP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
basic	basic	B200	JJ	I-NP	O
pH	pH	P000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
surface	surface	S612	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	O	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
acidic	acidic	A232	JJ	I-NP	O
pH	pH	P000	NN	I-NP	O
of	of	O100	IN	B-PP	O
intracellular	intracellular	I536	JJ	B-NP	O
vesicles	vesicle	V242	NNS	I-NP	O
.	.	0000	.	O	O

TfR	TfR	T160	NN	B-NP	O
HFE	HFE	H100	NN	I-NP	O
stoichiometry	stoichiometry	S325	NN	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
differs	differ	D162	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
TfR	TfR	T160	NN	B-NP	O
transferrin	transferrin	T652	NN	I-NP	O
stoichiometry	stoichiometry	S325	NN	I-NP	O
(	(	0000	(	O	O
2	2	0000	CD	B-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
implying	imply	I514	VBG	B-VP	O
a	a	A000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
mode	mode	M300	NN	I-NP	O
of	of	O100	IN	B-PP	O
binding	binding	B535	NN	B-NP	O
for	for	F600	IN	B-PP	O
HFE	HFE	H100	NN	B-NP	O
and	and	A530	CC	I-NP	O
transferrin	transferrin	T652	NN	I-NP	O
to	to	T000	TO	B-PP	O
TfR	TfR	T160	NN	B-NP	O
,	,	0000	,	O	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
demonstration	demonstration	D523	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
HFE	HFE	H100	NN	B-NP	O
,	,	0000	,	O	O
transferrin	transferrin	T652	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
TfR	TfR	T160	NN	B-NP	O
form	form	F650	VBP	B-VP	O
a	a	A000	DT	B-NP	O
ternary	ternary	T656	JJ	I-NP	O
complex	complex	C514	NN	I-NP	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Arg778Leu	Arg778Leu	A624	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
Korean	Korean	K650	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
R778L	R778L	R400	NN	B-NP	O
,	,	0000	,	O	O
A874V	A874V	A100	NN	B-NP	O
,	,	0000	,	O	O
L1083F	L1083F	L100	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
2304delC	2304delC	D420	NN	B-NP	O
-	-	0000	HYPH	O	O
-	-	0000	SYM	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
copper	copper	C160	NN	I-NP	O
-	-	0000	HYPH	O	O
transporting	transport	T652	VBG	B-VP	O
enzyme	enzyme	E525	NN	B-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
ATPase	ATPase	A312	NN	I-NP	O
(	(	0000	(	O	O
ATP7B	ATP7B	A310	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
Korean	Korean	K650	JJ	B-NP	O
Patients	Patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Arg778Leu	Arg778Leu	A624	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequently	frequently	F625	RB	I-NP	O
reported	report	R163	VBN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
six	six	S200	CD	B-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
studied	study	S300	VBN	B-VP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
37	37	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
considerably	considerably	C523	RB	B-ADJP	O
higher	high	H260	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
those	those	T200	DT	B-NP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
Asian	Asian	A250	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
single	single	S524	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
,	,	0000	,	O	O
2304delC	2304delC	D420	NN	B-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

Since	Since	S520	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
cDNA	cDNA	C350	NN	B-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
2302	2302	0000	CD	I-NP	O
(	(	0000	(	O	O
2302insC	2302insC	I520	NN	B-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
previously	previously	P612	RB	I-VP	O
described	describe	D261	VBN	I-VP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATP7B	ATP7B	A310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
susceptible	susceptible	S213	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
gene	gene	G500	NN	B-NP	O
rearrangements	rearrangement	R652	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Disruption	Disruption	D261	NN	B-NP	O
of	of	O100	IN	B-PP	O
splicing	splicing	S142	NN	B-NP	O
regulated	regulate	R243	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
CUG	CUG	C200	NN	I-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-NP	O
protein	protein	P635	NN	I-NP	O
in	in	I500	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
pathogenesis	pathogenesis	P325	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
RNAs	RNA	R520	NNS	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
create	create	C630	VB	B-VP	O
a	a	A000	DT	B-NP	O
gain	gain	G500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
function	function	F523	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
inappropriate	inappropriate	I516	JJ	I-NP	O
binding	binding	B535	NN	I-NP	O
of	of	O100	IN	B-PP	O
proteins	protein	P635	NNS	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
CUG	CUG	C200	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

Data	Datum	D300	NNS	B-NP	O
presented	present	P625	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
conserved	conserve	C526	VBN	I-NP	O
heterogeneous	heterogeneous	H362	JJ	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
ribonucleoprotein	ribonucleoprotein	R152	NN	I-NP	O
,	,	0000	,	O	O
CUG	CUG	C200	NN	B-NP	O
-	-	0000	HYPH	O	O
binding	bind	B535	VBG	B-VP	O
protein	protein	P635	NN	B-NP	O
(	(	0000	(	O	O
CUG	CUG	C200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
BP	BP	B100	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
may	may	M000	MD	B-VP	O
mediate	mediate	M300	VB	I-VP	O
the	the	T000	DT	B-NP	O
trans	trans	T652	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
effect	effect	E123	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RNA	RNA	R500	NN	I-NP	O
.	.	0000	.	O	O

CUG	CUG	C200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
BP	BP	B100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
bind	bind	B530	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
cardiac	cardiac	C632	JJ	I-NP	O
troponin	troponin	T615	NN	I-NP	O
T	T	T000	NN	I-NP	O
(	(	0000	(	O	O
cTNT	cTNT	C353	NN	B-NP	O
)	)	0000	)	O	O
pre	pre	P600	AFX	O	O
-	-	0000	HYPH	O	O
messenger	messenger	M252	NN	B-NP	O
RNA	RNA	R500	NN	I-NP	O
and	and	A530	CC	O	O
regulate	regulate	R243	VB	B-VP	O
its	its	I320	PRP$	B-NP	O
alternative	alternative	A436	JJ	I-NP	O
splicing	splicing	S142	NN	I-NP	O
.	.	0000	.	O	O

Splicing	Splicing	S142	NN	B-NP	O
of	of	O100	IN	B-PP	O
cTNT	cTNT	C353	NN	B-NP	O
was	be	W200	VBD	B-VP	O
disrupted	disrupt	D261	VBN	I-VP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
striated	striate	S363	VBN	I-NP	O
muscle	muscle	M240	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
expressing	express	E216	VBG	B-VP	O
transcripts	transcript	T652	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
contain	contain	C535	VBP	B-VP	O
CUG	CUG	C200	NN	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

Altered	Alter	A436	VBN	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
regulated	regulate	R243	VBN	B-VP	O
posttranscriptionally	posttranscriptionally	P236	RB	B-ADVP	O
by	by	B000	IN	B-PP	O
CUG	CUG	C200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
BP	BP	B100	NN	I-NP	O
therefore	therefore	T616	RB	B-ADVP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
pathogenesis	pathogenesis	P325	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
vasopressin	vasopressin	V216	NN	I-NP	O
-	-	0000	HYPH	O	O
neurophysin	neurophysin	N612	NN	B-NP	O
II	II	I000	CD	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
Spanish	Spanish	S152	JJ	I-NP	O
kindreds	kindred	K536	NNS	I-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
neurohypophyseal	neurohypophyseal	N612	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
.	.	0000	.	O	O

Familial	Familial	F540	JJ	B-NP	B-Disease
neurohypophyseal	neurohypophyseal	N612	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
insipidus	insipidus	I521	NN	I-NP	I-Disease
(	(	0000	(	O	O
FNDI	FNDI	F530	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
antidiuretic	antidiuretic	A536	JJ	I-NP	O
hormone	hormone	H650	NN	I-NP	O
arginine	arginine	A625	NN	I-NP	O
vasopressin	vasopressin	V216	NN	I-NP	O
(	(	0000	(	O	O
AVP	AVP	A100	NN	B-NP	O
)	)	0000	)	O	O
encoded	encode	E523	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
AVP	AVP	A100	NN	I-NP	O
-	-	0000	HYPH	O	O
neurophysin	neurophysin	N612	NN	B-NP	O
II	II	I000	CD	I-NP	O
(	(	0000	(	O	O
AVP	AVP	A100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
NPII	NPII	N100	NN	I-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
20p13	20p13	P000	CD	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
analyzed	analyze	A542	VBD	B-VP	O
two	two	T000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
FNDI	FNDI	F530	NN	B-NP	B-Disease
using	use	U252	VBG	B-VP	O
direct	direct	D623	JJ	B-NP	O
automated	automate	A353	VBN	I-NP	O
fluorescent	fluorescent	F462	JJ	I-NP	O
,	,	0000	,	I-NP	O
solid	solid	S430	JJ	I-NP	O
phase	phase	P200	NN	I-NP	O
,	,	0000	,	O	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
stranded	stranded	S365	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
PCR	PCR	P260	NN	B-NP	O
-	-	0000	HYPH	O	O
amplified	amplify	A514	VBN	B-NP	O
AVP	AVP	A100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
NPII	NPII	N100	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
presented	present	P625	VBD	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
consisting	consist	C523	VBG	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
G	G	G000	NN	I-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
2101	2101	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
produces	produce	P632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
signal	signal	S254	NN	I-NP	O
in	in	I500	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
82	82	0000	CD	I-NP	O
(	(	0000	(	O	O
Glu	Glu	G400	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
NPII	NPII	N100	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
premature	premature	P653	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
eliminates	eliminate	E453	VBZ	B-VP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
NPII	NPII	N100	NN	B-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
a	a	A000	DT	B-NP	O
cysteine	cysteine	C235	NN	I-NP	O
residue	residue	R230	NN	I-NP	O
in	in	I500	IN	B-PP	O
position	position	P235	NN	B-NP	O
85	85	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
correct	correct	C623	JJ	I-NP	O
folding	folding	F435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
prohormone	prohormone	P650	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
G279A	G279A	G000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
signal	signal	S254	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
replaces	replace	R142	VBZ	B-VP	O
Ala	Ala	A400	NN	B-NP	O
with	with	W300	IN	B-PP	O
Thr	Thr	T600	NN	B-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
frequent	frequent	F625	JJ	B-ADJP	O
among	among	A520	IN	B-PP	O
FNDI	FNDI	F530	NNP	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
reduce	reduce	R320	VB	I-VP	O
the	the	T000	DT	B-NP	O
efficiency	efficiency	E125	NN	I-NP	O
of	of	O100	IN	B-PP	O
cleavage	cleavage	C412	NN	B-NP	O
by	by	B000	IN	B-PP	O
signal	signal	S254	NN	B-NP	O
peptidases	peptidase	P132	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
of	of	O100	IN	B-PP	O
Saethre	Saethre	S360	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Chotzen	Chotzen	C325	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	I-PP	O
TWIST	TWIST	T230	NN	B-NP	O
and	and	A530	CC	I-NP	O
FGFR	FGFR	F216	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Thirty	Thirty	T630	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
two	two	T000	CD	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
features	feature	F362	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Saethre	Saethre	S360	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Chotzen	Chotzen	C325	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
condition	condition	C535	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	O
craniosynostosis	craniosynostosis	C652	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
limb	limb	L510	NN	I-NP	B-Disease
anomalies	anomaly	A542	NNS	I-NP	I-Disease
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
TWIST	TWIST	T230	NN	B-NP	O
,	,	0000	,	O	O
FGFR2	FGFR2	F216	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
FGFR3	FGFR3	F216	NN	B-NP	O
.	.	0000	.	O	O

Nine	Nine	N500	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
and	and	A530	CC	I-NP	O
three	three	T600	CD	I-NP	O
recurrent	recurrent	R265	JJ	I-NP	O
TWIST	TWIST	T230	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
12	12	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Seven	Seven	S150	CD	B-NP	O
families	family	F542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
the	the	T000	DT	B-NP	O
FGFR3	FGFR3	F216	NN	I-NP	O
P250R	P250R	P600	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
individual	individual	I531	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
an	an	A500	DT	B-NP	O
FGFR2	FGFR2	F216	NN	I-NP	O
VV269	VV269	V100	NN	I-NP	O
-	-	0000	HYPH	O	O
270	270	0000	CD	B-NP	O
deletion	deletion	D435	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
detection	detection	D323	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
for	for	F600	IN	B-PP	O
TWIST	TWIST	T230	NN	B-NP	O
or	or	O600	CC	I-NP	O
FGFR	FGFR	F216	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
68	68	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
Saethre	Saethre	S360	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Chotzen	Chotzen	C325	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
our	our	O600	PRP$	B-NP	O
five	five	F100	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
elsewhere	elsewhere	E426	RB	B-VP	O
reported	report	R163	VBN	I-VP	O
with	with	W300	IN	B-PP	O
TWIST	TWIST	T230	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

More	More	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
35	35	0000	CD	I-NP	O
different	different	D165	JJ	I-NP	O
TWIST	TWIST	T230	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
now	now	N000	RB	I-VP	O
known	know	K500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
literature	literature	L363	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
features	feature	F362	NNS	I-NP	O
,	,	0000	,	O	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
a	a	A000	DT	I-NP	O
third	third	T630	JJ	I-NP	O
of	of	O100	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
TWIST	TWIST	T230	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
are	be	A600	VBP	B-VP	O
coronal	coronal	C654	JJ	B-NP	B-Disease
synostosis	synostosis	S523	NN	I-NP	I-Disease
,	,	0000	,	O	O
brachycephaly	brachycephaly	B621	RB	B-ADVP	B-Disease
,	,	0000	,	O	O
low	low	L000	JJ	B-NP	B-Disease
frontal	frontal	F653	JJ	I-NP	I-Disease
hairline	hairline	H645	NN	I-NP	I-Disease
,	,	0000	,	O	O
facial	facial	F240	JJ	B-NP	B-Disease
asymmetry	asymmetry	A253	NN	I-NP	I-Disease
,	,	0000	,	O	O
ptosis	ptosis	P320	NN	B-NP	B-Disease
,	,	0000	,	O	O
hypertelorism	hypertelorism	H163	NN	B-NP	B-Disease
,	,	0000	,	O	O
broad	broad	B630	JJ	B-NP	B-Disease
great	great	G630	JJ	I-NP	I-Disease
toes	toe	T200	NNS	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
clinodactyly	clinodactyly	C453	RB	B-ADVP	B-Disease
.	.	0000	.	O	O

Significant	Significant	S251	JJ	B-NP	O
intra	intra	I536	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
and	and	A530	CC	I-NP	O
interfamilial	interfamilial	I536	JJ	I-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
variability	variability	V614	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
present	present	P625	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
either	either	E360	DT	B-NP	O
TWIST	TWIST	T230	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
or	or	O600	CC	O	O
FGFR	FGFR	F216	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
overlap	overlap	O164	NN	I-NP	O
in	in	I500	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
features	feature	F362	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
for	for	F600	IN	B-PP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
one	one	O500	CD	I-NP	O
craniosynostotic	craniosynostotic	C652	JJ	I-NP	B-Disease
condition	condition	C535	NN	I-NP	I-Disease
-	-	0000	HYPH	B-VP	O
such	such	S200	JJ	B-PP	O
as	as	A200	IN	I-PP	O
Saethre	Saethre	S360	NNP	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
Chotzen	Chotzen	C325	NNP	B-NP	I-Disease
,	,	0000	,	O	I-Disease
Crouzon	Crouzon	C625	NNP	B-NP	I-Disease
,	,	0000	,	O	I-Disease
and	and	A530	CC	O	I-Disease
Pfeiffer	Pfeiffer	P160	NN	B-NP	I-Disease
syndromes	syndrome	S536	NNS	I-NP	I-Disease
-	-	0000	HYPH	O	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
TWIST	TWIST	T230	NN	B-NP	O
and	and	A530	CC	I-NP	O
FGFRs	FGFR	F216	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
components	component	C515	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
pathway	pathway	P300	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
modulation	modulation	M343	NN	I-NP	O
of	of	O100	IN	B-PP	O
craniofacial	craniofacial	C651	JJ	B-NP	O
and	and	A530	CC	I-NP	O
limb	limb	L510	NN	I-NP	O
development	development	D141	NN	I-NP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
UBE3A	UBE3A	U100	NN	B-NP	O
in	in	I500	IN	B-PP	O
Angelman	Angelman	A524	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Angelman	Angelman	A524	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
AS	AS	A200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
of	of	O100	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
paternal	paternal	P365	JJ	B-NP	O
uniparental	uniparental	U516	JJ	I-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
(	(	0000	(	O	O
UPD	UPD	U130	NN	B-NP	B-Disease
)	)	0000	)	O	O
15	15	0000	CD	B-NP	O
,	,	0000	,	O	O
by	by	B000	IN	B-PP	O
imprinting	imprint	I516	VBG	B-VP	O
defects	defect	D123	NNS	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
UBE3A	UBE3A	U100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

UBE3A	UBE3A	U100	NN	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
ubiquitin	ubiquitin	U123	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
protein	protein	P635	NN	I-NP	O
ligase	ligase	L200	NN	I-NP	O
and	and	A530	CC	O	O
shows	show	S200	VBZ	B-VP	O
brain	brain	B650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
imprinting	imprinting	I516	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
UBE3A	UBE3A	U100	NN	B-NP	O
coding	coding	C352	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
region	region	R250	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
detected	detect	D323	VBN	B-VP	O
by	by	B000	IN	B-PP	O
SSCP	SSCP	S210	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
13	13	0000	CD	B-NP	O
AS	AS	A200	JJ	I-NP	B-Disease
individuals	individual	I531	NNS	I-NP	O
or	or	O600	CC	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
identical	identical	I353	JJ	I-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
duplications	duplication	D142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
16	16	0000	CD	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
11	11	0000	CD	I-NP	O
unique	unique	U520	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
8	8	0000	CD	B-NP	O
were	be	W600	VBD	B-VP	O
small	small	S540	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
or	or	O600	CC	I-NP	O
insertions	insertion	I526	NNS	I-NP	O
predicted	predict	P632	VBN	B-VP	O
to	to	T000	TO	B-VP	O
cause	cause	C200	VB	I-VP	O
frameshifts	frameshift	F652	NNS	B-NP	O
,	,	0000	,	O	O
1	1	0000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
stop	stop	S310	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
,	,	0000	,	O	O
1	1	0000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
1	1	0000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
cause	cause	C200	VB	I-VP	O
insertion	insertion	I526	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
isoleucine	isoleucine	I242	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
hect	hect	H230	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
UBE3A	UBE3A	U100	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
functions	function	F523	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
E2	E2	E000	NN	B-NP	O
binding	binding	B535	NN	I-NP	O
and	and	A530	CC	O	O
ubiquitin	ubiquitin	U123	NN	B-NP	O
transfer	transfer	T652	NN	I-NP	O
.	.	0000	.	O	O

Eight	Eight	E230	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
familial	familial	F540	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
five	five	F100	CD	B-NP	O
were	be	W600	VBD	B-VP	O
sporadic	sporadic	S163	JJ	B-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
familial	familial	F540	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
sporadic	sporadic	S163	JJ	I-NP	O
case	case	C200	NN	I-NP	O
,	,	0000	,	O	O
mosaicism	mosaicism	M250	NN	B-NP	O
for	for	F600	IN	B-PP	O
UBE3A	UBE3A	U100	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
AS	AS	A200	JJ	I-NP	B-Disease
sons	son	S520	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
grandfather	grandfather	G653	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
AS	AS	A200	JJ	I-NP	B-Disease
first	first	F623	JJ	I-NP	O
cousins	cousin	C252	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
mother	mother	M360	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
AS	AS	A200	JJ	I-NP	B-Disease
daughter	daughter	D236	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
frequencies	frequency	F625	NNS	I-NP	O
with	with	W300	IN	B-PP	O
which	which	W200	WDT	B-NP	O
we	we	W000	PRP	B-NP	O
detected	detect	D323	VBD	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
5	5	0000	CD	B-NP	O
(	(	0000	(	O	O
14	14	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
35	35	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
and	and	A530	CC	O	O
8	8	0000	CD	B-NP	O
(	(	0000	(	O	O
80	80	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	O
cases	case	C200	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
845	845	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	O	O
187	187	0000	CD	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
:	:	0000	:	O	O
prevalence	prevalence	P614	NN	B-NP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

Hemochromatosis	Hemochromatosis	H526	NN	B-NP	B-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
iron	iron	I650	NN	B-NP	I-Disease
metabolism	metabolism	M314	NN	I-NP	I-Disease
,	,	0000	,	O	O
leads	lead	L320	VBZ	B-VP	O
,	,	0000	,	O	O
if	if	I100	IN	B-SBAR	O
untreated	untreated	U536	JJ	B-ADJP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
progressive	progressive	P626	JJ	B-NP	O
iron	iron	I650	NN	I-NP	B-Disease
overload	overload	O164	NN	I-NP	I-Disease
and	and	A530	CC	O	O
premature	premature	P653	JJ	B-NP	B-Disease
death	death	D300	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
HFE	HFE	H100	NN	B-NP	O
,	,	0000	,	O	O
recently	recently	R253	RB	B-ADVP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
characterization	characterization	C623	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
contains	contain	C535	VBZ	B-VP	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
-	-	0000	HYPH	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
nucleotides	nucleotide	N243	NNS	I-NP	O
845	845	0000	CD	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
A	A	A000	NN	B-NP	O
(	(	0000	(	O	O
C282Y	C282Y	C000	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
187	187	0000	CD	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
G	G	G000	NN	B-NP	O
(	(	0000	(	O	O
H63D	H63D	H300	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
common	common	C500	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
Caucasians	Caucasian	C252	NNPS	B-NP	O
,	,	0000	,	O	O
affecting	affect	A123	VBG	B-VP	O
>	>	0000	SYM	B-NP	O
=	=	0000	SYM	B-VP	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	O	O
300	300	0000	CD	B-NP	O
individuals	individual	I531	NNS	I-NP	O
of	of	O100	IN	B-PP	O
northern	northern	N636	JJ	B-NP	O
European	European	E615	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
recognized	recognize	R252	VBN	I-VP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
used	use	U230	VBD	B-VP	O
PCR	PCR	P260	NN	B-NP	O
and	and	A530	CC	I-NP	O
restriction	restriction	R236	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
enzyme	enzyme	E525	NN	I-NP	O
digestion	digestion	D235	NN	I-NP	O
to	to	T000	TO	B-VP	O
analyze	analyze	A542	VB	I-VP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
845	845	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	O	O
187	187	0000	CD	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
typed	type	T130	VBN	I-NP	O
samples	sample	S514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
,	,	0000	,	O	O
comprising	comprise	C516	VBG	B-VP	O
Australian	Australian	A236	JJ	B-NP	O
Aboriginal	Aboriginal	A162	NNP	I-NP	O
,	,	0000	,	O	O
Chinese	Chinese	C520	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Pacific	Pacific	P212	NNP	B-NP	O
Islanders	Islander	I245	NNPS	I-NP	O
.	.	0000	.	O	O

Results	Result	R243	NNS	B-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
845	845	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
populations	population	P143	NNS	I-NP	O
(	(	0000	(	O	O
allele	allele	A400	NN	B-NP	O
frequency	frequency	F625	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	.	O	O
32	32	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
furthermore	furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
always	always	A420	RB	I-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
conjunction	conjunction	C525	NN	B-NP	O
with	with	W300	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
common	common	C500	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
Caucasians	Caucasian	C252	NNPS	B-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
845	845	0000	CD	B-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
been	be	B500	VBN	I-VP	O
introduced	introduce	I536	VBN	I-VP	O
into	into	I530	IN	B-PP	O
these	these	T200	DT	B-NP	O
populations	population	P143	NNS	I-NP	O
by	by	B000	IN	B-PP	O
Caucasian	Caucasian	C250	JJ	B-NP	O
admixture	admixture	A352	NN	I-NP	O
.	.	0000	.	O	O

187	187	0000	CD	B-NP	O
C	C	C000	JJ	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	B-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
an	an	A500	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
of	of	O100	IN	B-PP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O

68	68	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
populations	population	P143	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
(	(	0000	(	O	O
Australian	Australian	A236	JJ	B-NP	O
Aboriginal	Aboriginal	A162	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Australian	Australian	A236	JJ	I-NP	O
Aboriginal	Aboriginal	A162	JJ	I-NP	O
samples	sample	S514	NNS	I-NP	O
,	,	0000	,	O	O
187	187	0000	CD	B-NP	O
C	C	C000	JJ	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
common	common	C500	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
Caucasians	Caucasian	C252	NNPS	B-NP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
introduced	introduce	I536	VBN	I-VP	O
by	by	B000	IN	B-PP	O
recent	recent	R253	JJ	B-NP	O
admixture	admixture	A352	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Chinese	Chinese	C520	JJ	I-NP	O
samples	sample	S514	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
,	,	0000	,	O	O
187	187	0000	CD	B-NP	O
C	C	C000	JJ	I-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
>	>	0000	SYM	I-NP	O
G	G	G000	NN	B-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
wide	wide	W300	JJ	I-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
,	,	0000	,	O	O
showing	show	S520	VBG	B-VP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
widespread	widespread	W321	JJ	B-ADJP	O
and	and	A530	CC	I-ADJP	O
likely	likely	L240	JJ	I-ADJP	O
to	to	T000	TO	B-VP	O
predate	predate	P630	VB	I-VP	O
the	the	T000	DT	O	O
more	more	M600	RBR	B-ADVP	O
genetically	genetically	G532	RB	I-ADVP	O
restricted	restricted	R236	JJ	B-NP	O
845	845	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-VP	O
>	>	0000	SYM	B-NP	O
A	A	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Genotype	Genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
in	in	I500	IN	B-PP	O
attenuated	attenuate	A353	VBN	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
.	.	0000	.	O	O

Germ	Germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
APC	APC	A120	NN	I-NP	O
are	be	A600	VBP	B-VP	O
implicated	implicate	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
attenuated	attenuate	A353	VBN	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
AAPC	AAPC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

AAPC	AAPC	A120	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
recognized	recognize	R252	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
occurrence	occurrence	O265	NN	I-NP	O
of	of	O100	IN	B-PP	O
<	<	0000	SYM	B-NP	O
100	100	0000	CD	I-NP	O
colonic	colonic	C452	JJ	I-NP	B-Disease
adenomas	adenoma	A352	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
later	later	L360	JJ	I-NP	O
onset	onset	O523	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
(	(	0000	(	O	O
age	age	A200	NN	B-NP	O
>	>	0000	SYM	O	O
40	40	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
aim	aim	A500	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
was	be	W200	VBD	B-VP	O
to	to	T000	TO	B-VP	O
assess	assess	A200	VB	I-VP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
in	in	I500	IN	B-PP	O
AAPC	AAPC	A120	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
-	-	0000	HYPH	O	O
truncation	truncation	T652	NN	B-NP	O
test	test	T230	NN	I-NP	O
(	(	0000	(	O	O
PTT	PTT	P300	NN	B-NP	O
)	)	0000	)	O	O
assay	assay	A200	NN	B-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
entire	entire	E536	JJ	I-NP	O
coding	cod	C352	VBG	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
screened	screen	S265	VBN	I-VP	O
in	in	I500	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
individuals	individual	I531	NNS	I-NP	O
from	from	F650	IN	B-PP	O
11	11	0000	CD	B-NP	O
AAPC	AAPC	A120	NN	I-NP	B-Disease
kindreds	kindred	K536	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
differences	difference	D165	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
located	locate	L230	VBN	I-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
)	)	0000	)	O	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
spanning	span	S152	VBG	B-VP	O
exons	exon	E252	NNS	B-NP	O
4	4	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
5	5	0000	CD	I-NP	O
,	,	0000	,	O	O
(	(	0000	(	B-LST	O
2	2	0000	LS	I-LST	O
)	)	0000	)	O	O
within	within	W350	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
9	9	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
(	(	0000	(	B-LST	O
3	3	0000	LS	I-LST	O
)	)	0000	)	O	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
distal	distal	D234	JJ	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Variability	Variability	V614	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
adenomas	adenoma	A352	NNS	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
most	most	M230	RBS	B-ADJP	O
apparent	apparent	A165	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
region	region	R250	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
upper	upper	U160	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
gastrointestinal	gastrointestinal	G236	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
more	more	M600	RBR	B-ADJP	O
severe	severe	S160	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
them	them	T500	PRP	B-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
either	either	E360	CC	O	O
region	region	R250	NN	B-NP	O
2	2	0000	CD	I-NP	O
or	or	O600	CC	O	O
region	region	R250	NN	B-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
average	average	A162	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
adenomas	adenoma	A352	NNS	B-NP	B-Disease
tended	tend	T530	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
lower	low	L600	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
those	those	T200	DT	B-NP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
region	region	R250	NN	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
age	age	A200	NN	B-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
was	be	W200	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
AAPC	AAPC	A120	NN	I-NP	B-Disease
kindreds	kindred	K536	NNS	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
predominance	predominance	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
right	right	R230	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
sided	sided	S300	JJ	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
adenomas	adenoma	A352	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
rectal	rectal	R234	JJ	B-NP	B-Disease
polyp	polyp	P410	NN	I-NP	I-Disease
sparing	sparing	S165	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O

No	No	N000	DT	B-NP	O
desmoid	desmoid	D253	JJ	I-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
kindreds	kindred	K536	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
AAPC	AAPC	A120	NN	B-NP	B-Disease
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
location	location	L235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
may	may	M000	MD	B-VP	O
partially	partially	P634	RB	I-VP	O
predict	predict	P632	VB	I-VP	O
specific	specific	S121	JJ	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
should	should	S430	MD	B-VP	O
help	help	H410	VB	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
design	design	D250	NN	I-NP	O
of	of	O100	IN	B-PP	O
tailored	tailor	T463	VBN	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
management	management	M525	NN	I-NP	O
protocols	protocol	P632	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
subset	subset	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Wilms	Wilms	W452	NNP	B-NP	B-Disease
'	'	0000	POS	B-NP	I-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
1	1	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
Dax	Dax	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
modulate	modulate	M343	VBP	B-VP	O
the	the	T000	DT	B-NP	O
orphan	orphan	O615	NN	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
receptor	receptor	R213	NN	I-NP	O
SF	SF	S100	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
sex	sex	S200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

Products	Product	P632	NNS	B-NP	O
of	of	O100	IN	B-PP	O
steroidogenic	steroidogenic	S363	JJ	B-NP	O
factor	factor	F236	NN	I-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
SF	SF	S100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
Wilms	Wilms	W452	NNP	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
WT1	WT1	W300	NN	B-NP	O
)	)	0000	)	O	O
genes	gene	G520	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
essential	essential	E253	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
mammalian	mammalian	M545	JJ	B-NP	O
gonadogenesis	gonadogenesis	G532	NN	I-NP	O
prior	prior	P600	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
sexual	sexual	S240	JJ	B-NP	O
differentiation	differentiation	D165	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
males	male	M420	NNS	B-NP	O
,	,	0000	,	O	O
SF	SF	S100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
participates	participate	P632	NNS	I-NP	O
in	in	I500	IN	B-PP	O
sexual	sexual	S240	JJ	B-NP	O
development	development	D141	NN	I-NP	O
by	by	B000	IN	B-PP	O
regulating	regulate	R243	VBG	B-VP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
hormone	hormone	H650	NN	I-NP	O
Mullerian	Mullerian	M465	JJ	I-NP	O
inhibiting	inhibit	I513	VBG	I-NP	O
substance	substance	S123	NN	I-NP	O
(	(	0000	(	O	O
MIS	MIS	M200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
WT1	WT1	W300	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
KTS	KTS	K320	NN	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
associate	associate	A230	VBP	B-VP	O
and	and	A530	CC	I-VP	O
synergize	synergize	S562	VBP	I-VP	O
with	with	W300	IN	B-PP	O
SF	SF	S100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
to	to	T000	TO	B-VP	O
promote	promote	P653	VB	I-VP	O
MIS	MIS	M200	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
WT1	WT1	W300	NN	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
male	male	M400	JJ	B-NP	B-Disease
pseudohermaphroditism	pseudohermaphroditism	P236	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Denys	Denys	D520	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Drash	Drash	D620	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
,	,	0000	,	O	O
fail	fail	F400	VBP	B-VP	O
to	to	T000	TO	I-VP	O
synergize	synergize	S562	VB	I-VP	O
with	with	W300	IN	B-PP	O
SF	SF	S100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

Additionally	Additionally	A354	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
X	X	X000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
linked	link	L523	VBN	I-VP	O
,	,	0000	,	O	O
candidate	candidate	C530	NN	B-NP	O
dosage	dosage	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
sensitive	sensitive	S523	JJ	I-NP	O
sex	sex	S200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
reversal	reversal	R162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
Dax	Dax	D200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
antagonizes	antagonize	A532	VBZ	B-VP	O
synergy	synergy	S562	NN	B-NP	O
between	between	B350	IN	B-PP	O
SF	SF	S100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
WT1	WT1	W300	NN	I-NP	O
,	,	0000	,	O	O
most	most	M230	RBS	B-ADVP	O
likely	likely	L240	RB	I-ADVP	O
through	through	T620	IN	B-PP	O
a	a	A000	DT	B-NP	O
direct	direct	D623	JJ	I-NP	O
interaction	interaction	I536	NN	I-NP	O
with	with	W300	IN	B-PP	O
SF	SF	S100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
propose	propose	P612	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
WT1	WT1	W300	NN	B-NP	O
and	and	A530	CC	I-NP	O
Dax	Dax	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
functionally	functionally	F523	RB	B-ADVP	O
oppose	oppose	O120	VBP	B-VP	O
each	each	E200	DT	B-NP	O
other	other	O360	JJ	I-NP	O
in	in	I500	IN	B-PP	O
testis	testis	T232	NN	B-NP	O
development	development	D141	NN	I-NP	O
by	by	B000	IN	B-PP	O
modulating	modulate	M343	VBG	B-VP	O
SF	SF	S100	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
mediated	mediate	M300	VBN	I-NP	O
transactivation	transactivation	T652	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
imprinting	imprinting	I516	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
centre	centre	C536	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Imprinting	Imprinting	I516	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
15q11	15q11	Q000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
q13	q13	Q000	NN	I-NP	O
region	region	R250	NN	I-NP	O
involves	involve	I514	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
imprinting	imprinting	I516	NN	I-NP	O
centre	centre	C536	NN	I-NP	O
(	(	0000	(	O	O
IC	IC	I200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
mapping	map	M152	VBG	B-VP	O
in	in	I500	IN	B-PP	O
part	part	P630	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
promoter	promoter	P653	NN	I-NP	O
and	and	A530	CC	I-NP	O
first	first	F623	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
SNRPN	SNRPN	S561	NN	B-NP	O
.	.	0000	.	O	O

Deletion	Deletion	D435	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
IC	IC	I200	NN	I-NP	O
abolishes	abolish	A142	VBZ	B-VP	O
local	local	L240	JJ	B-NP	O
paternally	paternally	P365	RB	I-NP	O
derived	derive	D613	VBN	I-NP	O
gene	gene	G500	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
and	and	A530	CC	O	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
created	create	C630	VBN	I-VP	O
two	two	T000	CD	B-NP	O
deletion	deletion	D435	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
to	to	T000	TO	B-VP	O
understand	understand	U536	VB	I-VP	O
PWS	PWS	P200	NN	B-NP	B-Disease
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
IC	IC	I200	NN	I-NP	O
.	.	0000	.	O	O

Mice	Mouse	M200	NNS	B-NP	O
harbouring	harbour	H616	VBG	B-VP	O
an	an	A500	DT	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
in	in	I500	IN	B-PP	O
Snrpn	Snrpn	S561	NN	B-NP	O
are	be	A600	VBP	B-VP	O
phenotypically	phenotypically	P531	RB	B-ADJP	O
normal	normal	N654	JJ	I-ADJP	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
mutations	mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
SNRPN	SNRPN	S561	NN	B-NP	O
are	be	A600	VBP	B-VP	O
not	not	N300	RB	O	O
sufficient	sufficient	S125	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
induce	induce	I532	VB	I-VP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Mice	Mouse	M200	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
larger	large	L626	JJR	I-NP	O
deletion	deletion	D435	NN	I-NP	O
involving	involve	I514	VBG	B-VP	O
both	both	B300	CC	O	O
Snrpn	Snrpn	S561	NN	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
PWS	PWS	P200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
IC	IC	I200	NN	I-NP	O
lack	lack	L200	NN	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
imprinted	imprint	I516	VBN	I-NP	O
genes	gene	G520	NNS	I-NP	O
Zfp127	Zfp127	Z100	NN	I-NP	O
(	(	0000	(	O	O
mouse	mouse	M200	NN	B-NP	O
homologue	homologue	H542	NN	I-NP	O
of	of	O100	IN	B-PP	O
ZNF127	ZNF127	Z510	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
Ndn	Ndn	N350	NN	B-NP	O
and	and	A530	CC	I-NP	O
Ipw	Ipw	I100	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
manifest	manif	M512	JJS	B-NP	O
several	several	S164	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
common	common	C500	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
infants	infant	I515	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
both	both	B300	CC	O	O
the	the	T000	DT	B-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
IC	IC	I200	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
role	role	R400	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
coordinate	coordinate	C635	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
is	be	I200	VBZ	B-VP	O
conserved	conserve	C526	VBN	I-VP	O
between	between	B350	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
and	and	A530	CC	O	O
human	human	H500	JJ	B-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
suitable	suitable	S314	JJ	I-NP	O
model	model	M340	NN	I-NP	O
system	system	S235	NN	I-NP	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
imprinting	imprinting	I516	NN	B-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genome	genome	G500	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
detected	detect	D323	VBN	B-VP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
telangiectasia	telangiectasia	T452	NN	B-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
:	:	0000	:	O	O
possible	possible	P214	JJ	B-NP	O
preponderance	preponderance	P615	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
founder	founder	F536	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
4612del165	4612del165	D400	CD	B-NP	O
and	and	A530	CC	I-NP	O
7883del5	7883del5	D400	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
(	(	0000	(	O	O
A	A	A000	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
,	,	0000	,	O	O
mutated	mutate	M300	VBN	B-VP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
on	on	O500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
11q22	11q22	Q000	NN	I-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
has	have	H200	VBZ	B-VP	O
recently	recently	R253	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
T	T	T000	NN	B-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
types	type	T120	NNS	I-NP	O
of	of	O100	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
ATM	ATM	A350	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
to	to	T000	TO	B-VP	O
look	look	L200	VB	I-VP	O
for	for	F600	IN	B-PP	O
possible	possible	P214	JJ	B-NP	O
mutational	mutational	M354	JJ	I-NP	O
hotspots	hotspot	H321	NNS	I-NP	O
,	,	0000	,	O	O
reverse	reverse	R162	NN	B-NP	O
-	-	0000	HYPH	B-VP	O
transcribed	transcribe	T652	VBN	B-NP	O
RNA	RNA	R500	NN	I-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
ten	ten	T500	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
belonging	belong	B452	VBG	B-VP	O
to	to	T000	TO	B-PP	O
eight	eight	E230	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
restriction	restriction	R236	NN	I-NP	O
endonuclease	endonuclease	E535	NN	I-NP	O
fingerprinting	fingerprinting	F526	NN	I-NP	O
method	method	M300	NN	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
by	by	B000	IN	B-PP	O
others	other	O362	NNS	B-NP	O
,	,	0000	,	O	O
mutations	mutation	M352	NNS	B-NP	O
that	that	T300	WDT	B-NP	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	I-VP	O
exon	exon	E250	VB	I-VP	O
skipping	skipping	S215	NN	B-NP	O
or	or	O600	CC	O	O
premature	premature	P653	JJ	B-NP	O
protein	protein	P635	NN	I-NP	O
truncation	truncation	T652	NN	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
predominant	predominant	P635	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
mutants	mutant	M353	NNS	I-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
on	on	O500	IN	B-PP	O
12	12	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
16	16	0000	CD	I-NP	O
alleles	allele	A420	NNS	I-NP	O
examined	examine	E253	VBN	B-VP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
were	be	W600	VBD	B-VP	O
deletions	deletion	D435	NNS	B-NP	O
involving	involve	I514	VBG	B-VP	O
a	a	A000	DT	B-NP	O
loss	loss	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
7	7	0000	CD	I-NP	O
,	,	0000	,	O	O
exon	exon	E250	NN	B-NP	O
16	16	0000	CD	I-NP	O
,	,	0000	,	O	O
exon	exon	E250	NN	B-NP	O
33	33	0000	CD	I-NP	O
or	or	O600	CC	O	O
exon	exon	E250	NN	B-NP	O
35	35	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
others	other	O362	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
minute	minute	M530	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
4649delA	4649delA	D400	NN	B-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
33	33	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
7883del5	7883del5	D400	CD	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
55	55	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
4612del165	4612del165	D400	CD	I-NP	O
and	and	A530	CC	I-NP	O
7883del5	7883del5	D400	CD	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
two	two	T000	CD	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
;	;	0000	:	O	O
44	44	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
7	7	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
16	16	0000	CD	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
4612del165	4612del165	D400	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
all	all	A400	DT	O	O
ascribed	ascribe	A261	VBN	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
splice	splice	S142	NN	I-NP	O
donor	donor	D560	NN	I-NP	O
site	site	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
33	33	0000	CD	I-NP	O
.	.	0000	.	O	O

Microsatellite	Microsatellite	M262	NN	B-NP	O
genotyping	genotyping	G531	NN	I-NP	O
around	around	A653	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
was	be	W200	VBD	B-VP	O
shared	share	S630	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
founder	founder	F536	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
predominant	predominant	P635	JJ	B-ADJP	O
among	among	A520	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
ATM	ATM	A350	NN	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
.	.	0000	.	O	O

W474C	W474C	W200	NN	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
affects	affect	A123	VBZ	B-VP	O
early	early	E640	JJ	B-NP	O
processing	processing	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
of	of	O100	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
hexosaminidase	hexosaminidase	H253	NN	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
subacute	subacute	S123	JJ	B-NP	O
G	G	G000	NN	I-NP	B-Disease
(	(	0000	(	O	I-Disease
M2	M2	M000	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
gangliosidosis	gangliosidosis	G524	NN	B-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
HEXA	HEXA	H200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
encoding	encode	E523	VBG	B-VP	O
the	the	T000	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
of	of	O100	IN	B-PP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	O	O
hexosaminidase	hexosaminidase	H253	NN	B-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
Hex	Hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
that	that	T300	WDT	B-NP	O
abolish	abolish	A142	VBP	B-VP	O
Hex	Hex	H200	NNP	B-NP	O
A	A	A000	NNP	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
cause	cause	C200	VBP	B-VP	O
Tay	Tay	T000	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Sachs	Sachs	S200	NNP	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
TSD	TSD	T230	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
fatal	fatal	F340	JJ	I-NP	O
infantile	infantile	I515	JJ	I-NP	B-Disease
form	form	F650	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
G	G	G000	NN	B-NP	I-Disease
(	(	0000	(	O	I-Disease
M2	M2	M000	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
gangliosidosis	gangliosidosis	G524	NN	B-NP	I-Disease
,	,	0000	,	O	I-Disease
Type	Type	T100	NN	B-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
.	.	0000	.	O	O

Less	Less	L200	RBR	B-ADJP	O
severe	severe	S160	JJ	I-ADJP	O
,	,	0000	,	O	O
subacute	subacute	S123	JJ	O	O
(	(	0000	(	O	O
juvenile	juvenile	J154	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
chronic	chronic	C652	JJ	O	O
(	(	0000	(	O	O
adult	adult	A343	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
)	)	0000	)	O	O
variants	variant	V653	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
broad	broad	B630	JJ	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
residual	residual	R234	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Hex	Hex	H200	NNP	B-NP	O
A	A	A000	NNP	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
1422	1422	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	O	O
>	>	0000	SYM	O	O
C	C	C000	NN	B-NP	O
(	(	0000	(	O	O
amino	amino	A500	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
W474C	W474C	W200	NN	I-NP	O
)	)	0000	)	O	O
substitution	substitution	S123	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
13	13	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
HEXA	HEXA	H200	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
proband	proband	P615	NN	I-NP	O
who	who	W000	WP	B-NP	O
manifested	manifest	M512	VBD	B-VP	O
a	a	A000	DT	B-NP	O
subacute	subacute	S123	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
G	G	G000	NN	B-NP	B-Disease
(	(	0000	(	O	I-Disease
M2	M2	M000	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
gangliosidosis	gangliosidosis	G524	NN	B-NP	I-Disease
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
maternally	maternally	M365	RB	I-NP	O
inherited	inherit	I563	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
infantile	infantile	I515	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	O	O
causing	cause	C252	VBG	B-VP	O
4	4	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
bp	bp	B100	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
,	,	0000	,	O	O
+	+	0000	SYM	O	O
TATC	TATC	T320	NN	B-NP	O
1278	1278	0000	CD	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
11	11	0000	CD	I-NP	O
.	.	0000	.	O	O

Pulse	Pulse	P420	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
chase	chase	C200	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
using	use	U252	VBG	B-VP	O
proband	proband	P615	NN	B-NP	O
fibroblasts	fibroblast	F161	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
W474C	W474C	W200	NN	I-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
alpha	alpha	A410	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
subunit	subunit	S153	NN	I-NP	O
precursor	precursor	P626	NN	I-NP	O
was	be	W200	VBD	B-VP	O
normally	normally	N654	RB	I-VP	O
synthesized	synthesize	S532	VBN	I-VP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	B-VP	O
phosphorylated	phosphorylate	P216	VBN	I-VP	O
or	or	O600	CC	I-VP	O
secreted	secrete	S263	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
mature	mature	M360	JJ	I-NP	O
lysosomal	lysosomal	L254	JJ	I-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

When	When	W500	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
W474C	W474C	W200	NN	I-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
alpha	alpha	A410	SYM	B-NP	O
-	-	0000	HYPH	O	O
subunit	subunit	S153	NN	B-NP	O
was	be	W200	VBD	B-VP	O
transiently	transiently	T652	RB	B-ADVP	O
co	co	C000	AFX	B-ADJP	O
-	-	0000	HYPH	O	O
expressed	express	E216	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
beta	beta	B300	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
to	to	T000	TO	B-VP	O
produce	produce	P632	VB	I-VP	O
Hex	Hex	H200	NN	B-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
alphabeta	alphabeta	A413	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
COS	COS	C200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
7	7	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
mature	mature	M360	JJ	I-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	B-NP	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
its	its	I320	PRP$	B-NP	O
level	level	L140	NN	I-NP	O
was	be	W200	VBD	B-VP	O
much	much	M200	RB	B-ADJP	O
lower	low	L600	JJR	I-ADJP	O
than	than	T500	IN	B-PP	O
that	that	T300	DT	B-NP	O
from	from	F650	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
transfections	transfection	T652	NNS	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
higher	high	H260	JJR	B-ADJP	O
than	than	T500	IN	B-PP	O
in	in	I500	IN	B-PP	O
those	those	T200	DT	B-NP	O
cells	cell	C420	NNS	I-NP	O
transfected	transfecte	T652	VBN	B-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
infantile	infantile	I515	JJ	B-NP	O
TSD	TSD	T230	NN	I-NP	B-Disease
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
precursor	precursor	P626	NN	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
W474C	W474C	W200	NN	I-NP	O
alpha	alpha	A410	SYM	O	O
-	-	0000	HYPH	O	O
subunit	subunit	S153	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
accumulate	accumulate	A254	VB	I-VP	O
in	in	I500	IN	B-PP	O
comparison	comparison	C516	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
alpha	alpha	A410	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
precursor	precursor	P626	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
1422	1422	0000	CD	I-NP	O
G	G	G000	NN	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
C	C	C000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Hex	Hex	H200	NNP	B-NP	B-Disease
A	A	A000	NNP	I-NP	I-Disease
enzyme	enzyme	E525	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
resulting	result	R243	VBG	I-NP	O
W474C	W474C	W200	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
clearly	clearly	C464	RB	B-ADVP	O
interferes	interfere	I536	VBZ	B-VP	O
with	with	W300	IN	B-PP	O
alpha	alpha	A410	SYM	B-NP	O
-	-	0000	HYPH	I-NP	O
subunit	subunit	S153	NN	I-NP	O
processing	processing	P625	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
because	because	B200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
base	base	B200	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
falls	fall	F420	VBZ	B-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
13	13	0000	CD	I-NP	O
,	,	0000	,	O	O
aberrant	aberrant	A165	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
may	may	M000	MD	B-VP	O
also	also	A420	RB	I-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
Hex	Hex	H200	NNP	B-NP	B-Disease
A	A	A000	NNP	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Pendred	Pendred	P536	JJ	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Pendred	Pendre	P536	VBN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
early	early	E640	JJ	B-NP	O
childhood	childhood	C430	NN	I-NP	O
deafness	deafness	D152	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	O
goiter	goiter	G360	NN	I-NP	B-Disease
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
century	century	C536	NN	I-NP	O
after	after	A136	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
recognition	recognition	R253	NN	I-NP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
syndrome	syndrome	S536	NN	I-NP	O
by	by	B000	IN	B-PP	O
Vaughan	Vaughan	V250	NNP	B-NP	O
Pendred	Pendred	P536	NNP	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
PDS	PDS	P320	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
7q22	7q22	Q000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
q31	q31	Q000	NN	I-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
recently	recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
encode	encode	E523	VB	I-VP	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
sulfate	sulfate	S413	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
performed	perform	P616	VBD	B-VP	O
mutation	mutation	M350	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
from	from	F650	IN	B-PP	O
14	14	0000	CD	B-NP	O
Pendred	Pendred	P536	NNP	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
originating	originate	O625	VBG	B-VP	O
from	from	F650	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
countries	country	C536	NNS	I-NP	O
and	and	A530	CC	O	O
identified	identify	I353	VBD	B-VP	O
all	all	A400	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
include	include	I524	VBP	B-VP	O
three	three	T600	CD	B-NP	O
single	single	S524	JJ	I-NP	O
base	base	B200	NN	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
10	10	0000	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

One	One	O500	CD	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
L236P	L236P	L100	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
state	state	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
consanguineous	consanguineous	C525	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
state	state	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
additional	additional	A354	JJ	I-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
consanguineous	consanguineous	C525	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Another	Another	A536	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
T416P	T416P	T100	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
state	state	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
family	family	F540	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
state	state	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Pendred	Pendred	P536	JJ	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
consanguineous	consanguineous	C525	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
compound	compound	C515	JJ	B-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
L236P	L236P	L100	NN	B-NP	O
and	and	A530	CC	I-NP	O
T416P	T416P	T100	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
total	total	T340	NN	B-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
or	or	O600	CC	O	O
both	both	B300	DT	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
14	14	0000	CD	I-NP	O
families	family	F542	NNS	I-NP	O
analyzed	analyze	A542	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
PDS	PDS	P320	NN	I-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
will	will	W400	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
Pendred	Pendred	P536	NNP	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Insertional	Insertional	I526	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
by	by	B000	IN	B-PP	O
transposable	transposable	T652	JJ	B-NP	O
element	element	E453	NN	I-NP	O
,	,	0000	,	O	O
L1	L1	L000	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
linked	link	L523	VBN	B-VP	I-Disease
dilated	dilate	D430	VBN	B-NP	I-Disease
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	I-Disease
.	.	0000	.	O	O

X	X	X000	NN	B-NP	B-Disease
-	-	0000	HYPH	B-VP	I-Disease
linked	link	L523	VBN	I-VP	I-Disease
dilated	dilate	D430	VBN	B-NP	I-Disease
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	I-Disease
(	(	0000	(	O	O
XLDCM	XLDCM	X432	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
dystrophinopathy	dystrophinopathy	D236	NN	B-NP	B-Disease
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
preferential	preferential	P616	JJ	B-NP	O
myocardial	myocardial	M263	JJ	I-NP	B-Disease
involvement	involvement	I514	NN	I-NP	I-Disease
without	without	W300	IN	B-PP	O
any	any	A500	DT	B-NP	O
overt	overt	O163	JJ	I-NP	O
clinical	clinical	C452	JJ	I-NP	O
signs	sign	S252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	B-Disease
myopathy	myopathy	M130	NN	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
,	,	0000	,	O	O
several	several	S164	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Duchenne	Duchenne	D250	NNP	I-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
DMD	DMD	D530	NN	B-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
XLDCM	XLDCM	X432	NN	B-NP	B-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
a	a	A000	DT	B-NP	O
pathogenic	pathogenic	P325	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
cardiospecific	cardiospecific	C632	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
XLDCM	XLDCM	X432	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
remained	remain	R530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
elucidated	elucidate	E423	VBN	I-VP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
de	de	D000	FW	I-NP	O
novo	novo	N100	FW	I-NP	O
L1	L1	L000	NN	I-NP	O
insertion	insertion	I526	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
muscle	muscle	M240	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
1	1	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
XLDCM	XLDCM	X432	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
two	two	T000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
insertion	insertion	I526	NN	I-NP	O
was	be	W200	VBD	B-VP	O
a	a	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
truncated	truncate	T652	VBN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
L1	L1	L000	NN	I-NP	O
inversely	inversely	I516	RB	B-VP	O
integrated	integrate	I532	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
muscle	muscle	M240	NN	I-NP	O
exon	exon	E250	NN	I-NP	O
1	1	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
affected	affect	A123	VBD	B-VP	O
the	the	T000	DT	B-NP	O
transcription	transcription	T652	NN	I-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
stability	stability	S314	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
muscle	muscle	M240	NN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
dystrophin	dystrophin	D236	NN	B-NP	O
transcripts	transcript	T652	NNS	I-NP	O
but	but	B300	CC	B-NP	O
not	not	N300	RB	I-NP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
brain	brain	B650	NN	I-NP	O
or	or	O600	CC	I-NP	O
Purkinje	Purkinje	P625	NN	I-NP	O
cell	cell	C400	NN	I-NP	O
form	form	F650	NN	I-NP	O
,	,	0000	,	O	O
probably	probably	P614	RB	B-ADVP	O
due	due	D000	IN	B-PP	O
to	to	T000	TO	B-PP	O
its	its	I320	PRP$	B-NP	O
unique	unique	U520	JJ	I-NP	O
site	site	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
integration	integration	I532	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
speculate	speculate	S124	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
this	this	T200	DT	B-NP	O
insertion	insertion	I526	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
L1	L1	L000	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
in	in	I500	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
some	some	S500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
population	population	P143	NN	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
XLDCM	XLDCM	X432	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Severe	Severe	S160	JJ	B-NP	O
early	early	E640	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
obesity	obesity	O123	NN	I-NP	B-Disease
,	,	0000	,	O	O
adrenal	adrenal	A365	JJ	B-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
and	and	A530	CC	O	O
red	red	R300	JJ	B-NP	O
hair	hair	H600	NN	I-NP	O
pigmentation	pigmentation	P253	NN	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
POMC	POMC	P520	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
.	.	0000	.	O	O

Sequential	Sequential	S253	JJ	B-NP	O
cleavage	cleavage	C412	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
precursor	precursor	P626	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
pre	pre	P600	AFX	O	O
-	-	0000	HYPH	O	O
pro	pro	P600	AFX	O	O
-	-	0000	HYPH	O	O
opiomelanocortin	opiomelanocortin	O154	NN	B-NP	O
(	(	0000	(	O	O
POMC	POMC	P520	NN	B-NP	O
)	)	0000	)	O	O
generates	generate	G563	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
melanocortin	melanocortin	M452	NN	I-NP	O
peptides	peptide	P132	NNS	I-NP	O
adrenocorticotrophin	adrenocorticotrophin	A365	NN	I-NP	O
(	(	0000	(	O	O
ACTH	ACTH	A230	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
melanocyte	melanocyte	M452	NN	B-NP	O
-	-	0000	HYPH	O	O
stimulating	stimulate	S354	VBG	B-VP	O
hormones	hormone	H652	NNS	B-NP	O
(	(	0000	(	O	O
MSH	MSH	M200	NN	B-NP	O
)	)	0000	)	O	O
alpha	alpha	A410	NN	B-NP	O
,	,	0000	,	O	O
beta	beta	B300	NN	B-NP	O
and	and	A530	CC	I-NP	O
gamma	gamma	G500	NN	I-NP	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
the	the	T000	DT	B-NP	O
opioid	opioid	O130	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
receptor	receptor	R213	NN	I-NP	O
ligand	ligand	L253	NN	I-NP	O
beta	beta	B300	SYM	B-VP	O
-	-	0000	HYPH	O	O
endorphin	endorphin	E536	NN	B-NP	O
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
few	few	F000	JJ	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
isolated	isolate	I243	VBN	B-NP	O
ACTH	ACTH	A230	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
(	(	0000	(	O	O
OMIM	OMIM	O500	NN	B-NP	O
201400	201400	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	O
POMC	POMC	P520	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
been	be	B500	VBN	I-VP	O
described	describe	D261	VBN	I-VP	O
so	so	S000	RB	B-ADVP	O
far	far	F600	RB	I-ADVP	O
.	.	0000	.	O	O

Recent	Recent	R253	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
animal	animal	A540	NN	B-NP	O
models	model	M342	NNS	I-NP	O
elucidated	elucidate	E423	VBD	B-VP	O
a	a	A000	DT	B-NP	O
central	central	C536	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
alpha	alpha	A410	SYM	B-NP	O
-	-	0000	HYPH	B-VP	O
MSH	MSH	M200	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
food	food	F300	NN	B-NP	O
intake	intake	I532	NN	I-NP	O
by	by	B000	IN	B-PP	O
activation	activation	A231	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
brain	brain	B650	NN	I-NP	O
melanocortin	melanocortin	M452	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
4	4	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
receptor	receptor	R213	NN	I-NP	O
(	(	0000	(	O	O
MC4	MC4	M200	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
R	R	R000	NN	I-NP	O
;	;	0000	:	O	O
refs	ref	R120	NNS	B-NP	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
5	5	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
linkage	linkage	L520	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
obesity	obesity	O123	NN	I-NP	B-Disease
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
2	2	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
close	close	C420	JJ	B-NP	O
proximity	proximity	P625	NN	I-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
POMC	POMC	P520	NN	I-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
led	lead	L300	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
proposal	proposal	P612	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
association	association	A235	NN	I-NP	O
of	of	O100	IN	B-PP	O
POMC	POMC	P520	NN	B-NP	O
with	with	W300	IN	B-PP	O
human	human	H500	JJ	B-NP	O
obesity	obesity	O123	NN	I-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
dual	dual	D400	JJ	I-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
alpha	alpha	A410	SYM	B-NP	O
-	-	0000	HYPH	B-VP	O
MSH	MSH	M200	NN	B-NP	O
in	in	I500	IN	B-PP	O
regulating	regulate	R243	VBG	B-VP	O
food	food	F300	NN	B-NP	O
intake	intake	I532	NN	I-NP	O
and	and	A530	CC	O	O
influencing	influence	I514	VBG	B-VP	O
hair	hair	H600	NN	B-NP	O
pigmentation	pigmentation	P253	NN	I-NP	O
predicts	predict	P632	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
POMC	POMC	P520	NN	B-NP	O
function	function	F523	NN	I-NP	O
would	would	W430	MD	B-VP	O
include	include	I524	VB	I-VP	O
obesity	obesity	O123	NN	B-NP	B-Disease
,	,	0000	,	O	O
alteration	alteration	A436	NN	B-NP	O
in	in	I500	IN	B-PP	O
pigmentation	pigmentation	P253	NN	B-NP	O
and	and	A530	CC	O	O
ACTH	ACTH	A230	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
observation	observation	O126	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
symptoms	symptom	S513	NNS	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
probands	proband	P615	NNS	I-NP	O
prompted	prompt	P651	VBD	B-VP	O
us	us	U200	PRP	B-NP	O
to	to	T000	TO	B-VP	O
search	search	S620	VB	I-VP	O
for	for	F600	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
within	within	W350	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
POMC	POMC	P520	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

Patient	Patient	P353	NN	B-NP	O
1	1	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
compound	compound	C515	NN	I-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
for	for	F600	IN	B-PP	O
two	two	T000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
3	3	0000	CD	I-NP	O
(	(	0000	(	O	O
G7013T	G7013T	G300	NN	B-NP	O
,	,	0000	,	O	O
C7133delta	C7133delta	C343	NN	B-NP	O
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
interfere	interfere	I536	VBP	B-VP	O
with	with	W300	IN	B-PP	O
appropriate	appropriate	A161	JJ	B-NP	O
synthesis	synthesis	S532	NN	I-NP	O
of	of	O100	IN	B-PP	O
ACTH	ACTH	A230	NN	B-NP	O
and	and	A530	CC	O	O
alpha	alpha	A410	SYM	B-NP	O
-	-	0000	HYPH	O	O
MSH	MSH	M200	NN	B-NP	O
.	.	0000	.	O	O

Patient	Patient	P353	NN	B-NP	O
2	2	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
2	2	0000	CD	I-NP	O
(	(	0000	(	O	O
C3804A	C3804A	C000	NN	B-NP	O
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
abolishes	abolish	A142	VBZ	B-VP	O
POMC	POMC	P520	NN	B-NP	O
translation	translation	T652	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
represent	represent	R162	VBP	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
examples	example	E251	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
defect	defect	D123	NN	I-NP	I-Disease
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
POMC	POMC	P520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
define	define	D150	VB	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
monogenic	monogenic	M525	JJ	I-NP	B-Disease
endocrine	endocrine	E532	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
early	early	E640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
obesity	obesity	O123	NN	I-NP	B-Disease
,	,	0000	,	O	O
adrenal	adrenal	A365	JJ	B-NP	B-Disease
insufficiency	insufficiency	I521	NN	I-NP	I-Disease
and	and	A530	CC	O	O
red	red	R300	JJ	B-NP	O
hair	hair	H600	NN	I-NP	O
pigmentation	pigmentation	P253	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
European	European	E615	JJ	I-NP	O
multicenter	multicenter	M432	JJ	I-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenylalanine	phenylalanine	P545	NN	B-NP	B-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
classification	classification	C421	NN	B-NP	O
of	of	O100	IN	B-PP	O
105	105	0000	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
system	system	S235	NN	I-NP	O
for	for	F600	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
prediction	prediction	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
metabolic	metabolic	M314	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

Phenylketonuria	Phenylketonuria	P542	NN	B-NP	B-Disease
(	(	0000	(	O	O
PKU	PKU	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
mild	mild	M430	JJ	B-NP	B-Disease
hyperphenylalaninemia	hyperphenylalaninemia	H161	NN	I-NP	I-Disease
(	(	0000	(	O	O
MHP	MHP	M100	NN	B-NP	B-Disease
)	)	0000	)	O	O
are	be	A600	VBP	B-VP	O
allelic	allelic	A420	JJ	B-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
phenylalanine	phenylalanine	P545	NN	B-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
(	(	0000	(	O	O
PAH	PAH	P000	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
suggested	suggest	S230	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
variable	variable	V614	JJ	I-NP	O
metabolic	metabolic	M314	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
of	of	O100	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
correlate	correlate	C643	VBP	B-VP	O
with	with	W300	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	O
genotypes	genotype	G531	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
both	both	B300	CC	O	O
causative	causative	C231	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
686	686	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
European	European	E615	JJ	I-NP	O
centers	center	C536	NNS	I-NP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
characteristics	characteristic	C623	NNS	I-NP	O
of	of	O100	IN	B-PP	O
297	297	0000	CD	B-NP	O
functionally	functionally	F523	RB	I-NP	O
hemizygous	hemizygous	H520	JJ	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
105	105	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
assigned	assign	A253	VBN	I-VP	O
to	to	T000	TO	B-PP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
four	four	F600	CD	B-NP	O
arbitrary	arbitrary	A613	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
categories	category	C326	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
proposed	propose	P612	VBD	B-VP	O
and	and	A530	CC	I-VP	O
tested	test	T230	VBD	I-VP	O
a	a	A000	DT	B-NP	O
simple	simple	S514	JJ	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
correlation	correlation	C643	NN	B-NP	O
between	between	B350	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
and	and	A530	CC	O	O
phenotypic	phenotypic	P531	JJ	B-NP	O
outcome	outcome	O325	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
matched	match	M323	VBD	B-VP	O
the	the	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
79	79	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
only	only	O540	RB	B-NP	O
5	5	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
184	184	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
more	more	M600	JJR	B-NP	O
than	than	T500	IN	I-NP	O
one	one	O500	CD	I-NP	O
category	category	C326	NN	I-NP	O
away	away	A000	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
that	that	T300	DT	B-NP	O
expected	expect	E212	VBN	B-VP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
seven	seven	S150	CD	I-NP	O
contributing	contribute	C536	VBG	I-NP	O
centers	center	C536	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
for	for	F600	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
the	the	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
match	match	M320	VB	I-VP	O
the	the	T000	DT	B-NP	O
predicted	predict	P632	VBN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
was	be	W200	VBD	B-VP	O
4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
23	23	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
<	<	0000	SYM	B-NP	O
.	.	0000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
differences	difference	D165	NNS	B-NP	O
in	in	I500	IN	B-PP	O
methods	method	M320	NNS	B-NP	O
used	use	U230	VBN	B-VP	O
for	for	F600	IN	B-PP	O
mutation	mutation	M350	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
or	or	O600	CC	O	O
phenotype	phenotype	P531	NN	B-NP	O
classification	classification	C421	NN	I-NP	O
may	may	M000	MD	B-VP	O
account	account	A253	VB	I-VP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
considerable	considerable	C523	JJ	I-NP	O
proportion	proportion	P616	NN	I-NP	O
of	of	O100	IN	B-PP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
inconsistencies	inconsistency	I525	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
PAH	PAH	P000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
mutation	mutation	M350	NN	I-NP	O
genotype	genotype	G531	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
main	main	M500	JJ	I-NP	O
determinant	determinant	D365	NN	I-NP	O
of	of	O100	IN	B-PP	O
metabolic	metabolic	M314	JJ	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
PAH	PAH	P000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
present	present	P625	JJ	I-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
classification	classification	C421	NN	I-NP	O
of	of	O100	IN	B-PP	O
105	105	0000	CD	B-NP	O
PAH	PAH	P000	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
may	may	M000	MD	B-VP	O
allow	allow	A400	VB	I-VP	O
the	the	T000	DT	B-NP	O
prediction	prediction	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
>	>	0000	JJR	B-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
genotypes	genotype	G531	NNS	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
useful	useful	U214	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
management	management	M525	NN	I-NP	O
of	of	O100	IN	B-PP	O
hyperphenylalaninemia	hyperphenylalaninemia	H161	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
newborns	newborn	N165	NNS	B-NP	O
.	.	0000	.	O	O

Somatic	Somatic	S532	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
mice	mouse	M200	NNS	B-NP	O
transgenic	transgenic	T652	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
region	region	R250	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
age	age	A200	NN	B-NP	O
dependent	dependent	D153	JJ	I-NP	O
but	but	B300	CC	O	O
not	not	N300	RB	B-VP	O
correlated	correlate	C643	VBD	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
intertissue	intertissue	I536	NN	I-NP	O
transcription	transcription	T652	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
proliferative	proliferative	P641	JJ	B-NP	O
capacities	capacity	C123	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
nexpansion	nexpansion	N215	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
untranslated	untranslated	U536	JJ	I-NP	O
region	region	R250	NN	I-NP	O
(	(	0000	(	O	O
UTR	UTR	U360	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
kinase	kinase	K520	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
DMPK	DMPK	D512	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
causing	cause	C252	VBG	B-VP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Major	Major	M260	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
very	very	V600	RB	B-NP	O
large	large	L620	JJ	I-NP	O
expansions	expansion	E215	NNS	I-NP	O
between	between	B350	IN	B-PP	O
generations	generation	G563	NNS	B-NP	O
and	and	A530	CC	O	O
high	high	H200	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
good	good	G300	JJ	I-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
repeat	repeat	R130	NN	B-NP	O
size	size	S200	NN	I-NP	O
(	(	0000	(	O	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
in	in	I500	IN	B-PP	O
leucocytes	leucocyte	L232	NNS	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
clinical	clinical	C452	JJ	B-NP	O
severity	severity	S163	NN	I-NP	O
and	and	A530	CC	O	O
age	age	A200	NN	B-NP	O
of	of	O100	IN	B-PP	O
onset	onset	O523	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
instability	instability	I523	NN	I-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
human	human	H500	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
somatic	somatic	S532	JJ	B-NP	O
instability	instability	I523	NN	I-NP	O
by	by	B000	IN	B-PP	O
measuring	measure	M265	VBG	B-VP	O
the	the	T000	DT	B-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
length	length	L523	NN	I-NP	O
at	at	A300	IN	B-PP	O
several	several	S164	JJ	B-NP	O
ages	age	A200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
various	various	V620	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
transgenic	transgenic	T652	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
carrying	carry	C652	VBG	B-VP	O
a	a	A000	DT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
55expansion	55expansion	E215	NN	B-NP	O
surrounded	surround	S653	VBN	B-VP	O
by	by	B000	IN	B-PP	O
45	45	0000	CD	B-NP	O
kb	kb	K100	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
small	small	S540	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
pool	pool	P400	NN	I-NP	O
PCR	PCR	P260	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
reproduce	reproduce	R163	VB	I-VP	O
the	the	T000	DT	B-NP	O
intergenerational	intergenerational	I536	JJ	I-NP	O
and	and	A530	CC	I-NP	O
somatic	somatic	S532	JJ	I-NP	O
instability	instability	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
55	55	0000	CD	I-NP	O
CTG	CTG	C320	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
surrounding	surround	S653	VBG	B-VP	O
sequences	sequence	S252	NNS	B-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
chromatin	chromatin	C653	NN	I-NP	O
environment	environment	E516	NN	I-NP	O
are	be	A600	VBP	B-VP	O
involved	involve	I514	VBN	I-VP	O
in	in	I500	IN	B-PP	O
instability	instability	I523	NN	B-NP	O
mechanisms	mechanism	M252	NNS	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
tendency	tendency	T535	NN	I-NP	O
for	for	F600	IN	B-PP	O
repeat	repeat	R130	NN	B-NP	O
length	length	L523	NN	I-NP	O
and	and	A530	CC	O	O
somatic	somatic	S532	JJ	B-NP	O
mosaicism	mosaicism	M250	NN	I-NP	O
to	to	T000	TO	B-VP	O
increase	increase	I526	VB	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
age	age	A200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
observed	observe	O126	VBD	B-VP	O
no	no	N000	DT	B-NP	O
correlation	correlation	C643	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
rate	rate	R300	NN	I-NP	O
and	and	A530	CC	I-NP	O
tissue	tissue	T200	NN	I-NP	O
proliferation	proliferation	P641	NN	I-NP	O
capacity	capacity	C123	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
somatic	somatic	S532	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
rates	rate	R320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
different	different	D165	JJ	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
not	not	N300	RB	I-VP	O
correlated	correlate	C643	VBN	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
inter	inter	I536	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
tissue	tissue	T200	NN	I-NP	O
difference	difference	D165	NN	I-NP	O
in	in	I500	IN	B-PP	O
transcriptional	transcriptional	T652	JJ	B-NP	O
levels	level	L142	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
three	three	T600	CD	I-NP	O
genes	gene	G520	NNS	I-NP	O
(	(	0000	(	O	O
DMAHP	DMAHP	D510	NN	B-NP	O
,	,	0000	,	O	O
DMPK	DMPK	D512	NN	B-NP	O
and	and	A530	CC	O	O
59	59	0000	CD	B-NP	O
)	)	0000	)	O	O
surrounding	surround	S653	VBG	B-VP	O
the	the	T000	DT	B-NP	O
repeat	repeat	R130	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
pedigree	pedigree	P326	NN	I-NP	O
showing	show	S520	VBG	B-VP	O
only	only	O540	RB	B-NP	O
mild	mild	M430	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
used	use	U230	VBN	I-VP	O
single	single	S524	JJ	B-NP	O
strand	strand	S365	NN	I-NP	O
conformation	conformation	C516	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
to	to	T000	TO	B-VP	O
study	study	S300	VB	I-VP	O
the	the	T000	DT	B-NP	O
27	27	0000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
showing	show	S520	VBG	B-VP	O
mild	mild	M430	JJ	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
retinoblastoma	retinoblastoma	R351	NN	I-NP	B-Disease
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
affected	affect	A123	VBD	B-VP	O
individuals	individual	I531	NNS	B-NP	O
developed	develop	D141	VBD	B-VP	O
unilateral	unilateral	U543	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
,	,	0000	,	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
unaffected	unaffected	U512	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
pedigree	pedigree	P326	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
band	band	B530	NN	I-NP	O
shift	shift	S130	NN	I-NP	O
using	use	U252	VBG	B-VP	O
SSCP	SSCP	S210	NN	B-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
21	21	0000	CD	I-NP	O
which	which	W200	WDT	B-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
converting	convert	C516	VBG	B-VP	O
a	a	A000	DT	B-NP	O
cys	cy	C200	NNS	I-NP	O
-	-	0000	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
arg	arg	A620	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
position	position	P235	NN	I-NP	O
28	28	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
destroyed	destroy	D236	VBD	B-VP	O
an	an	A500	DT	B-NP	O
NdeI	NdeI	N300	NN	I-NP	O
restriction	restriction	R236	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

Analysis	Analysis	A542	NN	B-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
co	co	C000	AFX	O	O
-	-	0000	HYPH	O	O
segregated	segregate	S262	VBN	B-VP	O
with	with	W300	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
tumors	tumor	T562	NNS	B-NP	B-Disease
or	or	O600	CC	O	O
who	who	W000	WP	B-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
predicted	predict	P632	VBN	I-VP	O
to	to	T000	TO	I-VP	O
carry	carry	C600	VB	I-VP	O
the	the	T000	DT	B-NP	O
predisposing	predispose	P632	VBG	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
observations	observation	O126	NNS	I-NP	O
point	point	P530	VBP	B-VP	O
to	to	T000	TO	B-PP	O
another	another	A536	DT	B-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
RB1	RB1	R100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
where	where	W600	WRB	B-ADVP	O
mutations	mutation	M352	NNS	B-NP	O
only	only	O540	RB	B-ADVP	O
modify	modify	M310	VBP	B-VP	O
the	the	T000	DT	B-NP	O
function	function	F523	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
raise	raise	R200	VB	B-VP	O
important	important	I516	JJ	B-NP	O
questions	question	Q235	NNS	I-NP	O
for	for	F600	IN	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
counseling	counseling	C524	NN	I-NP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
with	with	W300	IN	B-PP	O
these	these	T200	DT	B-NP	O
distinctive	distinctive	D235	JJ	I-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Maternal	Maternal	M365	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
gamete	gamete	G530	NN	B-NP	O
complementation	complementation	C514	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	O
translocation	translocation	T652	NN	I-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
;	;	0000	:	O	O
15	15	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
p25	p25	P000	NN	B-NP	O
;	;	0000	:	O	O
q11	q11	Q000	NN	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Maternal	Maternal	M365	JJ	B-NP	B-Disease
uniparental	uniparental	U516	JJ	I-NP	I-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
UPD	UPD	U130	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
for	for	F600	IN	B-PP	I-Disease
chromosome	chromosome	C652	NN	B-NP	I-Disease
15	15	0000	CD	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
30	30	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Prader	Prader	P636	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Willi	Willi	W400	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
PWS	PWS	P200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
on	on	O500	IN	B-PP	O
an	an	A500	DT	B-NP	O
unusual	unusual	U524	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
15	15	0000	CD	I-NP	I-Disease
in	in	I500	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
most	most	M230	RBS	B-ADJP	O
consistent	consistent	C523	JJ	I-ADJP	O
with	with	W300	IN	B-PP	O
adjacent	adjacent	A325	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
1	1	0000	CD	I-NP	O
segregation	segregation	S262	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
t	t	T000	NN	I-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
;	;	0000	:	O	O
15	15	0000	CD	B-NP	O
)	)	0000	)	O	O
(	(	0000	(	O	O
p25	p25	P000	NN	B-NP	O
;	;	0000	:	O	O
q11	q11	Q000	NN	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
simultaneous	simultaneous	S543	JJ	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
meiotic	meiotic	M320	JJ	I-NP	O
nondisjunction	nondisjunction	N532	NN	I-NP	O
for	for	F600	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15	15	0000	CD	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
(	(	0000	(	O	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	I-NP	O
B	B	B000	NNP	I-NP	O
.	.	0000	.	O	O
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
17	17	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
old	old	O430	JJ	I-NP	O
white	white	W300	JJ	I-NP	O
male	male	M400	NN	I-NP	O
with	with	W300	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
47	47	0000	CD	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
supernumerary	supernumerary	S165	JJ	I-NP	O
,	,	0000	,	I-NP	O
paternal	paternal	P365	JJ	I-NP	O
der	der	D600	NN	I-NP	O
(	(	0000	(	O	O
15	15	0000	CD	B-NP	O
)	)	0000	)	O	O
consisting	consist	C523	VBG	B-VP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
short	short	S630	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
proximal	proximal	P625	JJ	I-NP	O
long	long	L520	JJ	I-NP	O
arm	arm	A650	NN	I-NP	O
of	of	O100	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
15	15	0000	CD	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
distal	distal	D234	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
arm	arm	A650	NN	I-NP	O
3p	3p	P000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
t	t	T000	NN	I-NP	O
(	(	0000	(	O	O
3	3	0000	CD	B-NP	O
;	;	0000	:	O	O
15	15	0000	CD	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
balanced	balanced	B452	JJ	I-NP	O
state	state	S300	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
father	father	F360	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
sister	sister	S236	NN	I-NP	O
.	.	0000	.	O	O

Fluorescent	Fluorescent	F462	JJ	B-NP	O
in	in	I500	FW	I-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
critical	critical	C632	JJ	I-NP	O
region	region	R250	NN	I-NP	O
resided	reside	R230	VBD	B-VP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
derivative	derivative	D613	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
3	3	0000	CD	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
was	be	W200	VBD	B-VP	O
no	no	N000	DT	B-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PWS	PWS	P200	NN	I-NP	B-Disease
region	region	R250	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
pair	pair	P600	NN	I-NP	O
of	of	O100	IN	B-PP	O
15s	15	S000	NNS	B-NP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	O	O

B	B	B000	NN	B-NP	O
.	.	0000	.	O	O

Methylation	Methylation	M343	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
at	at	A300	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
alpha	alpha	A410	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
small	small	S540	JJ	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
ribonucleoprotein	ribonucleoprotein	R152	NN	I-NP	O
-	-	0000	HYPH	O	O
associated	associate	A230	VBN	B-NP	O
polypeptide	polypeptide	P413	NN	I-NP	O
N	N	N000	NN	I-NP	O
(	(	0000	(	O	O
SNRPN	SNRPN	S561	NN	B-NP	O
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
showed	show	S300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
pattern	pattern	P365	NN	I-NP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
only	only	O540	RB	B-NP	O
the	the	T000	DT	I-NP	O
maternal	maternal	M365	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
15	15	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
J	J	J000	NNP	B-NP	O
.	.	0000	.	O	O

B	B	B000	NN	B-NP	O
.	.	0000	.	O	O

Maternal	Maternal	M365	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
was	be	W200	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
polymerase	polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
microsatellite	microsatellite	M262	NN	B-NP	O
repeats	repeat	R132	NNS	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
gamma	gamma	G500	SYM	I-NP	O
-	-	0000	HYPH	I-NP	O
aminobutyric	aminobutyric	A513	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
beta3	beta3	B300	NN	I-NP	O
subunit	subunit	S153	NN	I-NP	O
(	(	0000	(	O	O
GABRB3	GABRB3	G161	NN	B-NP	O
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
niece	niece	N200	NN	I-NP	O
(	(	0000	(	O	O
B	B	B000	NN	B-NP	O
.	.	0000	.	O	O
B	B	B000	NN	B-NP	O
.	.	0000	.	O	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
45	45	0000	CD	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
derivative	derivative	D613	JJ	I-NP	O
3	3	0000	CD	I-NP	O
but	but	B300	CC	O	O
without	without	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
der	der	D600	NN	I-NP	O
(	(	0000	(	O	O
15	15	0000	CD	B-NP	O
)	)	0000	)	O	O
demonstrated	demonstrate	D523	VBD	B-VP	O
a	a	A000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
that	that	T300	DT	B-NP	O
reported	report	R163	VBN	B-VP	O
for	for	F600	IN	B-PP	O
haploinsufficiency	haploinsufficiency	H145	NN	B-NP	O
of	of	O100	IN	B-PP	O
distal	distal	D234	JJ	B-NP	O
3	3	0000	CD	I-NP	O
p	p	P000	NN	I-NP	O
.	.	0000	.	O	O

Uniparental	Uniparental	U516	JJ	B-NP	B-Disease
disomy	disomy	D250	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
unbalanced	unbalanced	U514	JJ	B-NP	O
segregation	segregation	S262	NN	I-NP	O
of	of	O100	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
Robertsonian	Robertsonian	R163	JJ	I-NP	O
translocations	translocation	T652	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
but	but	B300	CC	O	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	O	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
knowledge	knowledge	K543	NN	I-NP	O
,	,	0000	,	O	O
been	be	B500	VBN	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
PWS	PWS	P200	NN	B-NP	B-Disease
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
best	best	B230	RB	I-VP	O
interpreted	interpret	I536	VBN	I-VP	O
as	as	A200	IN	B-PP	O
true	true	T600	JJ	B-NP	O
gamete	gamete	G530	NN	I-NP	O
complementation	complementation	C514	NN	I-NP	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
maternal	maternal	M365	JJ	B-NP	B-Disease
UPD	UPD	U130	NNP	I-NP	I-Disease
15	15	0000	CD	I-NP	I-Disease
and	and	A530	CC	O	O
PWS	PWS	P200	NN	B-NP	B-Disease

Schwartz	Schwartz	S263	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Jampel	Jampel	J514	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
type	type	T100	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
and	and	A530	CC	O	O
Stuve	Stuve	S310	NNP	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Wiedemann	Wiedemann	W350	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
case	case	C200	NN	I-NP	O
for	for	F600	IN	B-PP	O
"	"	0000	``	O	O
lumping	lump	L515	VBG	B-VP	O
"	"	0000	''	O	O
.	.	0000	.	O	O

Recent	Recent	R253	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
the	the	T000	DT	B-NP	O
existence	existence	E235	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
genetically	genetically	G532	RB	I-NP	O
distinct	distinct	D235	JJ	I-NP	O
,	,	0000	,	I-NP	O
usually	usually	U240	RB	I-NP	O
lethal	lethal	L340	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Schwartz	Schwartz	S263	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Jampel	Jampel	J514	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
SJS	SJS	S200	NN	B-NP	B-Disease
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
myotonia	myotonia	M350	NN	B-NP	B-Disease
and	and	A530	CC	O	O
skeletal	skeletal	S243	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
we	we	W000	PRP	B-NP	O
called	call	C430	VBD	B-VP	O
SJS	SJS	S200	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
reminiscent	reminiscent	R525	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
another	another	A536	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
condition	condition	C535	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
Stuve	Stuve	S310	NNP	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
Wiedemann	Wiedemann	W350	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
SWS	SWS	S200	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
comprises	comprise	C516	VBZ	B-VP	O
campomelia	campomelia	C515	NN	B-NP	B-Disease
at	at	A300	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
with	with	W300	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
,	,	0000	,	O	O
contractures	contracture	C536	NNS	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
early	early	E640	JJ	B-NP	B-Disease
death	death	D300	NN	I-NP	I-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
test	test	T230	VB	I-VP	O
for	for	F600	IN	B-PP	O
possible	possible	P214	JJ	B-NP	O
nosologic	nosologic	N242	JJ	I-NP	O
identity	identity	I353	NN	I-NP	O
between	between	B350	IN	B-PP	O
these	these	T200	DT	B-NP	O
disorders	disorder	D263	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
reviewed	review	R130	VBD	B-VP	O
the	the	T000	DT	B-NP	O
literature	literature	L363	NN	I-NP	O
and	and	A530	CC	O	O
obtained	obtain	O135	VBD	B-VP	O
a	a	A000	DT	B-NP	O
follow	follow	F400	VB	I-NP	O
-	-	0000	HYPH	O	O
up	up	U100	RP	B-PRT	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
two	two	T000	CD	I-NP	O
surviving	survive	S615	VBG	I-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
SJS	SJS	S200	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
10	10	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
and	and	A530	CC	O	O
another	another	A536	DT	B-NP	O
with	with	W300	IN	B-PP	O
SWS	SWS	S200	NN	B-NP	B-Disease
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
7	7	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
reported	report	R163	VBN	B-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
either	either	E360	CC	B-NP	O
neonatal	neonatal	N534	JJ	I-NP	O
SJS	SJS	S200	NN	I-NP	B-Disease
or	or	O600	CC	I-NP	O
SWS	SWS	S200	NN	I-NP	B-Disease
presented	present	P625	VBD	B-VP	O
a	a	A000	DT	B-NP	O
combination	combination	C515	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
severe	severe	S160	JJ	I-NP	O
,	,	0000	,	I-NP	O
prenatal	prenatal	P653	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
neuromuscular	neuromuscular	N652	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
(	(	0000	(	O	O
with	with	W300	IN	B-PP	O
congenital	congenital	C525	JJ	B-NP	B-Disease
joint	joint	J530	JJ	I-NP	I-Disease
contractures	contracture	C536	NNS	I-NP	I-Disease
,	,	0000	,	O	O
respiratory	respiratory	R216	JJ	B-NP	O
and	and	A530	CC	I-NP	O
feeding	feeding	F352	NN	I-NP	O
difficulties	difficulty	D124	NNS	I-NP	O
,	,	0000	,	O	O
tendency	tendency	T535	NN	B-NP	O
to	to	T000	TO	B-PP	O
hyperthermia	hyperthermia	H163	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
frequent	frequent	F625	JJ	B-NP	O
death	death	D300	NN	I-NP	O
in	in	I500	IN	B-PP	O
infancy	infancy	I515	NN	B-NP	O
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
distinct	distinct	D235	JJ	I-NP	O
campomelic	campomelic	C515	JJ	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
metaphyseal	metaphyseal	M312	JJ	I-NP	I-Disease
skeletal	skeletal	S243	JJ	I-NP	I-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
similarity	similarity	S546	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
and	and	A530	CC	I-NP	O
radiographic	radiographic	R326	JJ	I-NP	O
findings	finding	F535	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
so	so	S000	RB	B-ADJP	O
extensive	extensive	E235	JJ	I-ADJP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
disorders	disorder	D263	NNS	I-NP	O
appear	appear	A160	VBP	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
entity	entity	E530	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
follow	follow	F400	VB	I-NP	O
-	-	0000	HYPH	B-VP	O
up	up	U100	RP	B-PRT	O
observation	observation	O126	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
identical	identical	I353	JJ	I-NP	O
and	and	A530	CC	I-NP	O
unique	unique	U520	JJ	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
progressive	progressive	P626	JJ	B-NP	O
bone	bone	B500	NN	I-NP	B-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
(	(	0000	(	O	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
SJS	SJS	S200	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
with	with	W300	IN	B-PP	O
SWS	SWS	S200	NN	B-NP	B-Disease
)	)	0000	)	O	O
surviving	survive	S615	VBG	B-VP	O
beyond	beyond	B530	IN	B-PP	O
infancy	infancy	I515	NN	B-NP	O
adds	add	A320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
evidence	evidence	E135	NN	I-NP	O
in	in	I500	IN	B-PP	O
favor	favor	F160	NN	B-NP	O
of	of	O100	IN	B-PP	O
identity	identity	I353	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
SWS	SWS	S200	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
SJS	SJS	S200	NN	I-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
2	2	0000	CD	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
disorder	disorder	D263	NN	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
testable	testable	T231	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
methods	method	M320	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
:	:	0000	:	O	O
defects	defect	D123	NNS	B-NP	O
in	in	I500	IN	B-PP	O
hemostasis	hemostasis	H523	NN	B-NP	O
and	and	A530	CC	I-NP	O
thrombosis	thrombosis	T651	NN	I-NP	B-Disease
.	.	0000	.	O	O

von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
vWf	vWf	V100	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
causes	cause	C200	VBZ	B-VP	O
severe	severe	S160	JJ	B-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
humans	human	H520	NNS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
generated	generate	G563	VBD	B-VP	O
a	a	A000	DT	B-NP	O
mouse	mouse	M200	NN	I-NP	O
model	model	M340	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
by	by	B000	IN	B-PP	O
using	use	U252	VBG	B-VP	O
gene	gene	G500	NN	B-NP	O
targeting	targeting	T623	NN	I-NP	O
.	.	0000	.	O	O

vWf	vWf	V100	NN	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
mice	mouse	M200	NNS	I-NP	O
appeared	appear	A163	VBD	B-VP	O
normal	normal	N654	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
;	;	0000	:	O	O
they	they	T000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
viable	viable	V140	JJ	B-ADJP	O
and	and	A530	CC	I-ADJP	O
fertile	fertile	F634	JJ	I-ADJP	O
.	.	0000	.	O	O

Neither	Neither	N360	CC	O	O
vWf	vWf	V100	NN	B-NP	O
nor	nor	N600	CC	O	O
vWf	vWf	V100	NN	B-NP	O
propolypeptide	propolypeptide	P614	NN	I-NP	O
(	(	0000	(	O	O
von	von	V500	NN	B-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
antigen	antigen	A532	NN	I-NP	O
II	II	I000	CD	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
detectable	detectable	D323	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
plasma	plasma	P425	NN	B-NP	O
,	,	0000	,	O	O
platelets	platelet	P434	NNS	B-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
endothelial	endothelial	E534	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
mice	mouse	M200	NNS	I-NP	O
exhibited	exhibit	E213	VBD	B-VP	O
defects	defect	D123	NNS	B-NP	O
in	in	I500	IN	B-PP	O
hemostasis	hemostasis	H523	NN	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
prolonged	prolonged	P645	JJ	I-NP	O
bleeding	bleeding	B435	NN	I-NP	O
time	time	T500	NN	I-NP	O
and	and	A530	CC	O	O
spontaneous	spontaneous	S153	JJ	B-NP	O
bleeding	bleed	B435	VBG	I-NP	O
events	event	E153	NNS	I-NP	O
in	in	I500	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
10	10	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
neonates	neonate	N532	NNS	B-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-PP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
factor	factor	F236	NN	I-NP	O
VIII	VIII	V000	CD	I-NP	O
level	level	L140	NN	I-NP	O
in	in	I500	IN	B-PP	O
these	these	T200	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
reduced	reduce	R323	VBN	I-VP	O
strongly	strongly	S365	RB	B-ADVP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
protection	protection	P632	NN	B-NP	O
provided	provide	P613	VBN	B-VP	O
by	by	B000	IN	B-PP	O
vWf	vWf	V100	NN	B-NP	O
.	.	0000	.	O	O

Defective	Defective	D123	JJ	B-NP	O
thrombosis	thrombosis	T651	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
mice	mouse	M200	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
evident	evident	E135	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
in	in	I500	FW	I-NP	O
vivo	vivo	V100	FW	I-NP	O
model	model	M340	NN	I-NP	O
of	of	O100	IN	B-PP	O
vascular	vascular	V246	JJ	B-NP	B-Disease
injury	injury	I526	NN	I-NP	I-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
model	model	M340	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
exteriorized	exteriorize	E236	VBN	I-NP	O
mesentery	mesentery	M253	NN	I-NP	O
was	be	W200	VBD	B-VP	O
superfused	superfuse	S161	VBN	I-VP	O
with	with	W300	IN	B-PP	O
ferric	ferric	F620	JJ	B-NP	O
chloride	chloride	C463	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
accumulation	accumulation	A254	NN	I-NP	O
of	of	O100	IN	B-PP	O
fluorescently	fluorescently	F462	RB	B-NP	O
labeled	label	L143	VBN	I-NP	O
platelets	platelet	P434	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
by	by	B000	IN	B-PP	O
intravital	intravital	I536	JJ	B-NP	O
microscopy	microscopy	M262	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
mice	mouse	M200	NNS	I-NP	O
very	very	V600	RB	B-NP	O
closely	closely	C424	RB	I-NP	O
mimic	mimic	M520	JJ	I-NP	O
severe	severe	S160	JJ	I-NP	O
human	human	H500	JJ	I-NP	O
von	von	V500	NN	I-NP	B-Disease
Willebrand	Willebrand	W416	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
and	and	A530	CC	O	O
will	will	W400	MD	B-VP	O
be	be	B000	VB	I-VP	O
very	very	V600	RB	B-ADJP	O
useful	useful	U214	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
investigating	investigate	I512	VBG	B-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
vWf	vWf	V100	NN	B-NP	O
in	in	I500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
physiology	physiology	P242	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
disease	disease	D200	NN	B-NP	O
models	model	M342	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Oral	Oral	O640	JJ	B-NP	O
contraceptives	contraceptive	C536	NNS	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Hereditary	Hereditary	H636	NNP	B-NP	B-Disease
Ovarian	Ovarian	O165	NNP	I-NP	I-Disease
Cancer	Cancer	C526	NNP	I-NP	I-Disease
Clinical	Clinical	C452	NNP	I-NP	O
Study	Study	S300	NNP	I-NP	O
Group	Group	G610	NNP	I-NP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
Women	Woman	W500	NNS	I-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
either	either	E360	CC	O	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
lifetime	lifetime	L135	NN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

Oral	Oral	O640	JJ	B-NP	O
contraceptives	contraceptive	C536	NNS	I-NP	O
protect	protect	P632	VBP	B-VP	O
against	against	A252	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
general	general	G564	JJ	B-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
known	know	K500	VBN	I-VP	O
whether	whether	W360	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
protect	protect	P632	VBP	B-VP	O
against	against	A252	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
forms	form	F652	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
We	We	W000	PRP	B-NP	O
enrolled	enrol	E564	VBD	B-VP	O
207	207	0000	CD	B-NP	O
women	woman	W500	NNS	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
161	161	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
sisters	sister	S236	NNS	I-NP	O
as	as	A200	IN	B-PP	O
controls	control	C536	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
case	case	C200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
control	control	C536	NN	I-NP	O
study	study	S300	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
patients	patient	P353	NNS	I-NP	O
carried	carry	C630	VBD	B-VP	O
a	a	A000	DT	B-NP	O
pathogenic	pathogenic	P325	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
either	either	E360	CC	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
(	(	0000	(	O	O
179	179	0000	CD	B-NP	O
women	woman	W500	NNS	I-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
BRCA2	BRCA2	B620	NN	B-NP	O
(	(	0000	(	O	O
28	28	0000	CD	B-NP	O
women	woman	W500	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
control	control	C536	NN	I-NP	O
women	woman	W500	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
enrolled	enrol	E564	VBN	I-VP	O
regardless	regardless	R263	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
whether	whether	W360	IN	B-SBAR	O
or	or	O600	CC	O	O
not	not	N300	RB	O	O
they	they	T000	PRP	B-NP	O
had	have	H300	VBD	B-VP	O
either	either	E360	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Lifetime	Lifetime	L135	NN	B-NP	O
histories	history	H236	NNS	I-NP	O
of	of	O100	IN	B-PP	O
oral	oral	O640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
contraceptive	contraceptive	C536	JJ	I-NP	O
use	use	U200	NN	I-NP	O
were	be	W600	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
by	by	B000	IN	B-PP	O
interview	interview	I536	NN	B-NP	O
or	or	O600	CC	B-PP	O
by	by	B000	IN	B-PP	O
written	write	W635	VBN	B-NP	O
questionnaire	questionnaire	Q235	NN	I-NP	O
and	and	A530	CC	O	O
were	be	W600	VBD	B-VP	O
compared	compare	C516	VBN	I-VP	O
between	between	B350	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
and	and	A530	CC	O	O
control	control	C536	NN	B-NP	O
women	woman	W500	NNS	I-NP	O
,	,	0000	,	O	O
after	after	A136	IN	B-PP	O
adjustment	adjustment	A323	NN	B-NP	O
for	for	F600	IN	B-PP	O
year	year	Y600	NN	B-NP	O
of	of	O100	IN	B-PP	O
birth	birth	B630	NN	B-NP	O
and	and	A530	CC	I-NP	O
parity	parity	P630	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
The	The	T000	DT	B-NP	O
adjusted	adjust	A323	VBN	I-NP	O
odds	odd	O320	VBZ	B-VP	O
ratio	ratio	R300	NN	B-NP	O
for	for	F600	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
any	any	A500	DT	B-NP	O
past	past	P230	JJ	I-NP	O
use	use	U200	NN	I-NP	O
of	of	O100	IN	B-PP	O
oral	oral	O640	JJ	B-NP	O
contraceptives	contraceptive	C536	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
(	(	0000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
,	,	0000	,	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
to	to	T000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
8	8	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
decreased	decrease	D262	VBD	B-VP	O
with	with	W300	IN	B-PP	O
increasing	increase	I526	VBG	B-NP	O
duration	duration	D635	NN	I-NP	O
of	of	O100	IN	B-PP	O
use	use	U200	NN	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
for	for	F600	IN	B-PP	O
trend	trend	T653	NN	B-NP	O
,	,	0000	,	O	O
<	<	0000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	0000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
use	use	U200	NN	B-NP	O
for	for	F600	IN	B-PP	O
six	six	S200	CD	B-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
years	year	Y620	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
60	60	0000	CD	I-NP	O
percent	percent	P625	NN	I-NP	O
reduction	reduction	R323	NN	I-NP	O
in	in	I500	IN	B-PP	O
risk	risk	R200	NN	B-NP	O
.	.	0000	.	O	O

Oral	Oral	O640	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
contraceptive	contraceptive	C536	JJ	I-NP	O
use	use	U200	NN	I-NP	O
protected	protect	P632	VBD	B-VP	O
against	against	A252	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
both	both	B300	DT	O	O
for	for	F600	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
odds	odd	O320	NNS	B-NP	O
ratio	ratio	R300	NN	I-NP	O
,	,	0000	,	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
5	5	0000	CD	I-NP	O
;	;	0000	:	O	O
95	95	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
,	,	0000	,	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
3	3	0000	CD	I-NP	O
to	to	T000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
9	9	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
for	for	F600	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
odds	odd	O320	NNS	B-NP	O
ratio	ratio	R300	NN	I-NP	O
,	,	0000	,	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	I-NP	O
4	4	0000	CD	I-NP	O
;	;	0000	:	O	O
95	95	0000	CD	B-NP	O
percent	percent	P625	NN	I-NP	O
confidence	confidence	C513	NN	I-NP	O
interval	interval	I536	NN	I-NP	O
,	,	0000	,	O	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
to	to	T000	TO	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
Oral	Oral	O640	JJ	B-ADJP	O
-	-	0000	HYPH	B-NP	O
contraceptive	contraceptive	C536	JJ	I-NP	O
use	use	U200	NN	I-NP	O
may	may	M000	MD	B-VP	O
reduce	reduce	R320	VB	I-VP	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
women	woman	W500	NNS	B-NP	O
with	with	W300	IN	B-PP	O
pathogenic	pathogenic	P325	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
or	or	O600	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
gene	gene	G500	NN	I-NP	O

A	A	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
codon	codon	C350	NN	I-NP	O
291	291	0000	CD	I-NP	O
deletion	deletion	D435	NN	I-NP	O
:	:	0000	:	O	O
a	a	A000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
,	,	0000	,	I-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
,	,	0000	,	I-NP	O
pathological	pathological	P342	JJ	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
genetic	genetic	G532	JJ	B-NP	O
report	report	R163	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
adrenoleukodystrophy	adrenoleukodystrophy	A365	NN	B-NP	B-Disease
(	(	0000	(	O	O
ALD	ALD	A430	NN	B-NP	B-Disease
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
three	three	T600	CD	I-NP	O
base	base	B200	NN	I-NP	O
pair	pair	P600	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
(	(	0000	(	O	O
delGAG	delGAG	D420	NN	B-NP	O
291	291	0000	CD	I-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
variety	variety	V630	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotypes	phenotype	P531	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
within	within	W350	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

While	While	W400	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
proband	proband	P615	NN	I-NP	O
(	(	0000	(	O	O
patient	patient	P353	NN	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
classified	classify	C421	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
intermediate	intermediate	I536	JJ	I-NP	O
type	type	T100	NN	I-NP	O
of	of	O100	IN	B-PP	O
adult	adult	A343	JJ	B-NP	O
cerebral	cerebral	C616	JJ	I-NP	O
and	and	A530	CC	I-NP	O
cerebello	cerebello	C614	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
brain	brain	B650	NN	I-NP	O
stem	stem	S350	NN	I-NP	O
forms	form	F652	NNS	I-NP	O
,	,	0000	,	O	O
his	his	H200	PRP$	B-NP	O
younger	young	Y526	JJR	I-NP	O
brother	brother	B636	NN	I-NP	O
(	(	0000	(	O	O
patient	patient	P353	NN	B-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
nephew	nephew	N100	NN	B-NP	O
(	(	0000	(	O	O
patient	patient	P353	NN	B-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
childhood	childhood	C430	NN	I-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
type	type	T100	NN	I-NP	O
.	.	0000	.	O	O

Another	Another	A536	DT	B-NP	O
nephew	nephew	N100	JJ	I-NP	O
(	(	0000	(	O	O
patient	patient	P353	NN	B-NP	O
4	4	0000	CD	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
1	1	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
classified	classify	C421	VBN	I-VP	O
as	as	A200	IN	B-PP	O
having	have	H152	VBG	B-VP	O
an	an	A500	DT	B-NP	O
adolescent	adolescent	A342	JJ	I-NP	O
form	form	F650	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
tau	tau	T000	SYM	I-NP	O
level	level	L140	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
cerebrospinal	cerebrospinal	C616	JJ	I-NP	O
fluid	fluid	F430	NN	I-NP	O
(	(	0000	(	O	O
CSF	CSF	C210	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
1	1	0000	CD	I-NP	O
was	be	W200	VBD	B-VP	O
as	as	A200	RB	B-ADJP	O
high	high	H200	JJ	I-ADJP	O
as	as	A200	IN	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Alzheimers	Alzheimer	A425	NNS	B-NP	B-Disease
disease	disease	D200	NN	B-NP	I-Disease
(	(	0000	(	O	O
AD	AD	A300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

His	His	H200	PRP$	B-NP	O
brain	brain	B650	NN	I-NP	O
magnetic	magnetic	M253	JJ	I-NP	O
resonance	resonance	R252	NN	I-NP	O
image	image	I520	NN	I-NP	O
(	(	0000	(	O	O
MRI	MRI	M600	NN	B-NP	O
)	)	0000	)	O	O
showed	show	S300	VBD	B-VP	O
abnormalities	abnormality	A156	NNS	B-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
bilateral	bilateral	B436	JJ	I-NP	I-Disease
cerebellar	cerebellar	C614	JJ	I-NP	I-Disease
hemispheres	hemisphere	H521	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
brain	brain	B650	NN	B-NP	O
stem	stem	S350	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	B-PP	O
not	not	N300	RB	B-PP	O
in	in	I500	IN	I-PP	O
the	the	T000	DT	B-NP	O
cerebral	cerebral	C616	JJ	I-NP	O
white	white	W300	JJ	I-NP	O
matter	matter	M360	NN	I-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
marked	marked	M623	JJ	B-NP	O
reductions	reduction	R323	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cerebral	cerebral	C616	JJ	I-NP	O
blood	blood	B430	NN	I-NP	O
flow	flow	F400	NN	I-NP	O
and	and	A530	CC	O	O
oxygen	oxygen	O250	NN	B-NP	O
metabolism	metabolism	M314	NN	I-NP	O
were	be	W600	VBD	B-VP	O
clearly	clearly	C464	RB	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
by	by	B000	IN	B-PP	O
positron	positron	P236	NN	B-NP	O
emission	emission	E525	NN	I-NP	O
tomography	tomography	T526	NN	I-NP	O
(	(	0000	(	O	O
PET	PET	P300	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
2	2	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
3	3	0000	CD	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
autopsy	autopsy	A312	NN	I-NP	O
findings	finding	F535	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
massive	massive	M210	JJ	B-NP	O
demyelination	demyelination	D545	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
cerebral	cerebral	C616	JJ	I-NP	I-Disease
white	white	W300	JJ	I-NP	I-Disease
matter	matter	M360	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
sparing	spar	S165	VBG	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
U	U	U000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
fibers	fiber	F162	NNS	I-NP	O
,	,	0000	,	O	O
compatible	compatible	C513	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
of	of	O100	IN	B-PP	O
childhood	childhood	C430	NN	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
.	.	0000	.	O	O

Oleic	Oleic	O420	JJ	B-NP	O
and	and	A530	CC	I-NP	O
erucic	erucic	E620	JJ	I-NP	O
acids	acid	A232	NNS	I-NP	O
(	(	0000	(	O	O
Lorenzos	Lorenzos	L652	NNP	B-NP	O
Oil	Oil	O400	NNP	I-NP	O
)	)	0000	)	O	O
were	be	W600	VBD	B-VP	O
administered	administer	A352	VBN	I-VP	O
to	to	T000	TO	B-PP	O
patients	patient	P353	NNS	B-NP	O
1	1	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
4	4	0000	CD	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
sufficient	sufficient	S125	JJ	B-NP	O
effectiveness	effectiveness	E123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
obtained	obtain	O135	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
delGAG291	delGAG291	D420	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
ALD	ALD	A430	NN	I-NP	B-Disease
with	with	W300	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
variations	variation	V635	NNS	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
scale	scale	S240	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
study	study	S300	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
limited	limit	L530	VBN	I-VP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
possibility	possibility	P214	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
PET	PET	P300	NN	B-NP	O
can	can	C500	MD	B-VP	O
detect	detect	D323	VB	I-VP	O
an	an	A500	DT	B-NP	O
insidious	insidious	I523	JJ	I-NP	B-Disease
lesion	lesion	L250	NN	I-NP	I-Disease
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
undetectable	undetectable	U532	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
computed	compute	C513	VBN	B-NP	O
tomogram	tomogram	T526	NN	I-NP	O
(	(	0000	(	O	O
CT	CT	C300	NN	B-NP	O
)	)	0000	)	O	O
or	or	O600	CC	O	O
MRI	MRI	M600	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
level	level	L140	NN	I-NP	O
of	of	O100	IN	B-PP	O
tau	tau	T000	SYM	B-NP	O
reflects	reflect	R142	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
process	process	P620	NN	I-NP	O
of	of	O100	IN	B-PP	O
neuronal	neuronal	N654	JJ	B-NP	B-Disease
degeneration	degeneration	D256	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
ALD	ALD	A430	NN	B-NP	B-Disease
.	.	0000	.	O	O

Lorenzos	Lorenzos	L652	NNP	B-NP	O
Oil	Oil	O400	NNP	I-NP	O
should	should	S430	MD	B-VP	O
be	be	B000	VB	I-VP	O
given	give	G150	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
early	early	E640	JJ	I-NP	O
stage	stage	S320	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Nonsense	Nonsense	N525	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
complement	complement	C514	NN	I-NP	O
C9	C9	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
Japanese	Japanese	J152	JJ	B-NP	O
complement	complement	C514	NN	I-NP	B-Disease
C9	C9	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
ninth	ninth	N530	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
human	human	H500	JJ	B-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
(	(	0000	(	O	O
C9	C9	C000	NN	B-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
complement	complement	C514	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Japan	Japan	J150	NNP	B-NP	O
but	but	B300	CC	O	O
is	be	I200	VBZ	B-VP	O
rare	rare	R600	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
countries	country	C536	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
studied	study	S300	VBD	B-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
C9	C9	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
C9	C9	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
deficient	deficient	D125	JJ	B-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
who	who	W000	WP	B-NP	O
had	have	H300	VBD	B-VP	O
suffered	suffer	S163	VBN	I-VP	O
from	from	F650	IN	B-PP	O
meningococcal	meningococcal	M524	JJ	B-NP	B-Disease
meningitis	meningitis	M523	NN	I-NP	I-Disease
.	.	0000	.	O	O

Direct	Direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
amplified	amplify	A514	VBN	B-NP	O
C9	C9	C000	NN	I-NP	O
cDNA	cDNA	C350	NN	I-NP	O
and	and	A530	CC	I-NP	O
DNA	DNA	D500	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
nonsense	nonsense	N525	JJ	I-NP	O
substitution	substitution	S123	NN	I-NP	O
(	(	0000	(	O	O
CGA	CGA	C200	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
TGA	TGA	T200	NN	I-NP	O
)	)	0000	)	O	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
95	95	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
C9	C9	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
polymerase	polymerase	P456	NN	I-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
system	system	S235	NN	I-NP	O
designed	design	D253	VBN	B-VP	O
to	to	T000	TO	B-VP	O
detect	detect	D323	VB	I-VP	O
exclusively	exclusively	E242	RB	B-ADVP	O
only	only	O540	RB	B-NP	O
one	one	O500	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
and	and	A530	CC	I-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
four	four	F600	CD	I-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
parents	parent	P653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
2	2	0000	CD	I-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
95	95	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
4	4	0000	CD	I-NP	O
might	might	M230	MD	B-VP	O
be	be	B000	VB	I-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
most	most	M230	JJS	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
C9	C9	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
required	require	R263	VBN	B-VP	O
for	for	F600	IN	B-PP	O
transcription	transcription	T652	NN	B-NP	O
-	-	0000	HYPH	O	O
coupled	couple	C143	VBN	B-NP	O
repair	repair	R160	NN	I-NP	O
of	of	O100	IN	B-PP	O
oxidative	oxidative	O231	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
damage	damage	D520	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	I-NP	I-Disease
ovarian	ovarian	O165	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
zinc	zinc	Z520	NN	I-NP	O
finger	finger	F526	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
unknown	unknown	U525	JJ	B-NP	O
function	function	F523	NN	I-NP	O
.	.	0000	.	O	O

Association	Association	A235	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
repair	repair	R160	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
Rad51	Rad51	R300	NN	I-NP	O
and	and	A530	CC	O	O
changes	change	C520	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
phosphorylation	phosphorylation	P216	NN	I-NP	O
and	and	A530	CC	I-NP	O
cellular	cellular	C460	JJ	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
after	after	A136	IN	B-PP	O
exposure	exposure	E212	NN	B-NP	O
to	to	T000	TO	B-PP	O
DNA	DNA	D500	NN	B-NP	O
-	-	0000	HYPH	O	O
damaging	damage	D525	VBG	B-NP	O
agents	agent	A253	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
repair	repair	R160	NN	I-NP	O
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
shown	show	S500	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
mouse	mouse	M200	NN	B-NP	O
embryonic	embryonic	E516	JJ	I-NP	O
stem	stem	S350	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
deficient	deficient	D125	JJ	B-ADJP	B-Disease
in	in	I500	IN	B-PP	I-Disease
BRCA1	BRCA1	B620	NN	B-NP	I-Disease
are	be	A600	VBP	B-VP	O
defective	defective	D123	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ability	ability	A143	NN	I-NP	O
to	to	T000	TO	B-VP	O
carry	carry	C600	VB	I-VP	O
out	out	O300	RP	B-PRT	O
transcription	transcription	T652	NN	B-NP	O
-	-	0000	HYPH	B-VP	O
coupled	couple	C143	VBN	B-NP	O
repair	repair	R160	NN	I-NP	O
of	of	O100	IN	B-PP	O
oxidative	oxidative	O231	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
damage	damage	D520	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
are	be	A600	VBP	B-VP	O
hypersensitive	hypersensitive	H162	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
ionizing	ionize	I525	VBG	B-VP	O
radiation	radiation	R350	NN	B-NP	O
and	and	A530	CC	I-NP	O
hydrogen	hydrogen	H362	NN	I-NP	O
peroxide	peroxide	P623	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
participates	participate	P632	VBZ	B-VP	O
,	,	0000	,	O	O
directly	directly	D623	RB	B-ADVP	O
or	or	O600	CC	I-ADVP	O
indirectly	indirectly	I536	RB	I-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
transcription	transcription	T652	NN	B-NP	O
-	-	0000	HYPH	O	O
coupled	couple	C143	VBN	B-NP	O
repair	repair	R160	NN	I-NP	O
of	of	O100	IN	B-PP	O
oxidative	oxidative	O231	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
damage	damage	D520	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Truncation	Truncation	T652	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
transactivation	transactivation	T652	NN	I-NP	O
region	region	R250	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
dominant	dominant	D530	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
negative	negative	N231	JJ	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
.	.	0000	.	O	O

PAX6	PAX6	P200	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
with	with	W300	IN	B-PP	O
two	two	T000	CD	B-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
binding	bind	B535	VBG	B-NP	O
domains	domain	D520	NNS	I-NP	O
(	(	0000	(	O	O
paired	paired	P630	JJ	B-NP	O
box	box	B200	NN	I-NP	O
and	and	A530	CC	O	O
homeobox	homeobox	H512	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
proline	proline	P645	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
serine	serine	S650	NN	I-NP	O
-	-	0000	HYPH	O	O
threonine	threonine	T650	NN	B-NP	O
(	(	0000	(	O	O
PST	PST	P230	NN	B-NP	O
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
rich	rich	R200	JJ	I-NP	O
transactivation	transactivation	T652	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

PAX6	PAX6	P200	NN	B-NP	O
regulates	regulate	R243	VBZ	B-VP	O
eye	eye	E000	NN	B-NP	O
development	development	D141	NN	I-NP	O
in	in	I500	IN	B-PP	O
animals	animal	A542	NNS	B-NP	O
ranging	range	R525	VBG	B-VP	O
from	from	F650	IN	B-PP	O
jellyfish	jellyfish	J412	NN	B-NP	O
to	to	T000	TO	B-PP	O
Drosophila	Drosophila	D621	FW	B-NP	O
to	to	T000	TO	B-PP	O
humans	human	H520	NNS	B-NP	O
.	.	0000	.	O	O

Heterozygous	Heterozygous	H362	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
result	result	R243	VBP	B-VP	O
in	in	I500	IN	B-PP	O
various	various	V620	JJ	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
,	,	0000	,	O	O
Peters	Peters	P362	NNP	B-NP	B-Disease
anomaly	anomaly	A540	RB	B-ADVP	I-Disease
,	,	0000	,	O	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
keratitis	keratitis	K632	NN	I-NP	I-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
familial	familial	F540	JJ	B-NP	B-Disease
foveal	foveal	F140	JJ	I-NP	I-Disease
dysplasia	dysplasia	D214	NN	I-NP	I-Disease
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
believed	believe	B413	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutated	mutate	M300	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
produces	produce	P632	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
inactive	inactive	I523	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
and	and	A530	CC	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
genetic	genetic	G532	JJ	B-NP	O
haploinsufficiency	haploinsufficiency	H145	NN	I-NP	O
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
several	several	S164	JJ	B-NP	O
truncation	truncation	T652	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
occur	occur	O260	VB	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
terminal	terminal	T654	JJ	I-NP	O
half	half	H410	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
Aniridia	Aniridia	A563	NNP	B-NP	B-Disease
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
proteins	protein	P635	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
retain	retain	R350	VBP	B-VP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
binding	bind	B535	VBG	B-NP	O
domains	domain	D520	NNS	I-NP	O
but	but	B300	CC	O	O
have	have	H100	VBP	B-VP	O
lost	lose	L230	VBN	I-VP	O
most	most	M230	JJS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
transactivation	transactivation	T652	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
clear	clear	C460	JJ	B-ADJP	O
whether	whether	W360	IN	B-SBAR	O
such	such	S200	JJ	B-NP	O
mutants	mutant	M353	NNS	I-NP	O
really	really	R400	RB	B-ADVP	O
behave	behave	B100	VBP	B-VP	O
as	as	A200	IN	B-PP	O
loss	loss	L200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
of	of	O100	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
function	function	F523	NN	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
as	as	A200	IN	B-SBAR	O
predicted	predict	P632	VBN	B-VP	O
by	by	B000	IN	B-PP	O
haploinsufficiency	haploinsufficiency	H145	NN	B-NP	O
.	.	0000	.	O	O

Contrary	Contrary	C536	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
this	this	T200	DT	B-NP	O
theory	theory	T600	NN	I-NP	O
,	,	0000	,	O	O
our	our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
mutants	mutant	M353	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
dominant	dominant	D530	JJ	B-ADJP	O
-	-	0000	HYPH	B-ADJP	O
negative	negative	N231	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
transient	transient	T652	JJ	B-NP	O
transfection	transfection	T652	NN	I-NP	O
assays	assay	A200	NNS	I-NP	O
when	when	W500	WRB	B-ADVP	O
they	they	T000	PRP	B-NP	O
are	be	A600	VBP	B-VP	O
coexpressed	coexpresse	C216	VBN	I-VP	O
with	with	W300	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
found	find	F530	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
negative	negative	N231	JJ	I-NP	O
effects	effect	E123	NNS	I-NP	O
result	result	R243	VBP	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
enhanced	enhance	E523	VBN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
ability	ability	A143	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutants	mutant	M353	NNS	I-NP	O
.	.	0000	.	O	O

Kinetic	Kinetic	K532	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
binding	binding	B535	NN	B-NP	O
and	and	A530	CC	I-NP	O
dissociation	dissociation	D235	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
various	various	V620	JJ	B-NP	O
truncation	truncation	T652	NN	I-NP	O
mutants	mutant	M353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
3	3	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	O	O
fold	fold	F430	RB	B-NP	O
higher	high	H260	JJR	I-NP	O
affinity	affinity	A153	NN	I-NP	O
to	to	T000	TO	B-PP	O
various	various	V620	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
binding	bind	B535	VBG	B-NP	O
sites	site	S320	NNS	I-NP	O
when	when	W500	WRB	B-ADVP	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
provide	provide	P613	VBP	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
insight	insight	I523	NN	I-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
in	in	I500	IN	B-PP	O
causing	cause	C252	VBG	B-VP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Reversal	Reversal	R162	NN	B-NP	O
of	of	O100	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
hypertrophic	hypertrophic	H163	JJ	I-NP	B-Disease
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	I-Disease
and	and	A530	CC	O	O
excellent	excellent	E245	JJ	B-NP	O
neuropsychologic	neuropsychologic	N612	JJ	I-NP	O
outcome	outcome	O325	NN	I-NP	O
in	in	I500	IN	B-PP	O
very	very	V600	RB	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
long	long	L520	JJ	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
chain	chain	C500	NN	I-NP	I-Disease
acyl	acyl	A240	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
coenzyme	coenzyme	C525	NN	I-NP	I-Disease
A	A	A000	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

Very	Very	V600	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
long	long	L520	JJ	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
chain	chain	C500	NN	I-NP	I-Disease
acyl	acyl	A240	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	I-Disease
coenzyme	coenzyme	C525	NN	I-NP	I-Disease
A	A	A000	NN	I-NP	I-Disease
dehydrogenase	dehydrogenase	D362	NN	I-NP	I-Disease
(	(	0000	(	O	I-Disease
VLCAD	VLCAD	V423	NN	B-NP	I-Disease
)	)	0000	)	O	I-Disease
deficiency	deficiency	D125	NN	B-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
disorder	disorder	D263	NN	I-NP	O
of	of	O100	IN	B-PP	O
fatty	fatty	F300	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
beta	beta	B300	NN	I-NP	O
oxidation	oxidation	O235	NN	I-NP	O
that	that	T300	WDT	B-NP	O
reportedly	reportedly	R163	RB	B-ADVP	O
has	have	H200	VBZ	B-VP	O
high	high	H200	JJ	B-NP	O
rates	rate	R320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
morbidity	morbidity	M613	NN	B-NP	O
and	and	A530	CC	I-NP	O
mortality	mortality	M634	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
the	the	T000	DT	B-NP	O
outcome	outcome	O325	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
year	year	Y600	NN	I-NP	O
-	-	0000	HYPH	O	O
old	old	O430	JJ	B-NP	O
girl	girl	G640	NN	I-NP	O
with	with	W300	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
who	who	W000	WP	B-NP	O
was	be	W200	VBD	B-VP	O
first	first	F623	RB	I-VP	O
seen	see	S500	VBN	I-VP	O
at	at	A300	IN	B-PP	O
5	5	0000	CD	B-NP	O
months	month	M532	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
hypertrophic	hypertrophic	H163	JJ	I-NP	B-Disease
cardiomyopathy	cardiomyopathy	C635	NN	I-NP	I-Disease
,	,	0000	,	O	O
hepatomegaly	hepatomegaly	H135	NN	B-NP	B-Disease
,	,	0000	,	O	O
encephalopathy	encephalopathy	E521	NN	B-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
hypotonia	hypotonia	H135	NN	B-NP	B-Disease
.	.	0000	.	O	O

Biochemical	Biochemical	B252	JJ	B-NP	O
studies	study	S320	NNS	I-NP	O
indicated	indicate	I532	VBD	B-VP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
stable	stable	S314	JJ	I-NP	O
yet	yet	Y300	RB	I-NP	O
inactive	inactive	I523	JJ	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
her	her	H600	PRP$	B-NP	O
VLCAD	VLCAD	V423	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
T1372C	T1372C	T200	NN	I-NP	O
(	(	0000	(	O	O
F458L	F458L	F400	NN	B-NP	O
)	)	0000	)	O	O
missense	missense	M252	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
1668	1668	0000	CD	I-NP	O
ACAG	ACAG	A200	NN	I-NP	O
1669	1669	0000	CD	B-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

After	After	A136	IN	B-PP	O
initial	initial	I534	JJ	B-NP	O
treatment	treatment	T635	NN	I-NP	O
with	with	W300	IN	B-PP	O
intravenous	intravenous	I536	JJ	B-NP	O
glucose	glucose	G420	NN	I-NP	O
and	and	A530	CC	I-NP	O
carnitine	carnitine	C653	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
thrived	thrive	T613	VBN	I-VP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
fat	fat	F300	NN	I-NP	O
diet	diet	D300	NN	I-NP	O
supplemented	supplement	S145	VBN	B-VP	O
with	with	W300	IN	B-PP	O
medium	medium	M350	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
chain	chain	C500	NN	I-NP	O
triglyceride	triglyceride	T624	NN	I-NP	O
oil	oil	O400	NN	I-NP	O
and	and	A530	CC	I-NP	O
carnitine	carnitine	C653	NN	I-NP	O
and	and	A530	CC	I-NP	O
avoidance	avoidance	A135	NN	I-NP	O
of	of	O100	IN	B-PP	O
fasting	fast	F235	VBG	B-NP	O
.	.	0000	.	O	O

Her	Her	H600	PRP$	B-NP	O
ventricular	ventricular	V536	JJ	I-NP	O
hypertrophy	hypertrophy	H163	NN	I-NP	O
resolved	resolve	R241	VBN	B-VP	O
significantly	significantly	S251	RB	B-NP	O
over	over	O160	IN	I-NP	O
1	1	0000	CD	I-NP	O
year	year	Y600	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
cognitively	cognitively	C253	RB	B-ADVP	O
,	,	0000	,	O	O
she	she	S000	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
superior	superior	S160	JJ	I-NP	O
range	range	R520	NN	I-NP	O
for	for	F600	IN	B-PP	O
age	age	A200	NN	B-NP	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
recognition	recognition	R253	NN	I-NP	O
of	of	O100	IN	B-PP	O
VLCAD	VLCAD	V423	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
important	important	I516	JJ	B-ADJP	O
because	because	B200	IN	B-SBAR	O
it	it	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
few	few	F000	JJ	I-NP	O
directly	directly	D623	RB	I-NP	O
treatable	treatable	T631	JJ	I-NP	O
causes	cause	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cardiomyopathy	cardiomyopathy	C635	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
children	child	C436	NNS	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Cloning	Cloning	C452	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
insulin	insulin	I524	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
dependent	dependent	D153	JJ	I-NP	I-Disease
diabetes	diabetes	D132	NN	I-NP	I-Disease
mellitus	mellitus	M432	NN	I-NP	I-Disease
(	(	0000	(	O	O
IDDM	IDDM	I350	NN	B-NP	B-Disease
)	)	0000	)	O	O
locus	locus	L200	NN	B-NP	O
IDDM4	IDDM4	I350	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
11q13	11q13	Q000	NN	I-NP	O
.	.	0000	.	O	O

Based	Base	B230	VBN	B-PP	O
on	on	O500	IN	B-PP	O
its	its	I320	PRP$	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
position	position	P235	NN	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
for	for	F600	IN	B-PP	O
conferring	confer	C516	VBG	B-VP	O
susceptibility	susceptibility	S213	NN	B-NP	O
to	to	T000	TO	B-PP	O
diabetes	diabete	D132	NNS	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
termed	term	T653	VBN	B-VP	O
low	low	L000	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
related	related	R430	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
5	5	0000	CD	I-NP	O
(	(	0000	(	O	O
LRP5	LRP5	L610	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
encodes	encode	E523	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
of	of	O100	IN	B-PP	O
1615	1615	0000	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acids	acid	A232	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
contains	contain	C535	VBZ	B-VP	O
conserved	conserve	C526	VBN	B-NP	O
modules	module	M342	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
characteristic	characteristic	C623	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
low	low	L000	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
density	density	D523	NN	I-NP	O
lipoprotein	lipoprotein	L163	NN	I-NP	O
(	(	0000	(	O	O
LDL	LDL	L340	NN	B-NP	O
)	)	0000	)	O	O
receptor	receptor	R213	NN	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
modules	module	M342	NNS	I-NP	O
include	include	I524	VBP	B-VP	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
signal	signal	S254	NN	I-NP	O
peptide	peptide	P130	NN	I-NP	O
for	for	F600	IN	B-PP	O
protein	protein	P635	NN	B-NP	O
export	export	E216	NN	I-NP	O
,	,	0000	,	O	O
four	four	F600	CD	B-NP	O
epidermal	epidermal	E136	JJ	I-NP	O
growth	growth	G630	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
(	(	0000	(	O	O
EGF	EGF	E210	NN	B-NP	O
)	)	0000	)	O	O
repeats	repeat	R132	NNS	B-NP	O
with	with	W300	IN	B-PP	O
associated	associate	A230	VBN	B-NP	O
spacer	spacer	S126	NN	I-NP	O
domains	domain	D520	NNS	I-NP	O
,	,	0000	,	O	O
three	three	T600	CD	B-NP	O
LDL	LDL	L340	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
receptor	receptor	R213	NN	I-NP	O
(	(	0000	(	O	O
LDLR	LDLR	L346	NN	B-NP	O
)	)	0000	)	O	O
repeats	repeat	R132	NNS	B-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
single	single	S524	JJ	I-NP	O
transmembrane	transmembrane	T652	NN	I-NP	O
spanning	span	S152	VBG	I-NP	O
domain	domain	D500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
cytoplasmic	cytoplasmic	C314	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
encoded	encode	E523	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
unique	unique	U520	JJ	I-NP	O
organization	organization	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
EGF	EGF	E210	NN	B-NP	O
and	and	A530	CC	I-NP	O
LDLR	LDLR	L346	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
;	;	0000	:	O	O
therefore	therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
LRP5	LRP5	L610	NN	B-NP	O
likely	likely	L240	RB	B-VP	O
represents	represent	R162	VBZ	I-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
category	category	C326	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
LDLR	LDLR	L346	NN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
human	human	H500	JJ	O	O
and	and	A530	CC	O	O
mouse	mouse	M200	NN	B-NP	O
LRP5	LRP5	L610	NN	I-NP	O
cDNAs	cDNA	C352	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
isolated	isolate	I243	VBN	I-VP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
encoded	encode	E523	VBN	I-NP	O
mature	mature	M360	JJ	I-NP	O
proteins	protein	P635	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
95	95	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
identical	identical	I353	JJ	B-ADJP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
evolutionary	evolutionary	E143	JJ	B-NP	O
conservation	conservation	C526	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
variants	variant	V653	NNS	I-NP	O
I1307K	I1307K	I200	NN	I-NP	O
and	and	A530	CC	I-NP	O
E1317Q	E1317Q	E200	NN	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
not	not	N300	RB	B-ADVP	O
always	always	A420	RB	I-ADVP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
.	.	0000	.	O	O

Classical	Classical	C424	JJ	B-NP	O
familial	familial	F540	JJ	I-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
penetrance	penetrance	P536	NN	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
that	that	T300	WDT	B-NP	O
predisposes	predispose	P632	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
hundreds	hundred	H536	NNS	B-NP	O
or	or	O600	CC	I-NP	O
thousands	thousand	T253	NNS	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
adenomas	adenoma	A352	NNS	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
carcinoma	carcinoma	C625	NN	B-NP	I-Disease
and	and	A530	CC	O	O
that	that	T300	DT	B-NP	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
truncating	truncate	T652	VBG	B-VP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
attenuated	attenuate	A353	VBN	I-VP	B-Disease
adenomatous	adenomatous	A353	JJ	B-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
5	5	0000	CD	I-NP	O
and	and	A530	CC	I-NP	O
3	3	0000	CD	I-NP	O
regions	region	R252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Attenuated	Attenuate	A353	VBN	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
"	"	0000	``	B-NP	O
multiple	multiple	M431	JJ	I-NP	O
"	"	0000	''	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
adenomas	adenoma	A352	NNS	I-NP	I-Disease
(	(	0000	(	O	O
typically	typically	T124	RB	B-NP	O
fewer	few	F600	JJR	I-NP	O
than	than	T500	IN	I-NP	O
100	100	0000	CD	I-NP	O
)	)	0000	)	O	O
without	without	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
florid	florid	F463	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
classical	classical	C424	JJ	B-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
.	.	0000	.	O	O

Another	Another	A536	DT	B-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
adenomas	adenoma	A352	NNS	I-NP	B-Disease
has	have	H200	VBZ	B-VP	O
no	no	N000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
probably	probably	P614	RB	B-ADVP	O
results	result	R243	VBZ	B-VP	O
from	from	F650	IN	B-PP	O
variation	variation	V635	NN	B-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
loci	locus	L200	NNS	B-NP	O
,	,	0000	,	O	O
elsewhere	elsewhere	E426	RB	B-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
genome	genome	G500	NN	I-NP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
missense	missense	M252	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
(	(	0000	(	O	O
I1307K	I1307K	I200	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
described	describe	D261	VBN	I-VP	O
that	that	T300	WDT	B-NP	O
confers	confer	C516	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
tumors	tumor	T562	NNS	I-NP	I-Disease
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
adenomas	adenoma	A352	NNS	I-NP	B-Disease
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
Ashkenazim	Ashkenazim	A252	NNP	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
a	a	A000	DT	B-NP	O
set	set	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
164	164	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
adenomas	adenoma	A352	NNS	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
carcinoma	carcinoma	C625	NN	B-NP	I-Disease
and	and	A530	CC	O	O
analyzed	analyze	A542	VBN	B-NP	O
codons	codon	C352	NNS	I-NP	O
1263	1263	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
1377	1377	0000	CD	I-NP	O
(	(	0000	(	O	O
exon	exon	E250	NN	B-NP	O
15G	15G	G000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
.	.	0000	.	O	O

Three	Three	T600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
,	,	0000	,	O	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
descent	descent	D253	NNP	I-NP	O
.	.	0000	.	O	O

Four	Four	F600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
E1317Q	E1317Q	E200	NN	I-NP	O
missense	missense	M252	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
that	that	T300	WDT	B-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	O	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
controls	control	C536	NNS	B-NP	O
;	;	0000	:	O	O
one	one	O500	CD	B-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
individuals	individual	I531	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
unusually	unusually	U524	RB	I-NP	O
large	large	L620	JJ	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
metaplastic	metaplastic	M314	JJ	B-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
colorectum	colorectum	C462	NN	I-NP	I-Disease
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
increasing	increase	I526	VBG	I-VP	O
evidence	evidence	E135	NN	B-NP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
exist	exist	E230	VBP	B-VP	O
germ	germ	G650	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
line	line	L500	NN	I-NP	O
variants	variant	V653	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
predispose	predispose	P632	VBP	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
adenomas	adenoma	A352	NNS	I-NP	I-Disease
and	and	A530	CC	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
without	without	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
florid	florid	F463	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
of	of	O100	IN	B-PP	O
classical	classical	C424	JJ	B-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
,	,	0000	,	O	O
and	and	A530	CC	O	O
possibly	possibly	P214	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
importance	importance	I516	NN	B-NP	O
for	for	F600	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
risk	risk	R200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genomic	Genomic	G520	JJ	B-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
chloride	chloride	C463	NN	I-NP	I-Disease
diarrhea	diarrhea	D600	NN	I-NP	I-Disease
(	(	0000	(	O	O
CLD	CLD	C430	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
.	.	0000	.	O	O

Congenital	Congenital	C525	JJ	B-NP	B-Disease
chloride	chloride	C463	NN	I-NP	I-Disease
diarrhea	diarrhea	D600	NN	I-NP	I-Disease
(	(	0000	(	O	O
CLD	CLD	C430	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
encodes	encode	E523	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
intestinal	intestinal	I532	JJ	I-NP	O
anion	anion	A500	NN	I-NP	O
transporter	transporter	T652	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
organization	organization	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
CLD	CLD	C430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
which	which	W200	WDT	B-NP	O
spans	span	S152	VBZ	B-VP	O
approximately	approximately	A162	RB	B-ADJP	O
39kb	39kb	K100	JJ	I-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
comprises	comprise	C516	VBZ	B-VP	O
21	21	0000	CD	B-NP	O
exons	exon	E252	NNS	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
/	/	0000	SYM	B-VP	O
intron	intron	I536	NN	B-NP	O
boundaries	boundary	B536	NNS	I-NP	O
conform	conform	C516	VBP	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
GT	GT	G300	NN	I-NP	O
/	/	0000	SYM	B-VP	O
AG	AG	A200	NN	B-NP	O
rule	rule	R400	NN	I-NP	O
.	.	0000	.	O	O

An	An	A500	DT	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
promoter	promoter	P653	NN	I-NP	O
region	region	R250	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
shows	show	S200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
TATA	TATA	T300	NN	I-NP	O
box	box	B200	NN	I-NP	O
and	and	A530	CC	O	O
predicts	predict	P632	VBZ	B-VP	O
multiple	multiple	M431	JJ	B-NP	O
transcription	transcription	T652	NN	I-NP	O
factor	factor	F236	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
sites	site	S320	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
using	use	U252	VBG	B-VP	O
DNA	DNA	D500	NN	B-NP	O
from	from	F650	IN	B-PP	O
several	several	S164	JJ	B-NP	O
sources	source	S620	NNS	I-NP	O
including	include	I524	VBG	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
large	large	L620	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
insert	insert	I526	NN	I-NP	O
libaries	libary	L162	NNS	I-NP	O
and	and	A530	CC	O	O
genomic	genomic	G520	JJ	B-NP	O
DNA	DNA	D500	NN	I-NP	O
from	from	F650	IN	B-PP	O
Finnish	Finnish	F520	JJ	B-NP	O
CLD	CLD	C430	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	I-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

Exon	Exon	E250	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
specific	specific	S121	JJ	I-NP	O
primers	primer	P656	NNS	I-NP	O
developed	develop	D141	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
will	will	W400	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
mutation	mutation	M350	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

Genomic	Genomic	G520	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
BAC	BAC	B200	NN	I-NP	O
clone	clone	C450	NN	I-NP	O
H	H	H000	NN	I-NP	O
_	_	0000	NN	I-NP	O
RG364P16	RG364P16	R210	NN	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
another	another	A536	DT	B-NP	O
,	,	0000	,	O	O
highly	highly	H240	RB	B-NP	O
homologous	homologous	H542	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
3	3	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CLD	CLD	C430	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
similar	similar	S546	JJ	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
,	,	0000	,	O	O
recently	recently	R253	RB	B-VP	O
identified	identify	I353	VBN	I-VP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
Pendred	Pendred	P536	NNP	I-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
PDS	PDS	P320	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
APCI1307K	APCI1307K	A120	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	O	O
cancer	cancer	C526	NN	B-NP	B-Disease
risk	risk	R200	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
community	community	C530	NN	I-NP	O
-	-	0000	HYPH	O	O
based	base	B230	VBN	B-NP	O
study	study	S300	NN	I-NP	O
of	of	O100	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jews	Jews	J200	NNP	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
are	be	A600	VBP	B-VP	O
classically	classically	C424	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
highly	highly	H240	RB	I-NP	O
penetrant	penetrant	P536	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
multiple	multiple	M431	JJ	B-NP	O
intestinal	intestinal	I532	JJ	I-NP	O
polyps	polyp	P412	NNS	I-NP	B-Disease
and	and	A530	CC	O	O
,	,	0000	,	O	O
without	without	W300	IN	B-PP	O
surgical	surgical	S624	JJ	B-NP	O
intervention	intervention	I536	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
(	(	0000	(	O	O
CRC	CRC	C620	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

APC	APC	A120	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
tumour	tumour	T560	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
somatic	somatic	S532	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
tumours	tumour	T562	NNS	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
germline	germline	G654	NN	I-NP	O
T	T	T000	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
to	to	T000	TO	B-PP	O
-	-	0000	HYPH	B-NP	O
A	A	A000	NN	I-NP	O
transversion	transversion	T652	NN	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	O
I1307K	I1307K	I200	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
converts	convert	C516	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
homopolymer	homopolymer	H514	NN	I-NP	O
tract	tract	T623	NN	I-NP	O
(	(	0000	(	O	O
A8	A8	A000	NN	B-NP	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
genetically	genetically	G532	RB	B-ADJP	O
unstable	unstable	U523	JJ	I-ADJP	O
and	and	A530	CC	I-ADJP	O
prone	prone	P650	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
6	6	0000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
unselected	unselected	U524	JJ	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jews	Jew	J200	NNPS	I-NP	O
and	and	A530	CC	O	O
higher	high	H260	JJR	B-NP	O
proportions	proportion	P616	NNS	I-NP	O
of	of	O100	IN	B-PP	O
Ashkenazim	Ashkenazim	A252	NN	B-NP	O
with	with	W300	IN	B-PP	O
family	family	F540	NN	B-NP	O
or	or	O600	CC	O	O
personal	personal	P625	JJ	B-NP	O
histories	history	H236	NNS	I-NP	O
of	of	O100	IN	B-PP	O
CRC	CRC	C620	NN	B-NP	B-Disease
(	(	0000	(	O	O
ref	ref	R100	NN	B-NP	O
.	.	0000	.	O	O
2	2	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
evaluate	evaluate	E143	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
I1307K	I1307K	I200	NN	B-NP	O
in	in	I500	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
genotyped	genotype	G531	VBD	B-VP	O
5	5	0000	CD	B-NP	O
,	,	0000	,	O	O
081	081	0000	CD	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
volunteers	volunteer	V453	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
community	community	C530	NN	I-NP	O
survey	survey	S610	NN	I-NP	O
.	.	0000	.	O	O

Risk	Risk	R200	NN	B-NP	O
of	of	O100	IN	B-PP	O
developing	develop	D141	VBG	B-VP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
,	,	0000	,	I-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
other	other	O360	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
compared	compare	C516	VBN	I-VP	O
between	between	B350	IN	B-PP	O
genotyped	genotype	G531	VBN	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
and	and	A530	CC	O	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
first	first	F623	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
degree	degree	D260	NN	I-NP	O
relatives	relative	R431	NNS	I-NP	O
.	.	0000	.	O	O

Sperm	Sperm	S165	NN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Friedreich	Friedreich	F636	NNP	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
premutation	premutation	P653	NN	I-NP	O
carrier	carrier	C600	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
both	both	B300	CC	O	O
meiotic	meiotic	M320	JJ	B-NP	O
and	and	A530	CC	I-NP	O
mitotic	mitotic	M320	JJ	I-NP	O
expansion	expansion	E215	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Friedreich	Friedreich	F636	JJ	B-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
usually	usually	U240	RB	I-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
GAA	GAA	G000	NN	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeat	repeat	R130	NN	I-NP	O
in	in	I500	IN	B-PP	O
intron	intron	I536	NN	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FRDA	FRDA	F630	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Occasionally	Occasionally	O254	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
fully	fully	F400	RB	I-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
arise	arise	A620	VB	I-VP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
premutation	premutation	P653	NN	I-NP	O
of	of	O100	IN	B-PP	O
100	100	0000	CD	B-NP	O
or	or	O600	CC	I-NP	O
less	less	L200	JJR	I-NP	O
triplet	triplet	T614	JJ	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
examined	examine	E253	VBN	I-VP	O
the	the	T000	DT	B-NP	O
sperm	sperm	S165	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
premutation	premutation	P653	NN	I-NP	O
carrier	carrier	C600	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mans	man	M520	VBZ	B-VP	O
leucocyte	leucocyte	L230	NN	B-NP	O
DNA	DNA	D500	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
one	one	O500	CD	B-NP	O
normal	normal	N654	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
allele	allele	A400	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
100	100	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

His	His	H200	PRP$	B-NP	O
sperm	sperm	S165	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
an	an	A500	DT	B-NP	O
expanded	expand	E215	VBN	I-NP	O
allele	allele	A400	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
tight	tight	T230	JJ	I-NP	O
range	range	R520	NN	I-NP	O
centering	centering	C536	NN	I-NP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
size	size	S200	NN	I-NP	O
of	of	O100	IN	B-PP	O
approximately	approximately	A162	RB	B-NP	O
320	320	0000	CD	I-NP	O
trinucleotide	trinucleotide	T652	NN	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
.	.	0000	.	O	O

His	His	H200	PRP$	B-NP	O
affected	affected	A123	JJ	I-NP	O
son	son	S500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
repeat	repeat	R130	NN	B-NP	O
sizes	size	S200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
1040	1040	0000	CD	B-NP	O
and	and	A530	CC	I-NP	O
540	540	0000	CD	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
expansion	expansion	E215	NN	B-NP	O
occurs	occur	O262	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
stages	stage	S320	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
during	during	D652	IN	B-PP	O
meiosis	meiosis	M200	NN	B-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
second	second	S253	JJ	I-NP	O
mitotic	mitotic	M320	JJ	I-NP	O
expansion	expansion	E215	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
informative	informative	I516	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
father	father	F360	NN	I-NP	O
to	to	T000	TO	B-PP	O
affected	affect	A123	VBN	B-NP	O
child	child	C430	NN	I-NP	O
transmissions	transmission	T652	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
notable	notable	N314	JJ	I-NP	O
exception	exception	E213	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
premutation	premutation	P653	NN	I-NP	O
carrier	carrier	C600	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
size	size	S200	NN	I-NP	O
decreases	decrease	D262	VBZ	B-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
R496H	R496H	R000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
arylsulfatase	arylsulfatase	A642	NN	B-NP	O
A	A	A000	NN	I-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
cause	cause	C200	VB	I-VP	O
metachromatic	metachromatic	M326	JJ	B-NP	B-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
arylsulfatase	arylsulfatase	A642	NN	B-NP	I-Disease
A	A	A000	NN	I-NP	I-Disease
(	(	0000	(	O	O
ARSA	ARSA	A620	NN	B-NP	O
)	)	0000	)	O	O
enzyme	enzyme	E525	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
causes	cause	C200	VBZ	B-VP	O
metachromatic	metachromatic	M326	JJ	B-NP	B-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
(	(	0000	(	O	O
MLD	MLD	M430	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
ARSA	ARSA	A620	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
MLD	MLD	M430	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
R496H	R496H	R000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
ARSA	ARSA	A620	NN	B-NP	O
was	be	W200	VBD	B-VP	O
proposed	propose	P612	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
MLD	MLD	M430	NN	B-NP	B-Disease
(	(	0000	(	O	O
Draghia	Draghia	D620	NNP	B-NP	O
et	et	E300	FW	I-NP	O
al	al	A400	FW	I-NP	O
.	.	0000	FW	I-NP	O
,	,	0000	,	O	O
1997	1997	0000	CD	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
investigated	investigate	I512	VBN	I-VP	O
the	the	T000	DT	B-NP	O
R496H	R496H	R000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
found	find	F530	VBD	B-VP	O
this	this	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
relatively	relatively	R431	RB	I-NP	O
high	high	H200	JJ	I-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
African	African	A162	JJ	I-NP	O
American	American	A562	JJ	I-NP	O
population	population	P143	NN	I-NP	O
(	(	0000	(	O	O
f	f	F000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
09	09	0000	CD	I-NP	O
,	,	0000	,	O	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
61	61	0000	CD	B-NP	O
subjects	subject	S123	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
enzyme	enzyme	E525	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
in	in	I500	IN	B-PP	O
subjects	subject	S123	NNS	B-NP	O
with	with	W300	IN	B-PP	O
and	and	A530	CC	I-PP	O
without	without	W300	IN	I-PP	O
the	the	T000	DT	B-NP	O
R496H	R496H	R000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
determined	determine	D365	VBN	I-VP	O
and	and	A530	CC	O	O
found	find	F530	VBN	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
normal	normal	N654	JJ	B-ADJP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
therefore	therefore	T616	RB	I-VP	O
concluded	conclude	C524	VBN	I-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
R496H	R496H	R000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
ARSA	ARSA	A620	NN	B-NP	O
does	do	D200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
negatively	negatively	N231	RB	I-VP	O
influence	influence	I514	VB	I-VP	O
the	the	T000	DT	B-NP	O
activity	activity	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
ARSA	ARSA	A620	NN	B-NP	O
and	and	A530	CC	O	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
a	a	A000	DT	B-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
MLD	MLD	M430	NN	B-NP	B-Disease

Down	Down	D500	RB	B-ADVP	O
-	-	0000	HYPH	O	O
regulation	regulation	R243	NN	B-NP	O
of	of	O100	IN	B-PP	O
transmembrane	transmembrane	T652	NN	B-NP	O
carbonic	carbonic	C615	JJ	I-NP	O
anhydrases	anhydras	A536	NNS	I-NP	O
in	in	I500	IN	B-PP	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
by	by	B000	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
von	von	V500	NN	I-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
transgenes	transgene	T652	NNS	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
discover	discover	D216	VB	I-VP	O
genes	gene	G520	NNS	B-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
von	von	V500	NNP	B-NP	B-Disease
Hippel	Hippel	H140	NNP	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
Lindau	Lindau	L530	NNP	I-NP	I-Disease
(	(	0000	(	O	O
VHL	VHL	V400	NNP	B-NP	B-Disease
)	)	0000	)	O	O
-	-	0000	HYPH	B-NP	O
mediated	mediate	M300	VBN	I-NP	O
carcinogenesis	carcinogenesis	C625	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
renal	renal	R540	JJ	B-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
stably	stably	S314	RB	B-VP	O
transfected	transfecte	T652	VBN	I-VP	O
with	with	W300	IN	B-PP	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
VHL	VHL	V400	NN	I-NP	O
-	-	0000	HYPH	O	O
expressing	express	E216	VBG	B-VP	O
transgenes	transgene	T652	NNS	B-NP	O
.	.	0000	.	O	O

Large	Large	L620	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
scale	scale	S240	NN	I-NP	O
RNA	RNA	R500	NN	I-NP	O
differential	differential	D165	JJ	I-NP	O
display	display	D214	NN	I-NP	O
technology	technology	T254	NN	I-NP	O
applied	apply	A143	VBN	B-VP	O
to	to	T000	TO	B-PP	O
these	these	T200	DT	B-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
several	several	S164	JJ	B-NP	O
differentially	differentially	D165	RB	I-NP	O
expressed	express	E216	VBN	I-NP	O
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
an	an	A500	DT	B-NP	O
alpha	alpha	A410	NN	I-NP	O
carbonic	carbonic	C615	JJ	I-NP	O
anhydrase	anhydrase	A536	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
termed	term	T653	VBN	B-NP	O
CA12	CA12	C000	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
deduced	deduce	D323	VBN	I-NP	O
protein	protein	P635	NN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
was	be	W200	VBD	B-VP	O
classified	classify	C421	VBN	I-VP	O
as	as	A200	IN	B-PP	O
a	a	A000	DT	B-NP	O
one	one	O500	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
pass	pass	P200	NN	I-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
CA	CA	C000	NN	I-NP	O
possessing	possess	P252	VBG	B-VP	O
an	an	A500	DT	B-NP	O
apparently	apparently	A165	RB	I-NP	O
intact	intact	I532	JJ	I-NP	O
catalytic	catalytic	C343	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
extracellular	extracellular	E236	JJ	I-NP	O
CA	CA	C000	NN	I-NP	O
module	module	M340	NN	I-NP	O
.	.	0000	.	O	O

Reintroduced	Reintroduce	R536	VBN	B-NP	O
wild	wild	W430	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
strongly	strongly	S365	RB	B-ADVP	O
inhibited	inhibit	I513	VBD	B-VP	O
the	the	T000	DT	B-NP	O
overexpression	overexpression	O162	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CA12	CA12	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
parental	parental	P653	JJ	I-NP	O
renal	renal	R540	JJ	I-NP	B-Disease
cell	cell	C400	NN	I-NP	I-Disease
carcinoma	carcinoma	C625	NN	I-NP	I-Disease
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
.	.	0000	.	O	O

Similar	Similar	S546	JJ	B-NP	O
results	result	R243	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
obtained	obtain	O135	VBN	I-VP	O
with	with	W300	IN	B-PP	O
CA9	CA9	C000	NN	B-NP	O
,	,	0000	,	O	O
encoding	encode	E523	VBG	B-VP	O
another	another	A536	DT	B-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
CA	CA	C000	NN	I-NP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
intact	intact	I532	JJ	I-NP	O
catalytic	catalytic	C343	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
both	both	B300	DT	B-NP	O
domains	domain	D520	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
VHL	VHL	V400	NN	I-NP	B-Disease
protein	protein	P635	NN	I-NP	O
contribute	contribute	C536	VBP	B-VP	O
to	to	T000	TO	B-PP	O
regulation	regulation	R243	NN	B-NP	O
of	of	O100	IN	B-PP	O
CA12	CA12	C000	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
elongin	elongin	E452	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
domain	domain	D500	NN	I-NP	O
alone	alone	A450	RB	B-ADVP	O
could	could	C430	MD	B-VP	O
effectively	effectively	E123	RB	I-VP	O
regulate	regulate	R243	VB	I-VP	O
CA9	CA9	C000	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
mapped	map	M130	VBD	B-VP	O
CA12	CA12	C000	NN	B-NP	O
and	and	A530	CC	I-NP	O
CA9	CA9	C000	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
to	to	T000	TO	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
bands	band	B532	NNS	I-NP	O
15q22	15q22	Q000	NN	I-NP	O
and	and	A530	CC	I-NP	O
17q21	17q21	Q000	NN	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
respectively	respectively	R212	RB	I-NP	O
,	,	0000	,	O	O
regions	region	R252	NNS	B-NP	O
prone	prone	P650	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
amplification	amplification	A514	NN	B-NP	O
in	in	I500	IN	B-PP	O
some	some	S500	DT	B-NP	O
human	human	H500	JJ	I-NP	O
cancers	cancer	C526	NNS	I-NP	B-Disease
.	.	0000	.	O	O

Additional	Additional	A354	JJ	B-NP	O
experiments	experiment	E216	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
needed	need	N300	VBN	I-VP	O
to	to	T000	TO	B-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
CA	CA	C000	NN	B-NP	O
IX	IX	I200	CD	I-NP	O
and	and	A530	CC	O	O
CA	CA	C000	NN	B-NP	O
XII	XII	X000	NN	I-NP	O
enzymes	enzyme	E525	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
regulation	regulation	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
pH	pH	P000	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
extracellular	extracellular	E236	JJ	I-NP	O
microenvironment	microenvironment	M265	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
potential	potential	P353	JJ	I-NP	O
impact	impact	I512	NN	I-NP	O
on	on	O500	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
cell	cell	C400	NN	I-NP	O
growth	growth	G630	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
encoding	encode	E523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
mutated	mutate	M300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
diabetes	diabetes	D132	NN	B-NP	B-Disease
mellitus	mellitus	M432	NN	I-NP	I-Disease
and	and	A530	CC	O	O
optic	optic	O132	JJ	B-NP	B-Disease
atrophy	atrophy	A361	NN	I-NP	I-Disease
(	(	0000	(	O	O
Wolfram	Wolfram	W416	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Wolfram	Wolfram	W416	NN	B-NP	B-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
WFS	WFS	W120	NN	B-NP	B-Disease
;	;	0000	:	O	O
OMIM	OMIM	O500	NN	B-NP	O
222300	222300	0000	CD	I-NP	O
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
neurodegenerative	neurodegenerative	N632	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
defined	define	D153	VBN	B-VP	O
by	by	B000	IN	B-PP	O
young	young	Y520	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
onset	onset	O523	NN	I-NP	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	O	O
immune	immune	I500	JJ	B-NP	O
insulin	insulin	I524	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
dependent	dependent	D153	JJ	I-NP	I-Disease
diabetes	diabete	D132	NNS	I-NP	I-Disease
mellitus	mellitus	M432	NN	I-NP	I-Disease
and	and	A530	CC	O	O
progressive	progressive	P626	JJ	B-NP	O
optic	optic	O132	JJ	I-NP	B-Disease
atrophy	atrophy	A361	NN	I-NP	I-Disease
.	.	0000	.	O	O

Linkage	Linkage	L520	NN	B-NP	O
to	to	T000	TO	B-PP	O
markers	marker	M626	NNS	B-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
4p	4p	P000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
confirmed	confirm	C516	VBN	I-VP	O
in	in	I500	IN	B-PP	O
five	five	F100	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

On	On	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
meiotic	meiotic	M320	JJ	B-NP	O
recombinants	recombinant	R251	NNS	I-NP	O
and	and	A530	CC	I-NP	O
disease	disease	D200	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
WFS	WFS	W120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
localized	localized	L242	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
BAC	BAC	B200	NN	I-NP	O
/	/	0000	SYM	B-NP	O
P1	P1	P000	NN	I-NP	O
contig	contig	C532	NN	I-NP	O
of	of	O100	IN	B-PP	O
less	less	L200	JJR	B-NP	O
than	than	T500	IN	I-NP	O
250	250	0000	CD	I-NP	O
kb	kb	K100	NN	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
WFS1	WFS1	W120	NN	B-NP	O
)	)	0000	)	O	O
encoding	encode	E523	VBG	B-VP	O
a	a	A000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
transmembrane	transmembrane	T652	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
affected	affect	A123	VBN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
in	in	I500	IN	B-PP	O
six	six	S200	CD	B-NP	O
WFS	WFS	W120	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

WFS1	WFS1	W120	NN	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
function	function	F523	VB	I-VP	O
in	in	I500	IN	B-PP	O
survival	survival	S614	NN	B-NP	O
of	of	O100	IN	B-PP	O
islet	islet	I243	NN	B-NP	O
beta	beta	B300	SYM	B-NP	O
-	-	0000	HYPH	B-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	I-NP	O
neurons	neuron	N652	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Stable	Stable	S314	JJ	B-NP	O
interaction	interaction	I536	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
products	product	P632	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
tumor	tumor	T560	NN	I-NP	B-Disease
suppressor	suppressor	S162	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
mitotic	mitotic	M320	JJ	B-NP	O
and	and	A530	CC	I-NP	O
meiotic	meiotic	M320	JJ	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
most	most	M230	JJS	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
familial	familial	F540	JJ	B-NP	O
,	,	0000	,	I-NP	O
early	early	E640	JJ	I-NP	O
onset	onset	O523	NN	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
encode	encode	E523	VBP	B-VP	O
products	product	P632	NNS	B-NP	O
that	that	T300	IN	B-SBAR	O
each	each	E200	DT	B-NP	O
interact	interact	I536	NN	I-NP	O
with	with	W300	IN	B-PP	O
hRAD51	hRAD51	H630	NN	B-NP	O
.	.	0000	.	O	O

Results	Result	R243	NNS	B-NP	O
presented	present	P625	VBN	B-VP	O
here	here	H600	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
coexist	coexist	C230	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
biochemical	biochemical	B252	JJ	I-NP	O
complex	complex	C514	NN	I-NP	O
and	and	A530	CC	I-NP	O
colocalize	colocalize	C424	NN	I-NP	O
in	in	I500	IN	B-PP	O
subnuclear	subnuclear	S152	JJ	B-NP	O
foci	focus	F200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
somatic	somatic	S532	JJ	B-NP	O
cells	cell	C420	NNS	I-NP	O
and	and	A530	CC	B-PP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
axial	axial	A240	JJ	I-NP	O
elements	element	E453	NNS	I-NP	O
of	of	O100	IN	B-PP	O
developing	develop	D141	VBG	B-VP	O
synaptonemal	synaptonemal	S513	JJ	B-NP	O
complexes	complex	C514	NNS	I-NP	O
.	.	0000	.	O	O

Like	Like	L200	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
RAD51	RAD51	R300	NN	I-NP	O
,	,	0000	,	O	O
BRCA2	BRCA2	B620	NN	B-NP	O
relocates	relocate	R423	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
PCNA	PCNA	P250	NN	B-NP	O
+	+	0000	SYM	O	O
replication	replication	R142	NN	B-NP	O
sites	site	S320	NNS	I-NP	O
following	follow	F452	VBG	B-PP	O
exposure	exposure	E212	NN	B-NP	O
of	of	O100	IN	B-PP	O
S	S	S000	NN	B-NP	O
phase	phase	P200	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
to	to	T000	TO	B-PP	O
hydroxyurea	hydroxyurea	H362	NN	B-NP	O
or	or	O600	CC	I-NP	O
UV	UV	U100	NN	I-NP	O
irradiation	irradiation	I635	NN	I-NP	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
participate	participate	P632	VBP	B-VP	O
,	,	0000	,	O	O
together	together	T236	RB	B-ADVP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
pathway	pathway	P300	NN	I-NP	O
(	(	0000	(	I-NP	O
s	s	S000	NNS	I-NP	O
)	)	0000	)	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
activation	activation	A231	NN	I-NP	O
of	of	O100	IN	B-PP	O
double	double	D140	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
strand	strand	S365	NN	I-NP	O
break	break	B620	NN	I-NP	O
repair	repair	R160	NN	I-NP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
homologous	homologous	H542	JJ	B-NP	O
recombination	recombination	R251	NN	I-NP	O
.	.	0000	.	O	O

Dysfunction	Dysfunction	D215	NN	B-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
pathway	pathway	P300	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
general	general	G564	JJ	I-NP	O
phenomenon	phenomenon	P500	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
cases	case	C200	NNS	B-NP	O
of	of	O100	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
/	/	0000	SYM	B-NP	I-Disease
or	or	O600	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
Arg362Ser	Arg362Ser	A626	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sterol	sterol	S364	NN	I-NP	O
27	27	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CYP27	CYP27	C100	NN	B-NP	O
)	)	0000	)	O	O
:	:	0000	:	O	O
its	its	I320	PRP$	B-NP	O
effects	effect	E123	NNS	I-NP	O
on	on	O500	IN	B-PP	O
pre	pre	P600	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
splicing	splicing	S142	NN	I-NP	O
and	and	A530	CC	O	O
enzyme	enzyme	E525	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
C	C	C000	NN	I-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sterol	sterol	S364	NN	I-NP	O
27	27	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
(	(	0000	(	O	O
CYP27	CYP27	C100	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
by	by	B000	IN	B-PP	O
sequencing	sequence	S252	VBG	B-VP	O
amplified	amplify	A514	VBN	B-NP	O
CYP27	CYP27	C100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
products	product	P632	NNS	I-NP	O
from	from	F650	IN	B-PP	O
a	a	A000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
cerebrotendinous	cerebrotendinous	C616	JJ	B-NP	B-Disease
xanthomatosis	xanthomatosis	X535	NN	I-NP	I-Disease
(	(	0000	(	O	O
CTX	CTX	C320	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
changed	change	C523	VBD	B-VP	O
the	the	T000	DT	B-NP	O
adrenodoxin	adrenodoxin	A365	NN	I-NP	O
cofactor	cofactor	C123	NN	I-NP	O
binding	binding	B535	NN	I-NP	O
residue	residue	R230	NN	I-NP	O
362Arg	362Arg	A620	NN	I-NP	O
to	to	T000	TO	B-PP	O
362Ser	362Ser	S600	NN	B-NP	O
(	(	0000	(	O	O
CGT	CGT	C230	NN	B-NP	O
362Arg	362Arg	A620	NN	I-NP	O
to	to	T000	TO	B-PP	O
AGT	AGT	A230	NN	B-NP	O
362Ser	362Ser	S600	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
sterol	sterol	S364	NN	I-NP	O
27	27	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
hydroxylase	hydroxylase	H362	NN	I-NP	O
activity	activity	A231	NN	I-NP	O
,	,	0000	,	O	O
as	as	A200	IN	B-SBAR	O
confirmed	confirm	C516	VBN	B-VP	O
by	by	B000	IN	B-PP	O
expression	expression	E216	NN	B-NP	O
of	of	O100	IN	B-PP	O
mutant	mutant	M353	JJ	B-NP	O
cDNA	cDNA	C350	NN	I-NP	O
into	into	I530	IN	B-PP	O
COS	COS	C200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
.	.	0000	.	O	O

Quantitative	Quantitative	Q531	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
expression	expression	E216	NN	I-NP	O
of	of	O100	IN	B-PP	O
CYP27	CYP27	C100	NN	B-NP	O
gene	gene	G500	NN	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
represented	represent	R162	VBD	B-VP	O
52	52	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
level	level	L140	NN	I-NP	O
.	.	0000	.	O	O

As	As	A200	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
occurred	occur	O263	VBD	B-VP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
penultimate	penultimate	P543	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
2	2	0000	CD	B-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
intron	intron	I536	NN	I-NP	O
6	6	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
hypothesized	hypothesize	H132	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
may	may	M000	MD	B-VP	O
partially	partially	P634	RB	I-VP	O
affect	affect	A123	VB	I-VP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
splicing	splicing	S142	NN	I-NP	O
efficiency	efficiency	E125	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
and	and	A530	CC	O	O
cause	cause	C200	VB	B-VP	O
alternative	alternative	A436	JJ	B-NP	O
splicing	splicing	S142	NN	I-NP	O
elsewhere	elsewhere	E426	RB	B-ADVP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
decreased	decrease	D262	VBN	B-NP	O
transcript	transcript	T652	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
patient	patient	P353	NN	I-NP	O
.	.	0000	.	O	O

Transfection	Transfection	T652	NN	B-NP	O
of	of	O100	IN	B-PP	O
constructed	construct	C523	VBN	B-NP	O
minigenes	minigene	M525	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
or	or	O600	CC	B-PP	O
without	without	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
into	into	I530	IN	B-PP	O
COS	COS	C200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
cells	cell	C420	NNS	I-NP	O
confirmed	confirm	C516	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
minigene	minigene	M525	NN	I-NP	O
was	be	W200	VBD	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
mRNA	mRNA	M650	NN	I-NP	O
species	specie	S120	NNS	I-NP	O
alternatively	alternatively	A436	RB	B-VP	O
spliced	splice	S142	VBN	I-VP	O
at	at	A300	IN	B-PP	O
an	an	A500	DT	B-NP	O
activated	activate	A231	VBN	I-NP	O
cryptic	cryptic	C613	JJ	I-NP	O
5	5	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
88	88	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
upstream	upstream	U123	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
data	datum	D300	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
to	to	T000	TO	B-PP	O
A	A	A000	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
penultimate	penultimate	P543	JJ	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
of	of	O100	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
6	6	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CYP27	CYP27	C100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
not	not	N300	RB	B-CONJP	O
only	only	O540	RB	I-CONJP	O
causes	cause	C200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
sterol	sterol	S364	NN	I-NP	I-Disease
27	27	0000	CD	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
hydroxylase	hydroxylase	H362	NN	I-NP	I-Disease
activity	activity	A231	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
also	also	A420	RB	B-ADVP	O
partially	partially	P634	RB	B-ADVP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
alternative	alternative	A436	JJ	B-NP	O
pre	pre	P600	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
splicing	splicing	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
our	our	O600	PRP$	B-NP	O
knowledge	knowledge	K543	NN	I-NP	O
,	,	0000	,	O	O
this	this	T200	DT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
first	first	F623	JJ	I-NP	O
report	report	R163	NN	I-NP	O
regarding	regard	R263	VBG	B-PP	O
effects	effect	E123	NNS	B-NP	O
on	on	O500	IN	B-PP	O
pre	pre	P600	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
mRNA	mRNA	M650	NN	I-NP	O
splicing	splicing	S142	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
-	-	0000	SYM	I-NP	O
2	2	0000	CD	I-NP	O
position	position	P235	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
5	5	0000	CD	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

ATM	ATM	A350	NN	B-NP	O
germline	germline	G654	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
classical	classical	C424	JJ	B-NP	O
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Dutch	Dutch	D320	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Germline	Germline	G654	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
responsible	responsible	R215	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
ataxia	ataxia	A320	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
telangiectasia	telangiectasia	T452	NN	I-NP	I-Disease
(	(	0000	(	O	O
A	A	A000	NN	B-NP	B-Disease
-	-	0000	HYPH	O	I-Disease
T	T	T000	NN	B-NP	I-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
determined	determine	D365	VBN	I-VP	O
the	the	T000	DT	B-NP	O
ATM	ATM	A350	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
spectrum	spectrum	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
19	19	0000	CD	B-NP	O
classical	classical	C424	JJ	I-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
some	some	S500	DT	B-NP	O
immigrant	immigrant	I526	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
12	12	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
Dutch	Dutch	D320	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
.	.	0000	.	O	O

Both	Both	B300	CC	O	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
truncation	truncation	T652	NN	I-NP	O
test	test	T230	NN	I-NP	O
(	(	0000	(	O	O
PTT	PTT	P300	NN	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
restriction	restriction	R236	NN	I-NP	O
endonuclease	endonuclease	E535	NN	I-NP	O
fingerprinting	fingerprinting	F526	NN	I-NP	O
(	(	0000	(	O	O
REF	REF	R100	NN	B-NP	O
)	)	0000	)	O	O
method	method	M300	NN	B-NP	O
were	be	W600	VBD	B-VP	O
used	use	U230	VBN	I-VP	O
and	and	A530	CC	O	O
compared	compare	C516	VBN	B-VP	O
for	for	F600	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
detection	detection	D323	NN	I-NP	O
efficiency	efficiency	E125	NN	I-NP	O
,	,	0000	,	O	O
identifying	identify	I353	VBG	B-VP	O
76	76	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
and	and	A530	CC	O	O
60	60	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

Most	Most	M230	JJS	B-NP	O
patients	patient	P353	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
compound	compound	C515	JJ	B-NP	O
heterozygote	heterozygote	H362	NN	I-NP	O
.	.	0000	.	O	O

Seventeen	Seventeen	S153	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
distinct	distinct	D235	JJ	B-ADJP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
10	10	0000	CD	B-NP	O
were	be	W600	VBD	B-VP	O
not	not	N300	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
previously	previously	P612	RB	B-ADVP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
are	be	A600	VBP	B-VP	O
small	small	S540	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
or	or	O600	CC	O	O
point	point	P530	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
frequently	frequently	F625	RB	B-VP	O
affecting	affect	A123	VBG	I-VP	O
splice	splice	S142	NN	B-NP	O
sites	site	S320	NNS	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
16	16	0000	CD	I-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
kb	kb	K100	NN	I-NP	O
genomic	genomic	G520	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
most	most	M230	RBS	B-ADVP	O
likely	likely	L240	RB	I-ADVP	O
a	a	A000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
recombination	recombination	R251	NN	B-NP	O
between	between	B350	IN	B-PP	O
two	two	T000	CD	B-NP	O
LINE	LINE	L500	NNP	I-NP	O
elements	element	E453	NNS	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
frequently	frequently	F625	RB	I-NP	O
found	find	F530	VBN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
identified	identify	I353	VBN	B-VP	O
in	in	I500	IN	B-PP	O
three	three	T600	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Turkish	Turkish	T620	JJ	I-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
individuals	individual	I531	NNS	I-NP	O
,	,	0000	,	O	O
was	be	W200	VBD	B-VP	O
previously	previously	P612	RB	I-VP	O
described	describe	D261	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
a	a	A000	DT	B-NP	O
Turkish	Turkish	T620	JJ	I-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
founder	founder	F536	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
among	among	A520	IN	B-PP	O
relatively	relatively	R431	RB	B-NP	O
small	small	S540	JJ	I-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
population	population	P143	NN	I-NP	O
groups	group	G612	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Western	Western	W236	NNP	B-NP	O
Europe	Europe	E610	NNP	I-NP	O
could	could	C430	MD	B-VP	O
indicate	indicate	I532	VB	I-VP	O
a	a	A000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
carrier	carrier	C600	NN	I-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
such	such	S200	JJ	B-NP	O
communities	community	C532	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
of	of	O100	IN	B-PP	O
Dutch	Dutch	D320	JJ	B-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
no	no	N000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
founder	founder	F536	NN	I-NP	O
effect	effect	E123	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
identified	identify	I353	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
observed	observe	O126	VBN	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
including	include	I524	VBG	B-PP	O
the	the	T000	DT	B-NP	O
relative	relative	R431	JJ	I-NP	O
high	high	H200	JJ	I-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
splice	splice	S142	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
site	site	S300	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
no	no	N000	DT	B-NP	O
reflection	reflection	R142	NN	I-NP	O
on	on	O500	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
manifested	manifest	M512	VBD	B-VP	O
classical	classical	C424	JJ	B-NP	O
A	A	A000	NN	I-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
T	T	T000	NN	I-NP	I-Disease
and	and	A530	CC	O	O
increased	increase	I526	VBD	B-VP	O
cellular	cellular	C460	JJ	B-NP	O
radioresistant	radioresistant	R362	JJ	I-NP	O
DNA	DNA	D500	NN	I-NP	O
synthesis	synthesis	S532	NN	I-NP	O
.	.	0000	.	O	O

Determination	Determination	D365	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genomic	genomic	G520	JJ	I-NP	O
structure	structure	S362	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
COL4A4	COL4A4	C400	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	B-PP	O
of	of	O100	IN	B-PP	O
novel	novel	N140	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
causing	cause	C252	VBG	B-VP	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
Alport	Alport	A416	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Autosomal	Autosomal	A325	JJ	B-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
Alport	Alport	A416	NNP	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
progressive	progressive	P626	JJ	I-NP	O
hematuric	hematuric	H536	JJ	I-NP	B-Disease
glomerulonephritis	glomerulonephritis	G456	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
glomerular	glomerular	G456	JJ	B-NP	B-Disease
basement	basement	B253	NN	I-NP	I-Disease
membrane	membrane	M516	NN	I-NP	I-Disease
abnormalities	abnormality	A156	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
either	either	E360	CC	O	O
the	the	T000	DT	B-NP	O
COL4A3	COL4A3	C400	NN	I-NP	O
or	or	O600	CC	O	O
the	the	T000	DT	B-NP	O
COL4A4	COL4A4	C400	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
encode	encode	E523	VBP	B-VP	O
the	the	T000	DT	B-NP	O
alpha3	alpha3	A410	NN	I-NP	O
and	and	A530	CC	I-NP	O
alpha4	alpha4	A410	NN	I-NP	O
type	type	T100	NN	I-NP	O
IV	IV	I100	CD	I-NP	O
collagen	collagen	C425	NN	I-NP	O
chains	chain	C520	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
,	,	0000	,	O	O
mutation	mutation	M350	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
genes	gene	G520	NNS	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
hampered	hamper	H516	VBN	I-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
genomic	genomic	G520	JJ	B-NP	O
structure	structure	S362	NN	I-NP	O
information	information	I516	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
here	here	H600	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
complete	complete	C514	JJ	I-NP	O
characterization	characterization	C623	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
48	48	0000	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
COL4A4	COL4A4	C400	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
comprehensive	comprehensive	C516	JJ	I-NP	O
gene	gene	G500	NN	I-NP	O
screen	screen	S265	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
subsequent	subsequent	S125	JJ	I-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
10	10	0000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
diagnosed	diagnose	D252	VBN	B-VP	O
with	with	W300	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	B-Disease
recessive	recessive	R210	JJ	I-NP	I-Disease
Alport	Alport	A416	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
identified	identify	I353	VBD	B-VP	O
a	a	A000	DT	B-NP	O
glycine	glycine	G425	NN	I-NP	O
to	to	T000	TO	B-PP	O
alanine	alanine	A450	NN	B-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
collagenous	collagenous	C425	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
apparently	apparently	A165	RB	B-ADJP	O
silent	silent	S453	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
11	11	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
control	control	C536	NN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
one	one	O500	CD	B-NP	O
control	control	C536	NN	I-NP	O
individual	individual	I531	JJ	B-VP	O
homozygous	homozygous	H520	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
glycine	glycine	G425	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
.	.	0000	.	O	O

There	There	T600	EX	B-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
no	no	N000	DT	B-NP	O
previous	previous	P612	JJ	I-NP	O
finding	finding	F535	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
glycine	glycine	G425	NN	I-NP	O
substitution	substitution	S123	NN	I-NP	O
that	that	T300	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
any	any	A500	DT	B-NP	O
obvious	obvious	O120	JJ	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

Founder	Founder	F536	NN	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
French	French	F652	JJ	B-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
four	four	F600	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
each	each	E200	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
-	-	0000	HYPH	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
and	and	A530	CC	O	O
BRCA2	BRCA2	B620	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
French	French	F652	JJ	B-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
from	from	F650	IN	B-PP	O
Quebec	Quebec	Q120	NNP	B-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
founder	founder	F536	NN	B-NP	O
effects	effect	E123	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
independently	independently	I531	RB	I-VP	O
ascertained	ascertain	A263	VBN	I-VP	O
French	French	F652	JJ	B-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
these	these	T200	DT	B-NP	O
eight	eight	E230	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
41	41	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
97	97	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
of	of	O100	IN	B-PP	O
eight	eight	E230	CD	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
at	at	A300	IN	B-ADVP	O
least	least	L230	JJS	I-ADVP	O
twice	twice	T200	RB	B-ADVP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
C4446T	C4446T	C300	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
was	be	W200	VBD	B-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
common	common	C500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
found	find	F530	VBN	B-VP	O
,	,	0000	,	O	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
8765delAG	8765delAG	D420	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

Together	Together	T236	RB	B-ADVP	O
,	,	0000	,	O	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
28	28	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
41	41	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
identified	identify	I353	VBN	B-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
odds	odd	O320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
detection	detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
18	18	0000	CD	B-NP	O
.	.	0000	.	O	O

7x	7x	X000	LS	B-LST	O
greater	great	G636	JJR	B-NP	O
if	if	I100	IN	I-NP	O
one	one	O500	CD	I-NP	O
or	or	O600	CC	I-NP	O
more	more	M600	JJR	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
ovarian	ovarian	O165	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
odds	odd	O320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
detection	detection	D323	NN	B-NP	O
of	of	O100	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
four	four	F600	CD	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
5	5	0000	CD	B-NP	O
.	.	0000	.	O	O

3x	3x	X000	LS	B-LST	O
greater	great	G636	JJR	B-ADVP	O
if	if	I100	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
were	be	W600	VBD	B-VP	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
five	five	F100	CD	I-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Interestingly	Interestingly	I536	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
case	case	C200	NN	I-NP	O
<	<	0000	SYM	O	O
36	36	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
of	of	O100	IN	B-PP	O
age	age	A200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
strongly	strongly	S365	RB	B-ADJP	O
predictive	predictive	P632	JJ	I-ADJP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
any	any	A500	DT	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
eight	eight	E230	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
screened	screen	S265	VBN	B-VP	O
.	.	0000	.	O	O

Carriers	Carrier	C620	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
same	same	S500	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
,	,	0000	,	O	O
from	from	F650	IN	B-PP	O
different	different	D165	JJ	B-NP	O
families	family	F542	NNS	I-NP	O
,	,	0000	,	O	O
shared	share	S630	VBD	B-VP	O
similar	similar	S546	JJ	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
mutant	mutant	M353	JJ	I-NP	O
alleles	allele	A420	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
likely	likely	L240	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
be	be	B000	VB	I-VP	O
identical	identical	I353	JJ	B-ADJP	O
by	by	B000	IN	B-PP	O
descent	descent	D253	NN	B-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
identification	identification	I353	NN	I-NP	O
of	of	O100	IN	B-PP	O
common	common	C500	JJ	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
and	and	A530	CC	I-NP	O
BRCA2	BRCA2	B620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
will	will	W400	MD	B-VP	O
facilitate	facilitate	F243	VB	I-VP	O
carrier	carrier	C600	NN	B-NP	O
detection	detection	D323	NN	I-NP	O
in	in	I500	IN	B-PP	O
French	French	F652	JJ	B-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
breast	breast	B623	NN	I-NP	B-Disease
/	/	0000	SYM	B-NP	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
families	family	F542	NNS	I-NP	O
.	.	0000	.	O	O

Are	Be	A600	VBP	O	O
Dp71	Dp71	D100	NN	B-NP	O
and	and	A530	CC	I-NP	O
Dp140	Dp140	D100	NN	I-NP	O
brain	brain	B650	NN	I-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
isoforms	isoform	I216	NNS	I-NP	O
related	relate	R430	VBN	B-VP	O
to	to	T000	TO	B-PP	O
cognitive	cognitive	C253	JJ	B-NP	B-Disease
impairment	impairment	I516	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
Duchenne	Duchenne	D250	NNP	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
?	?	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
study	study	S300	NN	I-NP	O
and	and	A530	CC	O	O
neuropsychological	neuropsychological	N612	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
were	be	W600	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
concurrently	concurrently	C526	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
49	49	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
Duchenne	Duchenne	D250	JJ	B-NP	B-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DMD	DMD	D530	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-SBAR	O
order	order	O636	NN	O	O
to	to	T000	TO	B-VP	O
find	find	F530	VB	I-VP	O
a	a	A000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
explanation	explanation	E214	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
cognitive	cognitive	C253	JJ	I-NP	B-Disease
impairment	impairment	I516	NN	I-NP	I-Disease
observed	observe	O126	VBN	B-VP	O
in	in	I500	IN	B-PP	O
most	most	M230	JJS	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Complete	Complete	C514	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
dystrophin	dystrophin	D236	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
to	to	T000	TO	I-VP	O
define	define	D150	VB	I-VP	O
the	the	T000	DT	B-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
deletions	deletion	D435	NNS	B-NP	O
and	and	A530	CC	I-NP	O
duplications	duplication	D142	NNS	I-NP	O
in	in	I500	IN	B-PP	O
relation	relation	R435	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
different	different	D165	JJ	I-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
promoters	promoter	P653	NNS	I-NP	O
.	.	0000	.	O	O

Qualitative	Qualitative	Q431	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Dp71	Dp71	D100	NN	I-NP	O
transcript	transcript	T652	NN	I-NP	O
and	and	A530	CC	I-NP	O
testing	testing	T235	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
specific	specific	S121	JJ	I-NP	O
first	first	F623	JJ	I-NP	O
exon	exon	E250	NN	I-NP	O
of	of	O100	IN	B-PP	O
Dp140	Dp140	D100	NN	B-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
carried	carry	C630	VBN	I-VP	O
out	out	O300	RP	B-PRT	O
.	.	0000	.	O	O

Neuropsychological	Neuropsychological	N612	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
assessed	assess	A230	VBD	B-VP	O
verbal	verbal	V614	JJ	B-NP	O
and	and	A530	CC	I-NP	O
visuospatial	visuospatial	V213	JJ	I-NP	O
intelligence	intelligence	I534	NN	I-NP	O
,	,	0000	,	O	O
verbal	verbal	V614	JJ	B-NP	O
memory	memory	M560	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
reading	read	R352	VBG	B-VP	O
skills	skill	S242	NNS	B-NP	O
.	.	0000	.	O	O

Comparison	Comparison	C516	NN	B-NP	O
of	of	O100	IN	B-PP	O
molecular	molecular	M424	JJ	B-NP	O
and	and	A530	CC	I-NP	O
psychometric	psychometric	P253	JJ	I-NP	O
findings	finding	F535	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
that	that	T300	IN	B-SBAR	O
deletions	deletion	D435	NNS	B-NP	O
and	and	A530	CC	I-NP	O
duplications	duplication	D142	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
were	be	W600	VBD	B-VP	O
localized	localized	L242	JJ	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
distal	distal	D234	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
seemed	seem	S530	VBD	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
preferentially	preferentially	P616	RB	I-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
cognitive	cognitive	C253	JJ	B-NP	B-Disease
impairment	impairment	I516	NN	I-NP	I-Disease
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
altered	altered	A436	JJ	I-NP	O
Dp71	Dp71	D100	NN	I-NP	O
transcripts	transcript	T652	NNS	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
deleted	deleted	D430	JJ	I-NP	O
Dp140	Dp140	D100	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
sequences	sequence	S252	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
severe	severe	S160	JJ	B-NP	O
cerebral	cerebral	C616	JJ	I-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
some	some	S500	DT	B-NP	O
sequences	sequence	S252	NNS	I-NP	O
located	locate	L230	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
distal	distal	D234	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
particular	particular	P632	JJ	B-ADJP	O
,	,	0000	,	O	O
some	some	S500	DT	B-NP	O
DMD	DMD	D530	NN	I-NP	B-Disease
isoforms	isoform	I216	NNS	I-NP	O
expressed	express	E216	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
brain	brain	B650	NN	I-NP	O
may	may	M000	MD	B-VP	O
be	be	B000	VB	I-VP	O
related	related	R430	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
cognitive	cognitive	C253	JJ	I-NP	B-Disease
impairment	impairment	I516	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
DMD	DMD	D530	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

I1307K	I1307K	I200	NN	B-NP	O
APC	APC	A120	NN	I-NP	O
and	and	A530	CC	I-NP	O
hMLH1	hMLH1	H540	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
non	non	N500	AFX	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
describe	describe	D261	VBP	B-VP	O
a	a	A000	DT	B-NP	O
French	French	F652	JJ	I-NP	O
Canadian	Canadian	C535	JJ	I-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
non	non	N500	AFX	I-NP	I-Disease
-	-	0000	HYPH	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
(	(	0000	(	O	O
HNPCC	HNPCC	H512	NN	B-NP	B-Disease
)	)	0000	)	O	O
kindred	kindred	K536	NN	B-NP	O
which	which	W200	WDT	B-NP	O
carries	carry	C620	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
truncating	truncate	T652	VBG	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
hMLH1	hMLH1	H540	NN	B-NP	O
.	.	0000	.	O	O

Interestingly	Interestingly	I536	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
APC	APC	A120	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
,	,	0000	,	O	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
increased	increase	I526	VBN	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
present	present	P625	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
previously	previously	P612	RB	I-VP	O
only	only	O540	RB	I-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
of	of	O100	IN	B-PP	O
self	self	S410	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
reported	report	R163	VBN	I-NP	O
Ashkenazi	Ashkenazi	A252	NN	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
origins	origin	O625	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
addition	addition	A350	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
family	family	F540	NN	I-NP	O
,	,	0000	,	O	O
there	there	T600	EX	B-NP	O
appears	appear	A162	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
no	no	N000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
or	or	O600	CC	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
cancer	cancer	C526	NN	B-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Identification	Identification	I353	NN	B-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CPO	CPO	C100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
coproporphyria	coproporphyria	C161	NN	I-NP	I-Disease
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
coproporphyria	coproporphyria	C161	NN	I-NP	I-Disease
(	(	0000	(	O	O
HCP	HCP	H210	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
coproporphyrinogen	coproporphyrinogen	C161	NN	B-NP	I-Disease
oxidase	oxidase	O232	NN	I-NP	I-Disease
(	(	0000	(	O	O
CPO	CPO	C100	NN	B-NP	O
)	)	0000	)	O	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
CPO	CPO	C100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
.	.	0000	.	O	O

Only	Only	O540	RB	B-NP	O
11	11	0000	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
HCP	HCP	H210	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
report	report	R163	VBP	B-VP	O
another	another	A536	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Polymerase	Polymerase	P456	NN	B-NP	O
chain	chain	C500	NN	I-NP	O
reaction	reaction	R235	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
single	single	S524	JJ	I-NP	O
strand	strand	S365	NN	I-NP	O
conformational	conformational	C516	JJ	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analyses	analysis	A542	NNS	I-NP	O
demonstrated	demonstrate	D523	VBD	B-VP	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
to	to	T000	TO	B-PP	O
T	T	T000	NN	B-NP	O
substitution	substitution	S123	NN	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
1	1	0000	CD	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CPO	CPO	C100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
position	position	P235	NN	I-NP	O
85	85	0000	CD	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
lies	lie	L200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
putative	putative	P310	JJ	I-NP	O
presequence	presequence	P625	NN	I-NP	O
for	for	F600	IN	B-PP	O
targeting	target	T623	VBG	B-VP	O
to	to	T000	TO	B-PP	O
mitochondria	mitochondrion	M325	NNS	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
mutation	mutation	M350	NN	I-NP	O
changes	change	C520	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
codon	codon	C350	NN	I-NP	O
for	for	F600	IN	B-PP	O
glutamine	glutamine	G435	NN	B-NP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
at	at	A300	IN	B-PP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
position	position	P235	NN	I-NP	O
29	29	0000	CD	I-NP	O
.	.	0000	.	O	O

MaeI	MaeI	M000	NN	B-NP	O
restriction	restriction	R236	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
showed	show	S300	VBD	B-VP	O
two	two	T000	CD	B-NP	O
other	other	O360	JJ	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
C	C	C000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
T	T	T000	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
located	located	L230	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
recently	recently	R253	RB	I-NP	O
proposed	propose	P612	VBN	I-NP	O
putative	putative	P310	JJ	I-NP	O
alternative	alternative	A436	JJ	I-NP	O
translation	translation	T652	NN	I-NP	O
initiation	initiation	I535	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
(	(	0000	(	O	O
TIC	TIC	T200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
supporting	support	S163	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
TIC	TIC	T200	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
real	real	R400	JJ	I-NP	O
TIC	TIC	T200	NN	I-NP	O
rather	rather	R360	RB	B-CONJP	O
than	than	T500	IN	I-CONJP	O
TIC	TIC	T200	NN	B-NP	O
-	-	0000	HYPH	O	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	B-Disease
complement	complement	C514	NN	I-NP	I-Disease
factor	factor	F236	NN	I-NP	I-Disease
H	H	H000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
hemolytic	hemolytic	H543	JJ	B-NP	B-Disease
uremic	uremic	U652	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
reports	report	R163	VBZ	B-VP	O
on	on	O500	IN	B-PP	O
six	six	S200	CD	B-NP	O
cases	case	C200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
human	human	H500	JJ	I-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
regulatory	regulatory	R243	JJ	I-NP	I-Disease
protein	protein	P635	NN	I-NP	I-Disease
Factor	Factor	F236	NN	I-NP	I-Disease
H	H	H000	NN	I-NP	I-Disease
(	(	0000	(	O	O
FH	FH	F000	NN	B-NP	O
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
context	context	C532	NN	I-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
acute	acute	A230	JJ	I-NP	B-Disease
renal	renal	R540	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
cases	case	C200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
children	child	C436	NNS	B-NP	O
presenting	present	P625	VBG	B-VP	O
with	with	W300	IN	B-PP	O
idiopathic	idiopathic	I313	JJ	B-NP	O
hemolytic	hemolytic	H543	JJ	I-NP	B-Disease
uremic	uremic	U652	JJ	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
(	(	0000	(	O	O
HUS	HUS	H200	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Two	Two	T000	CD	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
children	child	C436	NNS	I-NP	O
exhibited	exhibit	E213	VBD	B-VP	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
150	150	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kD	kD	K300	NN	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
Factor	Factor	F236	NN	B-NP	O
H	H	H000	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
,	,	0000	,	O	O
upon	upon	U150	IN	B-PP	O
immunoblotting	immunoblotting	I514	NN	B-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
42	42	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kD	kD	K300	NN	I-NP	O
Factor	Factor	F236	NN	I-NP	O
H	H	H000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
protein	protein	P635	NN	I-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
FHL	FHL	F400	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
other	other	O360	JJ	B-NP	O
FH	FH	F000	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
related	relate	R430	VBN	B-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
FHR	FHR	F600	NN	B-NP	O
)	)	0000	)	O	O
bands	band	B532	NNS	B-NP	O
.	.	0000	.	O	O

Southern	Southern	S365	NN	B-NP	O
blot	blot	B430	NN	I-NP	O
and	and	A530	CC	O	O
PCR	PCR	P260	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
DNA	DNA	D500	NN	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
patient	patient	P353	NN	I-NP	O
with	with	W300	IN	B-PP	O
homozygous	homozygous	H520	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
ruled	rule	R430	VBD	B-VP	O
out	out	O300	RP	B-PRT	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
deletion	deletion	D435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FH	FH	F000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
underlying	underlie	U536	VBG	I-NP	O
defect	defect	D123	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
other	other	O360	JJ	I-NP	O
four	four	F600	CD	I-NP	O
children	child	C436	NNS	I-NP	O
presented	present	P625	VBD	B-VP	O
with	with	W300	IN	B-PP	O
heterozygous	heterozygous	H362	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
and	and	A530	CC	O	O
exhibited	exhibit	E213	VBD	B-VP	O
a	a	A000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
immunoblotting	immunoblotting	I514	NN	I-NP	O
pattern	pattern	P365	NN	I-NP	O
of	of	O100	IN	B-PP	O
proteins	protein	P635	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
FH	FH	F000	NN	I-NP	O
family	family	F540	NN	I-NP	O
.	.	0000	.	O	O

Factor	Factor	F236	NN	B-NP	B-Disease
H	H	H000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
only	only	O540	JJ	I-NP	O
complement	complement	C514	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
HUS	HUS	H200	NN	B-NP	B-Disease
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
observations	observation	O126	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
a	a	A000	DT	B-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
FH	FH	F000	NN	B-NP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
FH	FH	F000	NN	B-NP	O
receptors	receptor	R213	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
idiopathic	idiopathic	I313	JJ	B-NP	O
HUS	HUS	H200	NN	I-NP	B-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Further	Further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
ancient	ancient	A525	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
underlying	underlie	U536	VBG	B-VP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
from	from	F650	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
disequilibrium	disequilibrium	D241	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
myotonic	myotonic	M352	JJ	I-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
mutation	mutation	M350	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
unstable	unstable	U523	JJ	I-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	B-NP	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
,	,	0000	,	O	O
present	present	P625	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
copy	copy	C100	NN	I-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
37	37	0000	CD	I-NP	O
repeats	repeat	R132	NNS	I-NP	O
on	on	O500	IN	B-PP	O
normal	normal	N654	JJ	B-NP	O
chromosomes	chromosome	C652	NNS	I-NP	O
but	but	B300	CC	O	O
amplified	amplify	A514	VBN	B-VP	O
to	to	T000	TO	B-PP	O
50	50	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
3000	3000	0000	CD	I-NP	O
copies	copy	C120	NNS	I-NP	O
on	on	O500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
chromosomes	chromosome	C652	NNS	I-NP	O
.	.	0000	.	O	O

Previous	Previous	P612	JJ	B-NP	O
findings	finding	F535	NNS	I-NP	O
in	in	I500	IN	B-PP	O
Caucasian	Caucasian	C250	JJ	B-NP	O
populations	population	P143	NNS	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
founder	founder	F536	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
raise	raise	R200	VBP	B-VP	O
a	a	A000	DT	B-NP	O
question	question	Q235	NN	I-NP	O
about	about	A130	IN	B-PP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
events	event	E153	NNS	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
founder	founder	F536	NN	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
mutation	mutation	M350	NN	I-NP	O
exists	exist	E232	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
population	population	P143	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
genotyped	genotype	G531	VBD	B-VP	O
families	family	F542	NNS	B-NP	O
using	use	U252	VBG	B-VP	O
polymorphic	polymorphic	P456	JJ	B-NP	O
markers	marker	M626	NNS	I-NP	O
near	near	N600	IN	B-PP	O
the	the	T000	DT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
region	region	R250	NN	I-NP	O
and	and	A530	CC	O	O
constructed	construct	C523	VBN	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
.	.	0000	.	O	O

Six	Six	S200	CD	B-NP	O
different	different	D165	JJ	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
and	and	A530	CC	O	O
DM	DM	D500	NN	B-NP	B-Disease
alleles	allele	A420	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
always	always	A420	RB	B-ADVP	O
haplotype	haplotype	H143	NN	B-NP	O
A	A	A000	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
find	find	F530	VB	I-VP	O
an	an	A500	DT	B-NP	O
origin	origin	O625	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
(	(	0000	(	O	O
CTG	CTG	C320	NN	O	O
)	)	0000	)	O	O
n	n	N000	NN	B-NP	O
repeat	repeat	R130	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
mechanism	mechanism	M252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
expansion	expansion	E215	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
population	population	P143	NN	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
90	90	0000	CD	B-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
DM	DM	D500	NN	I-NP	B-Disease
families	family	F542	NNS	I-NP	O
comprising	comprise	C516	VBG	B-VP	O
190	190	0000	CD	B-NP	O
affected	affect	A123	VBN	B-VP	O
and	and	A530	CC	O	O
130	130	0000	CD	B-NP	O
unaffected	unaffected	U512	JJ	I-NP	O
members	member	M516	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
results	result	R243	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
few	few	F000	JJ	I-NP	O
common	common	C500	JJ	I-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
both	both	B300	CC	B-NP	O
Caucasian	Caucasian	C250	JJ	I-NP	O
and	and	A530	CC	I-NP	O
Japanese	Japanese	J152	JJ	I-NP	O
populations	population	P143	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
originated	originate	O625	VBN	I-VP	O
by	by	B000	IN	B-PP	O
expansion	expansion	E215	NN	B-NP	O
of	of	O100	IN	B-PP	O
an	an	A500	DT	B-NP	O
ancestral	ancestral	A523	JJ	I-NP	O
n	n	N000	NN	I-NP	O
=	=	0000	SYM	B-VP	O
5	5	0000	CD	B-NP	O
repeat	repeat	R130	NN	I-NP	O
to	to	T000	TO	B-PP	O
n	n	N000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
19	19	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
37	37	0000	CD	I-NP	O
copies	copy	C120	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
multistep	multistep	M432	JJ	B-NP	O
models	model	M342	NNS	I-NP	O
of	of	O100	IN	B-PP	O
triplet	triplet	T614	JJ	B-NP	O
repeat	repeat	R130	NN	I-NP	O
expansion	expansion	E215	NN	I-NP	O
that	that	T300	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
proposed	propose	P612	VBN	I-VP	O
for	for	F600	IN	B-PP	O
both	both	B300	CC	O	O
DM	DM	D500	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
Friedreichs	Friedreich	F636	NNS	I-NP	B-Disease
ataxia	ataxia	A320	NN	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
C6	C6	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
western	western	W236	JJ	I-NP	O
Cape	Cape	C100	NNP	I-NP	O
,	,	0000	,	O	O
South	South	S300	NNP	B-NP	O
Africa	Africa	A162	NNP	I-NP	O
.	.	0000	.	O	O

Deficiency	Deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
sixth	sixth	S230	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
human	human	H500	JJ	B-NP	I-Disease
complement	complement	C514	NN	I-NP	I-Disease
(	(	0000	(	O	O
C6	C6	C000	NN	B-NP	O
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
number	number	N516	NN	I-NP	O
of	of	O100	IN	B-PP	O
families	family	F542	NNS	B-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
western	western	W236	JJ	I-NP	O
Cape	Cape	C100	NNP	I-NP	O
,	,	0000	,	O	O
South	South	S300	NNP	B-NP	O
Africa	Africa	A162	NNP	I-NP	O
.	.	0000	.	O	O

Meningococcal	Meningococcal	M524	JJ	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
endemic	endemic	E535	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Cape	Cape	C100	NNP	I-NP	O
and	and	A530	CC	O	O
almost	almost	A452	RB	B-NP	O
all	all	A400	DT	I-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
of	of	O100	IN	B-PP	O
total	total	T340	JJ	B-NP	O
C6	C6	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
(	(	0000	(	O	O
C6Q0	C6Q0	C200	NN	B-NP	O
)	)	0000	)	O	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
ascertained	ascertain	A263	VBN	I-VP	O
because	because	B200	IN	B-PP	O
of	of	O100	IN	I-PP	O
recurrent	recurrent	R265	JJ	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
sequenced	sequence	S252	VBN	I-VP	O
the	the	T000	DT	B-NP	O
expressed	express	E216	VBN	I-NP	O
exons	exon	E252	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
C6	C6	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
from	from	F650	IN	B-PP	O
selected	select	S423	VBN	B-NP	O
cases	case	C200	NNS	I-NP	O
and	and	A530	CC	O	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
three	three	T600	CD	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
defects	defect	D123	NNS	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
total	total	T340	JJ	B-NP	O
deficiency	deficiency	D125	NN	I-NP	O
879delG	879delG	D420	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Cape	Cape	C100	NNP	I-NP	O
and	and	A530	CC	O	O
hitherto	hitherto	H363	RB	B-ADJP	O
unreported	unreported	U561	JJ	I-ADJP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
1195delC	1195delC	D420	NN	B-NP	O
and	and	A530	CC	I-NP	O
1936delG	1936delG	D420	NN	I-NP	O
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
been	be	B500	VBN	I-VP	O
previously	previously	P612	RB	I-VP	O
reported	report	R163	VBN	I-VP	O
in	in	I500	IN	B-PP	O
African	African	A162	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
Americans	American	A562	NNPS	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
also	also	A420	RB	B-ADVP	O
show	show	S000	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
879delG	879delG	D420	NN	I-NP	O
and	and	A530	CC	I-NP	O
1195delC	1195delC	D420	NN	I-NP	O
defects	defect	D123	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
characteristic	characteristic	C623	JJ	B-NP	O
C6	C6	C000	NN	I-NP	O
/	/	0000	SYM	B-NP	O
C7	C7	C000	NN	I-NP	O
region	region	R250	NN	I-NP	O
DNA	DNA	D500	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
small	small	S540	JJ	B-NP	O
variations	variation	V635	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
1936delG	1936delG	D420	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
was	be	W200	VBD	B-VP	O
observed	observe	O126	VBN	I-VP	O
only	only	O540	RB	B-ADVP	O
once	once	O520	RB	I-ADVP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Cape	Cape	C100	NNP	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
its	its	I320	PRP$	B-NP	O
associated	associate	A230	VBN	I-NP	O
haplotype	haplotype	H143	NN	I-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
deduced	deduce	D323	VBN	I-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
data	datum	D300	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
indicate	indicate	I532	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
three	three	T600	CD	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
defects	defect	D123	NNS	I-NP	O
account	account	A253	VBP	B-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
38	38	0000	CD	I-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
C6Q0	C6Q0	C200	NN	I-NP	O
individuals	individual	I531	NNS	I-NP	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
studied	study	S300	VBN	I-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
Cape	Cape	C100	NNP	I-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
observed	observe	O126	VBN	I-VP	O
the	the	T000	DT	B-NP	O
879delG	879delG	D420	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
Dutch	Dutch	D320	JJ	I-NP	O
C6	C6	C000	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
deficient	deficient	D125	JJ	I-NP	I-Disease
kindreds	kindred	K536	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
879delG	879delG	D420	NN	I-NP	O
defect	defect	D123	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
Cape	Cape	C100	NNP	I-NP	O
probably	probably	P614	RB	B-ADVP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
come	come	C500	VB	I-VP	O
from	from	F650	IN	B-PP	O
The	The	T000	DT	B-NP	O
Netherlands	Netherlands	N364	NNP	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Complement	Complement	C514	NN	B-NP	B-Disease
C7	C7	C000	NN	I-NP	I-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
:	:	0000	:	O	O
seven	seven	S150	CD	B-NP	O
further	further	F636	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
defects	defect	D123	NNS	I-NP	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
associated	associate	A230	VBN	I-NP	O
marker	marker	M626	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
.	.	0000	.	O	O

Seven	Seven	S150	CD	B-NP	O
further	further	F636	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
bases	base	B200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
C7	C7	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
described	describe	D261	VBN	I-VP	O
.	.	0000	.	O	O

All	All	A400	PDT	B-NP	O
these	these	T200	DT	I-NP	O
new	new	N000	JJ	I-NP	O
molecular	molecular	M424	JJ	I-NP	O
defects	defect	D123	NNS	I-NP	O
involve	involve	I514	VBP	B-VP	O
single	single	S524	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
nucleotide	nucleotide	N243	NN	I-NP	O
events	event	E153	NNS	I-NP	O
,	,	0000	,	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
and	and	A530	CC	I-NP	O
substitutions	substitution	S123	NNS	I-NP	O
,	,	0000	,	O	O
some	some	S500	DT	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
alter	alter	A436	VBP	B-VP	O
splice	splice	S142	NN	B-NP	O
sites	site	S320	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
others	other	O362	NNS	B-NP	O
codons	codon	C352	NNS	I-NP	O
.	.	0000	.	O	O

They	They	T000	PRP	B-NP	O
are	be	A600	VBP	B-VP	O
distributed	distribute	D236	VBN	I-VP	O
along	along	A452	IN	B-PP	O
the	the	T000	DT	B-NP	O
C7	C7	C000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
predominantly	predominantly	P635	RB	B-ADVP	O
towards	towards	T632	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
end	end	E530	NN	I-NP	O
.	.	0000	.	O	O

All	All	A400	DT	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
compound	compound	C515	NN	B-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
individuals	individual	I531	NNS	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
C6	C6	C000	NN	I-NP	O
/	/	0000	SYM	B-VP	O
C7	C7	C000	NN	B-NP	O
marker	marker	M626	NN	I-NP	O
haplotypes	haplotype	H143	NNS	I-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
most	most	M230	JJS	B-NP	O
C7	C7	C000	NN	I-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
tabulated	tabulate	T143	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
genome	genome	G500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
wide	wide	W300	JJ	I-NP	O
search	search	S620	NN	I-NP	O
for	for	F600	IN	B-PP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
loci	locus	L200	NNS	I-NP	O
linked	link	L523	VBN	B-VP	O
to	to	T000	TO	B-PP	O
mental	mental	M534	JJ	B-NP	O
health	health	H430	NN	I-NP	O
wellness	wellness	W452	NN	I-NP	O
in	in	I500	IN	B-PP	O
relatives	relative	R431	NNS	B-NP	O
at	at	A300	IN	B-PP	O
high	high	H200	JJ	B-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
bipolar	bipolar	B146	JJ	B-NP	B-Disease
affective	affective	A123	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
among	among	A520	IN	B-PP	O
the	the	T000	DT	B-NP	O
Old	Old	O430	NNP	I-NP	O
Order	Order	O636	NNP	I-NP	O
Amish	Amish	A520	NNP	I-NP	O
.	.	0000	.	O	O

Bipolar	Bipolar	B146	JJ	B-NP	B-Disease
affective	affective	A123	JJ	I-NP	I-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
(	(	0000	(	O	O
BPAD	BPAD	B130	NN	B-NP	B-Disease
;	;	0000	:	O	O
manic	manic	M520	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
depressive	depressive	D162	JJ	I-NP	I-Disease
illness	illness	I452	NN	I-NP	I-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
episodes	episode	E123	NNS	B-NP	O
of	of	O100	IN	B-PP	O
mania	mania	M500	NN	B-NP	B-Disease
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
hypomania	hypomania	H150	NN	B-NP	B-Disease
interspersed	intersperse	I536	VBN	B-VP	O
with	with	W300	IN	B-PP	O
periods	period	P632	NNS	B-NP	O
of	of	O100	IN	B-PP	O
depression	depression	D162	NN	B-NP	B-Disease
.	.	0000	.	O	O

Compelling	Compelling	C514	NN	B-NP	O
evidence	evidence	E135	NN	I-NP	O
supports	support	S163	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
genetic	genetic	G532	JJ	I-NP	O
component	component	C515	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
to	to	T000	TO	B-VP	O
develop	develop	D141	VB	I-VP	O
BPAD	BPAD	B130	NN	B-NP	B-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-PP	O
date	date	D300	NN	B-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
linkage	linkage	L520	NN	B-NP	O
studies	study	S320	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
attempted	attempt	A351	VBN	I-VP	O
only	only	O540	RB	B-ADVP	O
to	to	T000	TO	B-VP	O
identify	identify	I353	VB	I-VP	O
chromosomal	chromosomal	C652	JJ	B-NP	O
loci	locus	L200	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
cause	cause	C200	VBP	B-VP	O
or	or	O600	CC	I-VP	O
increase	increase	I526	VBP	I-VP	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
developing	develop	D141	VBG	B-VP	O
BPAD	BPAD	B130	NN	B-NP	B-Disease
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
whether	whether	W360	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
could	could	C430	MD	B-VP	O
be	be	B000	VB	I-VP	O
protective	protective	P632	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
that	that	T300	WDT	B-NP	O
prevent	prevent	P615	VBP	B-VP	O
or	or	O600	CC	I-VP	O
reduce	reduce	R320	VBP	I-VP	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
developing	develop	D141	VBG	B-VP	O
BPAD	BPAD	B130	NN	B-NP	B-Disease
,	,	0000	,	O	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
what	what	W300	WP	B-NP	O
is	be	I200	VBZ	B-VP	O
observed	observe	O126	VBN	I-VP	O
in	in	I500	IN	B-PP	O
other	other	O360	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
used	use	U230	VBD	B-VP	O
mental	mental	M534	JJ	B-NP	O
health	health	H430	NN	I-NP	O
wellness	wellness	W452	NN	I-NP	O
(	(	0000	(	O	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
any	any	A500	DT	B-NP	O
psychiatric	psychiatric	P236	JJ	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
)	)	0000	)	O	O
as	as	A200	IN	B-PP	O
the	the	T000	DT	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
in	in	I500	IN	B-PP	O
our	our	O600	PRP$	B-NP	O
genome	genome	G500	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
wide	wide	W300	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
scan	scan	S250	NN	I-NP	O
of	of	O100	IN	B-PP	O
several	several	S164	JJ	B-NP	O
large	large	L620	JJ	I-NP	O
multigeneration	multigeneration	M432	NN	I-NP	O
Old	Old	O430	NNP	I-NP	O
Order	Order	O636	NNP	I-NP	O
Amish	Amish	A520	NNP	I-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
exhibiting	exhibit	E213	VBG	B-VP	O
an	an	A500	DT	B-NP	O
extremely	extremely	E236	RB	I-NP	O
high	high	H200	JJ	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
BPAD	BPAD	B130	NN	B-NP	B-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
found	find	F530	VBN	I-VP	O
strong	strong	S365	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
4p	4p	P000	NN	I-NP	O
at	at	A300	IN	B-PP	O
D4S2949	D4S2949	D200	NN	B-NP	O
(	(	0000	(	O	O
maximum	maximum	M250	NN	B-NP	O
GENEHUNTER	GENEHUNTER	G536	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
PLUS	PLUS	P420	NN	I-NP	O
nonparametric	nonparametric	N516	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
score	score	S260	NN	I-NP	O
=	=	0000	SYM	B-VP	O
4	4	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
5	5	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
22	22	0000	CD	I-NP	O
x	x	X000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
4	4	0000	CD	B-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
SIBPAL	SIBPAL	S140	JJ	B-NP	O
Pempirical	Pempirical	P516	JJ	I-NP	O
value	value	V400	NN	I-NP	O
<	<	0000	SYM	B-NP	O
3	3	0000	CD	B-NP	O
x	x	X000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	O	O
5	5	0000	CD	B-NP	O
)	)	0000	)	O	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
suggestive	suggestive	S231	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
a	a	A000	DT	B-NP	O
locus	locus	L200	NN	I-NP	O
on	on	O500	IN	B-PP	O
chromosome	chromosome	C652	NN	B-NP	O
4q	4q	Q000	NN	I-NP	O
at	at	A300	IN	B-PP	O
D4S397	D4S397	D200	NN	B-NP	O
(	(	0000	(	O	O
maximum	maximum	M250	NN	B-NP	O
GENEHUNTER	GENEHUNTER	G536	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
PLUS	PLUS	P420	NN	I-NP	O
nonparametric	nonparametric	N516	JJ	I-NP	O
linkage	linkage	L520	NN	I-NP	O
score	score	S260	NN	I-NP	O
=	=	0000	SYM	B-VP	O
3	3	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
29	29	0000	CD	I-NP	O
,	,	0000	,	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
2	2	0000	CD	B-NP	O
.	.	0000	.	O	O
57	57	0000	CD	B-NP	O
x	x	X000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	B-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
;	;	0000	:	O	O
SIBPAL	SIBPAL	S140	JJ	B-NP	O
Pempirical	Pempirical	P516	JJ	I-NP	O
value	value	V400	NN	I-NP	O
<	<	0000	SYM	B-NP	O
1	1	0000	CD	I-NP	O
x	x	X000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	B-NP	O
3	3	0000	CD	I-NP	O
)	)	0000	)	O	O
)	)	0000	)	O	O
that	that	T300	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
mental	mental	M534	JJ	B-NP	O
health	health	H430	NN	I-NP	O
wellness	wellness	W452	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
findings	finding	F535	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
consistent	consistent	C523	JJ	B-ADJP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
certain	certain	C635	JJ	B-NP	O
alleles	allele	A420	NNS	I-NP	O
could	could	C430	MD	B-VP	O
prevent	prevent	P615	VB	I-VP	O
or	or	O600	CC	I-VP	O
modify	modify	M310	VB	I-VP	O
the	the	T000	DT	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
BPAD	BPAD	B130	NN	B-NP	B-Disease
and	and	A530	CC	O	O
perhaps	perhaps	P612	RB	B-ADVP	O
other	other	O360	JJ	B-NP	O
related	related	R430	JJ	I-NP	O
affective	affective	A123	JJ	I-NP	B-Disease
disorders	disorder	D263	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Segregation	Segregation	S262	NN	B-NP	O
distortion	distortion	D236	NN	I-NP	O
in	in	I500	IN	B-PP	O
myotonic	myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Myotonic	Myotonic	M352	JJ	B-NP	B-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
DM	DM	D500	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	B-Disease
dominant	dominant	D530	JJ	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
which	which	W200	WDT	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
typical	typical	T124	JJ	I-NP	O
pedigree	pedigree	P326	NN	I-NP	O
,	,	0000	,	O	O
shows	show	S200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
three	three	T600	CD	I-NP	O
generation	generation	G563	NN	I-NP	O
anticipation	anticipation	A532	NN	I-NP	O
cascade	cascade	C230	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
infertility	infertility	I516	NN	B-NP	B-Disease
and	and	A530	CC	O	O
congenital	congenital	C525	JJ	B-NP	B-Disease
myotonic	myotonic	M352	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
CDM	CDM	C350	NN	B-NP	B-Disease
)	)	0000	)	O	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
disappearance	disappearance	D216	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
that	that	T300	DT	B-NP	O
pedigree	pedigree	P326	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
concept	concept	C521	NN	I-NP	O
of	of	O100	IN	B-PP	O
segregation	segregation	S262	NN	B-NP	O
distortion	distortion	D236	NN	I-NP	O
,	,	0000	,	O	O
where	where	W600	WRB	B-ADVP	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
preferential	preferential	P616	JJ	B-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
larger	large	L626	JJR	I-NP	O
allele	allele	A400	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
put	put	P300	VBN	I-VP	O
forward	forward	F630	RB	B-ADVP	O
to	to	T000	TO	B-VP	O
explain	explain	E214	VB	I-VP	O
partially	partially	P634	RB	B-ADVP	O
the	the	T000	DT	B-NP	O
maintenance	maintenance	M535	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
survey	survey	S610	NN	I-NP	O
of	of	O100	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
Northern	Northern	N636	NNP	B-NP	O
Ireland	Ireland	I645	NNP	I-NP	O
,	,	0000	,	O	O
59	59	0000	CD	B-NP	O
pedigrees	pedigree	P326	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
ascertained	ascertain	A263	VBN	I-VP	O
.	.	0000	.	O	O

Sibships	Sibship	S121	NNS	B-NP	O
where	where	W600	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
status	status	S320	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	PDT	B-NP	O
the	the	T000	DT	I-NP	O
members	member	M516	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
expansion	expansion	E215	NN	I-NP	O
from	from	F650	IN	B-PP	O
affected	affect	A123	VBN	B-NP	O
parents	parent	P653	NNS	I-NP	O
to	to	T000	TO	B-PP	O
their	their	T600	PRP$	B-NP	O
offspring	offspring	O121	NN	I-NP	O
.	.	0000	.	O	O

Where	Where	W600	WRB	B-ADVP	O
the	the	T000	DT	B-NP	O
transmitting	transmit	T652	VBG	I-NP	O
parent	parent	P653	NN	I-NP	O
was	be	W200	VBD	B-VP	O
male	male	M400	JJ	B-ADJP	O
,	,	0000	,	O	O
58	58	0000	CD	B-NP	O
.	.	0000	.	O	O

3	3	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
offspring	offspring	O121	NN	I-NP	O
were	be	W600	VBD	B-VP	O
affected	affect	A123	VBN	I-VP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
female	female	F540	JJ	I-NP	O
transmitting	transmitting	T652	JJ	I-NP	O
parent	parent	P653	NN	I-NP	O
,	,	0000	,	O	O
68	68	0000	CD	B-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
were	be	W600	VBD	B-VP	O
affected	affect	A123	VBN	I-VP	O
.	.	0000	.	O	O

Studies	Study	S320	NNS	B-NP	O
on	on	O500	IN	B-PP	O
meiotic	meiotic	M320	JJ	B-NP	O
drive	drive	D610	NN	I-NP	O
in	in	I500	IN	B-PP	O
DM	DM	D500	NN	B-NP	B-Disease
have	have	H100	VBP	B-VP	O
shown	show	S500	VBN	I-VP	O
increased	increase	I526	VBN	B-NP	O
transmission	transmission	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
larger	large	L626	JJR	I-NP	O
allele	allele	A400	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
DM	DM	D500	NN	I-NP	O
heterozygotes	heterozygote	H362	NNS	I-NP	O
for	for	F600	IN	B-PP	O
CTGn	CTGn	C325	NN	B-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
provides	provide	P613	VBZ	B-VP	O
further	further	F636	JJ	B-NP	O
evidence	evidence	E135	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
DM	DM	D500	NN	I-NP	B-Disease
expansion	expansion	E215	NN	I-NP	O
tends	tend	T532	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
transmitted	transmit	T652	VBN	I-VP	O
preferentially	preferentially	P616	RB	B-ADVP	O
.	.	0000	.	O	O

Diagnosis	Diagnosis	D252	NN	B-NP	O
of	of	O100	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
.	.	0000	.	O	O

If	If	I100	IN	B-SBAR	O
untreated	untreated	U536	JJ	B-NP	O
,	,	0000	,	I-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
can	can	C500	MD	B-VP	O
cause	cause	C200	VB	I-VP	O
serious	serious	S620	JJ	B-NP	O
illness	illness	I452	NN	I-NP	O
and	and	A530	CC	O	O
early	early	E640	JJ	B-NP	B-Disease
death	death	D300	NN	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
still	still	S340	RB	B-ADVP	O
substantially	substantially	S123	RB	B-ADVP	O
under	under	U536	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
diagnosed	diagnose	D252	VBN	B-VP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
cornerstone	cornerstone	C656	NN	I-NP	O
of	of	O100	IN	B-PP	O
screening	screening	S265	NN	B-NP	O
and	and	A530	CC	I-NP	O
case	case	C200	NN	I-NP	O
detection	detection	D323	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
measurement	measurement	M265	NN	I-NP	O
of	of	O100	IN	B-PP	O
serum	serum	S650	NN	B-NP	O
transferrin	transferrin	T652	NN	I-NP	O
saturation	saturation	S363	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
serum	serum	S650	NN	I-NP	O
ferritin	ferritin	F635	NN	I-NP	O
level	level	L140	NN	I-NP	O
.	.	0000	.	O	O

Once	Once	O520	RB	O	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
suspected	suspect	S212	VBN	I-VP	O
,	,	0000	,	O	O
physicians	physician	P252	NNS	B-NP	O
must	must	M230	MD	B-VP	O
use	use	U200	VB	I-VP	O
serum	serum	S650	NN	B-NP	O
ferritin	ferritin	F635	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
and	and	A530	CC	O	O
hepatic	hepatic	H132	JJ	B-NP	O
iron	iron	I650	NN	I-NP	O
stores	store	S362	NNS	I-NP	O
on	on	O500	IN	B-PP	O
liver	liver	L160	NN	B-NP	O
biopsy	biopsy	B120	NN	I-NP	O
specimens	specimen	S125	NNS	I-NP	O
to	to	T000	TO	B-VP	O
assess	assess	A200	VB	I-VP	O
patients	patient	P353	NNS	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
iron	iron	I650	NN	B-NP	B-Disease
overload	overload	O164	NN	I-NP	I-Disease
.	.	0000	.	O	O

Liver	Liver	L160	NN	B-NP	O
biopsy	biopsy	B120	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	B-VP	O
establish	establish	E231	VB	I-VP	O
the	the	T000	DT	B-NP	O
presence	presence	P625	NN	I-NP	O
or	or	O600	CC	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
cirrhosis	cirrhosis	C620	NN	B-NP	B-Disease
,	,	0000	,	O	O
which	which	W200	WDT	B-NP	O
can	can	C500	MD	B-VP	O
affect	affect	A123	VB	I-VP	O
prognosis	prognosis	P625	NN	B-NP	O
and	and	A530	CC	I-NP	O
management	management	M525	NN	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
-	-	0000	HYPH	B-VP	O
based	base	B230	VBN	I-VP	O
test	test	T230	NN	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
HFE	HFE	H100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
commercially	commercially	C562	RB	B-ADJP	O
available	available	A141	JJ	I-ADJP	O
,	,	0000	,	O	O
but	but	B300	CC	O	O
its	its	I320	PRP$	B-NP	O
place	place	P420	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
diagnosis	diagnosis	D252	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
still	still	S340	RB	I-VP	O
being	be	B520	VBG	I-VP	O
evaluated	evaluate	E143	VBN	I-VP	O
.	.	0000	.	O	O

Currently	Currently	C653	RB	B-ADVP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
useful	useful	U214	JJ	I-NP	O
role	role	R400	NN	I-NP	O
for	for	F600	IN	B-PP	O
this	this	T200	DT	B-NP	O
test	test	T230	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
detection	detection	D323	NN	I-NP	O
of	of	O100	IN	B-PP	O
hemochromatosis	hemochromatosis	H526	NN	B-NP	B-Disease
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
family	family	F540	NN	I-NP	O
members	member	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
proven	proven	P615	JJ	I-NP	O
case	case	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
crucial	crucial	C624	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
diagnose	diagnose	D252	NN	B-NP	O
hemochromatosis	hemochromatosis	H526	NN	I-NP	B-Disease
before	before	B160	IN	B-PP	O
hepatic	hepatic	H132	JJ	B-NP	B-Disease
cirrhosis	cirrhosis	C620	NN	I-NP	I-Disease
develops	develop	D141	VBZ	B-VP	O
because	because	B200	IN	B-SBAR	O
phlebotomy	phlebotomy	P413	NN	B-NP	O
therapy	therapy	T610	NN	I-NP	O
can	can	C500	MD	B-VP	O
avert	avert	A163	VB	I-VP	O
serious	serious	S620	JJ	B-NP	O
chronic	chronic	C652	JJ	I-NP	O
disease	disease	D200	NN	I-NP	O
and	and	A530	CC	O	O
can	can	C500	MD	B-VP	O
even	even	E150	RB	I-VP	O
lead	lead	L300	VB	I-VP	O
to	to	T000	TO	B-PP	O
normal	normal	N654	JJ	B-NP	O
life	life	L100	NN	I-NP	O
expectancy	expectancy	E212	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Prevalence	Prevalence	P614	NN	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
in	in	I500	IN	B-PP	O
Israeli	Israeli	I264	JJ	B-NP	O
Jews	Jew	J200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
differing	differ	D165	VBG	B-VP	O
ethnic	ethnic	E352	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
and	and	A530	CC	I-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
&	&	0000	CC	I-NP	O
AIMS	AIMS	A520	NNS	I-NP	O
Israeli	Israeli	I264	JJ	B-NP	O
Jews	Jew	J200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
European	European	E615	JJ	B-NP	O
birth	birth	B630	NN	I-NP	O
,	,	0000	,	O	O
i	i	I000	NN	B-NP	O
.	.	0000	.	I-NP	O
e	e	E000	NN	I-NP	O
.	.	0000	.	O	O
,	,	0000	,	O	O
Ashkenazim	Ashkenazim	A252	NNP	B-NP	O
,	,	0000	,	O	O
have	have	H100	VBP	B-VP	O
the	the	T000	DT	B-NP	O
highest	high	H230	JJS	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
any	any	A500	DT	B-NP	O
Israeli	Israeli	I264	JJ	I-NP	O
ethnic	ethnic	E352	JJ	I-NP	O
group	group	G610	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
6	6	0000	CD	B-NP	O
.	.	0000	.	O	O

1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
American	American	A562	JJ	B-NP	O
Jews	Jew	J200	NNS	I-NP	O
,	,	0000	,	O	O
28	28	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
familial	familial	F540	JJ	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
cases	case	C200	NNS	I-NP	O
,	,	0000	,	B-PP	O
but	but	B300	CC	I-PP	O
not	not	N300	RB	B-PP	O
in	in	I500	IN	I-PP	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	O	O
Jews	Jew	J200	NNPS	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
assessed	assess	A230	VBD	B-VP	O
the	the	T000	DT	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
prevalence	prevalence	P614	NN	I-NP	O
in	in	I500	IN	B-PP	O
Israeli	Israeli	I264	JJ	B-NP	O
Jews	Jew	J200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
differing	differ	D165	VBG	B-VP	O
ethnic	ethnic	E352	JJ	B-NP	O
origin	origin	O625	NN	I-NP	O
and	and	A530	CC	I-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
DNA	DNA	D500	NN	I-NP	O
samples	sample	S514	NNS	I-NP	O
from	from	F650	IN	B-PP	O
500	500	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
Jews	Jew	J200	NNS	I-NP	O
of	of	O100	IN	B-PP	O
European	European	E615	JJ	B-NP	O
or	or	O600	CC	I-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
European	European	E615	JJ	I-NP	O
origin	origin	O625	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
or	or	O600	CC	B-PP	O
without	without	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
personal	personal	P625	JJ	I-NP	O
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
family	family	F540	NN	B-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
neoplasia	neoplasia	N142	NN	B-NP	B-Disease
,	,	0000	,	O	O
were	be	W600	VBD	B-VP	O
examined	examine	E253	VBN	I-VP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
by	by	B000	IN	B-PP	O
the	the	T000	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
oligonucleotide	oligonucleotide	O425	NN	I-NP	O
(	(	0000	(	O	O
ASO	ASO	A200	NN	B-NP	O
)	)	0000	)	O	O
method	method	M300	NN	B-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
In	In	I500	IN	B-PP	O
persons	person	P625	NNS	B-NP	O
at	at	A300	IN	B-PP	O
average	average	A162	JJ	B-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	O
I1307K	I1307K	I200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
5	5	0000	CD	B-NP	O
.	.	0000	.	O	O

0	0	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
120	120	0000	CD	B-NP	O
European	European	E615	JJ	I-NP	O
and	and	A530	CC	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
188	188	0000	CD	B-NP	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	O	O
European	European	E615	JJ	B-NP	O
Jews	Jew	J200	NNS	I-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	SYM	I-NP	O
08	08	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
occurred	occur	O263	VBD	B-VP	O
in	in	I500	IN	B-PP	O
15	15	0000	CD	B-NP	O
.	.	0000	.	O	O

4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
52	52	0000	CD	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Israelis	Israeli	I264	NNPS	I-NP	O
with	with	W300	IN	B-PP	O
familial	familial	F540	JJ	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O
02	02	0000	CD	B-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
detected	detect	D323	VBN	I-VP	O
in	in	I500	IN	B-PP	O
51	51	0000	CD	B-NP	O
non	non	N500	AFX	O	O
-	-	0000	HYPH	O	O
European	European	E615	JJ	B-NP	O
Jews	Jew	J200	NNS	I-NP	O
at	at	A300	IN	B-PP	O
increased	increase	I526	VBN	B-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
risk	risk	R200	NN	I-NP	O
.	.	0000	.	O	O

Colorectal	Colorectal	C462	JJ	B-NP	B-Disease
neoplasia	neoplasia	N142	NN	I-NP	I-Disease
occurred	occur	O263	VBD	B-VP	O
personally	personally	P625	RB	B-ADVP	O
or	or	O600	CC	O	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
families	family	F542	NNS	I-NP	O
of	of	O100	IN	B-PP	O
13	13	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
20	20	0000	CD	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
I1307K	I1307K	I200	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
,	,	0000	,	O	O
8	8	0000	CD	B-NP	O
of	of	O100	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
also	also	A420	RB	B-ADVP	O
had	have	H300	VBD	B-VP	O
a	a	A000	DT	B-NP	O
personal	personal	P625	JJ	I-NP	O
or	or	O600	CC	I-NP	O
family	family	F540	NN	I-NP	O
history	history	H236	NN	I-NP	O
of	of	O100	IN	B-PP	O
noncolonic	noncolonic	N524	JJ	B-NP	O
neoplasia	neoplasia	N142	NN	I-NP	B-Disease
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
The	The	T000	DT	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
APC	APC	A120	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
may	may	M000	MD	B-VP	O
represent	represent	R162	VB	I-VP	O
a	a	A000	DT	B-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-ADJP	B-Disease
,	,	0000	,	O	I-Disease
or	or	O600	CC	O	I-Disease
other	other	O360	JJ	B-ADJP	I-Disease
,	,	0000	,	O	I-Disease
cancers	cancer	C526	NNS	B-NP	I-Disease
in	in	I500	IN	B-PP	O
Ashkenazi	Ashkenazi	A252	NNP	B-NP	O
Jews	Jews	J200	NNP	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
partially	partially	P634	RB	B-VP	O
explains	explain	E214	VBZ	I-VP	O
the	the	T000	DT	B-NP	O
higher	high	H260	JJR	I-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
European	European	E615	JJ	B-NP	O
Israelis	Israeli	I264	NNPS	I-NP	O
.	.	0000	.	O	O

Systematic	Systematic	S235	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
coproporphyrinogen	coproporphyrinogen	C161	NN	B-NP	O
oxidase	oxidase	O232	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
defects	defect	D123	NNS	I-NP	O
in	in	I500	IN	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
coproporphyria	coproporphyria	C161	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
mutation	mutation	M350	NN	I-NP	O
update	update	U130	NN	I-NP	O
.	.	0000	.	O	O

Hereditary	Hereditary	H636	JJ	B-NP	B-Disease
coproporphyria	coproporphyria	C161	NN	I-NP	I-Disease
(	(	0000	(	O	O
HC	HC	H200	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
acute	acute	A230	JJ	I-NP	O
hepatic	hepatic	H132	JJ	I-NP	B-Disease
porphyria	porphyria	P616	NN	I-NP	I-Disease
with	with	W300	IN	B-PP	O
autosomal	autosomal	A325	JJ	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
caused	cause	C230	VBN	B-VP	O
by	by	B000	IN	B-PP	O
deficient	deficient	D125	JJ	B-NP	B-Disease
activity	activity	A231	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
coproporphyrinogen	coproporphyrinogen	C161	NN	B-NP	I-Disease
III	III	I000	CD	I-NP	I-Disease
oxidase	oxidase	O232	NN	I-NP	I-Disease
(	(	0000	(	O	O
CPO	CPO	C100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Clinical	Clinical	C452	JJ	B-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
are	be	A600	VBP	B-VP	O
characterized	characterize	C623	VBN	I-VP	O
by	by	B000	IN	B-PP	O
acute	acute	A230	JJ	B-NP	O
attacks	attack	A320	NNS	I-NP	O
of	of	O100	IN	B-PP	O
neurological	neurological	N642	JJ	B-NP	B-Disease
dysfunction	dysfunction	D215	NN	I-NP	I-Disease
often	often	O135	RB	B-VP	O
precipitated	precipitate	P621	VBN	I-VP	O
by	by	B000	IN	B-PP	O
drugs	drug	D620	NNS	B-NP	O
,	,	0000	,	O	O
fasting	fast	F235	VBG	B-VP	O
,	,	0000	,	O	O
cyclical	cyclical	C242	JJ	B-NP	O
hormonal	hormonal	H654	JJ	I-NP	O
changes	change	C520	NNS	I-NP	O
,	,	0000	,	O	O
or	or	O600	CC	O	O
infectious	infectious	I512	JJ	B-NP	B-Disease
diseases	disease	D200	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Skin	Skin	S250	NN	B-NP	O
photosensitivity	photosensitivity	P325	NN	I-NP	O
may	may	M000	MD	B-VP	O
also	also	A420	RB	I-VP	O
be	be	B000	VB	I-VP	O
present	present	P625	JJ	B-ADJP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
seven	seven	S150	CD	I-NP	O
exons	exon	E252	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
/	/	0000	SYM	B-VP	O
intron	intron	I536	NN	B-NP	O
boundaries	boundary	B536	NNS	I-NP	O
and	and	A530	CC	O	O
part	part	P630	NN	B-NP	O
of	of	O100	IN	B-PP	O
3	3	0000	CD	B-NP	O
noncoding	noncoding	N523	JJ	I-NP	O
sequence	sequence	S252	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CPO	CPO	C100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
were	be	W600	VBD	B-VP	O
systematically	systematically	S235	RB	I-VP	O
analyzed	analyze	A542	VBN	I-VP	O
by	by	B000	IN	B-PP	O
an	an	A500	DT	B-NP	O
exon	exon	E250	NN	I-NP	O
-	-	0000	HYPH	B-ADJP	O
by	by	B000	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
exon	exon	E250	NN	I-NP	O
denaturing	denature	D536	VBG	B-VP	O
gradient	gradient	G635	NN	B-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
(	(	0000	(	O	O
DGGE	DGGE	D200	NN	B-NP	O
)	)	0000	)	O	O
strategy	strategy	S363	NN	B-NP	O
followed	follow	F430	VBN	B-VP	O
by	by	B000	IN	B-PP	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
in	in	I500	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
heterozygous	heterozygous	H362	JJ	I-NP	O
HC	HC	H200	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
from	from	F650	IN	B-PP	O
France	France	F652	NNP	B-NP	O
,	,	0000	,	O	O
Holland	Holland	H453	NNP	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
Czech	Czech	C200	NNP	B-NP	O
Republic	Republic	R142	NNP	I-NP	O
.	.	0000	.	O	O

Seven	Seven	S150	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
new	new	N000	JJ	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
detected	detect	D323	VBN	I-VP	O
.	.	0000	.	O	O

Among	Among	A520	IN	B-PP	O
these	these	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
two	two	T000	CD	B-NP	O
are	be	A600	VBP	B-VP	O
missense	missense	M252	JJ	B-ADJP	O
(	(	0000	(	O	O
G197W	G197W	G000	NN	B-NP	O
,	,	0000	,	O	O
W427R	W427R	W600	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
are	be	A600	VBP	B-VP	O
nonsense	nonsense	N525	JJ	B-ADJP	O
(	(	0000	(	O	O
Q306X	Q306X	Q200	NN	B-NP	O
,	,	0000	,	O	O
Q385X	Q385X	Q200	NN	B-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
are	be	A600	VBP	B-VP	O
small	small	S540	JJ	B-NP	O
deletions	deletion	D435	NNS	I-NP	O
(	(	0000	(	O	O
662de14bp	662de14bp	D100	NN	B-NP	O
;	;	0000	:	O	O
1168del3bp	1168del3bp	D410	NN	B-NP	O
removing	remove	R515	VBG	B-VP	O
a	a	A000	DT	B-NP	O
glycine	glycine	G425	NN	I-NP	O
at	at	A300	IN	B-PP	O
position	position	P235	NN	B-NP	O
390	390	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
one	one	O500	CD	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
splicing	splicing	S142	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
IVS1	IVS1	I120	NN	B-NP	O
-	-	0000	HYPH	O	O
15c	15c	C000	SYM	B-NP	O
-	-	0000	SYM	I-NP	O
-	-	0000	SYM	I-NP	O
>	>	0000	SYM	I-NP	O
g	g	G000	NN	I-NP	O
)	)	0000	)	O	O
which	which	W200	WDT	B-NP	O
creates	create	C632	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
acceptor	acceptor	A213	NN	I-NP	O
splice	splice	S142	NN	I-NP	O
site	site	S300	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
pathological	pathological	P342	JJ	I-NP	O
significance	significance	S251	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
point	point	P530	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
G197W	G197W	G000	NN	I-NP	O
,	,	0000	,	O	O
W427R	W427R	W600	NN	B-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
in	in	I500	IN	B-PP	O
-	-	0000	HYPH	B-NP	O
frame	frame	F650	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
390delGly	390delGly	D424	NN	I-NP	O
were	be	W600	VBD	B-VP	O
assessed	assess	A230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
respective	respective	R212	JJ	I-NP	O
expression	expression	E216	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
prokaryotic	prokaryotic	P626	JJ	I-NP	O
system	system	S235	NN	I-NP	O
using	use	U252	VBG	B-VP	O
site	site	S300	NN	B-NP	O
-	-	0000	HYPH	O	O
directed	direct	D623	VBN	B-NP	O
mutagenesis	mutagenesis	M325	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
resulted	result	R243	VBD	B-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
absence	absence	A125	NN	I-NP	O
or	or	O600	CC	O	O
a	a	A000	DT	B-NP	O
dramatic	dramatic	D653	JJ	I-NP	O
decrease	decrease	D262	NN	I-NP	O
of	of	O100	IN	B-PP	O
CPO	CPO	C100	NN	B-NP	O
activity	activity	A231	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
polymorphisms	polymorphism	P456	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
localized	localize	L242	VBN	I-VP	O
in	in	I500	IN	B-PP	O
noncoding	noncoding	N523	JJ	B-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
1	1	0000	CD	I-NP	O
)	)	0000	)	O	O
a	a	A000	DT	B-NP	O
C	C	C000	NN	I-NP	O
/	/	0000	SYM	O	O
G	G	G000	NN	B-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
promotor	promotor	P653	NN	I-NP	O
region	region	R250	NN	I-NP	O
,	,	0000	,	O	O
142	142	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
upstream	upstream	U123	RB	B-ADVP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
transcriptional	transcriptional	T652	JJ	I-NP	O
initiation	initiation	I535	NN	I-NP	O
site	site	S300	NN	I-NP	O
(	(	0000	(	O	O
-	-	0000	SYM	B-NP	O
142C	142C	C000	NN	I-NP	O
/	/	0000	SYM	I-NP	O
G	G	G000	NN	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
2	2	0000	LS	B-LST	O
)	)	0000	)	O	O
a	a	A000	DT	B-NP	O
6	6	0000	CD	I-NP	O
bp	bp	B100	NN	I-NP	O
deletion	deletion	D435	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
3	3	0000	CD	I-NP	O
noncoding	noncoding	N523	JJ	I-NP	O
part	part	P630	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
CPO	CPO	C100	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
574	574	0000	CD	B-NP	O
bp	bp	B100	NN	I-NP	O
downstream	downstream	D523	RB	B-ADVP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
last	last	L230	JJ	I-NP	O
base	base	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
normal	normal	N654	JJ	I-NP	O
termination	termination	T653	NN	I-NP	O
codon	codon	C350	NN	I-NP	O
(	(	0000	(	O	O
+	+	0000	SYM	B-NP	O
574	574	0000	CD	B-NP	O
delATTCTT	delATTCTT	D432	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Five	Five	F100	CD	B-NP	O
intragenic	intragenic	I536	JJ	I-NP	O
dimorphisms	dimorphism	D561	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
now	now	N000	RB	I-VP	O
well	well	W400	RB	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
high	high	H200	JJ	I-NP	O
degree	degree	D260	NN	I-NP	O
of	of	O100	IN	B-PP	O
allelic	allelic	A420	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
in	in	I500	IN	B-PP	O
HC	HC	H200	NN	B-NP	B-Disease
is	be	I200	VBZ	B-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
with	with	W300	IN	B-PP	O
seven	seven	S150	CD	B-NP	O
new	new	N000	JJ	I-NP	O
different	different	D165	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
making	make	M252	VBG	B-VP	O
a	a	A000	DT	B-NP	O
total	total	T340	NN	I-NP	O
of	of	O100	IN	B-PP	O
nineteen	nineteen	N535	CD	B-NP	O
CPO	CPO	C100	NN	I-NP	O
gene	gene	G500	NN	I-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
reported	report	R163	VBN	B-VP	O
so	so	S000	RB	B-ADVP	O
far	far	F600	RB	I-ADVP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Coincidence	Coincidence	C523	NN	B-NP	O
of	of	O100	IN	B-PP	O
two	two	T000	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
arylsulfatase	arylsulfatase	A642	NN	I-NP	O
A	A	A000	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
and	and	A530	CC	O	O
mutation	mutation	M350	NN	B-NP	O
459	459	0000	CD	I-NP	O
+	+	0000	SYM	I-NP	O
1G	1G	G000	NN	I-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
within	within	W350	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
metachromatic	metachromatic	M326	JJ	B-NP	B-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
:	:	0000	:	O	O
molecular	molecular	M424	JJ	B-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
phenotypic	phenotypic	P531	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
with	with	W300	IN	B-PP	O
three	three	T600	CD	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
,	,	0000	,	O	O
one	one	O500	CD	B-NP	O
developed	develop	D141	VBD	B-VP	O
classical	classical	C424	JJ	B-NP	O
late	late	L300	JJ	I-NP	O
infantile	infantile	I515	JJ	I-NP	O
metachromatic	metachromatic	M326	JJ	I-NP	B-Disease
leukodystrophy	leukodystrophy	L232	NN	I-NP	I-Disease
(	(	0000	(	O	O
MLD	MLD	M430	NN	B-NP	B-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
fatal	fatal	F340	JJ	B-ADJP	O
at	at	A300	IN	B-PP	O
age	age	A200	NN	B-NP	O
5	5	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
deficient	deficient	D125	JJ	B-NP	O
arylsulfatase	arylsulfatase	A642	NN	I-NP	O
A	A	A000	NN	I-NP	O
(	(	0000	(	O	O
ARSA	ARSA	A620	NN	B-NP	O
)	)	0000	)	O	O
activity	activity	A231	NN	B-NP	O
and	and	A530	CC	O	O
increased	increase	I526	VBN	B-NP	O
galactosylsulfatide	galactosylsulfatide	G423	NN	I-NP	O
(	(	0000	(	I-NP	O
GS	GS	G200	NN	I-NP	O
)	)	0000	)	I-NP	O
excretion	excretion	E263	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
other	other	O360	JJ	I-NP	O
siblings	sibling	S145	NNS	I-NP	O
,	,	0000	,	O	O
apparently	apparently	A165	RB	B-ADJP	O
healthy	healthy	H430	JJ	I-ADJP	O
at	at	A300	IN	B-PP	O
12	12	0000	CD	B-NP	O
(	(	0000	(	O	O
1	1	0000	CD	B-NP	O
/	/	0000	SYM	I-NP	O
2	2	0000	CD	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
15	15	0000	CD	B-NP	O
years	year	Y620	NNS	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
their	their	T600	PRP$	B-NP	O
father	father	F360	NN	I-NP	O
,	,	0000	,	O	O
apparently	apparently	A165	RB	B-ADJP	O
healthy	healthy	H430	JJ	I-ADJP	O
as	as	A200	IN	B-ADVP	O
well	well	W400	RB	I-ADVP	O
,	,	0000	,	O	O
presented	present	P625	VBN	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
and	and	A530	CC	I-NP	O
GS	GS	G200	NN	I-NP	O
values	value	V420	NNS	I-NP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
MLD	MLD	M430	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
screening	screening	S265	NN	I-NP	O
and	and	A530	CC	O	O
sequence	sequence	S252	NN	B-NP	O
analysis	analysis	A542	NN	I-NP	O
disclosed	disclose	D242	VBD	B-VP	O
the	the	T000	DT	B-NP	O
involvement	involvement	I514	NN	I-NP	O
of	of	O100	IN	B-PP	O
three	three	T600	CD	B-NP	O
different	different	D165	JJ	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
being	be	B520	VBG	B-VP	O
the	the	T000	DT	B-NP	O
molecular	molecular	M424	JJ	I-NP	O
basis	basis	B200	NN	I-NP	O
of	of	O100	IN	B-PP	O
intrafamilial	intrafamilial	I536	JJ	B-NP	O
phenotypic	phenotypic	P531	JJ	I-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
late	late	L300	JJ	I-NP	O
infantile	infantile	I515	JJ	I-NP	O
patient	patient	P353	NN	I-NP	O
inherited	inherit	I563	VBN	B-VP	O
from	from	F650	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
mother	mother	M360	NN	I-NP	O
the	the	T000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
0	0	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
459	459	0000	CD	I-NP	O
+	+	0000	SYM	I-NP	O
1G	1G	G000	NN	I-NP	O
>	>	0000	SYM	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	B-PP	O
and	and	A530	CC	I-PP	O
from	from	F650	IN	B-PP	O
his	his	H200	PRP$	B-NP	O
father	father	F360	NN	I-NP	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
,	,	0000	,	I-NP	O
single	single	S524	JJ	I-NP	O
basepair	basepair	B216	NN	I-NP	O
microdeletion	microdeletion	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
guanine	guanine	G500	NN	B-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
7	7	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
1	1	0000	CD	I-NP	O
(	(	0000	(	O	O
7delG	7delG	D420	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
two	two	T000	CD	I-NP	O
clinically	clinically	C452	RB	I-NP	O
unaffected	unaffected	U512	JJ	I-NP	O
siblings	sibling	S145	NNS	I-NP	O
carried	carry	C630	VBD	B-VP	O
the	the	T000	DT	B-NP	O
maternal	maternal	M365	JJ	I-NP	O
mutation	mutation	M350	NN	I-NP	O
459	459	0000	CD	I-NP	O
+	+	0000	SYM	I-NP	O
1G	1G	G000	NN	I-NP	O
>	>	0000	SYM	B-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
on	on	O500	IN	B-PP	O
their	their	T600	PRP$	B-NP	O
paternal	paternal	P365	JJ	I-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
novel	novel	N140	JJ	I-NP	O
cytosine	cytosine	C325	NN	I-NP	O
to	to	T000	TO	B-PP	O
thymidine	thymidine	T535	NN	B-NP	O
transition	transition	T652	NN	I-NP	O
at	at	A300	IN	B-PP	O
nucleotide	nucleotide	N243	NN	B-NP	O
2435	2435	0000	CD	I-NP	O
in	in	I500	IN	B-PP	O
exon	exon	E250	NN	B-NP	O
8	8	0000	CD	I-NP	O
,	,	0000	,	O	O
resulting	result	R243	VBG	B-VP	O
in	in	I500	IN	B-PP	O
substitution	substitution	S123	NN	B-NP	O
of	of	O100	IN	B-PP	O
alanine	alanine	A450	NN	B-NP	O
464	464	0000	CD	I-NP	O
by	by	B000	IN	B-PP	O
valine	valine	V450	NN	B-NP	O
(	(	0000	(	O	O
A464V	A464V	A100	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
fathers	father	F362	NNS	I-NP	O
genotype	genotype	G531	NN	I-NP	O
thus	thus	T200	RB	B-ADVP	O
was	be	W200	VBD	B-VP	O
7delG	7delG	D420	NN	B-NP	O
/	/	0000	SYM	B-NP	O
A464V	A464V	A100	NN	I-NP	O
.	.	0000	.	O	O

Mutation	Mutation	M350	NN	B-NP	O
A464V	A464V	A100	NN	I-NP	O
was	be	W200	VBD	B-VP	O
not	not	N300	RB	I-VP	O
found	find	F530	VBN	I-VP	O
in	in	I500	IN	B-PP	O
18	18	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
MLD	MLD	M430	NN	I-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
and	and	A530	CC	O	O
50	50	0000	CD	B-NP	O
controls	control	C536	NNS	I-NP	O
.	.	0000	.	O	O

A464V	A464V	A100	NN	B-NP	O
,	,	0000	,	O	O
although	although	A432	IN	B-SBAR	O
clearly	clearly	C464	RB	B-ADVP	O
modifying	modify	M315	VBG	B-VP	O
ARSA	ARSA	A620	NN	B-NP	O
and	and	A530	CC	I-NP	O
GS	GS	G200	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
,	,	0000	,	O	O
apparently	apparently	A165	RB	B-ADVP	O
bears	bear	B620	VBZ	B-VP	O
little	little	L340	JJ	B-NP	O
significance	significance	S251	NN	I-NP	O
for	for	F600	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
manifestation	manifestation	M512	NN	I-NP	O
of	of	O100	IN	B-PP	O
MLD	MLD	M430	NN	B-NP	B-Disease
,	,	0000	,	O	O
mimicking	mimic	M525	VBG	B-VP	O
the	the	T000	DT	B-NP	O
frequent	frequent	F625	JJ	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
pseudodeficiency	pseudodeficiency	P231	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
demonstrate	demonstrate	D523	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
in	in	I500	IN	B-PP	O
certain	certain	C635	JJ	B-NP	O
genetic	genetic	G532	JJ	I-NP	O
conditions	condition	C535	NNS	I-NP	O
MLD	MLD	M430	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
like	like	L200	JJ	I-NP	O
ARSA	ARSA	A620	NN	I-NP	O
and	and	A530	CC	I-NP	O
GS	GS	G200	NN	I-NP	O
values	value	V420	NNS	I-NP	O
need	need	N300	VBP	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
paralleled	parallel	P643	VBN	I-VP	O
by	by	B000	IN	B-PP	O
clinical	clinical	C452	JJ	B-NP	O
disease	disease	D200	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
finding	finding	F535	NN	I-NP	O
with	with	W300	IN	B-PP	O
serious	serious	S620	JJ	B-NP	O
diagnostic	diagnostic	D252	JJ	I-NP	O
and	and	A530	CC	I-NP	O
prognostic	prognostic	P625	JJ	I-NP	O
implications	implication	I514	NNS	I-NP	O
.	.	0000	.	O	O

Moreover	Moreover	M616	RB	B-ADVP	O
,	,	0000	,	O	O
further	further	F636	JJ	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
functionally	functionally	F523	RB	B-ADJP	O
similar	similar	S546	JJ	I-ADJP	O
to	to	T000	TO	B-PP	O
A464V	A464V	A100	NN	B-NP	O
might	might	M230	MD	B-VP	O
exist	exist	E230	VB	I-VP	O
which	which	W200	WDT	B-NP	O
,	,	0000	,	O	O
together	together	T236	RB	B-ADVP	O
with	with	W300	IN	B-PP	O
0	0	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
may	may	M000	MD	B-VP	O
cause	cause	C200	VB	I-VP	O
pathological	pathological	P342	JJ	B-NP	O
ARSA	ARSA	A620	NN	I-NP	O
and	and	A530	CC	I-NP	O
GS	GS	G200	NN	I-NP	O
levels	level	L142	NNS	I-NP	O
,	,	0000	,	O	O
but	but	B300	CC	B-CONJP	O
not	not	N300	RB	I-CONJP	O
clinical	clinical	C452	JJ	B-NP	O
outbreak	outbreak	O316	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Human	Human	H500	JJ	B-NP	O
MLH1	MLH1	M400	NN	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
predisposes	predispose	P632	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
hematological	hematological	H534	JJ	B-NP	B-Disease
malignancy	malignancy	M425	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
neurofibromatosis	neurofibromatosis	N616	NN	I-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
.	.	0000	.	O	O

Heterozygous	Heterozygous	H362	JJ	B-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
DNA	DNA	D500	NN	I-NP	O
mismatch	mismatch	M253	NN	I-NP	O
repair	repair	R160	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
lead	lead	L300	VBP	B-VP	O
to	to	T000	TO	B-PP	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
nonpolyposis	nonpolyposis	N514	JJ	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
disease	disease	D200	NN	I-NP	O
susceptibility	susceptibility	S213	NN	I-NP	O
of	of	O100	IN	B-PP	O
individuals	individual	I531	NNS	B-NP	O
who	who	W000	WP	B-NP	O
constitutionally	constitutionally	C523	RB	B-ADVP	O
lack	lack	L200	VBP	B-VP	O
both	both	B300	CC	O	O
wild	wild	W430	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
type	type	T100	NN	I-NP	O
alleles	allele	A420	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
unknown	unknown	U525	JJ	B-ADJP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
three	three	T600	CD	B-NP	O
offspring	offspring	O121	NN	I-NP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
hereditary	hereditary	H636	JJ	I-NP	B-Disease
nonpolyposis	nonpolyposis	N514	NN	I-NP	I-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
family	family	F540	NN	I-NP	O
who	who	W000	WP	B-NP	O
developed	develop	D141	VBD	B-VP	O
hematological	hematological	H534	JJ	B-NP	B-Disease
malignancy	malignancy	M425	NN	I-NP	I-Disease
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
very	very	V600	RB	I-NP	O
early	early	E640	JJ	I-NP	O
age	age	A200	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
at	at	A300	IN	B-NP	O
least	least	L230	JJS	I-NP	O
two	two	T000	CD	I-NP	O
of	of	O100	IN	B-PP	O
them	them	T500	PRP	B-NP	O
displayed	display	D214	VBD	B-VP	O
signs	sign	S252	NNS	B-NP	O
of	of	O100	IN	B-PP	O
neurofibromatosis	neurofibromatosis	N616	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
(	(	0000	(	O	O
NF1	NF1	N100	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

DNA	DNA	D500	NN	B-NP	O
sequence	sequence	S252	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	I-NP	O
allele	allele	A400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
specific	specific	S121	JJ	I-NP	O
amplification	amplification	A514	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
siblings	sibling	S145	NNS	I-NP	O
revealed	reveal	R143	VBD	B-VP	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
MLH1	MLH1	M400	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
(	(	0000	(	O	O
C676T	C676T	C300	NN	B-NP	O
-	-	0000	SYM	O	O
-	-	0000	HYPH	B-NP	O
>	>	0000	SYM	I-NP	O
Arg226Stop	Arg226Stop	A623	NN	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Thus	Thus	T200	RB	B-ADVP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
homozygous	homozygous	H520	JJ	I-NP	O
germ	germ	G650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
MLH1	MLH1	M400	NN	I-NP	O
mutation	mutation	M350	NN	I-NP	O
and	and	A530	CC	O	O
consequent	consequent	C525	JJ	B-NP	O
mismatch	mismatch	M253	NN	I-NP	O
repair	repair	R160	NN	I-NP	O
deficiency	deficiency	D125	NN	I-NP	O
results	result	R243	VBZ	B-VP	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
mutator	mutator	M360	NN	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
characterized	characterize	C623	VBN	B-VP	O
by	by	B000	IN	B-PP	O
leukemia	leukemia	L250	NN	B-NP	B-Disease
and	and	A530	CC	O	O
/	/	0000	SYM	B-NP	O
or	or	O600	CC	O	O
lymphoma	lymphoma	L515	NN	B-NP	B-Disease
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
neurofibromatosis	neurofibromatosis	N616	NN	B-NP	B-Disease
type	type	T100	NN	I-NP	I-Disease
1	1	0000	CD	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

Missense	Missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
ancient	ancient	A525	JJ	I-NP	O
residues	residue	R232	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
paired	paired	P630	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
underlie	underlie	U536	VBP	B-VP	O
a	a	A000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
congenital	congenital	C525	JJ	I-NP	B-Disease
eye	eye	E000	NN	I-NP	I-Disease
malformations	malformation	M416	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
human	human	H500	JJ	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
underlie	underlie	U536	VBP	B-VP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
(	(	0000	(	O	O
congenital	congenital	C525	JJ	B-NP	B-Disease
absence	absence	A125	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
iris	iris	I620	NN	I-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
rare	rare	R600	JJ	I-NP	O
dominant	dominant	D530	JJ	I-NP	O
malformation	malformation	M416	NN	I-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
eye	eye	E000	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
spectrum	spectrum	S123	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
highly	highly	H240	RB	I-VP	O
biased	bias	B230	VBN	I-VP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
92	92	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
reported	report	R163	VBN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
premature	premature	P653	JJ	B-NP	O
truncation	truncation	T652	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
(	(	0000	(	O	O
nonsense	nonsense	N525	NN	B-NP	O
,	,	0000	,	O	O
splicing	splicing	S142	NN	B-NP	O
,	,	0000	,	O	O
insertions	insertion	I526	NNS	B-NP	O
and	and	A530	CC	I-NP	O
deletions	deletion	D435	NNS	I-NP	O
)	)	0000	)	O	O
and	and	A530	CC	O	O
just	just	J230	RB	B-NP	O
2	2	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
leading	lead	L352	VBG	B-VP	O
to	to	T000	TO	B-PP	O
substitution	substitution	S123	NN	B-NP	O
of	of	O100	IN	B-PP	O
one	one	O500	CD	B-NP	O
amino	amino	A500	NN	I-NP	O
acid	acid	A230	NN	I-NP	O
by	by	B000	IN	B-PP	O
another	another	A536	DT	B-NP	O
(	(	0000	(	O	O
missense	missense	M252	JJ	B-ADJP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
extraordinary	extraordinary	E236	JJ	I-NP	O
conservation	conservation	C526	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
level	level	L140	NN	I-NP	O
amongst	amongst	A523	IN	B-PP	O
vertebrates	vertebrate	V631	NNS	B-NP	O
predicts	predict	P632	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
pathological	pathological	P342	JJ	B-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
should	should	S430	MD	B-VP	O
in	in	I500	IN	B-PP	O
fact	fact	F230	NN	B-NP	O
be	be	B000	VB	B-VP	O
common	common	C500	JJ	B-ADJP	O
even	even	E150	RB	B-SBAR	O
though	though	T200	IN	I-SBAR	O
they	they	T000	PRP	B-NP	O
are	be	A600	VBP	B-VP	O
hardly	hardly	H634	RB	I-VP	O
ever	ever	E160	RB	I-VP	O
seen	see	S500	VBN	I-VP	O
in	in	I500	IN	B-PP	O
aniridia	aniridia	A563	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
indicates	indicate	I532	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
there	there	T600	EX	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
heavy	heavy	H100	JJ	I-NP	O
ascertainment	ascertainment	A263	NN	I-NP	O
bias	bias	B200	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
selection	selection	S423	NN	I-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
for	for	F600	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	O
mutation	mutation	M350	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
missing	miss	M252	VBG	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
frequently	frequently	F625	RB	B-ADVP	O
may	may	M000	MD	B-VP	O
underlie	underlie	U536	VB	I-VP	O
phenotypes	phenotype	P531	NNS	B-NP	O
distinct	distinct	D235	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
textbook	textbook	T231	NN	B-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
.	.	0000	.	O	O

Here	Here	H600	RB	B-ADVP	O
we	we	W000	PRP	B-NP	O
present	present	P625	VBP	B-VP	O
four	four	F600	CD	B-NP	O
novel	novel	N140	JJ	I-NP	O
PAX6	PAX6	P200	NN	I-NP	O
missense	missense	M252	JJ	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
atypical	atypical	A312	JJ	B-NP	O
phenotypes	phenotype	P531	NNS	I-NP	O
ectopia	ectopia	E231	NN	I-NP	B-Disease
pupillae	pupillae	P140	NNS	I-NP	I-Disease
(	(	0000	(	O	O
displaced	displace	D214	VBN	B-NP	B-Disease
pupils	pupil	P142	NNS	I-NP	I-Disease
)	)	0000	)	O	O
and	and	A530	CC	O	O
congenital	congenital	C525	JJ	B-NP	B-Disease
nystagmus	nystagmus	N232	NN	I-NP	I-Disease
(	(	0000	(	O	O
searching	search	S625	VBG	B-VP	B-Disease
gaze	gaze	G200	NN	B-NP	I-Disease
)	)	0000	)	O	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
two	two	T000	CD	B-NP	O
in	in	I500	IN	B-PP	O
association	association	A235	NN	B-NP	O
with	with	W300	IN	B-PP	O
more	more	M600	RBR	B-NP	O
recognizable	recognizable	R252	JJ	I-NP	O
aniridia	aniridia	A563	NN	I-NP	B-Disease
phenotypes	phenotype	P531	NNS	I-NP	O
.	.	0000	.	O	O

Strikingly	Strikingly	S362	RB	B-ADVP	O
,	,	0000	,	O	O
all	all	A400	DT	B-NP	O
four	four	F600	CD	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
located	located	L230	JJ	B-ADJP	O
within	within	W350	IN	B-PP	O
the	the	T000	DT	B-NP	O
PAX6	PAX6	P200	NN	I-NP	O
paired	paired	P630	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
and	and	A530	CC	O	O
affect	affect	A123	VB	B-VP	O
amino	amino	A500	JJ	B-NP	O
acids	acid	A232	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
are	be	A600	VBP	B-VP	O
highly	highly	H240	RB	I-VP	O
conserved	conserve	C526	VBN	I-VP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
known	know	K500	VBN	I-NP	O
paired	paired	P630	JJ	I-NP	O
domain	domain	D500	NN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
.	.	0000	.	O	O

Our	Our	O600	PRP$	B-NP	O
results	result	R243	NNS	I-NP	O
support	support	S163	VBP	B-VP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
under	under	U536	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
representation	representation	R162	NN	I-NP	O
of	of	O100	IN	B-PP	O
missense	missense	M252	JJ	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
is	be	I200	VBZ	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
ascertainment	ascertainment	A263	NN	B-NP	O
bias	bias	B200	NN	I-NP	O
and	and	A530	CC	O	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
a	a	A000	DT	B-NP	O
substantial	substantial	S123	JJ	I-NP	O
burden	burden	B635	NN	I-NP	O
of	of	O100	IN	B-PP	O
PAX6	PAX6	P200	NN	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
related	relate	R430	VBN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	I-Disease
remains	remain	R520	VBZ	B-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
uncovered	uncover	U521	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
order	order	O636	NN	I-NP	O
of	of	O100	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
controlling	control	C536	VBG	B-VP	O
the	the	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
histocompatibility	histocompatibility	H232	NN	I-NP	O
complex	complex	C514	NN	I-NP	O
,	,	0000	,	O	O
properdin	properdin	P616	NN	B-NP	O
factor	factor	F236	NN	I-NP	O
B	B	B000	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
second	second	S253	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
relationship	relationship	R435	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
coding	cod	C352	VBG	B-VP	O
for	for	F600	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
to	to	T000	TO	B-PP	O
those	those	T200	DT	B-NP	O
coding	cod	C352	VBG	B-VP	O
for	for	F600	IN	B-PP	O
properdin	properdin	P616	NN	B-NP	O
Factor	Factor	F236	NN	I-NP	O
B	B	B000	NN	I-NP	O
allotypes	allotype	A431	NNS	I-NP	O
and	and	A530	CC	B-PP	O
for	for	F600	IN	B-PP	O
deficiency	deficiency	D125	NN	B-NP	B-Disease
of	of	O100	IN	B-PP	I-Disease
the	the	T000	DT	B-NP	I-Disease
second	second	S253	JJ	I-NP	I-Disease
component	component	C515	NN	I-NP	I-Disease
of	of	O100	IN	B-PP	I-Disease
complement	complement	C514	NN	B-NP	I-Disease
(	(	0000	(	O	O
C2	C2	C000	NN	B-NP	O
)	)	0000	)	O	O
was	be	W200	VBD	B-VP	O
studied	study	S300	VBN	I-VP	O
in	in	I500	IN	B-PP	O
families	family	F542	NNS	B-NP	O
of	of	O100	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
with	with	W300	IN	B-PP	O
connective	connective	C523	JJ	B-NP	O
tissue	tissue	T200	NN	I-NP	O
disorders	disorder	D263	NNS	I-NP	O
.	.	0000	.	O	O

Patients	Patient	P353	NNS	B-NP	O
were	be	W600	VBD	B-VP	O
selected	select	S423	VBN	I-VP	O
because	because	B200	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
were	be	W600	VBD	B-VP	O
heterozygous	heterozygous	H362	JJ	B-ADJP	O
or	or	O600	CC	I-ADJP	O
homozygous	homozygous	H520	JJ	I-ADJP	O
for	for	F600	IN	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
.	.	0000	.	O	O

12	12	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
15	15	0000	CD	B-NP	O
matings	mating	M352	NNS	I-NP	O
informative	informative	I516	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
57	57	0000	CD	B-NP	O
informative	informative	I516	JJ	I-NP	O
meioses	meiosis	M200	NNS	I-NP	O
,	,	0000	,	O	O
two	two	T000	CD	B-NP	O
crossovers	crossover	C621	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
noted	note	N300	VBN	I-VP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
C2	C2	C000	NN	I-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
the	the	T000	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
B	B	B000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
with	with	W300	IN	B-PP	O
a	a	A000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

035	035	0000	CD	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
13	13	0000	CD	B-NP	O
was	be	W200	VBD	B-VP	O
calculated	calculate	C424	VBN	I-VP	O
for	for	F600	IN	B-PP	O
linkage	linkage	L520	NN	B-NP	O
between	between	B350	IN	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	O	O
B	B	B000	NN	B-NP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
likelihood	likelihood	L243	NN	I-NP	O
value	value	V400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

04	04	0000	CD	B-NP	O
.	.	0000	.	O	O

18	18	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
with	with	W300	IN	B-PP	O
21	21	0000	CD	B-NP	O
informative	informative	I516	JJ	I-NP	O
matings	mating	M352	NNS	I-NP	O
for	for	F600	IN	B-PP	O
both	both	B300	CC	O	O
properdin	properdin	P616	NN	B-NP	O
Factor	Factor	F236	NN	I-NP	O
B	B	B000	NN	I-NP	O
allotype	allotype	A431	NN	I-NP	O
and	and	A530	CC	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	O	O
B	B	B000	NN	B-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
.	.	0000	.	O	O

Of	Of	O100	IN	B-PP	O
72	72	0000	CD	B-NP	O
informative	informative	I516	JJ	I-NP	O
meioses	meiosis	M200	NNS	I-NP	O
,	,	0000	,	O	O
three	three	T600	CD	B-NP	O
recombinants	recombinant	R251	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
,	,	0000	,	O	O
giving	give	G152	VBG	B-VP	O
a	a	A000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

042	042	0000	CD	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
lod	lod	L300	NN	I-NP	O
score	score	S260	NN	I-NP	O
of	of	O100	IN	B-PP	O
16	16	0000	CD	B-NP	O
between	between	B350	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
B	B	B000	NN	I-NP	O
and	and	A530	CC	I-NP	O
Factor	Factor	F236	NN	I-NP	O
B	B	B000	NN	I-NP	O
allotypes	allotype	A431	NNS	I-NP	O
was	be	W200	VBD	B-VP	O
calculated	calculate	C424	VBN	I-VP	O
at	at	A300	IN	B-PP	O
a	a	A000	DT	B-NP	O
maximum	maximum	M250	NN	I-NP	O
likelihood	likelihood	L243	NN	I-NP	O
value	value	V400	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
recombinant	recombinant	R251	JJ	I-NP	O
fraction	fraction	F623	NN	I-NP	O
of	of	O100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	0000	.	O	O

04	04	0000	CD	B-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
crossover	crossover	C621	NN	I-NP	O
was	be	W200	VBD	B-VP	O
shown	show	S500	VBN	I-VP	O
to	to	T000	TO	I-VP	O
have	have	H100	VB	I-VP	O
occurred	occur	O263	VBN	I-VP	O
between	between	B350	IN	B-PP	O
genes	gene	G520	NNS	B-NP	O
for	for	F600	IN	B-PP	O
Factor	Factor	F236	NN	B-NP	O
B	B	B000	NN	I-NP	O
and	and	A530	CC	O	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	O	O
D	D	D000	NN	B-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
which	which	W200	WDT	B-NP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
D	D	D000	NN	I-NP	O
segregared	segregare	S262	VBN	B-VP	O
with	with	W300	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	I-NP	O
B	B	B000	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
studies	study	S320	NNS	I-NP	O
suggest	suggest	S230	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
for	for	F600	IN	B-PP	O
Factor	Factor	F236	NN	B-NP	O
B	B	B000	NN	I-NP	O
and	and	A530	CC	O	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
are	be	A600	VBP	B-VP	O
located	located	L230	JJ	B-ADJP	O
outside	outside	O323	IN	B-PP	O
those	those	T200	DT	B-NP	O
for	for	F600	IN	B-PP	O
HLA	HLA	H400	NN	B-NP	O
,	,	0000	,	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
order	order	O636	NN	I-NP	O
of	of	O100	IN	B-PP	O
genese	genese	G520	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
HLA	HLA	H400	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
-	-	0000	HYPH	B-NP	O
B	B	B000	NN	I-NP	O
,	,	0000	,	O	O
-	-	0000	HYPH	B-NP	O
D	D	D000	NN	I-NP	O
,	,	0000	,	O	O
Factor	Factor	F236	NN	B-NP	O
B	B	B000	NN	I-NP	O
allotype	allotype	A431	NN	I-NP	O
,	,	0000	,	O	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
,	,	0000	,	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
genes	gene	G520	NNS	I-NP	O
coding	cod	C352	VBG	B-VP	O
for	for	F600	IN	B-PP	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
and	and	A530	CC	O	O
Factor	Factor	F236	NN	B-NP	O
B	B	B000	NN	I-NP	O
allotypes	allotype	A431	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
approximately	approximately	A162	RB	B-NP	O
3	3	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
-	-	0000	SYM	I-NP	O
5	5	0000	CD	I-NP	O
centimorgans	centimorgan	C535	NNS	I-NP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
A	A	A000	NN	I-NP	O
and	and	A530	CC	I-NP	O
HLA	HLA	H400	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
B	B	B000	NN	I-NP	O
loci	locus	L200	NNS	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
apparent	apparent	A165	JJ	I-NP	O
lack	lack	L200	NN	I-NP	O
of	of	O100	IN	B-PP	O
recombinants	recombinant	R251	NNS	B-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
Factor	Factor	F236	NN	I-NP	O
B	B	B000	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
C2	C2	C000	NN	B-NP	B-Disease
deficiency	deficiency	D125	NN	I-NP	I-Disease
gene	gene	G500	NN	I-NP	O
suggests	suggest	S232	VBZ	B-VP	O
that	that	T300	IN	B-SBAR	O
these	these	T200	DT	B-NP	O
two	two	T000	CD	I-NP	O
genes	gene	G520	NNS	I-NP	O
lie	lie	L000	VBP	B-VP	O
in	in	I500	IN	B-PP	O
close	close	C420	JJ	B-NP	O
proximity	proximity	P625	NN	I-NP	O
to	to	T000	TO	B-PP	O
one	one	O500	CD	B-NP	O
another	another	A536	DT	I-NP	O
.	.	0000	.	O	O

Distribution	Distribution	D236	NN	B-NP	O
of	of	O100	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
and	and	A530	CC	I-NP	O
lamins	lamin	L520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
heart	heart	H630	NN	I-NP	O
and	and	A530	CC	I-NP	O
implications	implication	I514	NNS	I-NP	O
for	for	F600	IN	B-PP	O
Emery	Emery	E560	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
.	.	0000	.	O	O

Emerin	Emerin	E565	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
which	which	W200	WDT	B-NP	O
is	be	I200	VBZ	B-VP	O
missing	missing	M252	JJ	B-ADJP	O
or	or	O600	CC	I-ADJP	O
defective	defective	D123	JJ	I-ADJP	O
in	in	I500	IN	B-PP	O
Emery	Emery	E560	NNP	B-NP	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Dreifuss	Dreifuss	D612	NNP	I-NP	I-Disease
muscular	muscular	M246	JJ	I-NP	I-Disease
dystrophy	dystrophy	D236	NN	I-NP	I-Disease
(	(	0000	(	O	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

It	It	I300	PRP	B-NP	O
is	be	I200	VBZ	B-VP	O
one	one	O500	CD	B-NP	O
member	member	M516	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
family	family	F540	NN	I-NP	O
of	of	O100	IN	B-PP	O
lamina	lamina	L500	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
associated	associate	A230	VBN	I-NP	O
proteins	protein	P635	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
includes	include	I524	VBZ	B-VP	O
LAP1	LAP1	L100	NN	B-NP	O
,	,	0000	,	I-NP	O
LAP2	LAP2	L100	NN	I-NP	O
and	and	A530	CC	I-NP	O
lamin	lamin	L500	NN	I-NP	O
B	B	B000	NN	I-NP	O
receptor	receptor	R213	NN	I-NP	O
(	(	0000	(	O	O
LBR	LBR	L160	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
panel	panel	P540	NN	I-NP	O
of	of	O100	IN	B-PP	O
16	16	0000	CD	B-NP	O
monoclonal	monoclonal	M524	JJ	I-NP	O
antibodies	antibody	A531	NNS	I-NP	O
(	(	0000	(	O	O
mAbs	mAb	M120	NNS	B-NP	O
)	)	0000	)	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
mapped	map	M130	VBN	I-VP	O
to	to	T000	TO	B-PP	O
six	six	S200	CD	B-NP	O
specific	specific	S121	JJ	I-NP	O
sites	site	S320	NNS	I-NP	O
throughout	throughout	T623	IN	B-PP	O
the	the	T000	DT	B-NP	O
emerin	emerin	E565	NN	I-NP	O
molecule	molecule	M424	NN	I-NP	O
using	use	U252	VBG	B-VP	O
phage	phage	P200	NN	B-NP	O
-	-	0000	HYPH	O	O
displayed	display	D214	VBN	B-NP	O
peptide	peptide	P130	NN	I-NP	O
libraries	library	L162	NNS	I-NP	O
and	and	A530	CC	O	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
used	use	U230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
localize	localize	L242	VB	I-VP	O
emerin	emerin	E565	NN	B-NP	O
in	in	I500	IN	B-PP	O
human	human	H500	JJ	B-NP	O
and	and	A530	CC	I-NP	O
rabbit	rabbit	R130	NN	I-NP	O
heart	heart	H630	NN	I-NP	O
.	.	0000	.	O	O

Several	Several	S164	JJ	B-NP	O
mAbs	mAb	M120	NNS	I-NP	O
against	against	A252	IN	B-PP	O
different	different	D165	JJ	B-NP	O
emerin	emerin	E565	NN	I-NP	O
epitopes	epitope	E131	NNS	I-NP	O
did	do	D300	VBD	B-VP	O
not	not	N300	RB	I-VP	O
recognize	recognize	R252	VB	I-VP	O
intercalated	intercalate	I536	VBN	B-NP	O
discs	disc	D200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
heart	heart	H630	NN	I-NP	O
,	,	0000	,	O	O
though	though	T200	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
recognized	recognize	R252	VBD	B-VP	O
cardiomyocyte	cardiomyocyte	C635	NN	B-NP	O
nuclei	nucleus	N240	NNS	I-NP	O
strongly	strongly	S365	RB	B-ADVP	O
,	,	0000	,	O	O
both	both	B300	DT	B-NP	O
at	at	A300	IN	B-PP	O
the	the	T000	DT	B-NP	O
rim	rim	R500	NN	I-NP	O
and	and	A530	CC	B-PP	O
in	in	I500	IN	B-PP	O
intranuclear	intranuclear	I536	JJ	B-NP	O
spots	spot	S132	NNS	I-NP	O
or	or	O600	CC	I-NP	O
channels	channel	C542	NNS	I-NP	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
polyclonal	polyclonal	P424	JJ	I-NP	O
rabbit	rabbit	R130	NN	I-NP	O
antiserum	antiserum	A532	NN	I-NP	O
against	against	A252	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
did	do	D300	VBD	B-VP	O
recognize	recognize	R252	VB	I-VP	O
both	both	B300	CC	O	O
nuclear	nuclear	N246	JJ	B-NP	O
membrane	membrane	M516	NN	I-NP	O
and	and	A530	CC	O	O
intercalated	intercalated	I536	JJ	B-NP	O
discs	disc	D200	NNS	I-NP	O
but	but	B300	CC	O	O
,	,	0000	,	O	O
after	after	A136	IN	B-PP	O
affinity	affinity	A153	NN	B-NP	O
purification	purification	P612	NN	I-NP	O
against	against	A252	IN	B-PP	O
a	a	A000	DT	B-NP	O
pure	pure	P600	JJ	I-NP	O
-	-	0000	HYPH	I-NP	O
emerin	emerin	E565	NN	I-NP	O
band	band	B530	NN	I-NP	O
on	on	O500	IN	B-PP	O
a	a	A000	DT	B-NP	O
western	western	W236	JJ	I-NP	O
blot	blot	B430	NN	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
stained	stain	S353	VBD	B-VP	O
only	only	O540	RB	B-NP	O
the	the	T000	DT	I-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
membrane	membrane	M516	NN	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
results	result	R243	NNS	I-NP	O
would	would	W430	MD	B-VP	O
not	not	N300	RB	I-VP	O
be	be	B000	VB	I-VP	O
expected	expect	E212	VBN	I-VP	O
if	if	I100	IN	B-SBAR	O
immunostaining	immunostaining	I523	NN	B-NP	O
at	at	A300	IN	B-PP	O
intercalated	intercalated	I536	JJ	B-NP	O
discs	disc	D200	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
product	product	P632	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
emerin	emerin	E565	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
,	,	0000	,	O	O
therefore	therefore	T616	RB	B-ADVP	O
,	,	0000	,	O	O
cast	cast	C230	VBD	B-VP	O
some	some	S500	DT	B-NP	O
doubt	doubt	D130	NN	I-NP	O
upon	upon	U150	IN	B-PP	O
the	the	T000	DT	B-NP	O
hypothesis	hypothesis	H132	NN	I-NP	O
that	that	T300	IN	B-SBAR	O
cardiac	cardiac	C632	JJ	B-NP	B-Disease
defects	defect	D123	NNS	I-NP	I-Disease
in	in	I500	IN	B-PP	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
are	be	A600	VBP	B-VP	O
caused	cause	C230	VBN	I-VP	O
by	by	B000	IN	B-PP	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
from	from	F650	IN	B-PP	O
intercalated	intercalate	I536	VBN	B-NP	O
discs	disc	D200	NNS	I-NP	O
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
emerin	emerin	E565	NN	B-NP	O
was	be	W200	VBD	B-VP	O
abundant	abundant	A153	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
membranes	membrane	M516	NNS	I-NP	O
of	of	O100	IN	B-PP	O
cardiomyocyte	cardiomyocyte	C635	NN	B-NP	O
nuclei	nucleus	N240	NNS	I-NP	O
,	,	0000	,	O	O
it	it	I300	PRP	B-NP	O
was	be	W200	VBD	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
many	many	M500	JJ	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
myocyte	myocyte	M230	NN	I-NP	O
cells	cell	C420	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
heart	heart	H630	NN	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
distribution	distribution	D236	NN	I-NP	O
of	of	O100	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
was	be	W200	VBD	B-VP	O
similar	similar	S546	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
that	that	T300	DT	B-NP	O
of	of	O100	IN	B-PP	O
lamin	lamin	L500	NN	B-NP	O
A	A	A000	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
candidate	candidate	C530	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
for	for	F600	IN	B-PP	O
an	an	A500	DT	B-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
form	form	F650	NN	I-NP	O
of	of	O100	IN	B-PP	O
EDMD	EDMD	E353	NN	B-NP	B-Disease
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
contrast	contrast	C536	NN	B-NP	O
,	,	0000	,	O	O
lamin	lamin	L500	NN	B-NP	O
B1	B1	B000	NN	I-NP	O
was	be	W200	VBD	B-VP	O
absent	absent	A125	JJ	B-ADJP	O
from	from	F650	IN	B-PP	O
cardiomyocyte	cardiomyocyte	C635	NN	B-NP	O
nuclei	nucleus	N240	NNS	I-NP	O
,	,	0000	,	O	O
showing	show	S520	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
lamin	lamin	L500	NN	B-NP	O
B1	B1	B000	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
not	not	N300	RB	O	O
essential	essential	E253	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
localization	localization	L242	NN	B-NP	O
of	of	O100	IN	B-PP	O
emerin	emerin	E565	NN	B-NP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
lamina	lamina	L500	NN	I-NP	O
.	.	0000	.	O	O

Lamin	Lamin	L500	NN	B-NP	O
B1	B1	B000	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
also	also	A420	RB	B-ADVP	O
almost	almost	A452	RB	B-ADJP	O
completely	completely	C514	RB	I-ADJP	O
absent	absent	A125	JJ	I-ADJP	O
from	from	F650	IN	B-PP	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
nuclei	nucleus	N240	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
EDMD	EDMD	E353	NNP	B-NP	B-Disease
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
additional	additional	A354	JJ	I-NP	O
absence	absence	A125	NN	I-NP	O
of	of	O100	IN	B-PP	O
lamin	lamin	L500	NN	B-NP	O
B1	B1	B000	NN	I-NP	O
from	from	F650	IN	B-PP	O
heart	heart	H630	NN	B-NP	O
and	and	A530	CC	O	O
skeletal	skeletal	S243	JJ	B-NP	O
muscle	muscle	M240	NN	I-NP	O
nuclei	nucleus	N240	NNS	I-NP	O
which	which	W200	WDT	B-NP	O
already	already	A463	RB	B-ADVP	O
lack	lack	L200	VBP	B-VP	O
emerin	emerin	E565	NN	B-NP	O
may	may	M000	MD	B-VP	O
offer	offer	O160	VB	I-VP	O
an	an	A500	DT	B-NP	O
alternative	alternative	A436	JJ	I-NP	O
explanation	explanation	E214	NN	I-NP	O
of	of	O100	IN	B-PP	O
why	why	W000	WRB	B-ADVP	O
these	these	T200	DT	B-NP	O
tissues	tissue	T200	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
particularly	particularly	P632	RB	I-VP	O
affected	affect	A123	VBN	I-VP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Genetic	Genetic	G532	JJ	B-NP	O
mapping	mapping	M152	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
copper	copper	C160	NN	I-NP	B-Disease
toxicosis	toxicosis	T200	NN	I-NP	I-Disease
locus	locus	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
Bedlington	Bedlington	B345	NNP	B-NP	O
terriers	terrier	T620	NNS	I-NP	O
to	to	T000	TO	B-PP	O
dog	dog	D200	NN	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
10	10	0000	CD	I-NP	O
,	,	0000	,	O	O
in	in	I500	IN	B-PP	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
syntenic	syntenic	S535	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
region	region	R250	NN	I-NP	O
2p13	2p13	P000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
p16	p16	P000	NN	I-NP	O
.	.	0000	.	O	O

Abnormal	Abnormal	A156	JJ	B-NP	O
hepatic	hepatic	H132	JJ	I-NP	B-Disease
copper	copper	C160	NN	I-NP	I-Disease
accumulation	accumulation	A254	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
recognized	recognize	R252	VBN	I-VP	O
as	as	A200	IN	B-PP	O
an	an	A500	DT	B-NP	O
inherited	inherit	I563	VBN	I-NP	B-Disease
disorder	disorder	D263	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
,	,	0000	,	O	O
mouse	mouse	M200	NN	B-NP	O
,	,	0000	,	O	O
rat	rat	R300	NN	B-NP	O
and	and	A530	CC	I-NP	O
dog	dog	D200	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
major	major	M260	JJ	I-NP	O
cause	cause	C200	NN	I-NP	O
of	of	O100	IN	B-PP	O
hepatic	hepatic	H132	JJ	B-NP	B-Disease
copper	copper	C160	NN	I-NP	I-Disease
accumulation	accumulation	A254	NN	I-NP	I-Disease
in	in	I500	IN	B-PP	O
man	man	M500	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
a	a	A000	DT	B-NP	O
dysfunctional	dysfunctional	D215	JJ	I-NP	O
ATP7B	ATP7B	A310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
,	,	0000	,	O	O
causing	cause	C252	VBG	B-VP	O
Wilson	Wilson	W425	NNP	B-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
(	(	0000	(	O	O
WD	WD	W300	NN	B-NP	B-Disease
)	)	0000	)	O	O
.	.	0000	.	O	O

Mutations	Mutation	M352	NNS	B-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
ATP7B	ATP7B	A310	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
have	have	H100	VBP	B-VP	O
also	also	A420	RB	I-VP	O
been	be	B500	VBN	I-VP	O
demonstrated	demonstrate	D523	VBN	I-VP	O
in	in	I500	IN	B-PP	O
mouse	mouse	M200	NN	B-NP	O
and	and	A530	CC	O	O
rat	rat	R300	NN	B-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
ATP7B	ATP7B	A310	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
excluded	exclude	E243	VBN	I-VP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
much	much	M200	JJ	I-NP	O
rarer	rarer	R600	NN	I-NP	O
human	human	H500	JJ	I-NP	O
copper	copper	C160	NN	I-NP	B-Disease
overload	overload	O164	NN	I-NP	I-Disease
disease	disease	D200	NN	I-NP	O
non	non	N500	AFX	O	B-Disease
-	-	0000	HYPH	B-NP	I-Disease
Indian	Indian	I535	JJ	I-NP	I-Disease
childhood	childhood	C430	NN	I-NP	I-Disease
cirrhosis	cirrhosis	C620	NN	I-NP	I-Disease
,	,	0000	,	O	O
indicating	indicate	I532	VBG	B-VP	O
genetic	genetic	G532	JJ	B-NP	O
heterogeneity	heterogeneity	H362	NN	I-NP	O
.	.	0000	.	O	O

By	By	B000	IN	B-PP	O
investigating	investigate	I512	VBG	B-VP	O
the	the	T000	DT	B-NP	O
common	common	C500	JJ	I-NP	O
autosomal	autosomal	A325	JJ	I-NP	O
recessive	recessive	R210	JJ	I-NP	O
copper	copper	C160	NN	I-NP	B-Disease
toxicosis	toxicosis	T200	NN	I-NP	I-Disease
(	(	0000	(	O	O
CT	CT	C300	NN	B-NP	B-Disease
)	)	0000	)	O	O
in	in	I500	IN	B-PP	O
Bedlington	Bedlington	B345	NNP	B-NP	O
terriers	terrier	T620	NNS	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
identified	identify	I353	VBN	I-VP	O
a	a	A000	DT	B-NP	O
new	new	N000	JJ	I-NP	O
locus	locus	L200	NN	I-NP	O
involved	involve	I514	VBN	B-VP	O
in	in	I500	IN	B-PP	O
progressive	progressive	P626	JJ	B-NP	O
liver	liver	L160	NN	I-NP	B-Disease
disease	disease	D200	NN	I-NP	I-Disease
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
examined	examine	E253	VBD	B-VP	O
whether	whether	W360	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
WD	WD	W300	JJ	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
ATP7B	ATP7B	A310	NN	I-NP	O
was	be	W200	VBD	B-VP	O
also	also	A420	RB	B-ADVP	O
causative	causative	C231	JJ	B-ADJP	O
for	for	F600	IN	B-PP	O
CT	CT	C300	NN	B-NP	B-Disease
by	by	B000	IN	B-PP	O
investigating	investigate	I512	VBG	B-VP	O
the	the	T000	DT	B-NP	O
chromosomal	chromosomal	C652	JJ	I-NP	O
co	co	C000	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
ATP7B	ATP7B	A310	NN	B-NP	O
and	and	A530	CC	I-NP	O
C04107	C04107	C000	NN	I-NP	O
,	,	0000	,	O	O
using	use	U252	VBG	B-VP	O
fluorescence	fluorescence	F462	NN	B-NP	O
in	in	I500	FW	B-NP	O
situ	situ	S300	FW	I-NP	O
hybridization	hybridization	H163	NN	I-NP	O
(	(	0000	(	O	O
FISH	FISH	F200	NN	B-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

C04107	C04107	C000	NN	B-NP	O
is	be	I200	VBZ	B-VP	O
an	an	A500	DT	B-NP	O
anonymous	anonymous	A520	JJ	I-NP	O
microsatellite	microsatellite	M262	NN	I-NP	O
marker	marker	M626	NN	I-NP	O
closely	closely	C424	RB	B-VP	O
linked	link	L523	VBN	I-VP	O
to	to	T000	TO	B-PP	O
CT	CT	C300	NN	B-NP	B-Disease
.	.	0000	.	O	O

However	However	H160	RB	B-ADVP	O
,	,	0000	,	O	O
BAC	BAC	B200	NN	B-NP	O
clones	clone	C452	NNS	I-NP	O
containing	contain	C535	VBG	B-VP	O
ATP7B	ATP7B	A310	NN	B-NP	O
and	and	A530	CC	I-NP	O
C04107	C04107	C000	NN	I-NP	O
mapped	map	M130	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
canine	canine	C500	JJ	I-NP	O
chromosome	chromosome	C652	NN	I-NP	O
regions	region	R252	NNS	I-NP	O
CFA22q11	CFA22q11	C120	NN	I-NP	O
and	and	A530	CC	I-NP	O
CFA10q26	CFA10q26	C120	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
,	,	0000	,	O	O
demonstrating	demonstrate	D523	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
WD	WD	W300	NN	B-NP	B-Disease
cannot	cannot	C530	MD	B-VP	O
be	be	B000	VB	I-VP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
CT	CT	C300	NN	B-NP	B-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
copper	copper	C160	NN	I-NP	O
transport	transport	T652	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
CTR1	CTR1	C360	NN	I-NP	O
and	and	A530	CC	I-NP	O
CTR2	CTR2	C360	NN	I-NP	O
were	be	W600	VBD	B-VP	O
also	also	A420	RB	I-VP	O
excluded	exclude	E243	VBN	I-VP	O
as	as	A200	IN	B-PP	O
candidate	candidate	C530	NN	B-NP	O
genes	gene	G520	NNS	I-NP	O
for	for	F600	IN	B-PP	O
CT	CT	C300	NN	B-NP	B-Disease
since	since	S520	IN	B-SBAR	O
they	they	T000	PRP	B-NP	O
both	both	B300	DT	B-NP	O
mapped	map	M130	VBD	B-VP	O
to	to	T000	TO	B-PP	O
canine	canine	C500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
region	region	R250	NN	I-NP	O
CFA11q22	CFA11q22	C120	NN	I-NP	O
.	.	0000	.	O	O

2	2	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
22	22	0000	CD	I-NP	O
.	.	0000	.	O	O

5	5	0000	LS	B-LST	O
.	.	0000	.	O	O

A	A	A000	DT	B-NP	O
transcribed	transcribe	T652	VBN	I-NP	O
sequence	sequence	S252	NN	I-NP	O
identified	identify	I353	VBN	B-VP	O
from	from	F650	IN	B-PP	O
the	the	T000	DT	B-NP	O
C04107	C04107	C000	NN	I-NP	O
-	-	0000	HYPH	O	O
containing	contain	C535	VBG	B-VP	O
BAC	BAC	B200	NN	B-NP	O
was	be	W200	VBD	B-VP	O
found	find	F530	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
homologous	homologous	H542	JJ	B-ADJP	O
to	to	T000	TO	B-PP	O
a	a	A000	DT	B-NP	O
gene	gene	G500	NN	I-NP	O
expressed	express	E216	VBN	B-VP	O
from	from	F650	IN	B-PP	O
human	human	H500	JJ	B-NP	O
chromosome	chromosome	C652	NN	I-NP	O
2p13	2p13	P000	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
p16	p16	P000	NN	I-NP	O
,	,	0000	,	O	O
a	a	A000	DT	B-NP	O
region	region	R250	NN	I-NP	O
devoid	devoid	D130	JJ	B-ADJP	O
of	of	O100	IN	B-PP	O
any	any	A500	DT	B-NP	O
positional	positional	P235	JJ	I-NP	O
candidate	candidate	C530	NN	I-NP	O
genes	gene	G520	NNS	I-NP	O
.	.	0000	.	O	O

Molecular	Molecular	M424	JJ	B-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
in	in	I500	IN	B-PP	O
205	205	0000	CD	B-NP	O
families	family	F542	NNS	I-NP	O
:	:	0000	:	O	O
extended	extend	E235	VBN	B-NP	O
genotype	genotype	G531	NN	I-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
and	and	A530	CC	I-NP	O
evidence	evidence	E135	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
amino	amino	A500	JJ	I-NP	O
acid	acid	A230	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
predisposition	predisposition	P632	NN	I-NP	O
.	.	0000	.	O	O

BACKGROUND	BACKGROUND	B265	NN	B-NP	O
/	/	0000	SYM	I-NP	O
AIMS	AIMS	A520	NNS	I-NP	O
The	The	T000	DT	B-NP	O
development	development	D141	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
and	and	A530	CC	O	O
a	a	A000	DT	B-NP	O
variable	variable	V614	JJ	I-NP	O
range	range	R520	NN	I-NP	O
of	of	O100	IN	B-PP	O
extracolonic	extracolonic	E236	JJ	B-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
(	(	0000	(	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
)	)	0000	)	O	O
is	be	I200	VBZ	B-VP	O
the	the	T000	DT	B-NP	O
result	result	R243	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
dominant	dominant	D530	JJ	I-NP	O
inheritance	inheritance	I563	NN	I-NP	O
of	of	O100	IN	B-PP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
coli	coli	C400	NN	I-NP	I-Disease
(	(	0000	(	O	O
APC	APC	A120	NN	B-NP	B-Disease
)	)	0000	)	O	O
gene	gene	G500	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
,	,	0000	,	O	O
direct	direct	D623	JJ	B-NP	O
mutation	mutation	M350	NN	I-NP	O
analysis	analysis	A542	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
performed	perform	P616	VBN	I-VP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	B-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
for	for	F600	IN	B-PP	O
nine	nine	N500	CD	B-NP	O
extracolonic	extracolonic	E236	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
and	and	A530	CC	O	O
to	to	T000	TO	B-VP	O
investigate	investigate	I512	VB	I-VP	O
the	the	T000	DT	B-NP	O
incidence	incidence	I523	NN	I-NP	O
of	of	O100	IN	B-PP	O
APC	APC	A120	NN	B-NP	B-Disease
mutations	mutation	M352	NNS	I-NP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
FAP	FAP	F100	NN	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

METHODS	METHODS	M320	NNS	B-NP	O
The	The	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
was	be	W200	VBD	B-VP	O
analysed	analyse	A542	VBN	I-VP	O
in	in	I500	IN	B-PP	O
190	190	0000	CD	B-NP	O
unrelated	unrelated	U564	JJ	I-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
and	and	A530	CC	O	O
15	15	0000	CD	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
FAP	FAP	F100	NN	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
using	use	U252	VBG	B-VP	O
denaturing	denature	D536	VBG	B-VP	O
gradient	gradient	G635	NN	B-NP	O
gel	gel	G400	NN	I-NP	O
electrophoresis	electrophoresis	E423	NN	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
protein	protein	P635	NN	I-NP	O
truncation	truncation	T652	NN	I-NP	O
test	test	T230	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
direct	direct	D623	JJ	B-NP	O
sequencing	sequencing	S252	NN	I-NP	O
.	.	0000	.	O	O

RESULTS	RESULTS	R243	NNS	B-NP	O
Chain	Chain	C500	VBP	B-VP	O
terminating	terminate	T653	VBG	B-NP	O
signals	signal	S254	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
only	only	O540	RB	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
patients	patient	P353	NNS	B-NP	O
belonging	belong	B452	VBG	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
FAP	FAP	F100	NN	I-NP	B-Disease
group	group	G610	NN	I-NP	O
(	(	0000	(	O	O
105	105	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Amino	Amino	A500	NN	B-NP	O
acid	acid	A230	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
were	be	W600	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
four	four	F600	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
,	,	0000	,	O	O
three	three	T600	CD	B-NP	O
of	of	O100	IN	B-PP	O
whom	whom	W500	WP	B-NP	O
belonged	belong	B452	VBD	B-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
non	non	N500	AFX	I-NP	O
-	-	0000	HYPH	I-NP	O
FAP	FAP	F100	NN	I-NP	O
group	group	G610	NN	I-NP	O
of	of	O100	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Genotype	Genotype	G531	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
phenotype	phenotype	P531	NN	I-NP	O
correlations	correlation	C643	NNS	I-NP	O
identified	identify	I353	VBD	B-VP	O
significant	significant	S251	JJ	B-NP	O
differences	difference	D165	NNS	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
certain	certain	C635	JJ	B-NP	O
extracolonic	extracolonic	E236	JJ	I-NP	O
manifestations	manifestation	M512	NNS	I-NP	O
in	in	I500	IN	B-PP	O
FAP	FAP	F100	NN	B-NP	B-Disease
patients	patient	P353	NNS	I-NP	O
belonging	belong	B452	VBG	B-VP	O
to	to	T000	TO	B-PP	O
three	three	T600	CD	B-NP	O
mutation	mutation	M350	NN	I-NP	O
subgroups	subgroup	S126	NNS	I-NP	O
.	.	0000	.	O	O

CONCLUSIONS	CONCLUSIONS	C524	NNS	B-NP	O
Extended	Extend	E235	VBD	B-VP	O
genotype	genotype	G531	NN	B-NP	O
-	-	0000	HYPH	O	O
phenotype	phenotype	P531	NN	B-NP	O
correlations	correlation	C643	NNS	I-NP	O
made	make	M300	VBN	B-VP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
may	may	M000	MD	B-VP	O
have	have	H100	VB	I-VP	O
the	the	T000	DT	B-NP	O
potential	potential	P353	NN	I-NP	O
to	to	T000	TO	B-VP	O
determine	determine	D365	VB	I-VP	O
the	the	T000	DT	B-NP	O
most	most	M230	RBS	I-NP	O
appropriate	appropriate	A161	JJ	I-NP	O
surveillance	surveillance	S614	NN	I-NP	O
and	and	A530	CC	O	O
prophylactic	prophylactic	P614	JJ	B-NP	O
treatment	treatment	T635	NN	I-NP	O
regimens	regimen	R252	NNS	I-NP	O
for	for	F600	IN	B-PP	O
those	those	T200	DT	B-NP	O
patients	patient	P353	NNS	I-NP	O
with	with	W300	IN	B-PP	O
mutations	mutation	M352	NNS	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
life	life	L100	NN	B-NP	O
threatening	threatening	T635	JJ	I-NP	O
conditions	condition	C535	NNS	I-NP	O
.	.	0000	.	O	O

This	This	T200	DT	B-NP	O
study	study	S300	NN	I-NP	O
also	also	A420	RB	B-ADVP	O
provided	provide	P613	VBD	B-VP	O
evidence	evidence	E135	NN	B-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
pathological	pathological	P342	JJ	I-NP	O
nature	nature	N360	NN	I-NP	O
of	of	O100	IN	B-PP	O
amino	amino	A500	JJ	B-NP	O
acid	acid	A230	NN	I-NP	O
changes	change	C520	NNS	I-NP	O
in	in	I500	IN	B-PP	O
APC	APC	A120	NN	B-NP	O
associated	associate	A230	VBN	B-VP	O
with	with	W300	IN	B-PP	O
both	both	B300	CC	O	O
FAP	FAP	F100	NN	B-NP	B-Disease
and	and	A530	CC	O	O
non	non	N500	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
FAP	FAP	F100	NN	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O
.	.	0000	.	O	O

Inherited	Inherit	I563	VBN	B-NP	B-Disease
colorectal	colorectal	C462	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
and	and	A530	CC	I-NP	O
cancer	cancer	C526	NN	I-NP	B-Disease
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	O
I1307K	I1307K	I200	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
.	.	0000	.	O	O

Germ	Germ	G650	NN	B-NP	O
-	-	0000	HYPH	I-NP	O
line	line	L500	NN	I-NP	O
and	and	A530	CC	O	O
somatic	somatic	S532	JJ	B-NP	O
truncating	truncating	T652	NN	I-NP	O
mutations	mutation	M352	NNS	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
are	be	A600	VBP	B-VP	O
thought	think	T230	VBN	I-VP	O
to	to	T000	TO	I-VP	O
initiate	initiate	I530	VB	I-VP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
tumor	tumor	T560	NN	I-NP	I-Disease
formation	formation	F653	NN	I-NP	O
in	in	I500	IN	B-PP	O
familial	familial	F540	JJ	B-NP	B-Disease
adenomatous	adenomatous	A353	JJ	I-NP	I-Disease
polyposis	polyposis	P412	NN	I-NP	I-Disease
syndrome	syndrome	S536	NN	I-NP	I-Disease
and	and	A530	CC	O	O
sporadic	sporadic	S163	JJ	B-NP	O
colorectal	colorectal	C462	JJ	I-NP	O
carcinogenesis	carcinogenesis	C625	NN	I-NP	O
,	,	0000	,	O	O
respectively	respectively	R212	RB	B-ADVP	O
.	.	0000	.	O	O

Recently	Recently	R253	RB	B-ADVP	O
,	,	0000	,	O	O
an	an	A500	DT	B-NP	O
isoleucine	isoleucine	I242	NN	I-NP	O
-	-	0000	SYM	B-VP	O
-	-	0000	SYM	B-NP	O
>	>	0000	SYM	I-NP	O
lysine	lysine	L250	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
at	at	A300	IN	B-PP	O
codon	codon	C350	NN	B-NP	O
1307	1307	0000	CD	I-NP	O
(	(	0000	(	O	O
I1307K	I1307K	I200	NN	B-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	B-Disease
gene	gene	G500	NN	I-NP	O
has	have	H200	VBZ	B-VP	O
been	be	B500	VBN	I-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
6	6	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
7	7	0000	CD	I-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
the	the	T000	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

To	To	T000	TO	B-VP	O
assess	assess	A200	VB	I-VP	O
the	the	T000	DT	B-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
this	this	T200	DT	B-NP	O
common	common	C500	JJ	I-NP	O
APC	APC	A120	NN	I-NP	B-Disease
allelic	allelic	A420	JJ	I-NP	O
variant	variant	V653	NN	I-NP	O
in	in	I500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	O
carcinogenesis	carcinogenesis	C625	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
analyzed	analyze	A542	VBN	I-VP	O
a	a	A000	DT	B-NP	O
large	large	L620	JJ	I-NP	O
cohort	cohort	C630	NN	I-NP	O
of	of	O100	IN	B-PP	O
unselected	unselected	U524	JJ	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	JJ	I-NP	O
subjects	subject	S123	NNS	I-NP	O
with	with	W300	IN	B-PP	O
adenomatous	adenomatous	A353	JJ	B-NP	B-Disease
polyps	polyp	P412	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
.	.	0000	.	O	O
or	or	O600	CC	O	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
,	,	0000	,	O	I-Disease
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	O
I1307K	I1307K	I200	NN	I-NP	O
polymorphism	polymorphism	P456	NN	I-NP	O
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	O
I1307K	I1307K	I200	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
was	be	W200	VBD	B-VP	O
identified	identify	I353	VBN	I-VP	O
in	in	I500	IN	B-PP	O
48	48	0000	CD	B-NP	O
(	(	0000	(	O	O
10	10	0000	CD	B-NP	O
.	.	0000	.	O	O
1	1	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
)	)	0000	)	O	O
of	of	O100	IN	B-PP	O
476	476	0000	CD	B-NP	O
patients	patient	P353	NNS	I-NP	O
.	.	0000	.	O	O

Compared	Compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
the	the	T000	DT	B-NP	O
frequency	frequency	F625	NN	I-NP	O
in	in	I500	IN	B-PP	O
two	two	T000	CD	B-NP	O
separate	separate	S163	JJ	I-NP	O
population	population	P143	NN	I-NP	O
control	control	C536	NN	I-NP	O
groups	group	G612	NNS	I-NP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	O
I1307K	I1307K	I200	NN	I-NP	O
allele	allele	A400	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
associated	associate	A230	VBN	I-VP	O
with	with	W300	IN	B-PP	O
an	an	A500	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
relative	relative	R431	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
of	of	O100	IN	B-PP	O
1	1	0000	CD	B-NP	O
.	.	0000	.	O	O

5	5	0000	CD	B-NP	O
-	-	0000	HYPH	I-NP	O
1	1	0000	CD	I-NP	O
.	.	0000	.	O	O

7	7	0000	CD	B-NP	O
for	for	F600	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
neoplasia	neoplasia	N142	NN	I-NP	I-Disease
(	(	0000	(	O	O
both	both	B300	DT	B-NP	O
P	P	P000	NN	I-NP	O
=	=	0000	JJ	I-NP	O
.	.	0000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	0000	)	O	O
.	.	0000	.	O	O

Furthermore	Furthermore	F636	RB	B-ADVP	O
,	,	0000	,	O	O
compared	compare	C516	VBN	B-PP	O
with	with	W300	IN	B-PP	O
noncarriers	noncarrier	N526	NNS	B-NP	O
,	,	0000	,	O	O
APC	APC	A120	NN	B-NP	O
I1307K	I1307K	I200	NN	I-NP	O
carriers	carrier	C620	NNS	I-NP	O
had	have	H300	VBD	B-VP	O
increased	increase	I526	VBN	I-VP	O
numbers	number	N516	NNS	B-NP	O
of	of	O100	IN	B-PP	O
adenomas	adenoma	A352	NNS	B-NP	B-Disease
and	and	A530	CC	O	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
per	per	P600	IN	B-PP	O
patient	patient	P353	NN	B-NP	O
(	(	0000	(	O	O
P	P	P000	NN	B-NP	O
=	=	0000	SYM	B-VP	O
.	.	0000	.	B-NP	O
03	03	0000	CD	I-NP	O
)	)	0000	)	O	O
,	,	0000	,	O	O
as	as	A200	RB	B-CONJP	O
well	well	W400	RB	I-CONJP	O
as	as	A200	IN	I-CONJP	O
a	a	A000	DT	B-NP	O
younger	young	Y526	JJR	I-NP	O
age	age	A200	NN	I-NP	O
at	at	A300	IN	B-PP	O
diagnosis	diagnosis	D252	NN	B-NP	O
.	.	0000	.	O	O

We	We	W000	PRP	B-NP	O
conclude	conclude	C524	VBP	B-VP	O
that	that	T300	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
APC	APC	A120	NN	I-NP	O
I1307K	I1307K	I200	NN	I-NP	O
variant	variant	V653	NN	I-NP	O
leads	lead	L320	VBZ	B-VP	O
to	to	T000	TO	B-PP	O
increased	increase	I526	VBN	B-NP	O
adenoma	adenoma	A350	NN	I-NP	B-Disease
formation	formation	F653	NN	I-NP	O
and	and	A530	CC	O	O
directly	directly	D623	RB	B-VP	O
contributes	contribute	C536	VBZ	I-VP	O
to	to	T000	TO	B-PP	O
3	3	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
-	-	0000	HYPH	O	O
4	4	0000	CD	B-NP	O
%	%	0000	NN	I-NP	O
of	of	O100	IN	B-PP	O
all	all	A400	DT	B-NP	O
Ashkenazi	Ashkenazi	A252	NNP	I-NP	O
Jewish	Jewish	J200	NNP	I-NP	O
colorectal	colorectal	C462	JJ	I-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
.	.	0000	.	O	O

The	The	T000	DT	B-NP	O
estimated	estimate	E235	VBN	I-NP	O
relative	relative	R431	JJ	I-NP	O
risk	risk	R200	NN	I-NP	O
for	for	F600	IN	B-PP	O
carriers	carrier	C620	NNS	B-NP	O
may	may	M000	MD	B-VP	O
justify	justify	J231	VB	I-VP	O
specific	specific	S121	JJ	B-NP	O
clinical	clinical	C452	JJ	I-NP	O
screening	screening	S265	NN	I-NP	O
for	for	F600	IN	B-PP	O
the	the	T000	DT	B-NP	O
360	360	0000	CD	I-NP	O
,	,	0000	,	I-NP	O
000	000	0000	CD	I-NP	O
Americans	American	A562	NNPS	I-NP	O
expected	expect	E212	VBN	B-VP	O
to	to	T000	TO	I-VP	O
harbor	harbor	H616	VB	I-VP	O
this	this	T200	DT	B-NP	O
allele	allele	A400	NN	I-NP	O
,	,	0000	,	O	O
and	and	A530	CC	O	O
genetic	genetic	G532	JJ	B-NP	O
testing	testing	T235	NN	I-NP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
setting	setting	S352	NN	I-NP	O
of	of	O100	IN	B-PP	O
long	long	L520	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
term	term	T650	NN	I-NP	O
-	-	0000	HYPH	I-NP	O
outcome	outcome	O325	NN	I-NP	O
studies	study	S320	NNS	I-NP	O
may	may	M000	MD	B-VP	O
impact	impact	I512	VB	I-VP	O
significantly	significantly	S251	RB	B-ADVP	O
on	on	O500	IN	B-PP	O
colorectal	colorectal	C462	JJ	B-NP	B-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
prevention	prevention	P615	NN	I-NP	O
in	in	I500	IN	B-PP	O
this	this	T200	DT	B-NP	O
population	population	P143	NN	I-NP	O
.	.	0000	.	O	O

Localization	Localization	L242	NN	B-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
and	and	A530	CC	O	O
its	its	I320	PRP$	B-NP	O
loss	loss	L200	NN	I-NP	O
in	in	I500	IN	B-PP	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
grade	grade	G630	NN	I-NP	O
,	,	0000	,	O	O
non	non	N500	AFX	O	B-Disease
-	-	0000	HYPH	O	I-Disease
inherited	inherit	I563	VBN	B-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Although	Although	A432	IN	B-SBAR	O
the	the	T000	DT	B-NP	O
link	link	L520	NN	I-NP	O
between	between	B350	IN	B-PP	O
the	the	T000	DT	B-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
tumour	tumour	T560	NN	I-NP	B-Disease
-	-	0000	HYPH	B-NP	O
suppressor	suppressor	S162	NN	I-NP	O
gene	gene	G500	NN	I-NP	O
and	and	A530	CC	O	O
hereditary	hereditary	H636	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancer	cancer	C526	NN	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
established	establish	E231	VBN	I-VP	O
,	,	0000	,	O	O
the	the	T000	DT	B-NP	O
role	role	R400	NN	I-NP	O
,	,	0000	,	O	O
if	if	I100	IN	B-SBAR	O
any	any	A500	DT	B-NP	O
,	,	0000	,	O	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
familial	familial	F540	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
is	be	I200	VBZ	B-VP	O
unclear	unclear	U524	JJ	B-ADJP	O
.	.	0000	.	O	O

BRCA1	BRCA1	B620	NN	B-NP	O
mutations	mutation	M352	NNS	I-NP	O
are	be	A600	VBP	B-VP	O
rare	rare	R600	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
,	,	0000	,	O	O
but	but	B300	CC	O	O
loss	loss	L200	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
resulting	result	R243	VBG	B-VP	O
from	from	F650	IN	B-PP	O
reduced	reduce	R323	VBN	B-NP	O
expression	expression	E216	NN	I-NP	O
or	or	O600	CC	O	O
incorrect	incorrect	I526	JJ	B-NP	O
subcellular	subcellular	S124	JJ	I-NP	O
localization	localization	L242	NN	I-NP	O
is	be	I200	VBZ	B-VP	O
postulated	postulate	P234	VBN	I-VP	O
to	to	T000	TO	I-VP	O
be	be	B000	VB	I-VP	O
important	important	I516	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
non	non	N500	AFX	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
familial	familial	F540	JJ	I-NP	I-Disease
breast	breast	B623	NN	I-NP	I-Disease
and	and	A530	CC	O	I-Disease
ovarian	ovarian	O165	JJ	B-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Epigenetic	Epigenetic	E125	JJ	B-NP	O
loss	loss	L200	NN	I-NP	O
,	,	0000	,	O	O
however	however	H160	RB	B-ADVP	O
,	,	0000	,	O	O
has	have	H200	VBZ	B-VP	O
not	not	N300	RB	I-VP	O
received	receive	R213	VBN	I-VP	O
general	general	G564	JJ	B-NP	O
acceptance	acceptance	A213	NN	I-NP	O
due	due	D000	JJ	B-ADJP	O
to	to	T000	TO	B-VP	O
controversy	controversy	C536	VB	I-VP	O
regarding	regard	R263	VBG	I-VP	O
the	the	T000	DT	B-NP	O
subcellular	subcellular	S124	JJ	I-NP	O
localization	localization	L242	NN	I-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
proteins	protein	P635	NNS	I-NP	O
,	,	0000	,	O	O
reports	report	R163	NNS	B-NP	O
of	of	O100	IN	B-PP	O
which	which	W200	WDT	B-NP	O
have	have	H100	VBP	B-VP	O
ranged	range	R523	VBN	I-VP	O
from	from	F650	IN	B-PP	O
exclusively	exclusively	E242	RB	B-ADJP	O
nuclear	nuclear	N246	JJ	I-ADJP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
conditionally	conditionally	C535	RB	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
ER	ER	E600	NN	I-NP	O
/	/	0000	SYM	B-NP	O
golgi	golgi	G420	NN	I-NP	O
,	,	0000	,	O	O
to	to	T000	TO	B-PP	O
cytoplasmic	cytoplasmic	C314	JJ	B-NP	O
invaginations	invagination	I512	NNS	I-NP	O
into	into	I530	IN	B-PP	O
the	the	T000	DT	B-NP	O
nucleus	nucleus	N242	NN	I-NP	O
.	.	0000	.	O	O

In	In	I500	IN	B-PP	O
an	an	A500	DT	B-NP	O
attempt	attempt	A351	NN	I-NP	O
to	to	T000	TO	B-VP	O
resolve	resolve	R241	VB	I-VP	O
this	this	T200	DT	B-NP	O
issue	issue	I200	NN	I-NP	O
,	,	0000	,	O	O
we	we	W000	PRP	B-NP	O
have	have	H100	VBP	B-VP	O
comprehensively	comprehensively	C516	RB	I-VP	O
characterized	characterize	C623	VBN	I-VP	O
19	19	0000	CD	B-NP	O
anti	anti	A530	AFX	B-NP	O
-	-	0000	HYPH	I-NP	O
BRCA1	BRCA1	B620	NN	I-NP	O
antibodies	antibody	A531	NNS	I-NP	O
.	.	0000	.	O	O

These	These	T200	DT	B-NP	O
reagents	reagent	R253	NNS	I-NP	O
detect	detect	D323	VBP	B-VP	O
a	a	A000	DT	B-NP	O
220	220	0000	CD	I-NP	O
-	-	0000	HYPH	I-NP	O
kD	kD	K300	NN	I-NP	O
protein	protein	P635	NN	I-NP	O
localized	localize	L242	VBN	B-VP	O
in	in	I500	IN	B-PP	O
discrete	discrete	D263	JJ	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
foci	focus	F200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
all	all	A400	DT	B-NP	O
epithelial	epithelial	E134	JJ	I-NP	O
cell	cell	C400	NN	I-NP	O
lines	line	L520	NNS	I-NP	O
,	,	0000	,	O	O
including	include	I524	VBG	B-PP	O
those	those	T200	DT	B-NP	O
derived	derive	D613	VBN	B-VP	O
from	from	F650	IN	B-PP	O
breast	breast	B623	NN	B-NP	B-Disease
malignancies	malignancy	M425	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Immunohistochemical	Immunohistochemical	I523	JJ	B-NP	O
staining	staining	S352	NN	I-NP	O
of	of	O100	IN	B-PP	O
human	human	H500	JJ	B-NP	O
breast	breast	B623	NN	I-NP	O
specimens	specimen	S125	NNS	I-NP	O
also	also	A420	RB	B-ADVP	O
revealed	reveal	R143	VBD	B-VP	O
BRCA1	BRCA1	B620	NN	B-NP	O
nuclear	nuclear	N246	JJ	I-NP	O
foci	focus	F200	NNS	I-NP	O
in	in	I500	IN	B-PP	O
benign	benign	B525	JJ	B-NP	O
breast	breast	B623	NN	I-NP	O
,	,	0000	,	O	O
invasive	invasive	I512	JJ	B-NP	B-Disease
lobular	lobular	L146	JJ	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
and	and	A530	CC	O	O
low	low	L000	JJ	B-NP	B-Disease
-	-	0000	HYPH	I-NP	I-Disease
grade	grade	G630	NN	I-NP	I-Disease
ductal	ductal	D234	JJ	I-NP	I-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
.	.	0000	.	O	O

Conversely	Conversely	C516	RB	B-ADVP	O
,	,	0000	,	O	O
BRCA1	BRCA1	B620	NN	B-NP	O
expression	expression	E216	NN	I-NP	O
was	be	W200	VBD	B-VP	O
reduced	reduce	R323	VBN	I-VP	O
or	or	O600	CC	O	O
undetectable	undetectable	U532	JJ	B-ADJP	O
in	in	I500	IN	B-PP	O
the	the	T000	DT	B-NP	O
majority	majority	M263	NN	I-NP	O
of	of	O100	IN	B-PP	O
high	high	H200	JJ	B-NP	O
-	-	0000	HYPH	I-NP	O
grade	grade	G630	NN	I-NP	O
,	,	0000	,	O	O
ductal	ductal	D234	JJ	B-NP	B-Disease
carcinomas	carcinoma	C625	NNS	I-NP	I-Disease
,	,	0000	,	O	O
suggesting	suggest	S235	VBG	B-VP	O
that	that	T300	IN	B-SBAR	O
absence	absence	A125	NN	B-NP	O
of	of	O100	IN	B-PP	O
BRCA1	BRCA1	B620	NN	B-NP	O
may	may	M000	MD	B-VP	O
contribute	contribute	C536	VB	I-VP	O
to	to	T000	TO	B-PP	O
the	the	T000	DT	B-NP	O
pathogenesis	pathogenesis	P325	NN	I-NP	O
of	of	O100	IN	B-PP	O
a	a	A000	DT	B-NP	O
significant	significant	S251	JJ	I-NP	O
percentage	percentage	P625	NN	I-NP	O
of	of	O100	IN	B-PP	O
sporadic	sporadic	S163	JJ	B-NP	B-Disease
breast	breast	B623	NN	I-NP	I-Disease
cancers	cancer	C526	NNS	I-NP	I-Disease
.	.	0000	.	O	O
.	.	0000	.	O	O

